There O 
is O 
a O 
single O 
methionine B-DNA 
codon I-DNA 
- I-DNA 
initiated I-DNA 
open I-DNA 
reading I-DNA 
frame I-DNA 
of O 
1 O 
, O 
458 O 
nt O 
in O 
frame O 
with O 
a O 
homeobox B-DNA 
and O 
a O 
CAX B-DNA 
repeat I-DNA 
, O 
and O 
the O 
open B-DNA 
reading I-DNA 
frame I-DNA 
is O 
predicted O 
to O 
encode O 
a O 
protein O 
of O 
51 O 
, O 
659 O 
daltons O 
. O 

When O 
the O 
homeodomain B-DNA 
from O 
HB24 B-DNA 
was O 
compared O 
to O 
known O 
mammalian O 
and O 
Drosophila O 
homeodomains O 
it O 
was O 
found O 
to O 
be O 
only O 
moderately O 
conserved O 
, O 
but O 
when O 
it O 
was O 
compared O 
to O 
a O 
highly O 
diverged O 
Drosophila B-DNA 
homeodomain B-DNA I-DNA 
, O 
H2 O 
. O 
0 O 
, O 
it O 
was O 
found O 
to O 
be O 
80 O 
% O 
identical O 
. O 

The O 
HB24 B-RNA 
mRNA I-RNA 
was O 
absent O 
or O 
present O 
at O 
low O 
levels O 
in O 
normal O 
B O 
and O 
T B-cell_type 
lymphocytes I-cell_type 
; O 
however O 
, O 
with O 
the O 
appropriate O 
activation O 
signal O 
HB24 B-RNA 
mRNA I-RNA 
was O 
induced O 
within O 
several O 
hours O 
even O 
in O 
the O 
presence O 
of O 
cycloheximide O 
. O 

Characterization O 
of O 
HB24 B-DNA 
expression O 
in O 
lymphoid O 
and O 
select O 
developing O 
tissues O 
was O 
performed O 
by O 
in O 
situ O 
hybridization O 
. O 

Positive O 
hybridization O 
was O 
found O 
in O 
thymus O 
, O 
tonsil O 
, O 
bone O 
marrow O 
, O 
developing O 
vessels O 
, O 
and O 
in O 
fetal O 
brain O 
. O 

HB24 B-DNA 
is O 
likely O 
to O 
have O 
an O 
important O 
role O 
in O 
lymphocytes B-cell_type 
as O 
well O 
as O 
in O 
certain O 
developing O 
tissues O 
. O 

Platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
induces O 
phospholipid O 
turnover O 
, O 
calcium O 
flux O 
, O 
arachidonic O 
acid O 
liberation O 
, O 
eicosanoid O 
generation O 
, O 
and O 
oncogene B-DNA 
expression O 
in O 
a O 
human B-cell_line 
B I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

Platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
is O 
a O 
potent O 
mediator O 
of O 
the O 
inflammatory O 
response O 
. O 

Studies O 
of O 
the O 
actions O 
of O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
have O 
centered O 
mainly O 
around O 
neutrophils B-cell_type 
, O 
monocytes B-cell_type 
, O 
and O 
platelets B-cell_type 
. O 

In O 
this O 
report O 
we O 
begin O 
to O 
uncover O 
the O 
influence O 
of O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
on O 
B B-cell_type 
lymphocytes I-cell_type 
. O 

Employing O 
the O 
EBV B-cell_line 
- I-cell_line 
transformed I-cell_line 
human B-cell_line I-cell_line 
B I-cell_line I-cell_line 
cell I-cell_line I-cell_line 
line I-cell_line I-cell_line 
SKW6 B-cell_line 
. I-cell_line 
4 I-cell_line 
, O 
we O 
demonstrate O 
that O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
significantly O 
alters O 
membrane O 
phospholipid O 
metabolism O 
indicated O 
by O 
the O 
incorporation O 
of O 
32P O 
into O 
phosphatidylcholine O 
, O 
phosphatidylinositol O 
, O 
and O 
phosphatidic O 
acid O 
but O 
not O 
significantly O 
into O 
phosphatidylethanolamine O 
at O 
concentrations O 
ranging O 
from O 
10 O 
( O 
- O 
9 O 
) O 
to O 
10 O 
( O 
- O 
6 O 
) O 
M O 
. O 

The O 
inactive O 
precursor O 
, O 
lyso B-protein 
- I-protein 
platelet I-protein 
- I-protein 
activating I-protein 
factor I-protein 
, O 
at O 
a O 
concentration O 
as O 
high O 
as O 
10 O 
( O 
- O 
7 O 
) O 
M O 
had O 
no O 
effect O 
on O 
any O 
of O 
the O 
membrane O 
phospholipids O 
. O 

We O 
also O 
show O 
that O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
from O 
10 O 
( O 
- O 
12 O 
) O 
to O 
10 O 
( O 
- O 
6 O 
) O 
M O 
induced O 
rapid O 
and O 
significant O 
elevation O 
in O 
intracellular O 
calcium O 
levels O 
, O 
whereas O 
lyso O 
- O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
was O 
again O 
ineffective O 
. O 

We O 
further O 
demonstrate O 
the O 
impact O 
of O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
binding O 
to O 
B B-cell_type 
cells I-cell_type 
by O 
measuring O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
induced O 
arachidonic O 
acid O 
release O 
and O 
5 O 
- O 
hydroxyeicosatetraenoic O 
acid O 
production O 
. O 

Moreover O 
, O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
was O 
capable O 
of O 
inducing O 
transcription O 
of O 
the O 
nuclear B-DNA 
proto I-DNA 
- I-DNA 
oncogenes I-DNA 
c B-DNA 
- I-DNA 
fos I-DNA 
and O 
c B-DNA 
- I-DNA 
jun I-DNA 
. O 

Finally O 
we O 
explored O 
the O 
possible O 
role O 
of O 
5 O 
- O 
hydroxyeicosatetraenoic O 
acid O 
as O 
a O 
regulator O 
of O 
arachidonic O 
acid O 
liberation O 
demonstrating O 
that O 
endogenous O 
5 B-protein 
- I-protein 
lipoxygenase I-protein 
activity O 
modulates O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
induced O 
arachidonic O 
acid O 
release O 
perhaps O 
acting O 
at O 
the O 
level O 
of O 
phospholipase B-protein 
A2 I-protein 
. O 

In O 
summary O 
, O 
platelet B-protein 
- I-protein 
activating I-protein 
factor I-protein 
is O 
shown O 
here O 
to O 
have O 
a O 
direct O 
and O 
profound O 
effect O 
on O 
a O 
pure B-cell_line 
B I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

Positive O 
and O 
negative O 
regulation O 
of O 
immunoglobulin B-DNA 
gene I-DNA 
expression O 
by O 
a O 
novel O 
B B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
enhancer I-DNA 
element I-DNA 
. O 

A O 
new O 
B B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
enhancer I-DNA 
element I-DNA 
has O 
been O 
identified O 
3 O 
' O 
of O 
E4 O 
and O 
the O 
octamerlike O 
motifs O 
in O 
the O 
human B-protein B-DNA 
immunoglobulin I-protein I-DNA 
heavy I-protein I-DNA 
- I-protein I-DNA 
chain I-protein I-DNA 
gene I-DNA 
enhancer I-DNA 
. O 

Tandem O 
copies O 
of O 
this O 
67 B-DNA 
- I-DNA 
bp I-DNA 
MnlI I-DNA 
- I-DNA 
AluI I-DNA 
fragment I-DNA 
, O 
when O 
fused O 
to O 
the O 
chloramphenicol B-DNA 
acetyltransferase I-DNA 
gene I-DNA 
driven O 
by O 
the O 
conalbumin B-DNA 
promoter I-DNA 
, O 
stimulated O 
transcription O 
in O 
B B-cell_type 
cells I-cell_type 
but O 
not O 
in O 
Jurkat B-cell_line 
T I-cell_line 
cells I-cell_line 
or O 
HeLa B-cell_line 
cells I-cell_line 
. O 

Footprinting O 
analysis O 
revealed O 
that O 
the O 
identical O 
sequence O 
CCGAAACTGAAAAGG O 
, O 
designated O 
E6 B-DNA 
, O 
was O 
protected O 
by O 
nuclear O 
extracts O 
from O 
B B-cell_type 
cells I-cell_type 
, O 
T B-cell_type 
cells I-cell_type 
, O 
or O 
HeLa O 
cells O 
. O 

Gel O 
mobility O 
shift O 
assays O 
using O 
a O 
synthetic B-DNA 
E6 I-DNA 
motif I-DNA 
detected O 
a O 
B B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
complex I-protein 
in O 
addition O 
to O 
a O 
ubiquitous O 
band O 
found O 
also O 
in O 
T B-cell_type 
cells I-cell_type 
and O 
HeLa B-cell_line 
cells I-cell_line 
. O 

In O 
agreement O 
with O 
the O 
results O 
of O 
gel O 
retardation O 
assays O 
, O 
tandem O 
copies O 
of O 
the O 
E6 B-DNA 
motif I-DNA 
stimulated O 
transcription O 
in O 
ARH77 B-cell_line 
and O 
Raji B-cell_line 
cells I-cell_line 
but O 
not O 
in O 
Jurkat B-cell_line 
or O 
HeLa B-cell_line 
cells I-cell_line 
. O 

Furthermore O 
, O 
a O 
mutant B-DNA 
E6 I-DNA 
motif I-DNA 
lost O 
both O 
in O 
vitro O 
binding O 
activity O 
and O 
in O 
vivo O 
enhancer O 
activity O 
. O 

In O 
striking O 
contrast O 
to O 
the O 
mouse B-DNA 
Ig I-DNA 
heavy I-DNA 
- I-DNA 
chain I-DNA 
enhancer I-DNA 
, O 
in O 
which O 
the O 
octamer B-DNA 
motif I-DNA 
acts O 
as O 
a O 
B B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
enhancer I-DNA 
element I-DNA 
, O 
the O 
human B-DNA 
enhancer I-DNA 
contains O 
an O 
octamerlike B-DNA 
sequence I-DNA 
with O 
one O 
base O 
substitution O 
which O 
bound O 
octamer B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
with O 
only O 
very O 
low O 
affinity O 
and O 
showed O 
no O 
enhancer O 
activity O 
of O 
its O 
own O 
. O 

Interestingly O 
, O 
the O 
MnlI B-DNA 
- I-DNA 
AluI I-DNA 
fragment I-DNA 
could O 
suppress O 
the O 
basal O 
- O 
level O 
activity O 
of O 
the O 
conalbumin B-DNA 
promoter I-DNA 
in O 
both O 
Jurkat B-cell_line 
and O 
HeLa B-cell_line 
cells I-cell_line 
. O 

Moreover O 
, O 
simian O 
virus O 
40 O 
enhancer O 
activity O 
was O 
blocked O 
by O 
the O 
MnlI B-DNA 
- I-DNA 
AluI I-DNA 
fragment I-DNA 
in O 
HeLa B-cell_line 
cells I-cell_line 
but O 
not O 
in O 
B B-cell_type 
cells I-cell_type 
. O 

Thus O 
, O 
the O 
novel O 
enhancer O 
element O 
identified O 
in O 
this O 
study O 
is O 
probably O 
a O 
target O 
site O 
for O 
both O 
positive B-protein 
and O 
negative B-protein 
factors I-protein 
. O 

Charybdotoxin O 
- O 
sensitive O 
, O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
membrane O 
potential O 
changes O 
are O 
not O 
involved O 
in O 
human O 
T O 
or O 
B O 
cell O 
activation O 
and O 
proliferation O 
. O 

The O 
involvement O 
of O 
ion B-protein 
channels I-protein 
in O 
B O 
and O 
T O 
lymphocyte O 
activation O 
is O 
supported O 
by O 
many O 
reports O 
of O 
changes O 
in O 
ion O 
fluxes O 
and O 
membrane O 
potential O 
after O 
mitogen B-protein 
binding O 
. O 

Human O 
T O 
and O 
B O 
lymphocytes O 
demonstrate O 
an O 
early O 
and O 
transient O 
hyperpolarization O 
after O 
ligand O 
binding O 
. O 

Inasmuch O 
as O 
the O 
change O 
in O 
membrane O 
potential O 
is O 
dependent O 
on O 
elevation O 
of O 
free O 
cytosolic O 
calcium O 
, O 
the O 
hyperpolarization O 
is O 
presumably O 
through O 
opening O 
of O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
stimulated O 
K O 
+ O 
channels O 
. O 

We O 
have O 
used O 
charybdotoxin O 
, O 
a O 
known O 
inhibitor O 
of O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
dependent I-protein 
K I-protein 
+ I-protein 
channels I-protein 
, O 
to O 
study O 
the O 
role O 
of O 
these O 
channels O 
in O 
lymphocyte O 
activation O 
and O 
mitogenesis O 
. O 

We O 
demonstrate O 
that O 
charybdotoxin O 
inhibits O 
the O 
ligand O 
- O 
induced O 
transient O 
membrane O 
hyperpolarization O 
in O 
B O 
and O 
T O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
, O 
without O 
affecting O 
changes O 
in O 
cytosolic O 
Ca2 O 
+ O 
. O 

However O 
, O 
blockade O 
of O 
the O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
activated I-protein 
K I-protein 
+ I-protein 
channel I-protein 
is O 
not O 
associated O 
with O 
changes O 
in O 
cell O 
- O 
cycle O 
gene O 
activation O 
, O 
IL B-protein 
- I-protein 
2 I-protein 
production O 
, O 
IL B-protein 
- I-protein 
2R I-protein 
expression O 
or O 
B O 
and O 
T O 
cell O 
mitogenesis O 
. O 

These O 
results O 
imply O 
that O 
membrane O 
potential O 
changes O 
secondary O 
to O 
the O 
ligand O 
- O 
dependent O 
opening O 
of O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
activated I-protein 
K I-protein 
+ I-protein 
channels I-protein 
are O 
not O 
involved O 
in O 
B O 
and O 
T O 
lymphocyte O 
activation O 
and O 
mitogenesis O 
. O 

Activity O 
of O 
the O 
kappa B-DNA 
B I-DNA 
enhancer I-DNA 
of O 
the O 
interleukin B-protein 
- I-protein 
2 I-protein 
receptor I-protein 
alpha I-protein 
chain I-protein 
in O 
somatic B-cell_line 
cell I-cell_line 
hybrids I-cell_line 
is O 
accompanied O 
by O 
the O 
nuclear O 
localization O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

The O 
two B-protein 
nuclear I-protein 
proteins I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
( O 
consisting O 
of O 
subunits O 
p50 B-protein 
an O 
dp65 B-protein 
) O 
and O 
the O 
DNA B-protein 
- I-protein 
binding I-protein 
subunit I-protein 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
( O 
p50 B-protein 
) O 
by O 
itself O 
, O 
also O 
called O 
KBF1 B-protein 
, O 
are O 
constitutively O 
expressed O 
and O 
localized O 
in O 
the O 
nucleus O 
of O 
the O 
human B-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
IARC B-cell_line 
301 I-cell_line 
. I-cell_line 
5 I-cell_line 
. O 

In O 
order O 
to O 
define O 
the O 
roles O 
of O 
these O 
two O 
factors B-protein 
, O 
which O 
bind O 
to O 
the O 
same O 
kappa B-DNA 
B I-DNA 
enhancers I-DNA 
, O 
in O 
transcription O 
activation O 
we O 
have O 
prepared O 
somatic O 
cell O 
hybrids O 
between O 
IARC B-cell_line 
301 I-cell_line 
. I-cell_line 
5 I-cell_line 
and O 
a O 
murine B-cell_line 
myeloma I-cell_line 
. O 

Most O 
hybrids O 
express O 
both O 
KBF1 B-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
their O 
nuclei O 
, O 
but O 
one O 
hybrid O 
expresses O 
only O 
KBF1 B-protein 
. O 

The O 
kappa B-DNA 
B I-DNA 
enhancer I-DNA 
of O 
the O 
gene O 
encoding O 
the O 
interleukin B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
( I-protein 
IL B-protein I-protein 
- I-protein I-protein 
2 I-protein I-protein 
) I-protein 
receptor I-protein 
alpha I-protein 
chain I-protein 
( O 
IL B-protein 
- I-protein 
2R I-protein 
alpha I-protein 
) O 
is O 
functional O 
only O 
in O 
the O 
hybrids B-cell_line 
expressing O 
nuclear B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
. O 

These O 
findings O 
show O 
that O 
nuclear B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
is O 
necessary O 
to O 
activate O 
the O 
kappa B-DNA 
B I-DNA 
enhancer I-DNA 
, O 
while O 
KBF1 B-protein 
by O 
itself O 
is O 
not O 
sufficient O 
. O 

We O 
propose O 
that O 
KBF1 B-protein 
is O 
a O 
competitive O 
inhibitor O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
discuss O 
how O 
these O 
factors O 
may O 
be O 
involved O 
in O 
the O 
transient O 
expression O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
and O 
IL B-protein 
- I-protein 
2 I-protein 
alpha I-protein 
genes O 
during O 
the O 
immune O 
response O 
. O 

T B-protein 
- I-protein 
helper I-protein 
- I-protein 
cell I-protein 
determinants I-protein 
in O 
protein B-protein 
antigens I-protein 
are O 
preferentially O 
located O 
in O 
cysteine B-protein 
- I-protein 
rich I-protein 
antigen I-protein 
segments I-protein 
resistant O 
to O 
proteolytic O 
cleavage O 
by O 
cathepsin O 
B O 
, O 
L O 
, O 
and O 
D O 
. O 

We O 
report O 
on O 
a O 
computer O 
algorithm O 
capable O 
of O 
predicting O 
the O 
location O 
of O 
T B-protein 
- I-protein 
helper I-protein 
- I-protein 
cell I-protein 
epitopes I-protein 
in O 
protein B-protein 
antigen I-protein 
( O 
Ag B-protein 
) O 
by O 
analysing O 
the O 
Ag B-protein 
amino B-protein 
acid I-protein 
sequence I-protein 
. O 

The O 
algorithm O 
was O 
constructed O 
with O 
the O 
aim O 
of O 
identifying O 
segments O 
in O 
Ag B-protein 
which O 
are O 
resistant O 
to O 
proteolytic O 
degradation O 
by O 
the O 
enzymes O 
cathepsin O 
B O 
, O 
L O 
, O 
and O 
D O 
. O 

These O 
are O 
prominent O 
enzymes B-protein 
in O 
the O 
endocytic O 
pathway O 
through O 
which O 
soluble B-protein 
protein I-protein 
Ag B-protein I-protein 
enter O 
APC B-protein 
, O 
and O 
resistant B-protein 
segments I-protein 
in O 
Ag B-protein 
may O 
, O 
therefore O 
, O 
be O 
expected O 
to O 
contain O 
more O 
T B-protein 
- I-protein 
cell I-protein 
determinants I-protein 
than O 
susceptible B-protein 
segments I-protein 
. O 

From O 
information O 
available O 
in O 
the O 
literature O 
on O 
the O 
substrate O 
specificity O 
of O 
the O 
three O 
enzymes B-protein 
, O 
it O 
is O 
clear O 
that O 
a O 
cysteine O 
is O 
not O 
accepted O 
in O 
any O 
of O 
the O 
S2 O 
, O 
S1 O 
, O 
S1 O 
' O 
, O 
and O 
S2 O 
' O 
subsites O 
of O 
cathepsin O 
B O 
and O 
L O 
, O 
and O 
not O 
in O 
the O 
S1 B-protein 
and O 
S1 B-protein 
' I-protein 
subsites O 
of O 
cathepsin B-protein 
D I-protein 
. O 

Moreover O 
, O 
we O 
have O 
noticed O 
that O 
cysteine B-protein 
- I-protein 
containing I-protein 
T I-protein 
- I-protein 
cell I-protein 
determinants I-protein 
in O 
a O 
number O 
of O 
protein B-protein 
Ag B-protein I-protein 
are O 
particularly O 
rich O 
in O 
the O 
amino O 
acids O 
alanine O 
, O 
glycine O 
, O 
lysine O 
, O 
leucine O 
, O 
serine O 
, O 
threonine O 
, O 
and O 
valine O 
. O 

By O 
searching O 
protein O 
Ag B-protein 
for O 
clusters O 
of O 
amino O 
acids O 
containing O 
cysteine O 
and O 
two O 
of O 
the O 
other O 
amino O 
acids O 
we O 
were O 
able O 
to O 
predict O 
17 O 
out O 
of O 
23 O 
empirically O 
known O 
T B-protein 
- I-protein 
cell I-protein 
determinants I-protein 
in O 
the O 
Ag B-protein 
with O 
a O 
relatively O 
low O 
number O 
of O 
false O 
( O 
positive O 
) O 
predictions O 
. O 

Furthermore O 
, O 
we O 
present O 
a O 
new O 
principle O 
for O 
searching O 
Ag B-protein 
for O 
potential O 
amphipatic B-protein 
alpha I-protein 
- I-protein 
helical I-protein 
protein I-protein 
segments I-protein 
. O 

Such O 
segments O 
accord O 
well O 
with O 
empirically O 
known O 
T B-protein 
- I-protein 
cell I-protein 
determinants I-protein 
and O 
our O 
algorithm O 
produces O 
a O 
lower O 
number O 
of O 
false O 
positive O 
predictions O 
than O 
the O 
principle O 
based O 
on O 
discrete O 
Fourier O 
transformations O 
previously O 
described O 
. O 

Contribution O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
Sp1 B-DNA 
binding I-DNA 
motifs I-DNA 
to O 
the O 
replicative O 
capacity O 
of O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
: O 
distinct O 
patterns O 
of O 
viral O 
growth O 
are O 
determined O 
by O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
types I-cell_type 
. O 

Starting O 
with O 
a O 
replication O 
- O 
incompetent O 
molecular O 
clone O 
of O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
, O 
lacking O 
all O 
the O 
NF O 
- O 
kappa O 
B O 
and O 
Sp1 O 
binding O 
sites O 
present O 
in O 
the O 
native B-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
, O 
proviruses O 
containing O 
reconstructed B-DNA 
LTRs I-DNA 
with O 
individual O 
or O 
combinations O 
of O 
NF O 
- O 
kappa O 
B O 
and O 
Sp1 O 
elements O 
were O 
generated O 
and O 
evaluated O 
for O 
their O 
capacity O 
to O 
produce O 
virus O 
progeny O 
following O 
transfection O 
- O 
cocultivation O 
. O 

Virus O 
stocks O 
obtained O 
from O 
these O 
experiments O 
exhibited O 
a O 
continuum O 
of O 
replicative O 
capacities O 
in O 
different O 
human B-cell_type 
T B-cell_type I-cell_type 
- I-cell_type I-cell_type 
cell I-cell_type I-cell_type 
types I-cell_type I-cell_type 
depending O 
on O 
which O 
element B-DNA 
( O 
s O 
) O 
was O 
present O 
in O 
the O 
LTR B-DNA 
. O 

For O 
example O 
, O 
in O 
experiments O 
involving O 
proviral O 
clones O 
with O 
LTRs B-DNA 
containing O 
one O 
or O 
two O 
NF B-protein B-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
elements I-DNA 
( O 
and O 
no O 
Sp1 B-DNA 
binding I-DNA 
sites I-DNA 
) O 
, O 
a O 
hierarchy O 
of O 
cellular O 
permissivity O 
to O 
virus O 
replication O 
( O 
peripheral B-cell_type 
blood I-cell_type 
lymphocytes B-cell_type I-cell_type 
= O 
MT4 B-cell_line 
greater O 
than O 
H9 B-cell_line 
greater O 
than O 
CEM B-cell_line 
greater O 
than O 
Jurkat B-cell_line 
) O 
was O 
observed O 
. O 

Of O 
note O 
was O 
the O 
associated O 
emergence O 
of O 
second B-DNA 
- I-DNA 
site I-DNA 
LTR I-DNA 
revertants O 
which O 
involved O 
an O 
alteration O 
of O 
the O 
TATA B-DNA 
box I-DNA 
. O 

These O 
results O 
suggest O 
that O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
type I-DNA 
1 I-DNA 
LTR I-DNA 
possesses O 
functional O 
redundancy O 
which O 
ensures O 
virus O 
replication O 
in O 
different O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
types I-cell_type 
and O 
is O 
capable O 
of O 
changing O 
depending O 
on O 
the O 
particular O 
combination O 
of O 
transcriptional B-protein 
factors I-protein 
present O 
. O 

Stimulation O 
of O 
interferon B-DNA 
beta I-DNA 
gene I-DNA 
transcription O 
in O 
vitro O 
by O 
purified O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
a O 
novel O 
TH B-protein 
protein I-protein 
. O 

The O 
human B-protein B-DNA 
interferon I-protein I-DNA 
beta I-protein I-DNA 
( I-DNA 
IFN B-protein I-DNA 
- I-protein I-DNA 
beta I-protein I-DNA 
) I-DNA 
regulatory I-DNA 
element I-DNA 
consists O 
of O 
multiple O 
enhanson B-DNA 
domains I-DNA 
which O 
are O 
targets O 
for O 
transcription B-protein 
factors I-protein 
involved O 
in O 
inducible O 
expression O 
of O 
the O 
promoter B-DNA 
. O 

To O 
further O 
characterize O 
the O 
protein O 
- O 
DNA O 
interactions O 
mediating O 
IFN B-protein 
- I-protein 
beta I-protein 
induction O 
, O 
positive B-DNA B-protein 
regulatory I-DNA I-protein 
domain I-DNA I-protein 
( I-DNA I-protein 
PRD I-DNA I-protein 
) I-DNA I-protein 
II I-DNA I-protein 
binding I-protein 
proteins I-protein 
were O 
purified O 
from O 
phorbol O 
ester O 
induced O 
Jurkat B-cell_line 
T I-cell_line 
- I-cell_line 
cells I-cell_line 
and O 
from O 
IFN B-protein B-cell_line 
primed I-cell_line 
, I-cell_line 
cycloheximide I-cell_line 
/ I-cell_line 
polyinosinic I-cell_line 
- I-cell_line 
polycytidylic I-cell_line 
acid I-cell_line 
treated I-cell_line 
HeLa I-cell_line 
S3 I-cell_line 
cells I-cell_line 
. O 

From O 
HeLa B-cell_line 
cells I-cell_line 
, O 
two O 
major O 
proteins O 
of O 
52 O 
and O 
45 O 
kilodaltons O 
( O 
kD O 
) O 
copurified O 
with O 
DNA O 
binding O 
activity O 
, O 
whereas O 
from O 
T B-cell_type 
- I-cell_type 
cells I-cell_type 
, O 
four O 
proteins O 
- O 
- O 
a O 
major B-protein 
protein I-protein 
of O 
52 B-protein 
kD I-protein 
and O 
three O 
minor B-protein 
proteins I-protein 
of O 
82 B-protein 
, O 
67 B-protein 
, O 
and O 
43 B-protein 
- I-protein 
47 I-protein 
kD I-protein 
- O 
- O 
were O 
purified O 
. O 

Also O 
, O 
an O 
induction O 
specific B-protein 
DNA I-protein 
binding I-protein 
protein I-protein 
was O 
purified O 
from O 
HeLa B-cell_line 
cells I-cell_line 
that O 
interacted O 
with O 
the O 
( O 
AAGTGA O 
) O 
4 O 
tetrahexamer B-DNA 
sequence I-DNA 
and O 
the O 
PRDI B-DNA 
domain I-DNA 
. O 

This O 
protein O 
is O 
immunologically O 
distinct O 
from O 
IRF B-protein 
- I-protein 
1 I-protein 
/ I-protein 
ISGF2 I-protein 
. O 

Uninduced O 
or O 
Sendai O 
virus O 
induced O 
HeLa O 
extracts O 
were O 
used O 
to O 
examine O 
transcription O 
in O 
vitro O 
using O 
a O 
series O 
of O 
IFN B-DNA 
beta I-DNA 
promoter I-DNA 
deletions I-DNA 
. O 

Deletions O 
upstream O 
of O 
the O 
PRDII B-DNA 
element I-DNA 
increased O 
transcription O 
in O 
the O 
uninduced O 
extract O 
, O 
indicating O 
predominantly O 
negative O 
regulation O 
of O 
the O 
promoter B-DNA 
. O 

A O 
2 O 
- O 
4 O 
- O 
fold O 
increase O 
in O 
IFN B-DNA 
- I-DNA 
beta I-DNA 
promoter I-DNA 
transcription O 
was O 
observed O 
in O 
Sendai O 
virus O 
induced O 
extracts O 
, O 
and O 
deletion O 
of O 
PRDI B-DNA 
and O 
PRDII B-DNA B-DNA 
elements I-DNA 
decreased O 
this O 
induced O 
level O 
of O 
transcription O 
. O 

When O 
purified O 
PRDII O 
and O 
tetrahexamer O 
binding O 
proteins O 
were O 
added O 
to O 
the O 
induced O 
extract O 
, O 
a O 
4 O 
- O 
fold O 
increase O 
in O 
transcription O 
was O 
observed O 
. O 

These O 
experiments O 
demonstrate O 
that O 
it O 
is O 
possible O 
to O 
modulate O 
IFN O 
- O 
beta O 
transcription O 
in O 
vitro O 
but O 
indicate O 
that O 
additional O 
proteins O 
may O 
be O 
required O 
to O 
fully O 
activate O 
IFN B-protein 
- I-protein 
beta I-protein 
transcription O 
. O 

The O 
rhombotin B-DNA 
family I-DNA 
of O 
cysteine B-DNA 
- I-DNA 
rich I-DNA 
LIM I-DNA 
- I-DNA 
domain I-DNA 
oncogenes I-DNA 
: O 
distinct O 
members O 
are O 
involved O 
in O 
T B-DNA 
- I-DNA 
cell I-DNA 
translocations I-DNA 
to O 
human O 
chromosomes O 
11p15 O 
and O 
11p13 O 
. O 

A O 
chromosomal O 
translocation O 
in O 
a O 
T O 
- O 
cell O 
leukemia O 
involving O 
the O 
short B-DNA 
arm I-DNA 
of O 
human B-DNA 
chromosome I-DNA 
11 I-DNA 
at O 
band B-DNA 
11p15 I-DNA 
disrupts O 
the O 
rhombotin B-DNA 
gene I-DNA 
. O 

This O 
gene O 
encodes O 
a O 
protein O 
with O 
duplicated O 
cysteine B-protein 
- I-protein 
rich I-protein 
regions I-protein 
called O 
LIM B-protein 
domains I-protein 
, O 
which O 
show O 
homology O 
to O 
zinc B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
and O 
to O 
iron B-protein 
- I-protein 
sulfur I-protein 
centers I-protein 
of O 
ferredoxins B-protein 
. O 

Two O 
homologues O 
of O 
the O 
rhombotin B-DNA 
gene I-DNA 
have O 
now O 
been O 
isolated O 
. O 

One O 
of O 
these O 
, O 
designated O 
Rhom B-DNA 
- I-DNA 
2 I-DNA 
, O 
is O 
located O 
on O 
human B-DNA 
chromosome I-DNA 
11 I-DNA 
at O 
band B-DNA 
11p13 I-DNA 
, O 
where O 
a O 
cluster O 
of O 
T B-DNA 
- I-DNA 
cell I-DNA 
leukemia I-DNA 
- I-DNA 
specific I-DNA 
translocations I-DNA 
occur O 
; O 
all O 
translocation O 
breakpoints O 
at O 
11p13 B-DNA 
are O 
upstream O 
of O 
the O 
Rhom B-DNA B-DNA 
- I-DNA I-DNA 
2 I-DNA I-DNA 
gene I-DNA 
. O 

Human O 
and O 
mouse O 
Rhom O 
- O 
2 O 
are O 
highly O 
conserved O 
and O 
, O 
like O 
rhombotin B-DNA 
, O 
encode O 
two O 
tandem B-DNA 
cysteine I-DNA 
- I-DNA 
rich I-DNA 
LIM B-protein I-DNA 
domains I-protein I-DNA 
. O 

Rhom B-DNA B-RNA 
- I-DNA I-RNA 
2 I-DNA I-RNA 
mRNA I-RNA 
is O 
expressed O 
in O 
early O 
mouse O 
development O 
in O 
central O 
nervous O 
system O 
, O 
lung O 
, O 
kidney O 
, O 
liver O 
, O 
and O 
spleen O 
but O 
only O 
very O 
low O 
levels O 
occur O 
in O 
thymus O 
. O 

The O 
other O 
gene O 
, O 
designated O 
Rhom B-DNA 
- I-DNA 
3 I-DNA 
, O 
is O 
not O 
on O 
chromosome O 
11 O 
but O 
also O 
retains O 
homology O 
to O 
the O 
LIM B-DNA 
domain I-DNA 
of O 
rhombotin B-DNA 
. O 

Since O 
the O 
Rhom B-DNA B-DNA 
- I-DNA I-DNA 
2 I-DNA I-DNA 
gene I-DNA 
is O 
such O 
a O 
common O 
site O 
of O 
chromosomal O 
damage O 
in O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
tumors I-cell_type 
, O 
the O 
consistency O 
of O 
translocations O 
near O 
the O 
rhombotin B-DNA B-DNA 
gene I-DNA 
was O 
further O 
examined O 
. O 

A O 
second O 
translocation O 
adjacent O 
to O 
rhombotin B-DNA 
was O 
found O 
and O 
at O 
the O 
same O 
position O 
as O 
in O 
the O 
previous O 
example O 
. O 

Therefore O 
, O 
chromosome B-DNA 
bands I-DNA 
11p15 I-DNA 
( O 
rhombotin B-DNA 
) O 
and O 
11p13 B-DNA 
( O 
Rhom B-DNA 
- I-DNA 
2 I-DNA 
) O 
are O 
consistent O 
sites O 
of O 
chromosome O 
translocation O 
in O 
T O 
- O 
cell O 
leukemia O 
, O 
with O 
the O 
11p15 B-DNA 
target I-DNA 
more O 
rarely O 
involved O 
. O 

The O 
results O 
define O 
the O 
rhombotin B-DNA 
gene O 
family O 
as O 
a O 
class O 
of O 
T B-DNA 
- I-DNA 
cell I-DNA 
oncogenes I-DNA 
with O 
duplicated O 
cysteine O 
- O 
rich O 
LIM B-protein 
domains I-protein 
. O 

NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
by O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
alpha I-protein 
in O 
the O 
Jurkat B-cell_line 
T I-cell_line 
cell I-cell_line 
line I-cell_line 
is O 
independent O 
of O 
protein B-protein 
kinase I-protein 
A I-protein 
, O 
protein B-protein 
kinase I-protein 
C I-protein 
, O 
and O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
regulated I-protein 
kinases I-protein 
. O 

NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
is O 
a O 
DNA B-protein 
- I-protein 
binding I-protein 
regulatory I-protein 
factor I-protein 
able O 
to O 
control O 
transcription O 
of O 
a O 
number O 
of O 
genes O 
, O 
including O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
( I-DNA 
HIV I-DNA 
) I-DNA 
genes I-DNA 
. O 

In O 
T B-cell_type 
cells I-cell_type 
, O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
is O 
activated O 
upon O 
cellular O 
treatment O 
by O 
phorbol O 
esters O 
and O 
the O 
cytokine O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
alpha I-protein 
( O 
TNF B-protein 
alpha I-protein 
) O 
. O 

In O 
the O 
present O 
work O 
, O 
we O 
investigated O 
the O 
molecular O 
events O 
leading O 
to O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
by O 
TNF B-protein 
alpha I-protein 
in O 
a O 
human B-cell_line 
T I-cell_line 
cell I-cell_line 
line I-cell_line 
( O 
Jurkat B-cell_line 
) O 
and O 
its O 
subclone O 
JCT6 B-cell_line 
, O 
which O 
presents O 
a O 
deficiency O 
in O 
the O 
PKA B-protein 
transduction O 
pathway O 
. O 

We O 
found O 
that O 
in O 
both O 
cell O 
lines O 
, O 
both O 
phorbol O 
ester O 
and O 
TNF B-protein 
alpha I-protein 
were O 
able O 
to O 
activate O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Phorbol O 
activation O 
was O 
positively O 
modulated O 
by O 
Ca2 O 
+ O 
influx O 
while O 
TNF B-protein 
alpha I-protein 
activation O 
was O 
not O 
. O 

Furthermore O 
, O 
while O 
PMA O 
activation O 
was O 
inhibited O 
by O 
the O 
PKC B-protein 
inhibitor O 
staurosporin O 
, O 
the O 
TNF B-protein 
alpha I-protein 
effect O 
was O 
unchanged O 
. O 

TNF B-protein 
alpha I-protein 
did O 
not O 
activate O 
cAMP O 
production O 
and O 
its O 
signal O 
was O 
not O 
modulated O 
by O 
cAMP O 
activators O 
. O 

Moreover O 
, O 
cAMP O 
activators O 
did O 
not O 
activate O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
Jurkat B-cell_line 
cells I-cell_line 
. O 

Thus O 
, O 
TNF B-protein 
alpha I-protein 
- O 
induced O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
was O 
found O 
to O 
be O 
mediated O 
by O 
none O 
of O 
the O 
major O 
signal B-protein 
- I-protein 
mediating I-protein 
kinases I-protein 
such O 
as O 
protein B-protein 
kinase I-protein 
C I-protein 
( O 
PKC B-protein 
) O 
, O 
protein B-protein 
kinase I-protein 
A I-protein 
, O 
or O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
regulated I-protein 
kinases I-protein 
. O 

Furthermore O 
, O 
we O 
found O 
that O 
cytoplasmic O 
acidification O 
facilitated O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
by O 
both O 
TNF B-protein 
alpha I-protein 
and O 
PKC B-protein 
, O 
by O 
a O 
mechanism O 
that O 
increases O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
/ B-protein 
I I-protein 
kappa I-protein 
B I-protein 
dissociation O 
without O 
affecting O 
the O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
step O 
. O 

The O 
functional O 
domains O 
of O 
the O 
murine B-DNA 
Thy I-DNA 
- I-DNA 
1 I-DNA 
gene I-DNA 
promoter I-DNA 
. O 

The O 
Thy B-DNA 
- I-DNA 
1 I-DNA 
gene I-DNA 
promoter I-DNA 
resembles O 
a O 
" B-DNA 
housekeeping I-DNA 
" I-DNA 
promoter I-DNA 
in O 
that O 
it O 
is O 
located O 
within O 
a O 
methylation B-DNA 
- I-DNA 
free I-DNA 
island I-DNA 
, O 
lacks O 
a O 
canonical B-DNA 
TATA I-DNA 
box I-DNA 
, O 
and O 
displays O 
heterogeneity O 
in O 
the O 
5 B-RNA 
' I-RNA 
- I-RNA 
end I-RNA 
termini I-RNA 
of O 
the O 
mRNA B-RNA 
. O 

Using O 
transgenic O 
mice O 
, O 
we O 
show O 
that O 
this O 
promoter B-DNA 
does O 
not O 
confer O 
any O 
tissue O 
specificity O 
and O 
is O 
active O 
only O 
in O 
a O 
position O 
- O 
dependent O 
manner O 
. O 

It O 
can O 
only O 
be O 
activated O 
in O 
a O 
tissue O 
- O 
specific O 
manner O 
by O 
elements O 
that O 
lie O 
downstream O 
of O 
the O 
initiation B-DNA 
site I-DNA 
. O 

We O 
have O 
analyzed O 
the O 
functional O 
domains O 
of O 
the O 
minimal B-DNA 
Thy I-DNA 
- I-DNA 
1 I-DNA 
promoter I-DNA 
and O 
show O 
that O 
the O 
dominant B-DNA 
promoter I-DNA 
elements I-DNA 
consist O 
of O 
multiple B-DNA 
binding I-DNA 
sites I-DNA 
for O 
the O 
transcription B-protein 
factor I-protein 
Sp1 B-protein 
, O 
an O 
inverted O 
CCAAT B-DNA 
box I-DNA 
, O 
and O 
sequences O 
proximal O 
to O 
the O 
transcription B-DNA 
start I-DNA 
site I-DNA 
. O 

DNase O 
I O 
and O 
gel O 
mobility O 
shift O 
assays O 
show O 
the O 
binding O 
of O 
a O 
number O 
of O 
nuclear B-protein 
factors I-protein 
to O 
these O 
elements B-DNA 
, O 
including O 
Sp1 B-protein 
and O 
CP1 B-protein 
. O 

Our O 
results O 
show O 
that O 
the O 
structure O 
of O 
this O 
promoter B-DNA 
only O 
permits O 
productive O 
interactions O 
of O 
the O 
two O 
transcription B-protein 
factors I-protein 
Sp1 B-protein 
and O 
CP1 B-protein 
with O 
the O 
basal O 
transcription O 
machinery O 
in O 
the O 
presence O 
of O 
enhancer B-DNA 
sequences I-DNA 
. O 

Nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
activates O 
proenkephalin O 
transcription O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

Upon O 
activation O 
, O 
T B-cell_type 
lymphocytes I-cell_type 
accumulate O 
high O 
levels O 
of O 
the O 
neuropeptide O 
enkephalin O 
which O 
correlate O 
with O 
high O 
levels O 
of O 
proenkephalin B-RNA 
mRNA I-RNA 
in O 
the O 
cells O 
. O 

Here O 
we O 
investigated O 
the O 
transcriptional O 
basis O 
for O 
these O 
changes O 
. O 

The O 
proenkephalin O 
promoter O 
contains O 
a O 
sequence O 
GGGGACGTCCCC O 
, O 
named O 
B2 B-DNA 
, O 
which O 
is O 
similar O 
to O 
the O 
kappa B-DNA 
B I-DNA 
sequence I-DNA 
GGGGACTTTCC O 
, O 
the O 
binding O 
site O 
of O 
the O 
transcription B-protein 
factor I-protein 
nuclear B-protein 
factor I-protein 
( I-protein 
NF I-protein 
) I-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Activation O 
of O 
T B-cell_type 
lymphocytes I-cell_type 
induces O 
an O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
- O 
like O 
binding O 
activity O 
to O 
the O 
B2 B-DNA 
site O 
, O 
concomitant O 
with O 
activation O 
of O 
the O 
proenkephalin B-DNA 
promoter I-DNA 
. O 

Mutations O 
at O 
the O 
B2 B-DNA 
site O 
abolish O 
this O 
transcriptional O 
activation O 
. O 

The O 
purified O 
homodimer B-protein 
( O 
two O 
p50s B-protein 
) O 
of O 
the O 
DNA B-protein 
- I-protein 
binding I-protein 
subunit I-protein 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binds O 
the O 
B2 B-DNA 
site O 
of O 
proenkephalin O 
relatively O 
better O 
than O 
does O 
the O 
heterotetramer B-protein 
( O 
two O 
p65s B-protein 
plus O 
two O 
p50s B-protein 
) O 
form O 
of O 
the O 
factor O 
. O 

Thus O 
, O 
it O 
appears O 
that O 
the O 
T O 
- O 
cell O 
- O 
specific O 
activation O 
of O 
the O 
proenkephalin B-DNA 
promoter I-DNA 
is O 
mediated O 
by O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

However O 
, O 
as O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
is O 
ubiquitous O 
and O 
the O 
transcriptional O 
activation O 
through O 
the O 
B2 B-DNA 
site O 
is O 
T O 
cell O 
specific O 
, O 
yet O 
another O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
factor I-protein 
which O 
synergizes O 
with O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
should O 
be O 
considered O 
. O 

Induction O 
of O 
NF B-protein 
- I-protein 
KB I-protein 
during O 
monocyte B-cell_type 
differentiation O 
by O 
HIV O 
type O 
1 O 
infection O 
. O 

The O 
production O 
of O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
progeny O 
was O 
followed O 
in O 
the O 
U937 B-cell_line 
promonocytic I-cell_line 
cell I-cell_line 
line I-cell_line 
after O 
stimulation O 
either O 
with O 
retinoic O 
acid O 
or O 
PMA O 
, O 
and O 
in O 
purified O 
human O 
monocytes O 
and O 
macrophages O 
. O 

Electrophoretic O 
mobility O 
shift O 
assays O 
and O 
Southwestern O 
blotting O 
experiments O 
were O 
used O 
to O 
detect O 
the O 
binding O 
of O 
cellular B-protein 
transactivation I-protein 
factor I-protein 
NF B-protein 
- I-protein 
KB I-protein 
to O 
the O 
double B-DNA 
repeat I-DNA 
- I-DNA 
KB I-DNA 
enhancer I-DNA 
sequence I-DNA 
located O 
in O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
. O 

PMA O 
treatment O 
, O 
and O 
not O 
retinoic O 
acid O 
treatment O 
of O 
the O 
U937 B-cell_line 
cells I-cell_line 
acts O 
in O 
inducing O 
NF B-protein 
- I-protein 
KB I-protein 
expression O 
in O 
the O 
nuclei O 
. O 

In O 
nuclear O 
extracts O 
from O 
monocytes B-cell_type 
or O 
macrophages B-cell_type 
, O 
induction O 
of O 
NF B-protein 
- I-protein 
KB I-protein 
occurred O 
only O 
if O 
the O 
cells O 
were O 
previously O 
infected O 
with O 
HIV O 
- O 
1 O 
. O 

When O 
U937 B-cell_line 
cells I-cell_line 
were O 
infected O 
with O 
HIV O 
- O 
1 O 
, O 
no O 
induction O 
of O 
NF B-protein B-protein 
- I-protein I-protein 
KB I-protein I-protein 
factor I-protein 
was O 
detected O 
, O 
whereas O 
high O 
level O 
of O 
progeny O 
virions O 
was O 
produced O 
, O 
suggesting O 
that O 
this O 
factor O 
was O 
not O 
required O 
for O 
viral O 
replication O 
. O 

These O 
results O 
indicate O 
that O 
in O 
monocytic B-cell_line 
cell I-cell_line 
lineage I-cell_line 
, O 
HIV O 
- O 
1 O 
could O 
mimic O 
some O 
differentiation O 
/ O 
activation O 
stimuli O 
allowing O 
nuclear O 
NF B-protein 
- I-protein 
KB I-protein 
expression O 
. O 

Disruption O 
of O 
the O 
human B-DNA 
SCL I-DNA 
locus I-DNA 
by O 
" O 
illegitimate O 
" O 
V O 
- O 
( O 
D O 
) O 
- O 
J O 
recombinase O 
activity O 
. O 

A O 
fusion B-DNA 
complementary I-DNA 
DNA I-DNA 
in O 
the O 
T B-cell_line 
cell I-cell_line 
line I-cell_line 
HSB I-cell_line 
- I-cell_line 
2 I-cell_line 
elucidates O 
a O 
provocative O 
mechanism O 
for O 
the O 
disruption O 
of O 
the O 
putative O 
hematopoietic B-protein 
transcription I-protein 
factor I-protein 
SCL B-protein 
. O 

The O 
fusion B-DNA 
cDNA I-DNA 
results O 
from O 
an O 
interstitial O 
deletion O 
between O 
a O 
previously O 
unknown B-DNA 
locus I-DNA 
, O 
SIL B-DNA 
( O 
SCL B-protein B-DNA 
interrupting I-DNA 
locus I-DNA 
) O 
, O 
and O 
the O 
5 B-DNA 
' I-DNA 
untranslated I-DNA 
region I-DNA 
of O 
SCL B-protein 
. O 

Similar O 
to O 
1 O 
; O 
14 O 
translocations O 
, O 
this O 
deletion O 
disrupts O 
the O 
SCL B-protein B-DNA 
5 I-DNA 
' I-DNA 
regulatory I-DNA 
region I-DNA 
. O 

This O 
event O 
is O 
probably O 
mediated O 
by O 
V O 
- O 
( O 
D O 
) O 
- O 
J O 
recombinase O 
activity O 
, O 
although O 
neither O 
locus O 
is O 
an O 
immunoglobulin B-protein 
or O 
a O 
T B-protein 
cell I-protein 
receptor I-protein 
. O 

Two O 
other O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
CEM B-cell_line 
and O 
RPMI B-cell_line 
8402 I-cell_line 
, O 
have O 
essentially O 
identical O 
deletions O 
. O 

Thus O 
, O 
in O 
lymphocytes B-cell_type 
, O 
growth B-DNA 
- I-DNA 
affecting I-DNA 
genes I-DNA 
other O 
than O 
immune B-protein 
receptors I-protein 
risk O 
rearrangements O 
. O 

Thyroid B-protein 
hormone I-protein 
receptors I-protein 
form O 
distinct O 
nuclear O 
protein O 
- O 
dependent O 
and O 
independent O 
complexes O 
with O 
a O 
thyroid B-DNA 
hormone I-DNA 
response I-DNA 
element I-DNA 
. O 

We O 
have O 
examined O 
the O 
binding O 
of O 
nuclear B-protein 
proteins I-protein 
and O 
recombinant B-protein 
thyroid I-protein 
hormone I-protein 
receptors I-protein 
( O 
TRs B-protein 
) O 
to O 
the O 
palindromic B-DNA 
thyroid I-DNA 
hormone I-DNA 
responsive I-DNA 
element I-DNA 
AGGTCATGACCT O 
( O 
TREp B-DNA 
) O 
using O 
a O 
gel O 
electrophoretic O 
mobility O 
shift O 
assay O 
. O 

Four O 
specific O 
protein B-protein 
- I-protein 
DNA I-protein 
complexes I-protein 
were O 
detected O 
after O 
incubation O 
of O 
nuclear O 
extracts O 
( O 
NE O 
) O 
from O 
T3 B-cell_line 
- I-cell_line 
responsive I-cell_line 
pituitary I-cell_line 
( I-cell_line 
GH3 I-cell_line 
) I-cell_line 
cells I-cell_line 
with O 
a O 
TREp B-DNA B-DNA 
- I-DNA 
containing I-DNA 
DNA I-DNA 
fragment I-DNA 
. O 

This O 
was O 
compared O 
with O 
the O 
TREp B-DNA 
binding O 
of O 
reticulocyte B-protein 
lysate I-protein 
- I-protein 
synthesized I-protein 
TRs B-protein I-protein 
. O 

TR B-protein 
alpha I-protein 
1 I-protein 
and O 
TR B-protein 
beta I-protein 
2 I-protein 
each O 
formed O 
a O 
single O 
major O 
TR B-protein B-protein 
: I-protein 
TREp B-DNA I-protein 
complex I-protein 
which O 
comigrated O 
with O 
the O 
least O 
retarded O 
complex O 
formed O 
by O 
GH3 O 
NE O 
, O 
while O 
TR B-protein 
beta I-protein 
1 I-protein 
formed O 
multiple O 
complexes O 
suggesting O 
that O 
it O 
can O 
bind O 
to O 
TREp B-DNA 
as O 
an O 
oligomer B-protein 
. O 

Interestingly O 
, O 
coincubation O 
of O 
35S B-protein 
- I-protein 
TR B-protein I-protein 
alpha I-protein I-protein 
1 I-protein I-protein 
, O 
GH3 O 
NE O 
, O 
and O 
unlabeled O 
TREp B-DNA 
resulted O 
in O 
not O 
only O 
the O 
35S B-protein 
- I-protein 
TR I-protein 
: I-protein 
TREp B-DNA I-protein 
complex I-protein 
, O 
but O 
in O 
two O 
additional O 
more O 
greatly O 
retarded O 
complexes O 
containing O 
35S B-protein 
- I-protein 
TR B-protein I-protein 
alpha I-protein I-protein 
1 I-protein I-protein 
and O 
comigrating O 
with O 
those O 
formed O 
by O 
GH3 O 
extract O 
alone O 
. O 

Incubation O 
of O 
each O 
of O 
the O 
TRs B-protein 
with O 
NE O 
from O 
COS B-cell_line 
- I-cell_line 
7 I-cell_line 
cells I-cell_line 
, O 
which O 
do O 
not O 
possess O 
sufficient O 
endogenous O 
TRs B-protein 
to O 
mediate O 
T3 O 
- O 
responses O 
, O 
resulted O 
in O 
formation O 
of O 
a O 
new O 
, O 
more O 
greatly B-protein 
shifted I-protein 
complex I-protein 
. O 

A O 
similar O 
, O 
heat O 
labile O 
activity O 
which O 
altered O 
mobility O 
of O 
the O 
TR B-protein 
: I-protein 
TRE I-protein 
complex I-protein 
was O 
also O 
present O 
in O 
NE O 
from O 
T3 B-cell_line 
- I-cell_line 
unresponsive I-cell_line 
JEG I-cell_line 
- I-cell_line 
3 I-cell_line 
cells I-cell_line 
. O 

At O 
high O 
concentration O 
of O 
NE O 
, O 
all O 
of O 
the O 
TR B-protein 
bound O 
to O 
TREp B-DNA 
was O 
more O 
greatly O 
retarded O 
than O 
in O 
the O 
absence O 
of O 
NE O 
. O 

Truncation O 
of O 
TR B-protein 
alpha I-protein 
1 I-protein 
at O 
amino B-protein 
acid I-protein 
210 I-protein 
prevented O 
additional O 
complex O 
formation O 
in O 
the O 
presence O 
of O 
NE O 
without O 
affecting O 
DNA O 
binding O 
, O 
suggesting O 
that O 
the O 
carboxyl B-protein 
- I-protein 
terminus I-protein 
of O 
the O 
TRs B-protein 
is O 
essential O 
for O 
interaction O 
with O 
nuclear B-protein 
proteins I-protein 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
250 O 
WORDS O 
) O 
. O 

Cell O 
- O 
specific O 
differences O 
in O 
activation O 
of O 
NF B-protein B-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
regulatory I-DNA 
elements I-DNA 
of O 
human O 
immunodeficiency O 
virus O 
and O 
beta O 
interferon O 
promoters O 
by O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
. O 

Three O 
aspects O 
of O 
the O 
involvement O 
of O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
in O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
pathogenesis O 
were O 
examined O 
. O 

Tumor B-protein B-RNA 
necrosis I-protein I-RNA 
factor I-protein I-RNA 
alpha I-protein I-RNA 
( I-RNA 
TNF B-protein I-RNA 
- I-protein I-RNA 
alpha I-protein I-RNA 
) I-RNA 
mRNA I-RNA 
production O 
was O 
analyzed O 
by O 
polymerase O 
chain O 
reaction O 
amplification O 
in O 
monocytic B-cell_line 
U937 I-cell_line 
cells I-cell_line 
and O 
in O 
a O 
chronically B-cell_line 
HIV I-cell_line 
infected I-cell_line 
U937 I-cell_line 
cell I-cell_line 
line I-cell_line 
( O 
U9 B-cell_line 
- I-cell_line 
IIIB I-cell_line 
) O 
. O 

TNF B-protein B-RNA 
- I-protein I-RNA 
alpha I-protein I-RNA 
RNA I-RNA 
was O 
undetectable O 
in O 
U937 B-cell_line 
cells I-cell_line 
, O 
whereas O 
a O 
low O 
constitutive O 
level O 
was O 
detected O 
in O 
U9 B-cell_line 
- I-cell_line 
IIIB I-cell_line 
cells I-cell_line 
. O 

Paramyxovirus O 
infection O 
induced O 
a O 
5 O 
- O 
to O 
10 O 
- O 
fold O 
increase O 
in O 
the O 
steady O 
- O 
state O 
level O 
of O 
TNF B-protein B-RNA 
- I-protein I-RNA 
alpha I-protein I-RNA 
RNA I-RNA 
in O 
U9 B-cell_line 
- I-cell_line 
IIIB I-cell_line 
cells I-cell_line 
compared O 
with O 
U937 B-cell_line 
cells I-cell_line 
, O 
suggesting O 
that O 
HIV B-cell_line 
- I-cell_line 
infected I-cell_line 
monocytic I-cell_line 
cells I-cell_line 
produced O 
higher O 
levels O 
of O 
TNF B-protein 
- I-protein 
alpha I-protein 
than O 
did O 
normal O 
cells O 
after O 
a O 
secondary O 
virus O 
infection O 
. O 

The O 
effects O 
of O 
TNF B-protein 
- I-protein 
alpha I-protein 
on O 
gene O 
expression O 
were O 
examined O 
by O 
transient O 
expression O 
assays O 
using O 
reporter B-DNA 
chloramphenicol I-DNA 
acetyltransferase I-DNA 
plasmids I-DNA 
linked O 
to O 
regulatory B-DNA 
elements I-DNA 
from O 
the O 
HIV B-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
and O 
the O 
beta B-DNA 
interferon I-DNA 
promoter I-DNA 
. O 

In O 
U937 O 
and O 
Jurkat O 
T O 
lymphoid O 
cells O 
, O 
the O 
inducibility O 
of O 
the O 
different O 
hybrid B-DNA 
promoters I-DNA 
by O 
TNF B-protein 
- I-protein 
alpha I-protein 
or O 
phorbol O 
ester O 
varied O 
in O 
a O 
cell O 
type O 
- O 
and O 
promoter O 
context O 
- O 
specific O 
manner O 
; O 
the O 
levels O 
of O 
gene O 
activity O 
of O 
NF B-protein B-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
- I-DNA 
containing I-DNA 
plasmids I-DNA 
correlated O 
directly O 
with O 
induction O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
DNA O 
- O 
binding O 
activity O 
. O 

Although O 
the O 
intact O 
beta B-DNA 
interferon I-DNA 
promoter I-DNA 
was O 
only O 
weakly O 
stimulated O 
by O 
phorbol O 
ester O 
or O 
TNF B-protein 
- I-protein 
alpha I-protein 
, O 
multimers O 
of O 
the O 
PRDII B-DNA 
NF B-protein I-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
- I-DNA 
binding I-DNA 
domain I-DNA 
were O 
inducible O 
by O 
both O 
agents O 
. O 

TNF B-protein 
- I-protein 
alpha I-protein 
was O 
able O 
to O 
increase O 
expression O 
of O 
the O 
HIV B-DNA 
LTR I-DNA 
in O 
T B-cell_type 
cells I-cell_type 
, O 
but O 
in O 
monocytic B-cell_type 
cells I-cell_type 
, O 
TNF B-protein 
- I-protein 
alpha I-protein 
did O 
not O 
induce O 
the O 
HIV B-DNA 
LTR I-DNA 
above O 
a O 
constitutive O 
level O 
of O 
activity O 
. O 

This O 
level O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
- O 
independent O 
activity O 
appears O 
to O 
be O 
sufficient O 
for O 
virus O 
multiplication O 
, O 
since O 
TNF B-protein 
- I-protein 
alpha I-protein 
treatment O 
had O 
no O 
effect O 
on O 
the O 
kinetics O 
of O 
de O 
novo O 
HIV O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
infection O 
and O 
viral B-RNA 
RNA I-RNA 
production O 
in O 
U937 B-cell_line 
cells I-cell_line 
. O 

However O 
, O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
, O 
TNF B-protein 
- I-protein 
alpha I-protein 
dramatically O 
enhanced O 
the O 
spread O 
of O 
HIV O 
- O 
1 O 
through O 
the O 
cell O 
population O 
and O 
increased O 
viral B-RNA 
RNA I-RNA 
synthesis O 
, O 
indicating O 
that O 
in O 
T B-cell_type 
cells I-cell_type 
HIV O 
- O 
1 O 
multiplication O 
was O 
stimulated O 
by O 
TNF B-protein 
- I-protein 
alpha I-protein 
treatment O 
. O 

Functional O 
analysis O 
of O 
cis B-DNA 
- I-DNA 
linked I-DNA 
regulatory I-DNA 
sequences I-DNA 
in O 
the O 
HLA B-DNA 
DRA I-DNA 
promoter I-DNA 
by O 
transcription O 
in O 
vitro O 
. O 

Two O 
consensus O 
sequences O 
, O 
called O 
X O 
and O 
Y O 
boxes O 
, O 
capable O 
of O 
binding O 
nuclear B-protein 
proteins I-protein 
and O 
regulating O 
expression O 
in O 
B B-cell_type 
cells I-cell_type 
have O 
been O 
defined O 
within O 
the O 
immediate O 
upstream O 
region O 
of O 
major B-DNA 
histocompatibility I-DNA 
complex I-DNA 
( I-DNA 
MHC I-DNA 
) I-DNA 
class I-DNA 
II I-DNA 
promoters I-DNA 
. O 

Unlike O 
other O 
class B-DNA 
II I-DNA 
promoters I-DNA 
, O 
the O 
HLA B-DNA 
- I-DNA 
DR I-DNA 
alpha I-DNA 
( I-DNA 
DRA I-DNA 
) I-DNA 
promoter I-DNA 
also O 
contains O 
one O 
element O 
identical O 
to O 
the O 
" B-DNA 
octamer I-DNA 
" I-DNA 
motif I-DNA 
of O 
immunoglobulin B-DNA 
variable I-DNA 
region I-DNA 
promoters I-DNA 
that O 
is O 
responsible O 
for O 
B O 
cell O 
- O 
specific O 
transcription O 
. O 

This O 
" O 
octamer B-DNA 
" O 
in O 
the O 
context O 
of O 
DRA B-protein 
appears O 
capable O 
of O 
binding O 
both O 
the O 
ubiquitous B-protein 
( O 
OTF B-protein 
- I-protein 
1 I-protein 
) O 
and O 
lymphoid B-protein 
- I-protein 
specific I-protein 
( I-protein 
OTF B-protein I-protein 
- I-protein I-protein 
2 I-protein I-protein 
) I-protein 
" I-protein 
octamer I-protein 
" I-protein 
binding I-protein 
proteins I-protein 
, O 
but O 
at O 
least O 
one O 
other O 
distinct O 
" B-protein 
octamer I-protein 
" I-protein 
complex I-protein 
was O 
found O 
. O 

In O 
order O 
to O 
characterize O 
the O 
function O 
of O 
cis B-DNA 
- I-DNA 
acting I-DNA 
elements I-DNA 
, O 
we O 
have O 
developed O 
an O 
in O 
vitro O 
system O 
in O 
which O 
a O 
DRA B-DNA 
promoter I-DNA 
construct I-DNA 
is O 
transcribed O 
more O 
efficiently O 
in O 
extracts O 
from O 
B B-cell_type 
cells I-cell_type 
than O 
in O 
extracts O 
from O 
class B-cell_line 
II I-cell_line 
- I-cell_line 
negative I-cell_line 
HeLa I-cell_line 
cells I-cell_line 
. O 

5 O 
' O 
deletion O 
constructs O 
which O 
lacked O 
the O 
Y B-DNA 
box I-DNA 
, O 
but O 
retained O 
the O 
" B-DNA 
octamer I-DNA 
" I-DNA 
motif I-DNA 
and O 
TATA B-DNA 
box I-DNA 
were O 
completely O 
inactive O 
, O 
and O 
internal O 
deletion O 
of O 
the O 
Y B-DNA 
box I-DNA 
reduced O 
transcription O 
by O 
95 O 
% O 
. O 

Using O 
supercoiled O 
, O 
but O 
not O 
linear O 
templates O 
, O 
we O 
observed O 
differences O 
in O 
transcription O 
efficiencies O 
from O 
templates O 
lacking O 
or O 
disrupting O 
the O 
X B-DNA 
consensus I-DNA 
element I-DNA 
that O 
reflect O 
effects O 
of O 
random O 
replacement O 
of O 
X B-DNA 
box I-DNA 
sequences I-DNA 
in O 
transient O 
expression O 
assays O 
. O 

Demonstration O 
of O 
the O 
complete O 
dependence O 
on O 
the O 
Y B-DNA 
box I-DNA 
in O 
this O 
system O 
suggests O 
that O 
, O 
despite O 
its O 
demonstrated O 
importance O 
in O 
the O 
DRA B-DNA 
promoter I-DNA 
, O 
the O 
DRA B-DNA 
" I-DNA 
octamer I-DNA 
" I-DNA 
does O 
not O 
utilize O 
OTF B-protein 
- I-protein 
2 I-protein 
in O 
a O 
manner O 
analogous O 
to O 
immunoglobulin B-DNA 
promoters I-DNA 
in O 
B B-cell_type 
cells I-cell_type 
. O 

Lipopolysaccharide O 
is O 
a O 
potent O 
monocyte O 
/ O 
macrophage O 
- O 
specific O 
stimulator O 
of O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
expression O 
. O 

Lipopolysaccharide O 
( O 
LPS O 
) O 
potently O 
stimulates O 
human B-DNA B-DNA 
immunodeficiency I-DNA I-DNA 
virus I-DNA I-DNA 
type I-DNA I-DNA 
1 I-DNA I-DNA 
- I-DNA I-DNA 
long I-DNA I-DNA 
terminal I-DNA I-DNA 
repeat I-DNA I-DNA 
( I-DNA 
HIV B-DNA I-DNA 
- I-DNA I-DNA 
1 I-DNA I-DNA 
- I-DNA I-DNA 
LTR I-DNA I-DNA 
) I-DNA 
CAT I-DNA 
constructs I-DNA 
transfected O 
into O 
monocyte B-cell_line 
/ I-cell_line 
macrophage I-cell_line 
- I-cell_line 
like I-cell_line 
cell I-cell_line 
lines I-cell_line 
but O 
not O 
a O 
T B-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

This O 
effect O 
appears O 
to O 
be O 
mediated O 
through O 
the O 
induction O 
of O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
) O 
. O 

Electrophoretic O 
mobility O 
shift O 
assays O 
demonstrate O 
that O 
LPS O 
induces O 
a O 
DNA O 
binding O 
activity O 
indistinguishable O 
from O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
U937 B-cell_line 
and O 
THP B-cell_line 
- I-cell_line 
1 I-cell_line 
cells I-cell_line 
. O 

LPS O 
is O 
also O 
shown O 
to O 
dramatically O 
increase O 
HIV O 
- O 
1 O 
production O 
from O 
a O 
chronically B-cell_line 
infected I-cell_line 
monocyte I-cell_line 
/ I-cell_line 
macrophage I-cell_line 
- I-cell_line 
like I-cell_line 
cloned I-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
U1 B-cell_line 
, O 
which O 
produces O 
very O 
low O 
levels O 
of O 
HIV O 
- O 
1 O 
at O 
baseline O 
. O 

The O 
stimulation O 
of O 
viral O 
production O 
from O 
this O 
cell O 
line O 
occurs O 
only O 
if O 
these O 
cells O 
are O 
treated O 
with O 
granulocyte B-protein 
/ I-protein 
macrophage I-protein 
colony I-protein 
- I-protein 
stimulating I-protein 
factor I-protein 
( O 
GM B-protein 
- I-protein 
CSF I-protein 
) O 
before O 
treatment O 
with O 
LPS O 
. O 

This O 
stimulation O 
of O 
HIV O 
- O 
1 O 
production O 
is O 
correlated O 
with O 
an O 
increase O 
in O 
the O 
level O 
of O 
HIV B-RNA 
- I-RNA 
1 I-RNA 
RNA I-RNA 
and O 
and O 
activation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

LPS O 
is O 
not O 
able O 
to O 
induce O 
HIV O 
- O 
1 O 
production O 
in O 
a O 
cloned O 
T B-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

The O 
effect O 
of O 
LPS O 
on O 
HIV O 
- O 
1 O 
replication O 
occurs O 
at O 
picogram O 
per O 
milliliter O 
concentrations O 
and O 
may O 
be O 
clinically O 
significant O 
in O 
understanding O 
the O 
variability O 
of O 
the O 
natural O 
history O 
of O 
HIV O 
- O 
1 O 
infection O 
. O 

Steroid O 
dose O 
sparing O 
: O 
pharmacodynamic O 
responses O 
to O 
single O 
versus O 
divided O 
doses O 
of O 
methylprednisolone O 
in O 
man O 
. O 

Inhibitory O 
drug O 
interactions O 
affecting O 
the O 
metabolism O 
of O 
methylprednisolone O 
( O 
MP O 
) O 
may O 
produce O 
either O 
steroid O 
sparing O 
or O 
adverse O 
effects O 
partly O 
by O 
increasing O 
the O 
exposure O 
time O 
to O 
the O 
steroid O 
. O 

This O 
phenomenon O 
can O 
be O 
mimicked O 
by O 
administering O 
MP O 
in O 
divided O 
doses O 
. O 

Two O 
types O 
of O 
responses O 
were O 
compared O 
after O 
a O 
single O 
MP O 
dose O 
( O 
40 O 
mg O 
bolus O 
) O 
and O 
a O 
divided O 
regimen O 
( O 
20 O 
mg O 
bolus O 
and O 
a O 
5 O 
mg O 
bolus O 
8 O 
hours O 
later O 
) O 
in O 
six O 
healthy O 
male O 
volunteers O 
. O 

The O 
suppression O 
of O 
basophils B-cell_type 
measured O 
as O 
whole O 
blood O 
histamine O 
and O 
plasma O 
cortisol O 
concentrations O 
was O 
assessed O 
during O 
32 O 
hours O 
. O 

The O 
37 O 
. O 
5 O 
% O 
reduction O 
in O 
dose O 
produced O 
a O 
23 O 
% O 
overall O 
decreased O 
blood O 
histamine O 
response O 
. O 

A O 
pharmacodynamic O 
model O 
for O 
basophil O 
cell O 
distribution O 
to O 
and O 
from O 
an O 
extravascular O 
compartment O 
describes O 
the O 
effects O 
of O 
MP O 
after O 
both O 
regimens O 
. O 

A O 
slower O 
initial O 
decline O 
in O 
blood O 
histamine O 
after O 
the O 
divided O 
regimen O 
may O 
be O 
related O 
to O 
incomplete O 
suppression O 
of O 
basophil B-cell_type 
cell I-cell_type 
return O 
to O 
blood O 
. O 

The O 
50 O 
% O 
inhibitory O 
concentrations O 
of O 
MP O 
of O 
about O 
5 O 
ng O 
/ O 
ml O 
were O 
similar O 
for O 
both O 
regimens O 
. O 

The O 
decline O 
and O 
return O 
of O 
cortisol O 
concentrations O 
were O 
similar O 
between O 
MP O 
treatments O 
with O 
suppression O 
continuing O 
for O 
24 O 
hours O 
. O 

The O 
50 O 
% O 
inhibitory O 
concentrations O 
of O 
MP O 
values O 
for O 
adrenal O 
suppression O 
were O 
about O 
1 O 
ng O 
/ O 
ml O 
. O 

Pharmacodynamic O 
modeling O 
is O 
useful O 
in O 
quantitating O 
corticosteroid O 
responses O 
and O 
generally O 
predicted O 
the O 
" O 
dose O 
- O 
sparing O 
" O 
effects O 
that O 
were O 
achieved O 
by O 
prolonging O 
MP O 
plasma O 
concentrations O 
. O 

This O 
study O 
supports O 
previous O 
clinical O 
observations O 
that O 
patients O 
may O 
require O 
morning O 
through O 
evening O 
exposure O 
to O 
MP O 
to O 
optimize O 
efficacy O 
while O 
adrenal O 
suppression O 
is O 
being O 
minimized O 
. O 

1 O 
, O 
25 O 
( O 
OH O 
) O 
2D2 O 
production O 
by O 
T B-cell_type 
lymphocytes I-cell_type 
and O 
alveolar B-cell_type 
macrophages I-cell_type 
recovered O 
by O 
lavage O 
from O 
normocalcemic O 
patients O 
with O 
tuberculosis O 
. O 

To O 
compare O 
extra O 
- O 
renal O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
production O 
in O 
different O 
types O 
of O 
granulomatous O 
disease O 
, O 
and O 
to O 
identify O 
the O 
cell O 
types O 
responsible O 
, O 
we O 
have O 
evaluated O 
the O 
conversion O 
of O 
25 O 
( O 
OH O 
) O 
D3 O 
in O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
by O 
uncultured B-cell_type 
cells I-cell_type 
recovered O 
by O 
bronchoalveolar O 
lavage O 
and O 
blood B-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
from O 
normocalcemic O 
patients O 
with O 
sarcoidosis O 
and O 
tuberculosis O 
. O 

1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
was O 
produced O 
both O 
by O 
lavage B-cell_type 
cells I-cell_type 
( O 
12 O 
/ O 
12 O 
tuberculosis O 
patients O 
, O 
2 O 
/ O 
6 O 
sarcoidosis O 
patients O 
) O 
and O 
blood B-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
( O 
3 O 
/ O 
5 O 
tuberculosis O 
patients O 
, O 
0 O 
/ O 
3 O 
sarcoidosis O 
patients O 
) O 
from O 
patients O 
but O 
not O 
controls O 
, O 
but O 
significantly O 
greater O 
amounts O 
were O 
produced O 
by O 
lavage O 
cells O 
from O 
tuberculosis O 
patients O 
than O 
those O 
of O 
sarcoidosis O 
patients O 
( O 
P O 
less O 
than O 
0 O 
. O 
001 O 
) O 
. O 

1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
production O 
by O 
lavage B-cell_type 
cells I-cell_type 
from O 
tuberculosis O 
patients O 
correlated O 
with O 
the O 
number O 
of O 
CD8 O 
+ O 
T B-cell_type 
lymphocytes I-cell_type 
present O 
but O 
not O 
other O 
cell O 
types O 
. O 

T B-cell_type 
lymphocytes I-cell_type 
appeared O 
to O 
be O 
an O 
important O 
source O 
of O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
production O 
, O 
since O 
purified O 
T B-cell_type 
lymphocytes I-cell_type 
from O 
all O 
patients O 
with O 
tuberculosis O 
produced O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
, O 
and O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
production O 
by O 
these O 
cells O 
correlated O 
closely O 
with O 
that O 
produced O 
by O 
unseparated O 
lavage B-cell_type 
cells I-cell_type 
. O 

Because O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
can O 
improve O 
the O 
capacity O 
of O 
macrophages B-cell_type 
to O 
kill O 
mycobacteria O 
, O 
our O 
results O 
support O 
the O 
conclusion O 
that O 
macrophage O 
- O 
lymphocyte O 
interactions O 
, O 
mediated O 
at O 
least O 
in O 
part O 
by O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
, O 
may O 
be O 
an O 
important O 
component O 
of O 
a O 
successful O 
antituberculous O 
immune O 
response O 
. O 

Megakaryocytic O 
and O 
erythrocytic O 
lineages O 
share O 
specific O 
transcription B-protein 
factors I-protein 
. O 

Erythroid B-DNA 
- I-DNA 
specific I-DNA 
genes I-DNA 
contain O 
binding O 
sites O 
for O 
NF B-protein 
- I-protein 
E1 I-protein 
( O 
also O 
called O 
GF B-protein 
- I-protein 
1 I-protein 
and O 
Eryf B-protein 
- I-protein 
1 I-protein 
; O 
refs O 
1 O 
- O 
3 O 
respectively O 
) O 
, O 
the O 
principal O 
DNA B-protein 
- I-protein 
binding I-protein 
protein I-protein 
of O 
the O 
erythrocytic B-cell_type 
lineage I-cell_type 
. O 

NF B-protein 
- I-protein 
E1 I-protein 
expression O 
seems O 
to O 
be O 
restricted O 
to O 
the O 
erythrocytic B-cell_type 
lineage I-cell_type 
. O 

A O 
closely O 
related O 
( O 
if O 
not O 
identical O 
) O 
protein O 
is O 
found O 
in O 
both O 
a O 
human B-cell_line 
megakaryocytic I-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
purified B-cell_line 
human I-cell_line 
megakaryocytes I-cell_line 
; O 
it O 
binds O 
to O 
promoter B-DNA 
regions I-DNA 
of O 
two O 
megakaryocytic B-DNA 
- I-DNA 
specific I-DNA 
genes I-DNA 
. O 

The O 
binding O 
sites O 
and O 
partial O 
proteolysis O 
profile O 
of O 
this O 
protein O 
are O 
indistinguishable O 
from O 
those O 
of O 
the O 
erythroid B-protein 
protein I-protein 
; O 
also O 
, O 
NF B-protein B-RNA 
- I-protein I-RNA 
E1 I-protein I-RNA 
messenger I-RNA 
RNA I-RNA 
is O 
the O 
same O 
size O 
in O 
both O 
the O 
megakaryocytic O 
and O 
erythroid O 
cell O 
lines O 
. O 

Furthermore O 
, O 
point O 
mutations O 
that O 
abolish O 
binding O 
of O 
NF B-protein 
- I-protein 
E1 I-protein 
result O 
in O 
a O 
70 O 
% O 
decrease O 
in O 
the O 
transcriptional O 
activity O 
of O 
a O 
megakaryocytic B-DNA 
- I-DNA 
specific I-DNA 
promoter I-DNA 
. O 

We O 
also O 
find O 
that O 
NF B-protein 
- I-protein 
E2 I-protein 
, O 
another O 
trans B-protein 
- I-protein 
acting I-protein 
factor I-protein 
of O 
the O 
erythrocytic B-cell_type 
lineage I-cell_type 
, O 
is O 
present O 
in O 
megakaryocytes B-cell_line 
. O 

Transcriptional O 
effects O 
in O 
both O 
lineages O 
might O 
then O 
be O 
mediated O 
in O 
part O 
by O 
the O 
same O 
specific O 
trans B-protein 
- I-protein 
acting I-protein 
factors I-protein 
. O 

Our O 
data O 
strengthen O 
the O 
idea O 
of O 
a O 
close O 
association O 
between O 
the O 
erythrocytic O 
and O 
the O 
megakaryocytic O 
lineages O 
and O 
could O 
also O 
explain O 
the O 
expression O 
of O 
markers O 
specific O 
to O 
the O 
erythrocytic O 
and O 
megakaryocytic O 
lineages O 
in O 
most O 
erythroblastic O 
and O 
megakaryoblastic O 
permanent O 
cell O 
lines O 
. O 

Transcriptional O 
down O 
- O 
regulation O 
of O 
c B-DNA 
- I-DNA 
myc I-DNA 
expression O 
by O 
protein O 
synthesis O 
- O 
dependent O 
and O 
- O 
independent O 
pathways O 
in O 
a O 
human B-cell_line 
T I-cell_line 
lymphoblastic I-cell_line 
tumor I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

We O 
show O 
that O 
in O 
the O 
human B-cell_line 
T I-cell_line 
lymphoblastic I-cell_line 
tumor I-cell_line 
cell I-cell_line 
line I-cell_line 
Molt4 B-RNA 
c B-DNA I-RNA 
- I-DNA I-RNA 
myc I-DNA I-RNA 
mRNA I-RNA 
and O 
protein O 
expression O 
is O 
down O 
- O 
regulated O 
after O 
exposure O 
to O 
dimethyl O 
sulfoxide O 
, O 
to O 
phorbol O 
myristate O 
acetate O 
, O 
or O 
to O 
the O 
calcium O 
ionophore O 
A23187 O 
, O 
which O 
raises O 
the O 
intracellular O 
calcium O 
concentration O 
. O 

A O 
block O 
to O 
RNA O 
elongation O 
is O 
largely O 
responsible O 
for O 
decreased O 
c B-DNA 
- I-DNA 
myc I-DNA 
transcription O 
. O 

Although O 
negative O 
regulation O 
by O 
dimethyl O 
sulfoxide O 
takes O 
place O 
even O 
when O 
protein O 
synthesis O 
is O 
inhibited O 
by O 
cycloheximide O 
, O 
the O 
phorbol O 
myristate O 
acetate O 
effect O 
is O 
blocked O 
to O 
some O 
extent O 
only O 
by O 
cycloheximide O 
. O 

The O 
calcium O 
ionophore O 
- O 
induced O 
c B-DNA 
- I-DNA 
myc I-DNA 
suppression O 
, O 
however O 
, O 
strictly O 
requires O 
de O 
novo O 
protein O 
synthesis O 
. O 

Therefore O 
, O 
two O 
different O 
negative O 
regulatory O 
pathways O 
are O 
involved O 
in O 
c B-DNA 
- I-DNA 
myc I-DNA 
regulation O 
: O 
one O 
which O 
is O 
independent O 
and O 
one O 
which O 
depends O 
on O 
de O 
novo O 
protein O 
synthesis O 
. O 

The O 
latter O 
one O 
appears O 
to O 
be O 
mediated O 
by O 
a O 
rapidly O 
calcium B-protein 
- I-protein 
dependent I-protein 
induced I-protein 
gene I-protein 
product I-protein 
. O 

Oestrogen B-protein 
receptor I-protein 
( O 
ER B-protein 
) O 
analysis O 
in O 
B O 
- O 
cell O 
chronic O 
lymphocytic O 
leukemia O 
: O 
correlation O 
of O 
biochemical O 
and O 
immunocytochemical O 
methods O 
. O 

Oestrogen B-protein 
receptors I-protein 
( O 
ER B-protein 
) O 
are O 
present O 
in O 
neoplastic B-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
and O 
have O 
been O 
considered O 
a O 
physiological O 
marker O 
of O 
growth O 
rate O 
or O 
differentiation O 
. O 

Tamoxifen O 
, O 
an O 
oestrogen O 
antagonist O 
, O 
has O 
been O 
given O 
in O 
some O 
patients O 
with O 
CLL O 
and O 
Hodgkin O 
' O 
s O 
disease O 
, O 
with O 
dramatic O 
response O 
in O 
single O 
cases O 
. O 

Until O 
now O 
, O 
ER B-protein 
status O 
has O 
been O 
assessed O 
using O 
a O 
steroid O 
binding O 
assay O 
( O 
SBA O 
) O 
which O 
has O 
many O 
inherent O 
problems O 
. O 

Recently O 
, O 
the O 
development O 
of O 
monoclonal O 
antibodies O 
directed O 
against O 
ER B-protein 
has O 
been O 
applied O 
to O 
the O 
study O 
of O 
breast O 
carcinomas O 
and O 
results O 
obtained O 
show O 
good O 
correlation O 
with O 
the O 
quantitative O 
SBA O 
. O 

We O 
studied O 
49 O 
cases O 
of O 
B O 
- O 
cell O 
chronic O 
lymphocytic O 
leukemia O 
( O 
CLL O 
) O 
using O 
immunostaining O 
of O 
cytospin O 
preparations O 
. O 

In O 
30 O 
of O 
these O 
cases O 
ER B-protein 
enzyme O 
immunoassay O 
( O 
ER B-protein 
- O 
EIA O 
) O 
was O 
also O 
performed O 
. O 

Cultured B-cell_line 
MCF I-cell_line 
- I-cell_line 
7 I-cell_line 
cells I-cell_line 
, O 
derived O 
from O 
a O 
pleural O 
effusion O 
of O 
a O 
breast O 
cancer O 
patient O 
, O 
known O 
to O 
contain O 
high O 
levels O 
of O 
ER B-protein 
were O 
used O 
as O 
a O 
positive O 
control O 
( O 
40 O 
- O 
48 O 
% O 
ER B-protein B-cell_type 
positive I-cell_type 
cells I-cell_type 
by O 
immunocytochemistry O 
; O 
200 O 
fmol O 
/ O 
mg O 
protein O 
by O 
EIA O 
) O 
. O 

All O 
of O 
the O 
CLL O 
cases O 
except O 
two O 
( O 
96 O 
% O 
) O 
were O 
negative O 
for O 
ER B-protein 
( O 
less O 
than O 
1 O 
% O 
staining O 
; O 
less O 
than O 
4 O 
fmol O 
/ O 
mg O 
protein O 
) O 
. O 

The O 
two O 
positive O 
cases O 
expressed O 
granular O 
ER B-protein 
staining O 
over O 
the O 
nucleus O 
( O 
9 O 
. O 
2 O 
and O 
12 O 
. O 
1 O 
% O 
positive O 
cells O 
) O 
and O 
were O 
positive O 
by O 
EIA O 
and O 
SBA O 
. O 

It O 
is O 
concluded O 
that O 
( O 
i O 
) O 
patients O 
with O 
CLL O 
rarely O 
express O 
ER B-protein 
and O 
( O 
ii O 
) O 
immunocytochemical O 
staining O 
of O 
cytospin O 
preparations O 
is O 
a O 
valid O 
technique O 
for O 
the O 
measurement O 
of O 
ER B-protein 
. O 

It O 
is O 
of O 
interest O 
that O 
one O 
of O 
the O 
positive O 
cases O 
was O 
diagnosed O 
as O 
CLL O 
with O 
Richter O 
' O 
s O 
transformation O 
confirming O 
earlier O 
findings O 
. O 

Type B-protein 
- I-protein 
II I-protein 
estrogen I-protein 
binding I-protein 
sites I-protein 
in O 
a O 
lymphoblastoid B-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
growth O 
- O 
inhibitory O 
effect O 
of O 
estrogen O 
, O 
anti O 
- O 
estrogen O 
and O 
bioflavonoids O 
. O 

Type B-protein 
- I-protein 
II I-protein 
estrogen I-protein 
- I-protein 
binding I-protein 
sites I-protein 
( O 
type B-protein 
- I-protein 
II I-protein 
EBS I-protein 
) O 
have O 
been O 
demonstrated O 
in O 
the O 
human B-cell_line 
lymphoblastoid B-cell_line I-cell_line 
cell I-cell_line I-cell_line 
line I-cell_line I-cell_line 
IM B-cell_line 
- I-cell_line 
9 I-cell_line 
using O 
a O 
whole O 
- O 
cell O 
assay O 
with O 
( O 
6 O 
, O 
7 O 
- O 
3H O 
) O 
estradiol O 
( O 
3H O 
- O 
E2 O 
) O 
as O 
tracer O 
. O 

Competition O 
analysis O 
showed O 
that O 
the O 
anti O 
- O 
estrogen O 
tamoxifen O 
and O 
the O 
flavonoids O 
quercetin O 
and O 
rutin O 
competed O 
for O 
( O 
3H O 
) O 
- O 
E2 O 
binding O 
to O 
type B-protein 
- I-protein 
II I-protein 
EBS I-protein 
. O 

Growth O 
experiments O 
demonstrated O 
that O 
diethylstilbestrol O 
( O 
DES O 
) O 
tamoxifen O 
( O 
TAM O 
) O 
, O 
quercetin O 
and O 
rutin O 
exerted O 
a O 
reversible O 
dose O 
- O 
dependent O 
inhibition O 
of O 
cell O 
proliferation O 
in O 
the O 
range O 
of O 
concentrations O 
between O 
10 O 
nM O 
and O 
10 O 
microM O 
. O 

The O 
relative O 
binding O 
affinity O 
of O 
quercetin O 
, O 
rutin O 
, O 
DES O 
and O 
TAM O 
for O 
type B-protein 
- I-protein 
II I-protein 
EBS I-protein 
correlated O 
well O 
with O 
their O 
potency O 
as O 
cell O 
growth O 
inhibitors O 
. O 

Moreover O 
, O 
hesperidin O 
, O 
a O 
flavonoid O 
which O 
does O 
not O 
bind O 
to O 
type B-protein 
- I-protein 
II I-protein 
EBS I-protein 
, O 
was O 
ineffective O 
in O 
inhibiting O 
cell O 
growth O 
. O 

Cell O 
- O 
cycle O 
analysis O 
showed O 
that O 
the O 
growth O 
- O 
inhibitory O 
effect O 
of O 
DES O 
, O 
TAM O 
or O 
quercetin O 
was O 
due O 
to O 
a O 
blocking O 
effect O 
in O 
the O 
G0 O 
- O 
G1 O 
phases O 
. O 

Our O 
results O 
suggest O 
that O 
high O 
estrogen O 
and O 
anti O 
- O 
estrogen O 
concentrations O 
and O 
flavonoids O 
may O 
regulate O 
IM B-cell_line 
- I-cell_line 
9 I-cell_line 
cell O 
growth O 
through O 
a O 
common O 
mechanism O 
involving O 
a O 
binding O 
interaction O 
with O 
type B-protein 
- I-protein 
II I-protein 
EBS I-protein 
. O 

[ O 
Glucocorticoid B-protein 
receptors I-protein 
in O 
peripheral B-cell_type 
blood I-cell_type 
lymphocytes I-cell_type 
of O 
patients O 
with O 
bronchial O 
asthma O 
] O 
. O 

Quantitation O 
of O 
glucocorticoid B-protein 
receptors I-protein 
( O 
GCR B-protein 
) O 
and O 
the O 
study O 
of O 
their O 
affinity O 
for O 
glucocorticosteroids O 
( O 
GCS O 
) O 
were O 
made O 
in O 
peripheral B-cell_type 
blood I-cell_type 
lymphocytes I-cell_type 
of O 
bronchial O 
asthma O 
( O 
BA O 
) O 
patients O 
in O 
consideration O 
of O 
GCR B-protein 
treatment O 
and O 
serum O 
levels O 
of O 
endogenous O 
cortisol O 
. O 

It O 
is O 
stated O 
that O 
GCR B-protein 
of O 
healthy O 
controls O 
and O 
GCS O 
- O 
untreated O 
patients O 
outnumbered O 
those O 
of O 
cortisol O 
- O 
dependent O 
BA O 
patients O 
on O 
hormone O 
therapy O 
. O 

Following O 
discontinuation O 
of O 
glucocorticoid O 
drugs O 
GCR B-protein 
count O 
in O 
cortisol O 
- O 
dependent O 
BA O 
tends O 
to O 
rise O 
. O 

Endogenous O 
cortisol O 
has O 
no O 
effect O 
on O 
GCR B-protein 
level O 
estimated O 
by O 
3H O 
- O 
triamcinolone O 
acetonide O 
. O 

Two O 
glucocorticoid B-protein 
binding I-protein 
sites I-protein 
on O 
the O 
human B-protein 
glucocorticoid I-protein 
receptor I-protein 
. O 

Glucocorticoids O 
are O 
known O 
to O 
have O 
a O 
lytic O 
effect O 
in O 
leukemic B-cell_type 
cells I-cell_type 
via O 
interactions O 
with O 
the O 
glucocorticoid B-protein 
receptor I-protein 
( O 
GR B-protein 
) O 
. O 

Cortisol O 
and O 
various O 
synthetic O 
glucocorticoids O 
bind O 
to O 
the O 
GR B-protein 
with O 
one O 
- O 
site O 
kinetics O 
. O 

Cortivazol O 
( O 
CVZ O 
) O 
is O 
a O 
unique O 
, O 
high O 
potency O 
synthetic O 
glucocorticoid O 
, O 
which O 
has O 
a O 
phenylpyrazol O 
fused O 
to O 
the O 
A O 
- O 
ring O 
of O 
the O 
steroid O 
nucleus O 
and O 
displays O 
binding O 
consistent O 
with O 
two O 
or O 
more O 
sites O 
in O 
the O 
cytosol O 
from O 
CEM B-cell_line 
C7 I-cell_line 
cells I-cell_line 
( O 
a O 
human B-cell_line 
acute I-cell_line 
lymphoblastic I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
) O 
. O 

It O 
has O 
previously O 
been O 
shown O 
that O 
the O 
lower O 
affinity O 
class O 
of O 
sites O 
are O 
similar O 
in O 
affinity O 
and O 
site O 
molarity O 
to O 
those O 
recognized O 
by O 
dexamethasone O 
. O 

The O 
higher O 
affinity O 
sites O 
bind O 
CVZ O 
with O 
20 O 
- O 
to O 
50 O 
- O 
fold O 
greater O 
affinity O 
, O 
consistent O 
with O 
CVZ O 
' O 
s O 
enhanced O 
biological O 
effects O 
. O 

In O 
mutant O 
leukemic B-cell_type 
cells I-cell_type 
resistant O 
to O 
the O 
lytic O 
effects O 
of O 
dexamethasone O 
, O 
CVZ O 
both O 
lyses O 
the O 
cells O 
and O 
recognizes O 
a O 
single O 
class O 
of O 
sites O 
similar O 
to O 
the O 
high O 
affinity O 
site O 
in O 
CEM B-cell_line 
C7 I-cell_line 
cells I-cell_line 
. O 

We O 
have O 
carried O 
out O 
experiments O 
to O 
define O 
the O 
nature O 
of O 
the O 
higher B-protein 
affinity I-protein 
CVZ I-protein 
binding I-protein 
site I-protein 
. O 

We O 
now O 
show O 
that O 
: O 
1 O 
) O 
CVZ O 
has O 
more O 
than O 
one O 
binding O 
site O 
in O 
a O 
second O 
, O 
independent O 
, O 
B B-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
IM B-cell_line 
- I-cell_line 
9 I-cell_line 
; O 
2 O 
) O 
the O 
antiglucocorticoid O 
RU O 
38486 O 
is O 
able O 
to O 
block O 
both O 
CVZ O 
' O 
s O 
higher O 
and O 
lower O 
affinity O 
sites O 
; O 
3 O 
) O 
all O 
of O 
CVZ B-protein 
' I-protein 
s I-protein 
binding I-protein 
sites I-protein 
are O 
on O 
a O 
protein O 
immunologically O 
indistinguishable O 
from O 
the O 
human O 
GR B-protein 
; O 
and O 
4 O 
) O 
freshly O 
isolated O 
clones O 
of O 
CVZ O 
- O 
resistant O 
cells O 
have O 
lost O 
all O 
binding O 
sites O 
for O 
CVZ O 
. O 

These O 
data O 
indicate O 
that O 
CVZ O 
is O 
recognizing O 
two O 
glucocorticoid B-protein 
binding I-protein 
sites I-protein 
on O 
the O 
human O 
GR B-protein 
or O 
a O 
protein O 
very O 
similar O 
to O 
it O 
. O 

Retroviral O 
mediated O 
transfer O 
and O 
expression O 
of O 
exogenous B-DNA 
genes I-DNA 
in O 
primary B-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
: O 
assaying O 
for O 
a O 
viral O 
transactivator B-protein 
activity O 
in O 
normal O 
and O 
malignant O 
cells O 
. O 

In O 
this O 
report O 
we O 
describe O 
the O 
use O 
of O 
recombinant O 
retroviruses O 
to O 
characterize O 
the O 
activity O 
of O 
an O 
exogenous B-DNA 
promoter I-DNA 
in O 
primary O 
cells O 
obtained O 
from O 
patients O 
with O 
lymphoproliferative O 
disorders O 
. O 

The O 
infection O 
of O 
a O 
variety O 
of O 
cultured O 
and O 
primary B-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
with O 
a O 
recombinant O 
retrovirus O 
containing O 
a O 
histone B-protein B-DNA 
promoter I-protein I-DNA 
- I-protein I-DNA 
driven I-protein I-DNA 
beta I-protein I-DNA 
- I-protein I-DNA 
galactosidase I-protein I-DNA 
gene I-DNA 
is O 
shown O 
to O 
result O 
in O 
the O 
expression O 
of O 
beta B-protein 
- I-protein 
galactosidase I-protein 
in O 
50 O 
% O 
to O 
100 O 
% O 
of O 
the O 
cells O 
. O 

A O 
similar O 
infection O 
with O 
a O 
recombinant O 
retrovirus O 
containing O 
the O 
beta B-protein B-DNA 
- I-protein I-DNA 
galactosidase I-protein I-DNA 
gene I-DNA 
with O 
an O 
adenovirus B-DNA 
E2 I-DNA 
promoter I-DNA 
, O 
results O 
in O 
beta B-protein 
- I-protein 
galactosidase I-protein 
activity O 
in O 
a O 
limited O 
number O 
of O 
cultured B-cell_line 
and O 
primary B-cell_type 
cells I-cell_type 
. O 

Since O 
the O 
adenovirus B-DNA 
E2 I-DNA 
promoter I-DNA 
has O 
been O 
well O 
characterized O 
and O 
is O 
known O 
to O 
be O 
regulated O 
by O 
transactivators B-protein 
encoded O 
by O 
many O 
viruses O 
, O 
the O 
activity O 
of O 
this O 
promoter O 
in O 
specific O 
cell O 
types O 
is O 
discussed O 
in O 
reference O 
to O 
both O 
the O 
biology O 
of O 
the O 
cell O 
and O 
the O 
possible O 
presence O 
of O 
as O 
yet O 
undetected O 
viral B-protein 
gene I-protein 
products I-protein 
. O 

[ O 
The O 
effect O 
of O 
24 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
dioxyvit O 
) O 
on O 
Ca O 
metabolism O 
and O 
immune O 
status O 
during O 
chronic O 
kidney O 
failure O 
] O 
. O 

Active O 
metabolite O 
of O 
vitamin O 
D3 O 
, O 
24R O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
( O 
dioxyvit O 
) O 
was O 
used O 
at O 
a O 
daily O 
dose O 
of O 
100 O 
micrograms O 
in O 
treatment O 
of O 
children O 
affected O 
with O 
tubulointerstitial O 
disease O 
of O 
kidney O 
and O 
with O 
chronic O 
glomerulonephritis O 
under O 
conditions O 
of O 
kidney O 
insufficiency O 
. O 

The O 
drug O 
exhibited O 
distinct O 
normalizing O 
effect O 
on O 
patterns O 
of O 
calcium O 
metabolism O 
: O 
increase O 
of O 
total O 
and O 
ionized O 
Ca2 O 
+ O 
and O 
of O 
25 O 
- O 
OHD O 
, O 
decrease O 
in O 
concentration O 
of O 
parath O 
hormone O 
and O 
osteocalcine O 
in O 
blood O 
serum O 
as O 
well O 
as O 
on O 
immunological O 
parameters O 
: O 
restoration O 
of O 
decreased O 
content O 
of O 
T O 
- O 
and O 
0 O 
- O 
lymphocytes O 
. O 

Concentration O 
of O 
receptors O 
of O 
hormonal O 
form O 
of O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
was O 
found O 
to O 
be O 
minimal O 
in O 
lymphocytes B-cell_type 
under O 
conditions O 
of O 
chronic O 
kidney O 
insufficiency O 
, O 
while O 
their O 
expression O 
, O 
after O 
the O 
dioxyvit O 
action O 
, O 
was O 
detected O 
only O 
in O 
patients O 
with O 
glomerulonephritis O 
. O 

Specific O 
calcitropic O 
effect O 
of O 
dioxyvit O 
with O 
simultaneous O 
correction O 
of O 
vitamin O 
D O 
deficiency O 
were O 
apparently O 
responsible O 
for O 
high O 
efficacy O 
of O 
the O 
drug O 
in O 
treatment O 
of O 
calcium O 
metabolism O 
and O 
immunity O 
impairments O 
in O 
children O 
with O 
renal O 
deteriorations O 
at O 
the O 
step O 
of O 
chronic O 
kidney O 
insufficiency O 
. O 

[ O 
The O 
role O 
of O 
glucocorticoid B-protein 
receptors I-protein 
and O 
HLA B-protein 
antigens I-protein 
in O 
the O 
pathogenesis O 
of O 
Cushing B-protein 
' I-protein 
s I-protein 
syndrome I-protein 
] O 
. O 

Lymphocytic O 
levels O 
of O 
glucocorticoid B-protein 
receptors I-protein 
were O 
evaluated O 
in O 
114 O 
patients O 
suffering O 
from O 
Icenko O 
- O 
Cushing B-protein 
' I-protein 
s I-protein 
syndrome I-protein 
. O 

Incidence O 
of O 
HLA B-protein 
antigens I-protein 
was O 
determined O 
in O 
94 O 
of O 
them O 
. O 

A O 
significant O 
rise O 
of O 
A10 B-protein 
and O 
B27 B-protein 
antigen I-protein 
incidence O 
compared O 
to O 
that O 
in O 
normal O 
subjects O 
allows O 
these O 
antigens O 
to O 
be O 
considered O 
genetic O 
markers O 
of O 
Icenko O 
- O 
Cushing B-protein 
' I-protein 
s I-protein 
syndrome I-protein 
. O 

The O 
levels O 
of O 
glucocorticoid B-protein 
receptors I-protein 
in O 
lymphocytes B-cell_type 
of O 
the O 
patients O 
are O 
lower O 
than O 
in O 
normal O 
subjects O 
both O 
in O 
the O 
active O 
stage O 
of O 
the O 
disease O 
and O 
following O 
bilateral O 
total O 
adrenalectomy O 
. O 

The O 
patients O 
carrying O 
B27 B-protein 
antigen I-protein 
had O 
lymphocytic O 
receptor O 
concentrations O 
under O 
the O 
levels O 
of O 
such O 
in O 
patients O 
free O 
of O 
the O 
antigen O 
carriage O 
. O 

Antigen B-protein 
B27 I-protein 
seems O 
to O 
be O 
a O 
cause O 
of O 
lower O 
levels O 
of O 
glucocorticoid B-protein 
receptors I-protein 
in O 
blood B-cell_type 
lymphocytes B-cell_type I-cell_type 
. O 

Effects O 
of O 
1 O 
alpha O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
on O 
the O 
human B-cell_line 
chronic I-cell_line 
myelogenous I-cell_line 
leukemia I-cell_line 
cell I-cell_line 
line I-cell_line 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
. O 

The O 
effects O 
of O 
1 O 
alpha O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
VD3 O 
) O 
on O 
proliferation O 
, O 
differentiation O 
, O 
and O 
macromolecular O 
synthesis O 
in O 
the O 
new O 
Philadelphia B-cell_line 
chromosome I-cell_line 
- I-cell_line 
positive I-cell_line 
chronic I-cell_line 
myelogenous I-cell_line 
leukemia I-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
, O 
were O 
investigated O 
. O 

Binding O 
of O 
[ O 
3H O 
] O 
VD3 O 
was O 
saturable O 
, O 
with O 
approximately O 
2000 O 
- O 
3000 O 
sites O 
/ O 
cell O 
, O 
and O 
half O 
- O 
maximal O 
binding O 
occurring O 
at O 
0 O 
. O 
21 O 
- O 
0 O 
. O 
33 O 
nM O 
. O 

Treatment O 
of O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
cells I-cell_line 
with O 
VD3 O 
induced O 
24R B-protein 
- I-protein 
hydroxylase I-protein 
activity O 
, O 
a O 
marker O 
of O 
vitamin O 
D3 O 
responsiveness O 
in O 
many O 
tissues O 
. O 

Exposure O 
of O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
cells I-cell_line 
to O 
VD3 O 
also O 
inhibited O 
proliferation O 
and O 
DNA O 
synthesis O 
with O 
a O 
50 O 
% O 
effective O 
dose O 
of O 
3 O 
. O 
5 O 
- O 
10 O 
nM O 
within O 
72 O 
h O 
; O 
in O 
addition O 
, O 
protein O 
and O 
RNA O 
synthesis O 
were O 
inhibited O 
by O 
VD3 O 
treatment O 
. O 

Exposure O 
of O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
cells I-cell_line 
to O 
5 O 
nM O 
VD3 O 
for O 
72 O 
h O 
caused O 
50 O 
% O 
of O 
the O 
cells O 
to O 
differentiate O 
into O 
macrophage B-cell_type 
/ I-cell_type 
monocyte I-cell_type 
type I-cell_type 
cells I-cell_type 
as O 
judged O 
by O 
nitroblue O 
tetrazolium O 
staining O 
and O 
adherence O 
to O 
plastic O 
. O 

Progressive O 
expression O 
of O 
cell B-protein 
surface I-protein 
maturation I-protein 
- I-protein 
specific I-protein 
antigens I-protein 
of O 
the O 
monocyte B-cell_type 
/ I-cell_type 
macrophage I-cell_type 
lineage I-cell_type 
was O 
induced O 
by O 
treatment O 
of O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
cells I-cell_line 
with O 
VD3 O 
for O 
24 O 
to O 
72 O 
h O 
at O 
doses O 
that O 
inhibited O 
cellular O 
proliferation O 
. O 

c B-RNA 
- I-RNA 
myc I-RNA 
RNA I-RNA 
, O 
which O 
is O 
constitutively O 
expressed O 
in O 
RWLeu B-cell_line 
- I-cell_line 
4 I-cell_line 
cells I-cell_line 
, O 
increased O 
after O 
0 O 
. O 
5 O 
h O 
of O 
treatment O 
with O 
50 O 
nM O 
VD3 O 
and O 
then O 
rapidly O 
decreased O 
to O 
barely O 
detectable O 
levels O 
after O 
4 O 
h O 
of O 
treatment O 
. O 

Finally O 
, O 
the O 
in O 
vitro O 
tyrosine O 
kinase O 
activity O 
associated O 
with O 
the O 
p210bcr B-DNA B-protein 
- I-DNA I-protein 
abl I-DNA I-protein 
oncogene I-DNA I-protein 
product I-protein 
was O 
decreased O 
approximately O 
50 O 
% O 
by O 
VD3 O 
treatment O 
. O 

Because O 
of O 
the O 
presence O 
of O 
a O 
functional O 
receptor O 
- O 
effector O 
system O 
for O 
VD3 O 
and O 
multiple O 
biological O 
responses O 
to O 
the O 
hormone O 
, O 
these O 
cells O 
provide O 
a O 
unique O 
model O 
system O 
with O 
which O 
to O 
probe O 
the O 
specific O 
effects O 
of O 
VD3 O 
on O 
cell O 
growth O 
and O 
differentiation O 
in O 
chronic O 
myelogenous O 
leukemia O 
. O 

A O 
new O 
member O 
of O 
the O 
leucine B-protein B-protein 
zipper I-protein I-protein 
class I-protein 
of O 
proteins O 
that O 
binds O 
to O 
the O 
HLA B-DNA 
DR I-DNA 
alpha I-DNA 
promoter I-DNA 
. O 

Several O 
mutants O 
derived O 
from O 
transformed B-cell_line 
human I-cell_line 
B I-cell_line 
cell I-cell_line 
lines I-cell_line 
are O 
defective O 
in O 
expressing O 
major B-DNA 
histocompatibility I-DNA 
complex I-DNA 
( I-DNA 
MHC I-DNA 
) I-DNA 
class I-DNA 
II I-DNA 
genes I-DNA 
. O 

The O 
failure O 
to O 
express O 
a O 
class B-DNA 
II I-DNA 
gene I-DNA 
in O 
at O 
least O 
one O 
such O 
mutant B-cell_line 
line I-cell_line 
has O 
been O 
mapped O 
to O 
the O 
MHC B-DNA 
class I-DNA 
II I-DNA 
X I-DNA 
box I-DNA 
, O 
a O 
conserved B-DNA 
transcriptional I-DNA 
element I-DNA 
in O 
the O 
promoter B-DNA 
region I-DNA 
. O 

A O 
complementary B-DNA 
DNA I-DNA 
encoding O 
a O 
DNA B-protein 
- I-protein 
binding I-protein 
protein I-protein 
( O 
human B-protein 
X I-protein 
box I-protein 
binding I-protein 
protein I-protein 
, O 
hXBP B-protein 
- I-protein 
1 I-protein 
) O 
whose O 
target O 
is O 
the O 
human B-DNA 
DR I-DNA 
alpha I-DNA 
X I-DNA 
box I-DNA 
and O 
the O 
3 B-DNA 
' I-DNA 
flanking I-DNA 
region I-DNA 
has O 
now O 
been O 
cloned O 
. O 

This O 
complementary B-DNA 
DNA I-DNA 
encoded O 
a O 
protein O 
with O 
structural O 
similarities O 
to O 
the O 
c B-protein 
- I-protein 
jun I-protein 
proto I-protein 
- I-protein 
oncogene I-protein 
product I-protein 
, O 
and O 
its O 
target O 
sequence O 
was O 
closely O 
related O 
to O 
the O 
palindromic B-DNA 
target I-DNA 
sequence I-DNA 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
. O 

Mutation O 
of O 
the O 
hXBP B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
DNA I-DNA 
target I-DNA 
sequence I-DNA 
decreased O 
DR B-DNA 
alpha I-DNA 
promoter I-DNA 
activity O 
in O 
vivo O 
. O 

These O 
studies O 
suggest O 
that O 
the O 
hXBP B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
acts O 
as O 
a O 
transcription B-protein 
factor I-protein 
in O 
B B-cell_type 
cells I-cell_type 
. O 

Pseudohypoaldosteronism O 
in O 
eight O 
families O 
: O 
different O 
forms O 
of O 
inheritance O 
are O 
evidence O 
for O 
various O 
genetic O 
defects O 
. O 

Pseudohypoaldosteronism O 
is O 
a O 
rare O 
hereditary O 
disorder O 
presenting O 
in O 
early O 
infancy O 
with O 
renal O 
salt O 
loss O 
leading O 
to O 
hyponatremia O 
and O 
hyperkalemia O 
despite O 
high O 
levels O 
of O 
plasma O 
aldosterone O 
. O 

The O 
patients O 
are O 
insensitive O 
to O 
mineralocorticoids O 
; O 
however O 
, O 
sodium O 
supplementation O 
is O 
able O 
to O 
correct O 
electrolyte O 
abnormalities O 
. O 

Absent O 
or O 
greatly O 
diminished O 
type O 
I B-protein 
aldosterone I-protein 
receptors I-protein 
in O 
peripheral B-cell_type 
mononuclear I-cell_type 
leucocytes I-cell_type 
have O 
been O 
recently O 
demonstrated O 
and O 
explain O 
the O 
lack O 
of O 
response O 
to O 
mineralocorticoids O 
. O 

We O 
have O 
studied O 
the O 
mode O 
of O 
inheritance O 
in O 
eight O 
families O 
with O 
a O 
total O 
of O 
nine O 
patients O 
. O 

There O 
was O 
evidence O 
for O 
an O 
autosomal O 
recessive O 
form O 
of O 
inheritance O 
in O 
four O 
families O 
, O 
while O 
the O 
other O 
four O 
families O 
appeared O 
to O 
have O 
an O 
autosomal O 
dominant O 
mode O 
of O 
transmission O 
. O 

In O 
three O 
families O 
the O 
autosomal O 
recessive O 
form O 
was O 
characterized O 
by O 
normal B-protein 
receptor I-protein 
as O 
well O 
as O 
hormone O 
data O 
in O 
both O 
parents O 
, O 
while O 
in O 
one O 
family O 
receptor O 
levels O 
in O 
both O 
parents O 
were O 
greatly O 
reduced O 
, O 
but O 
hormone O 
levels O 
were O 
normal O 
. O 

In O 
the O 
four O 
families O 
with O 
an O 
autosomal O 
dominant O 
mode O 
of O 
transmission O 
there O 
was O 
always O 
one O 
parent O 
with O 
reduced O 
receptor O 
binding O 
in O 
peripheral B-cell_type 
mononuclear I-cell_type 
leucocytes I-cell_type 
and O 
elevated O 
serum O 
hormone O 
levels O 
. O 

These O 
parents O 
were O 
entirely O 
asymptomatic O 
. O 

In O 
an O 
extended O 
family O 
we O 
were O 
able O 
to O 
study O 
an O 
aunt O 
and O 
her O 
newborn O 
daughter O 
, O 
who O 
were O 
both O 
also O 
biochemically O 
affected O 
but O 
clinically O 
asymptomatic O 
. O 

It O 
, O 
therefore O 
, O 
appears O 
that O 
this O 
dual O 
pattern O 
of O 
genetic O 
transmission O 
may O 
indicate O 
differing O 
genetic O 
defects O 
which O 
cause O 
the O 
same O 
clinical O 
picture O 
of O 
pseudohypoaldosteronism O 
. O 

Perceived O 
social O 
support O 
and O 
tumor O 
estrogen B-protein 
/ I-protein 
progesterone I-protein 
receptor I-protein 
status O 
as O 
predictors O 
of O 
natural B-cell_type B-protein 
killer I-cell_type I-protein 
cell I-cell_type I-protein 
activity I-protein 
in O 
breast O 
cancer O 
patients O 
. O 

This O 
report O 
is O 
concerned O 
with O 
the O 
prediction O 
of O 
natural O 
killer B-cell_type 
( I-cell_type 
NK I-cell_type 
) I-cell_type 
cell I-cell_type 
activity O 
in O 
61 O 
Stage O 
I O 
and O 
II O 
breast O 
cancer O 
patients O 
, O 
between O 
the O 
ages O 
of O 
25 O 
and O 
70 O 
, O 
who O 
were O 
accrued O 
to O 
this O 
project O 
. O 

All O 
baseline O 
interview O 
and O 
testing O 
data O 
were O 
obtained O 
either O 
just O 
before O 
patients O 
were O 
discharged O 
from O 
the O 
hospital O 
, O 
or O 
at O 
their O 
first O 
outpatient O 
visit O 
, O 
within O 
two O 
weeks O 
of O 
discharge O 
. O 

A O 
major O 
interest O 
of O 
this O 
project O 
is O 
the O 
predictive O 
value O 
of O 
perceived O 
social O 
support O 
, O 
as O 
a O 
potential O 
" O 
stress O 
" O 
buffer O 
, O 
related O 
to O 
NK O 
activity O 
. O 

In O 
the O 
main O 
model O 
reported O 
here O 
, O 
we O 
found O 
that O 
a O 
significant O 
amount O 
of O 
NK O 
activity O 
variance O 
could O 
be O 
explained O 
by O 
five O 
variables O 
. O 

Higher O 
NK O 
activity O 
could O 
be O 
predicted O 
by O 
the O 
perception O 
of O 
high O 
quality O 
emotional O 
support O 
from O 
a O 
spouse O 
or O 
intimate O 
other O 
, O 
perceived O 
social O 
support O 
from O 
the O 
patient O 
' O 
s O 
physician O 
, O 
estrogen B-protein 
receptor I-protein 
- O 
negative O 
tumor O 
status O 
, O 
having O 
an O 
excisional B-protein 
biopsy I-protein 
as O 
surgical B-protein 
treatment I-protein 
, O 
and O 
actively O 
seeking O 
social B-protein 
support I-protein 
as O 
a O 
major O 
coping O 
strategy O 
( O 
R2 O 
= O 
0 O 
. O 
33 O 
, O 
F O 
( O 
5 O 
, O 
55 O 
) O 
= O 
5 O 
. O 
5 O 
, O 
p O 
less O 
than O 
0 O 
. O 
0004 O 
) O 
. O 

Findings O 
are O 
discussed O 
in O 
terms O 
of O 
host O 
interaction O 
with O 
tumor B-protein 
endocrine I-protein 
status I-protein 
, O 
and O 
the O 
role O 
that O 
social B-protein 
support I-protein 
might O 
play O 
in O 
modulating O 
such O 
activity O 
. O 

[ O 
Estrogen B-protein 
receptor I-protein 
content O 
of O 
peripheral B-cell_type 
blood I-cell_type 
lymphocytes I-cell_type 
in O 
patients O 
with O 
systemic O 
lupus O 
erythematosus O 
] O 
. O 

ER O 
content O 
in O 
lymphocytes B-cell_type 
of O 
peripheral O 
blood O 
from O 
27 O 
SLE O 
patients O 
and O 
20 O 
healthy O 
controls O 
were O 
determined O 
by O 
dextran O 
- O 
coated O 
charcoal O 
assay O 
. O 

ER B-protein 
content O 
in O 
lymphocytes B-cell_type 
of O 
each O 
sample O 
was O 
expressed O 
by O 
both O 
fmol O 
/ O 
mg O 
of O 
lymphocyte B-protein 
cytosolic I-protein 
protein I-protein 
and O 
fmol O 
/ O 
micrograms O 
of O 
lymphocyte B-DNA 
DNA I-DNA 
. O 

The O 
results O 
showed O 
that O 
there O 
was O 
no O 
significant O 
difference O 
between O 
the O 
ER B-protein 
content O 
of O 
lymphocytes B-cell_type 
from O 
the O 
controls O 
and O 
that O 
from O 
patients O 
with O 
SLE O 
. O 

But O 
the O 
logarithmic O 
mean O 
of O 
ER B-protein 
content O 
in O 
lymphocytes B-cell_type 
, O 
expressed O 
by O 
fmol O 
/ O 
mg O 
of O 
cytosolic B-protein 
protein I-protein 
, O 
in O 
14 O 
patients O 
with O 
active O 
SLE O 
( O 
0 O 
. O 
9356 O 
+ O 
/ O 
- O 
0 O 
. O 
31 O 
) O 
was O 
significantly O 
higher O 
than O 
that O 
in O 
13 O 
patients O 
with O 
inactive O 
SLE O 
( O 
0 O 
. O 
2979 O 
+ O 
/ O 
- O 
0 O 
. O 
23 O 
, O 
P O 
less O 
than O 
0 O 
. O 
001 O 
) O 
and O 
in O 
the O 
controls O 
( O 
0 O 
. O 
6204 O 
+ O 
/ O 
- O 
0 O 
. O 
52 O 
, O 
P O 
less O 
than O 
0 O 
. O 
001 O 
) O 
. O 

The O 
normal O 
upper O 
limit O 
of O 
ER B-protein 
content O 
in O 
lymphocytes B-cell_type 
, O 
expressed O 
by O 
fmol O 
/ O 
micrograms O 
of O 
DNA O 
, O 
was O 
0 O 
. O 
136 O 
. O 

The O 
elevated O 
rate O 
of O 
ER B-protein 
content O 
in O 
lymphocytes B-cell_type 
in O 
14 O 
active O 
SLE O 
( O 
92 O 
. O 
9 O 
% O 
) O 
was O 
also O 
higher O 
than O 
that O 
in O 
quieiescent O 
patients O 
( O 
23 O 
. O 
1 O 
% O 
, O 
P O 
less O 
than O 
0 O 
. O 
001 O 
) O 
and O 
in O 
the O 
controls O 
( O 
10 O 
% O 
, O 
P O 
less O 
than O 
0 O 
. O 
001 O 
) O 
. O 

Moreover O 
, O 
the O 
elevated O 
level O 
of O 
ER B-protein 
content O 
was O 
found O 
to O 
be O 
related O 
to O 
the O 
positive O 
antidsDNA B-protein 
antibody I-protein 
and O 
hypocomplementemia O 
. O 

An O 
in O 
vitro O 
globin B-DNA 
gene I-DNA 
switching O 
model O 
based O 
on O 
differentiated B-cell_type 
embryonic I-cell_type 
stem I-cell_type 
cells I-cell_type 
. O 

We O 
used O 
mouse B-cell_type 
embryonic I-cell_type 
stem I-cell_type 
( I-cell_type 
ES I-cell_type 
) I-cell_type 
cells I-cell_type 
to O 
study O 
globin B-DNA 
gene I-DNA 
expression O 
and O 
switching O 
in O 
vitro O 
. O 

We O 
show O 
that O 
ES B-cell_type 
- I-cell_type 
derived I-cell_type 
embryoid I-cell_type 
bodies I-cell_type 
express O 
the O 
full O 
complement O 
of O 
mouse B-DNA 
embryonic I-DNA 
globin I-DNA 
genes I-DNA 
in O 
the O 
correct O 
temporal O 
order O 
and O 
that O 
on O 
further O 
differentiation O 
, O 
a O 
switch O 
occurs O 
to O 
the O 
fetal B-DNA 
/ I-DNA 
adult I-DNA 
genes I-DNA 
. O 

In O 
addition O 
, O 
the O 
erythroid B-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
NF B-protein 
- I-protein 
E1 I-protein 
was O 
shown O 
to O 
be O 
expressed O 
coordinately O 
with O 
that O 
of O 
globin B-protein 
in O 
embryoid B-cell_type 
bodies I-cell_type 
. O 

We O 
conclude O 
from O 
these O 
experiments O 
that O 
the O 
ES O 
cell O 
system O 
provides O 
a O 
good O 
model O 
to O 
study O 
hematopoietic O 
development O 
. O 

When O 
the O 
human O 
epsilon O 
- O 
or O 
beta O 
- O 
globin O 
genes O 
driven O 
by O 
the O 
dominant B-DNA 
control I-DNA 
region I-DNA 
( O 
DCR B-DNA 
) O 
are O 
introduced O 
into O 
this O 
system O 
, O 
the O 
human B-DNA 
epsilon I-DNA 
- I-DNA 
globin B-DNA I-DNA 
gene I-DNA I-DNA 
, O 
in O 
contrast O 
to O 
the O 
beta B-DNA 
- I-DNA 
globin B-DNA I-DNA 
gene I-DNA I-DNA 
, O 
is O 
not O 
deregulated O 
by O 
the O 
presence O 
of O 
the O 
DCR B-DNA 
and O 
is O 
expressed O 
strictly O 
as O 
an O 
embryonic B-DNA 
gene I-DNA 
. O 

We O 
conclude O 
from O 
this O 
that O 
the O 
epsilon B-DNA 
- I-DNA 
globin B-DNA I-DNA 
gene I-DNA I-DNA 
is O 
not O 
regulated O 
by O 
competition O 
with O 
other O 
genes O 
in O 
the O 
human B-DNA 
beta I-DNA 
- I-DNA 
globin I-DNA 
locus I-DNA 
. O 

Cloning O 
of O 
a O 
mitogen B-DNA 
- I-DNA 
inducible I-DNA 
gene I-DNA 
encoding O 
a O 
kappa B-protein 
B I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
protein I-protein 
with O 
homology O 
to O 
the O 
rel B-DNA 
oncogene I-DNA 
and O 
to O 
cell B-DNA 
- I-DNA 
cycle I-DNA 
motifs I-DNA 
. O 

We O 
have O 
cloned O 
and O 
characterized O 
a O 
mitogen B-DNA 
- I-DNA 
inducible I-DNA 
gene I-DNA 
isolated O 
from O 
human B-cell_type 
T I-cell_type 
cells I-cell_type 
that O 
predicts O 
a O 
protein O 
of O 
968 B-protein 
amino I-protein 
acids I-protein 
. O 

The O 
amino B-protein 
- I-protein 
terminal I-protein 
domain I-protein 
has O 
regions O 
homologous O 
to O 
the O 
oncogene B-DNA 
rel I-DNA 
and O 
to O 
the O 
developmentally O 
important O 
gene O 
dorsal B-DNA 
of O 
Drosophila O 
. O 

The O 
carboxy B-protein 
- I-protein 
terminal I-protein 
domain I-protein 
contains O 
repeat O 
structures O 
found O 
in O 
a O 
variety O 
of O 
proteins O 
that O 
are O 
involved O 
in O 
cell O 
- O 
cycle O 
control O 
of O 
yeast O 
and O 
in O 
tissue O 
differentiation O 
in O 
Drosophila O 
and O 
Ceanorhabditis O 
elegans O 
, O 
as O 
well O 
as O 
in O 
the O 
putative B-DNA 
human I-DNA 
oncogene I-DNA 
bcl I-DNA 
- I-DNA 
3 I-DNA 
and O 
in O 
the O 
ankyrin B-protein 
protein I-protein 
. O 

A O 
truncated O 
form O 
of O 
the O 
product O 
of O 
this O 
gene O 
translated O 
in O 
vitro O 
is O 
a O 
DNA B-protein 
- I-protein 
binding I-protein 
protein I-protein 
which O 
interacts O 
specifically O 
with O 
the O 
kappa B-DNA 
B I-DNA 
binding I-DNA 
site I-DNA 
found O 
in O 
many O 
inducible B-DNA 
genes I-DNA 
, O 
including O 
the O 
enhancer O 
in O 
human O 
immunodeficiency O 
virus O 
. O 

This O 
gene O 
is O 
yet O 
another O 
in O 
a O 
growing O 
list O 
of O 
important O 
regulatory O 
molecules O 
whose O 
expression O 
is O 
transcriptionally O 
induced O 
upon O 
cellular O 
activation O 
. O 

Extrarenal O 
receptor O 
- O 
effector O 
- O 
mechanisms O 
for O 
aldosterone O 
: O 
the O 
sequence O 
of O 
effects O 
on O 
the O 
cellular O 
electrolyte O 
transport O 
in O 
human B-cell_type 
lymphocytes B-cell_type I-cell_type 
and O 
their O 
implications O 
for O 
disorders O 
of O 
the O 
water O 
and O 
electrolyte O 
balances O 
. O 

High O 
affinity O 
aldosterone O 
binding O 
sites O 
have O 
not O 
only O 
been O 
described O 
in O 
the O 
classic O 
target O 
tissues O 
such O 
as O 
the O 
renal O 
tubules O 
, O 
but O 
also O 
in O 
non O 
- O 
classic O 
target O 
tissues O 
such O 
as O 
the O 
hippocampus O 
, O 
mammary O 
gland O 
, O 
endothelial B-cell_type 
cells I-cell_type 
and O 
, O 
recently O 
, O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
. O 

An O 
in O 
vitro O 
effect O 
of O 
aldosterone O 
on O 
intracellular O 
sodium O 
, O 
potassium O 
and O 
calcium O 
concentrations O 
and O 
cell O 
volume O 
was O 
shown O 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
. O 

In O 
the O 
absence O 
of O 
aldosterone O 
, O 
the O 
intracellular O 
Na O 
+ O 
, O 
K O 
+ O 
and O 
Ca2 O 
+ O 
concentrations O 
and O 
the O 
cell O 
volume O 
decreased O 
significantly O 
, O 
but O 
remained O 
constant O 
when O 
aldosterone O 
( O 
1 O 
. O 
4 O 
nmol O 
/ O 
l O 
) O 
was O 
added O 
to O 
the O 
incubation O 
medium O 
. O 

These O 
effects O 
of O 
aldosterone O 
were O 
blocked O 
by O 
the O 
aldosterone O 
antagonist O 
canrenone O 
( O 
140 O 
nmol O 
/ O 
l O 
) O 
. O 

The O 
sodium B-protein 
/ I-protein 
proton I-protein 
exchanger I-protein 
of O 
the O 
cell O 
membrane O 
could O 
be O 
identified O 
as O 
the O 
primary O 
target O 
of O 
the O 
aldosterone O 
action O 
, O 
possibly O 
non O 
- O 
genomically O 
mediated O 
through O 
membrane B-protein 
receptors I-protein 
. O 

The O 
clinical O 
significance O 
of O 
this O 
model O 
was O 
underlined O 
by O 
the O 
demonstration O 
of O 
absent O 
or O 
a O 
decreased O 
number O 
of O 
mineralocorticoid B-protein 
receptors I-protein 
and O 
the O 
lack O 
of O 
electrolyte O 
response O 
to O 
aldosterone O 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
of O 
patients O 
with O 
pseudohypoaldosteronism O 
and O 
aldosteronism O 
. O 

Additionally O 
, O 
an O 
abnormal O 
effector O 
mechanism O 
could O 
be O 
demonstrated O 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
from O 
essential O 
hypertensives O 
. O 

These O 
studies O 
are O 
the O 
first O 
to O 
demonstrate O 
the O 
significance O 
of O 
extrarenal B-protein 
, I-protein 
nonepithelial I-protein 
mineralocorticoid B-protein I-protein 
receptors I-protein I-protein 
and O 
the O 
related O 
effector O 
mechanism O 
in O 
different O 
disorders O 
of O 
the O 
water O 
and O 
electrolyte O 
balance O 
in O 
man O 
. O 

Immunohistochemical O 
study O 
of O 
steroid O 
hormones O 
and O 
an O 
estrogen O 
binding O 
assay O 
in O 
malignant B-cell_type 
soft I-cell_type 
tissue I-cell_type 
tumors I-cell_type 
. O 

Immunohistochemically O 
, O 
the O 
immunoreaction O 
against O 
5 O 
steroid O 
hormone O 
anti O 
- O 
sera O 
( O 
estradiol O 
, O 
estriol O 
, O 
cortisol O 
, O 
progesterone O 
and O 
testosterone O 
) O 
was O 
examined O 
in O 
39 O 
cases O 
with O 
the O 
malignant B-cell_type 
soft I-cell_type 
tissue I-cell_type 
tumors I-cell_type 
( O 
fibrosarcoma O 
: O 
8 O 
, O 
malignant O 
fibrous O 
histiocytoma O 
: O 
6 O 
, O 
rhabdomyosarcoma O 
: O 
10 O 
, O 
leiomyosarcoma O 
: O 
10 O 
, O 
liposarcoma O 
: O 
5 O 
) O 
. O 

Seventeen O 
cases O 
revealed O 
distinct O 
immunostaining O 
against O 
at O 
least O 
1 O 
of O 
the O 
5 O 
steroid O 
hormones O 
. O 

Immunostained B-cell_type 
tumor I-cell_type 
cells I-cell_type 
were O 
more O 
frequently O 
distributed O 
in O 
the O 
area O 
where O 
tumor O 
cell O 
infiltration O 
was O 
more O 
invasive O 
. O 

The O 
majority O 
of O 
the O 
positive O 
cases O 
occurred O 
in O 
female O 
cases O 
. O 

Furthermore O 
, O 
the O 
existence O 
of O 
estrogen B-protein 
receptor I-protein 
( O 
estrogen O 
binding O 
activity O 
) O 
was O 
examined O 
histochemically O 
in O 
39 O 
cases O 
and O 
it O 
was O 
detected O 
in O 
8 O 
. O 

We O 
concluded O 
that O 
steroid O 
hormones O 
might O 
be O 
closely O 
related O 
to O 
tumor O 
cell O 
infiltration O 
of O 
some O 
malignant B-cell_type 
soft I-cell_type 
tissue I-cell_type 
tumors I-cell_type 
. O 

Involvement O 
of O 
cyclic B-protein 
AMP I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinases I-protein 
in O 
the O 
signal O 
transduction O 
pathway O 
for O 
interleukin B-protein 
- I-protein 
1 I-protein 
. O 

Expression O 
of O 
a O 
highly O 
specific O 
protein O 
inhibitor O 
for O 
cyclic B-protein 
AMP I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinases I-protein 
in O 
interleukin B-protein B-cell_line 
- I-protein I-cell_line 
1 I-protein I-cell_line 
( I-cell_line 
IL I-cell_line 
- I-cell_line 
1 I-cell_line 
) I-cell_line 
- I-cell_line 
responsive I-cell_line 
cells I-cell_line 
blocked O 
IL B-DNA 
- I-DNA 
1 I-DNA 
- I-DNA 
induced I-DNA 
gene I-DNA 
transcription O 
that O 
was O 
driven O 
by O 
the O 
kappa B-DNA 
immunoglobulin I-DNA 
enhancer I-DNA 
or O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
. O 

This O 
inhibitor O 
did O 
not O 
affect O 
protein B-protein 
kinase I-protein 
C I-protein 
- O 
mediated O 
gene O 
transcription O 
, O 
suggesting O 
that O 
cyclic B-protein 
AMP I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinases I-protein 
are O 
involved O 
in O 
the O 
signal O 
transduction O 
pathway O 
for O 
IL B-protein 
- I-protein 
1 I-protein 
in O 
a O 
number O 
of O 
responsive B-cell_type 
cell I-cell_type 
types I-cell_type 
. O 

The O 
Epstein B-DNA 
- I-DNA 
Barr I-DNA 
virus I-DNA 
( I-DNA 
EBV I-DNA 
) I-DNA 
ORI1yt I-DNA 
enhancer I-DNA 
is O 
not O 
B O 
- O 
cell O 
specific O 
and O 
does O 
not O 
respond O 
synergistically O 
to O 
the O 
EBV O 
transcription O 
factors O 
R O 
and O 
Z O 
. O 

The O 
Epstein B-DNA 
- I-DNA 
Barr I-DNA 
virus I-DNA 
DR I-DNA 
promoter I-DNA 
is O 
located O 
upstream O 
of O 
the O 
PstI B-DNA 
repeats I-DNA 
, O 
and O 
in O 
addition O 
to O 
the O 
TATA B-DNA 
box I-DNA 
, O 
it O 
contains O 
an O 
upstream B-DNA 
region I-DNA 
( O 
positions O 
- O 
69 O 
to O 
- O 
220 O 
) O 
responsive O 
to O 
EB1 B-protein 
( I-protein 
Z I-protein 
) I-protein 
( O 
the O 
BZLF1 B-protein 
- I-protein 
encoded I-protein 
transcription I-protein 
factor I-protein 
) O 
and O 
an O 
enhancer B-DNA 
with O 
two O 
functionally O 
distinct O 
domains O 
, O 
A B-DNA 
and O 
B B-DNA 
. O 

Domain B-DNA 
B I-DNA 
has O 
been O 
described O 
as O 
a O 
B B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
EB1 B-protein I-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
( O 
P O 
. O 
M O 
. O 
Lieberman O 
, O 
J O 
. O 
M O 
. O 
Hardwick O 
, O 
and O 
S O 
. O 
D O 
. O 
Hayward O 
, O 
J O 
. O 
Virol O 
. O 
63 O 
: O 
3040 O 
- O 
3050 O 
, O 
1989 O 
) O 
activated O 
synergistically O 
by O 
EB1 B-protein 
and O 
R B-protein 
, O 
an O 
EBV B-protein 
early I-protein 
product I-protein 
encoded O 
by O 
the O 
open B-DNA 
reading I-DNA 
frame I-DNA 
BRLF1 B-DNA I-DNA 
( O 
M O 
. O 
A O 
. O 
Cox O 
, O 
J O 
. O 
Leahy O 
, O 
and O 
J O 
. O 
M O 
. O 
Hardwick O 
, O 
J O 
. O 
Virol O 
. O 
64 O 
: O 
313 O 
- O 
321 O 
, O 
1990 O 
) O 
. O 

We O 
show O 
here O 
that O 
domain B-DNA 
B I-DNA 
is O 
an O 
R B-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
in O 
HeLa B-cell_line 
cells I-cell_line 
and O 
is O 
therefore O 
not O 
an O 
EB1 B-protein B-DNA 
- I-DNA 
responsive I-DNA 
B I-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
element I-DNA 
. O 

However O 
, O 
there O 
is O 
an O 
EB1 B-protein B-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
( O 
ZRE B-DNA 
- I-DNA 
B I-DNA 
) O 
located O 
within O 
the O 
R B-DNA 
- I-DNA 
responsive I-DNA 
enhancer I-DNA 
region I-DNA 
. O 

ZRE B-DNA 
- I-DNA 
B I-DNA 
can O 
be O 
deleted O 
without O 
affecting O 
the O 
R O 
- O 
dependent O 
enhancer O 
activity O 
. O 

Moreover O 
, O 
there O 
is O 
no O 
cooperation O 
or O 
synergy O 
between O 
R B-protein 
and O 
EB1 B-protein 
when O 
activating O 
the O 
B B-DNA 
domain I-DNA 
( O 
ZRE B-DNA 
- I-DNA 
B I-DNA 
plus O 
the O 
R B-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
) O 
positioned O 
as O 
an O 
enhancer B-DNA 
. O 

ZRE B-DNA 
- I-DNA 
B I-DNA 
is O 
therefore O 
not O 
part O 
of O 
the O 
R B-DNA 
- I-DNA 
inducible I-DNA 
enhancer I-DNA 
. O 

We O 
have O 
tested O 
several O 
subregions O 
of O 
the O 
DR B-DNA 
enhancer I-DNA 
B B-DNA 
domain I-DNA 
, O 
either O 
alone O 
or O 
in O 
combination O 
, O 
for O 
their O 
capacity O 
to O 
transmit O 
the O 
R O 
- O 
activating O 
signal O 
to O 
the O 
rabbit B-DNA 
beta I-DNA 
- I-DNA 
globin I-DNA 
promoter I-DNA 
. O 

We O 
found O 
that O 
the O 
R B-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
is O 
composed O 
of O 
four O 
protoenhancers B-DNA 
that O 
span O 
the O 
whole O 
B B-DNA 
domain I-DNA 
. O 

These O 
protoenhancers B-DNA 
alone O 
are O 
weakly O 
or O 
not O 
responsive O 
to O 
R B-protein 
. O 

One O 
of O 
the O 
protoenhancers B-DNA 
contains O 
the O 
overlapping B-DNA 
palindromes I-DNA 
5 O 
' O 
- O 
TTGTCCcgtGGACAAaTGTCC O 
- O 
3 O 
' O 
. O 

However O 
, O 
one O 
palindrome B-DNA 
, O 
either O 
alone O 
or O 
duplicated O 
, O 
or O 
the O 
overlapping B-DNA 
palindromes I-DNA 
did O 
not O 
respond O 
to O 
R O 
. O 

Nuclear O 
3 B-protein 
, I-protein 
5 I-protein 
, I-protein 
3 I-protein 
' I-protein 
- I-protein 
triiodothyronine I-protein 
receptors I-protein 
( O 
T3R B-protein 
) O 
of O 
circulating B-cell_type 
human I-cell_type 
lymphocytes B-cell_type I-cell_type 
in O 
hyper O 
- O 
and O 
hypothyroidism O 
and O 
nonthyroidal O 
diseases O 
. O 

The O 
clinical O 
implications O 
of O 
nuclear O 
T3R B-protein 
alterations O 
of O 
circulating B-cell_type 
lymphocytes B-cell_type I-cell_type 
in O 
hyperthyroidism O 
, O 
hypothyroidism O 
and O 
nonthyroidal O 
diseases O 
were O 
investigated O 
. O 

Nuclear O 
T3R B-protein 
in O 
lymphocytes B-cell_type 
was O 
determined O 
by O 
radio O 
- O 
ligand O 
binding O 
analysis O 
. O 

The O 
results O 
showed O 
that O 
in O 
hyper O 
- O 
and O 
hypothyroid O 
patients O 
the O 
nuclear O 
affinity O 
( O 
Ka O 
) O 
for O 
T3 O 
was O 
similar O 
to O 
that O 
of O 
normal O 
subjects O 
. O 

In O 
hyperthyroidism O 
nuclear O 
T3 O 
maximal O 
binding O 
capacity O 
( O 
MBC O 
) O 
was O 
unaltered O 
, O 
whereas O 
in O 
hypothyroidism O 
the O 
MBC O 
was O 
significantly O 
increased O 
. O 

In O 
the O 
patients O 
with O 
diabetes O 
mellitus O 
, O 
chronic O 
renal O 
failure O 
and O 
hepatic O 
cirrhosis O 
, O 
the O 
nuclear B-protein 
T3R B-protein I-protein 
MBC O 
of O 
lymphocytes B-cell_type 
was O 
about O 
1 O 
. O 
5 O 
- O 
1 O 
. O 
6 O 
times O 
of O 
the O 
normal O 
controls O 
. O 

It O 
was O 
concluded O 
that O 
there O 
existed O 
hormonal O 
regulation O 
of O 
nuclear B-protein 
T3R B-protein I-protein 
, O 
and O 
up O 
- O 
regulation O 
was O 
seen O 
in O 
hypothyroidism O 
and O 
low O 
T3 O 
syndrome O 
. O 

Lymphocyte B-cell_line 
cell I-cell_line 
lines I-cell_line 
from O 
vitamin O 
D O 
- O 
dependent O 
rickets O 
type O 
II O 
show O 
functional O 
defects O 
in O 
the O 
1 B-protein 
alpha I-protein 
, I-protein 
25 I-protein 
- I-protein 
dihydroxyvitamin I-protein 
D3 I-protein 
receptor I-protein 
. O 

Lymphocyte B-cell_line 
cell I-cell_line 
lines I-cell_line 
were O 
established O 
from O 
five O 
patients O 
with O 
vitamin O 
D O 
- O 
dependent O 
rickets O 
, O 
type O 
II O 
( O 
VDDR O 
- O 
II O 
) O 
. O 

These O 
lines O 
were O 
established O 
by O 
infection O 
with O 
human O 
T O 
- O 
lymphotrophic O 
virus O 
type O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
. O 

Binding O 
of O 
[ O 
3H O 
] O 
1 O 
alpha O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
) O 
to O 
its O 
receptor O 
in O 
these O 
cell O 
lines O 
was O 
compared O 
to O 
binding O 
studies O 
using O 
a O 
T B-cell_line 
- I-cell_line 
lymphocyte I-cell_line 
cell I-cell_line 
line I-cell_line 
( O 
S B-cell_line 
- I-cell_line 
LB1 I-cell_line 
) O 
from O 
a O 
normal O 
individual O 
. O 

The O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
receptor O 
of O 
S B-cell_line 
- I-cell_line 
LB1 I-cell_line 
was O 
comparable O 
to O 
the O 
well O 
- O 
characterized O 
chick B-protein 
intestinal I-protein 
1 I-protein 
, I-protein 
25 I-protein 
( I-protein 
OH I-protein 
) I-protein 
2D3 I-protein 
receptor I-protein 
in O 
terms O 
of O 
its O 
ligand O 
binding O 
affinity O 
and O 
capacity O 
, O 
its O 
mobility O 
on O 
5 O 
- O 
20 O 
% O 
sucrose O 
gradients O 
, O 
and O 
its O 
adsorption O 
to O 
and O 
elution O 
properties O 
from O 
DNA O 
- O 
cellulose O 
. O 

Three O 
cell B-cell_line 
lines I-cell_line 
established O 
from O 
patients O 
with O 
VDDR O 
- O 
II O 
( O 
Rh O 
- O 
VDR B-protein 
, O 
Sh O 
- O 
VDR B-protein 
, O 
and O 
Ab O 
- O 
VDR B-protein 
) O 
showed O 
no O 
specific O 
binding O 
of O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
to O 
a O 
receptor B-protein 
and O 
treatment O 
of O 
the O 
cultured B-cell_line 
cells I-cell_line 
with O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
did O 
not O 
stimulate O 
production O 
of O 
24 O 
, O 
25 O 
- O 
dihydroxy O 
- O 
vitamin O 
D3 O 
( O 
24 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
) O 
, O 
a O 
response O 
which O 
is O 
diagnostic O 
of O 
the O 
presence O 
of O 
a O 
functional B-protein 
1 I-protein 
, I-protein 
25 I-protein 
( I-protein 
OH I-protein 
) I-protein 
2D3 I-protein 
receptor I-protein 
. O 

In O 
a O 
fourth O 
cell B-cell_line 
line I-cell_line 
, O 
A1 B-cell_line 
- I-cell_line 
VDR I-cell_line 
, O 
the O 
receptor O 
for O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
had O 
a O 
low O 
binding O 
capacity O 
and O 
25 B-protein 
( I-protein 
OH I-protein 
) I-protein 
D3 I-protein 
- I-protein 
24 I-protein 
- I-protein 
hydroxylase I-protein 
activity O 
was O 
not O 
detectable O 
. O 

Induction O 
of O 
24 O 
, O 
25 O 
- O 
( O 
OH O 
) O 
2D3 O 
synthesis O 
by O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
was O 
observed O 
in O 
the O 
fifth O 
cell B-cell_line 
line I-cell_line 
, O 
designated O 
Ro B-cell_line 
- I-cell_line 
VDR I-cell_line 
, O 
although O 
the O 
sensitivity O 
to O 
hormone O 
treatment O 
was O 
lower O 
than O 
in O 
the O 
control B-cell_line 
cell I-cell_line 
line I-cell_line 
from O 
a O 
normal O 
donor O 
. O 

The O 
capacity O 
of O 
the O 
receptor B-protein 
for O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
was O 
low O 
in O 
Ro B-cell_line 
- I-cell_line 
VDR I-cell_line 
. O 

In O 
all O 
cell B-cell_line 
lines I-cell_line 
where O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
binding O 
to O 
a O 
receptor B-protein 
was O 
detectable O 
, O 
the O 
receptor B-protein 
had O 
the O 
typical O 
sedimentation O 
coefficient O 
of O 
3 O 
. O 
7 O 
S O 
on O 
sucrose O 
density O 
gradient O 
analysis O 
. O 

Binding O 
and O 
elution O 
properties O 
to O 
DNA O 
- O 
cellulose O 
, O 
however O 
, O 
differed O 
from O 
normal O 
in O 
both O 
Ro B-cell_line 
- I-cell_line 
VDR I-cell_line 
and O 
A1 B-cell_line B-cell_line 
- I-cell_line I-cell_line 
VDR I-cell_line I-cell_line 
cells I-cell_line 
where O 
elution O 
from O 
DNA O 
- O 
cellulose O 
occurred O 
at O 
a O 
lower O 
salt O 
concentration O 
than O 
is O 
typical O 
of O 
the O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
receptor B-protein 
. O 

While O 
Ro B-cell_line B-cell_line 
- I-cell_line I-cell_line 
VDR I-cell_line I-cell_line 
cells I-cell_line 
showed O 
typical O 
nuclear O 
localization O 
of O 
the O 
unoccupied B-protein 
1 I-protein 
, I-protein 
25 I-protein 
( I-protein 
OH I-protein 
) I-protein 
2D3 I-protein 
receptor B-protein I-protein 
, O 
neither O 
the O 
unoccupied O 
nor O 
the O 
occupied O 
receptor B-protein 
from O 
A1 B-cell_line B-cell_line 
- I-cell_line I-cell_line 
VDR I-cell_line I-cell_line 
cells I-cell_line 
was O 
completely O 
localized O 
in O 
the O 
nucleus O 
. O 

In O 
a O 
series O 
of O 
functional O 
studies O 
we O 
found O 
that O 
modulation O 
of O 
the O 
level O 
of O 
the O 
mRNAs B-RNA 
coding O 
for O 
both O 
the O 
c B-DNA 
- I-DNA 
myc I-DNA 
oncogene I-DNA 
and O 
the O 
growth O 
factor O 
known O 
as O 
granulocyte O 
- O 
monocyte O 
colony O 
stimulating O 
activity O 
by O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
correlated O 
with O 
the O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
receptor B-protein 
status O 
of O 
these O 
cells O 
. O 

Use O 
of O 
these O 
cell B-cell_line 
lines I-cell_line 
will O 
facilitate O 
further O 
study O 
of O 
the O 
molecular O 
defect O 
( O 
s O 
) O 
in O 
the O 
receptor B-protein 
for O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
in O 
vitamin O 
D O 
- O 
dependent O 
rickets O 
type O 
II O 
and O 
will O 
allow O 
a O 
correlation O 
with O 
impairment O 
of O 
cellular O 
functions O 
. O 

Transcriptional O 
and O 
post O 
- O 
transcriptional O 
regulation O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
expression O 
during O 
monocytic O 
differentiation O 
of O 
human B-cell_line 
myeloid I-cell_line 
leukemic I-cell_line 
cells I-cell_line 
. O 

AP B-protein 
- I-protein 
1 I-protein 
, O 
the O 
polypeptide O 
product O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
, O 
recognizes O 
and O 
binds O 
to O 
specific B-DNA 
DNA I-DNA 
sequences I-DNA 
and O 
stimulates O 
transcription O 
of O 
genes B-DNA 
responsive O 
to O 
certain O 
growth O 
factors O 
and O 
phorbol O 
esters O 
such O 
as O 
12 O 
- O 
O O 
- O 
tetradecanoylphorbol O 
- O 
13 O 
- O 
acetate O 
( O 
TPA O 
) O 
. O 

We O 
studied O 
the O 
effects O 
of O 
TPA O 
on O 
the O 
regulation O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
gene O 
expression O 
in O 
HL B-cell_line 
- I-cell_line 
60 I-cell_line 
cells I-cell_line 
during O 
monocytic O 
differentiation O 
. O 

Low O 
levels O 
of O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
transcripts I-RNA 
were O 
detectable O 
in O 
untreated B-cell_line 
HL I-cell_line 
- I-cell_line 
60 I-cell_line 
leukemic I-cell_line 
cells I-cell_line 
, O 
increased O 
significantly O 
by O 
6 O 
h O 
, O 
and O 
reached O 
near O 
maximal O 
levels O 
by O 
24 O 
h O 
of O 
exposure O 
to O 
32 O 
nM O 
TPA O 
. O 

Similar O 
kinetics O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
induction O 
by O 
TPA O 
were O 
observed O 
in O 
human B-cell_line 
U I-cell_line 
- I-cell_line 
937 I-cell_line 
and O 
THP B-cell_line 
- I-cell_line 
1 I-cell_line 
monocytic I-cell_line 
leukemia I-cell_line 
cells I-cell_line 
. O 

Similar O 
findings O 
were O 
obtained O 
with O 
bryostatin O 
1 O 
( O 
10 O 
nM O 
) O 
, O 
another O 
activator O 
of O 
protein B-protein 
kinase I-protein 
C I-protein 
and O 
inducer O 
of O 
monocytic O 
differentiation O 
. O 

Furthermore O 
, O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
0 O 
. O 
5 O 
microM O 
) O 
, O 
a O 
structurally O 
distinct O 
agent O 
which O 
also O 
induces O 
HL O 
- O 
60 O 
monocytic O 
differentiation O 
, O 
increased O 
c B-DNA 
- I-DNA 
jun I-DNA 
expression O 
. O 

TPA O 
treatment O 
of O 
HL B-cell_line 
- I-cell_line 
60 I-cell_line 
cells I-cell_line 
in O 
the O 
presence O 
of O 
cycloheximide O 
was O 
associated O 
with O 
superinduction O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
transcripts O 
. O 

Run O 
- O 
on O 
analysis O 
demonstrated O 
detectable O 
levels O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
gene O 
transcription O 
in O 
untreated B-cell_line 
HL B-cell_line I-cell_line 
- I-cell_line I-cell_line 
60 I-cell_line I-cell_line 
cells I-cell_line I-cell_line 
, O 
and O 
that O 
exposure O 
to O 
TPA O 
increases O 
this O 
rate O 
3 O 
. O 
3 O 
- O 
fold O 
. O 

Treatment O 
of O 
HL B-cell_line 
- I-cell_line 
60 I-cell_line 
cells I-cell_line 
with O 
both O 
TPA O 
and O 
cycloheximide O 
had O 
no O 
effect O 
on O 
the O 
rates O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
transcription O 
. O 

The O 
half O 
- O 
life O 
of O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
RNA I-RNA 
as O 
determined O 
by O 
treating O 
HL B-cell_line 
- I-cell_line 
60 I-cell_line 
cells I-cell_line 
with O 
TPA O 
and O 
actinomycin O 
D O 
was O 
30 O 
min O 
. O 

In O 
contrast O 
, O 
the O 
half O 
- O 
life O 
of O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
RNA I-RNA 
in O 
TPA O 
- O 
treated O 
HL B-cell_line 
- I-cell_line 
60 I-cell_line 
cells I-cell_line 
exposed O 
to O 
cycloheximide O 
and O 
actinomycin O 
D O 
was O 
greater O 
than O 
2 O 
h O 
. O 

These O 
findings O 
suggested O 
that O 
the O 
increase O 
in O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
RNA I-RNA 
observed O 
during O 
TPA O 
- O 
induced O 
monocytic O 
differentiation O 
is O 
mediated O 
by O 
both O 
transcriptional O 
and O 
post O 
- O 
transcriptional O 
mechanisms O 
. O 

[ O 
Hormonal O 
interactions O 
and O 
glucocorticoid B-protein 
receptors I-protein 
in O 
patients O 
with O 
the O 
nephrotic O 
syndrome O 
] O 
. O 

As O 
many O 
as O 
27 O 
children O 
aged O 
6 O 
to O 
15 O 
years O 
with O 
morphologically O 
verified O 
nephropathies O 
were O 
examined O 
. O 

Four O 
variants O 
of O 
changes O 
in O 
the O 
thyroid O 
status O 
, O 
characteristic O 
of O 
children O 
with O 
different O 
variants O 
of O 
nephrotic O 
syndrome O 
were O 
distinguished O 
: O 
1 O 
) O 
biochemical O 
signs O 
of O 
primary O 
hypothyroidism O 
, O 
2 O 
) O 
biochemical O 
signs O 
of O 
secondary O 
hypothyroidism O 
, O 
3 O 
) O 
low O 
content O 
of O 
T3 O 
, O 
4 O 
) O 
dysfunction O 
of O 
the O 
hypophyseal O 
and O 
thyroid O 
system O 
. O 

It O 
is O 
shown O 
that O 
the O 
low O 
level O 
of O 
steroid B-protein 
receptors I-protein 
, O 
thyroid O 
hormones O 
that O 
the O 
low O 
level O 
of O 
steroid B-protein 
receptors I-protein 
, O 
thyroid O 
hormones O 
( O 
T3 O 
and O 
T4 O 
) O 
and O 
cortisol O 
is O 
typical O 
of O 
children O 
with O 
the O 
signs O 
of O 
renal O 
dysplasia O 
. O 

It O 
is O 
assumed O 
that O 
superaddition O 
under O 
such O 
conditions O 
of O 
immune O 
glomerulopathy O 
( O 
glomerulonephritis O 
and O 
nephrotic O 
syndrome O 
) O 
gives O 
rise O 
to O 
the O 
resistance O 
to O 
the O 
treatment O 
with O 
glucocorticoids O 
. O 

Lymphoid O 
specific O 
gene O 
expression O 
of O 
the O 
adenovirus B-DNA 
early I-DNA 
region I-DNA 
3 I-DNA 
promoter I-DNA 
is O 
mediated O 
by O 
NF B-DNA 
- I-DNA 
kappa I-DNA 
B I-DNA 
binding I-DNA 
motifs I-DNA 
. O 

A O 
primary O 
site O 
of O 
infection O 
by O 
human O 
adenoviruses O 
is O 
lymphoid B-cell_type 
cells I-cell_type 
. O 

However O 
, O 
analysis O 
of O 
the O 
viral B-DNA 
control I-DNA 
elements I-DNA 
and O 
the O 
cellular B-protein 
factors I-protein 
that O 
regulate O 
adenoviral O 
gene O 
expression O 
in O 
lymphocytes B-cell_type 
has O 
not O 
been O 
reported O 
. O 

The O 
adenovirus B-DNA B-protein 
early I-DNA I-protein 
region I-DNA I-protein 
3 I-DNA I-protein 
( I-protein 
ES B-DNA I-protein 
) I-protein 
gene I-protein 
products I-protein 
are O 
involved O 
in O 
the O 
maintenance O 
of O 
viral O 
persistence O 
by O 
complexing O 
with O 
the O 
class B-protein 
I I-protein 
MHC I-protein 
antigens I-protein 
, O 
thus O 
preventing O 
their O 
cell O 
surface O 
expression O 
with O 
a O 
resultant O 
decrease O 
in O 
host O 
immunologic O 
destruction O 
. O 

To O 
determine O 
whether O 
different O 
cellular B-protein 
factors I-protein 
were O 
involved O 
in O 
E3 O 
regulation O 
in O 
lymphocytes B-cell_type 
as O 
compared O 
with O 
HeLa B-cell_line 
cells I-cell_line 
, O 
both O 
DNA O 
binding O 
and O 
transfection O 
analysis O 
with O 
the O 
E3 B-DNA 
promoter I-DNA 
in O 
both O 
cell O 
types O 
were O 
performed O 
. O 

These O 
studies O 
detected O 
two O 
novel B-DNA 
domains I-DNA 
referred O 
to O 
as O 
L1 B-DNA 
and O 
L2 B-DNA 
with O 
a O 
variety O 
of O 
lymphoid O 
but O 
not O 
HeLa O 
extracts O 
. O 

Each O 
of O 
these O 
domains O 
possessed O 
strong O 
homology O 
to O 
motifs O 
previously O 
found O 
to O 
bind O 
the O 
cellular B-protein 
factor I-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
. O 

Transfections O 
of O 
E3 B-DNA 
constructs I-DNA 
linked O 
to O 
the O 
chloramphenicol B-DNA 
acetyltransferase I-DNA 
gene I-DNA 
revealed O 
that O 
mutagenesis O 
of O 
the O 
distal B-DNA 
NF B-protein I-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
motif I-DNA 
( O 
L2 B-DNA 
) O 
had O 
minimal O 
effects O 
on O 
promoter O 
expression O 
in O 
HeLa B-cell_line 
cells I-cell_line 
, O 
but O 
resulted O 
in O 
dramatic O 
decreases O 
in O 
expression O 
by O 
lymphoid B-cell_type 
cells I-cell_type 
. O 

In O 
contrast O 
, O 
mutagenesis O 
of O 
proximal B-DNA 
NF I-DNA 
- I-DNA 
kappa I-DNA 
B I-DNA 
motif I-DNA 
( O 
L1 B-DNA 
) O 
had O 
minimal O 
effects O 
on O 
gene O 
expression O 
in O 
both O 
HeLa B-cell_line 
cells I-cell_line 
and O 
lymphoid B-cell_type 
cells I-cell_type 
but O 
resulted O 
in O 
a O 
small O 
, O 
but O 
reproducible O 
, O 
increase O 
in O 
gene O 
expression O 
in O 
lymphoid B-cell_type 
cells I-cell_type 
when O 
coupled O 
to O 
the O 
L2 B-DNA 
mutation O 
. O 

Reversing O 
the O 
position O 
and O 
subsequent O 
mutagenesis O 
of O 
the O 
L1 B-DNA 
and O 
L2 B-DNA B-DNA 
domains I-DNA 
indicated O 
that O 
the O 
primary B-DNA 
sequence I-DNA 
of O 
these O 
motifs O 
rather O 
than O 
their O 
position O 
in O 
the O 
E3 B-DNA 
promoter I-DNA 
was O 
critical O 
for O 
regulating O 
gene O 
expression O 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
250 O 
WORDS O 
) O 
. O 

Characterization O 
of O 
defensin B-protein 
resistance O 
phenotypes O 
associated O 
with O 
mutations O 
in O 
the O 
phoP B-DNA 
virulence I-DNA 
regulon I-DNA 
of O 
Salmonella O 
typhimurium O 
. O 

The O 
defensin B-protein 
sensitivities O 
of O 
Salmonella O 
typhimurium O 
strains O 
with O 
mutations O 
in O 
the O 
phoP B-DNA 
/ I-DNA 
phoQ I-DNA 
two I-DNA 
- I-DNA 
component I-DNA 
virulence I-DNA 
regulon I-DNA 
were O 
tested O 
by O 
using O 
purified B-protein 
defensins I-protein 
NP B-protein 
- I-protein 
1 I-protein 
and O 
NP B-protein 
- I-protein 
2 I-protein 
. O 

Strains O 
with O 
mutations O 
in O 
either O 
gene O 
of O 
the O 
regulatory B-DNA 
pair I-DNA 
( O 
phoP B-DNA 
[ O 
transcriptional B-DNA 
activator I-DNA 
] O 
or O 
phoQ B-DNA 
[ O 
membrane B-protein 
sensor I-protein 
kinase I-protein 
] O 
) O 
had O 
increased O 
sensitivities O 
to O 
defensin B-protein 
. O 

The O 
predicted O 
periplasmic B-protein 
domain I-protein 
of O 
the O 
PhoQ B-protein 
protein I-protein 
contained O 
a O 
markedly O 
anionic O 
domain O 
that O 
could O 
interact O 
with O 
cationic B-protein 
proteins I-protein 
and O 
that O 
could O 
be O 
responsible O 
for O 
resistance O 
to O 
defensin B-protein 
. O 

Because O 
insertion O 
mutations O 
in O 
phoP B-DNA 
are O 
polar O 
on O 
phoQ B-DNA 
, O 
we O 
constructed O 
strains O 
that O 
expressed O 
the O 
PhoQ B-protein 
protein I-protein 
in O 
the O 
absence O 
of O 
PhoP B-protein 
to O 
test O 
whether O 
resistance O 
to O 
defensin O 
requires O 
only O 
the O 
phoQ B-DNA B-protein 
gene I-protein 
product I-protein 
. O 

We O 
found O 
that O 
resistance O 
to O 
defensin O 
requires O 
the O 
function O 
of O 
both O 
components O 
of O 
this O 
regulatory O 
system O 
, O 
because O 
strains O 
expressing O 
PhoQ B-protein 
without O 
PhoP B-protein 
were O 
still O 
markedly O 
sensitive O 
to O 
defensins B-protein 
. O 

This O 
implied O 
that O 
a O 
pag B-DNA B-protein 
( I-protein 
phoP B-DNA B-DNA I-protein 
- I-DNA I-protein 
activated I-DNA I-protein 
gene I-DNA I-protein 
) I-protein 
product I-protein 
is O 
responsible O 
for O 
defensin B-protein 
resistance O 
. O 

We O 
also O 
tested O 
for O 
the O 
ability O 
of O 
defensins B-protein 
NP B-protein 
- I-protein 
1 I-protein 
, O 
NP B-protein 
- I-protein 
5 I-protein 
, O 
and O 
HNP B-protein 
- I-protein 
1 I-protein 
to O 
activate O 
pag B-DNA 
expression O 
and O 
found O 
that O 
these O 
peptides O 
have O 
no O 
effect O 
. O 

Defensin O 
resistance O 
is O 
not O 
the O 
only O 
virulence O 
characteristic O 
controlled O 
by O 
the O 
PhoP B-protein B-protein 
- B-protein I-protein 
PhoQ I-protein I-protein 
regulon I-protein 
because O 
mutations O 
in O 
pagC B-DNA 
, O 
as O 
well O 
as O 
ones O 
in O 
the O 
phoP B-DNA B-DNA 
locus I-DNA 
that O 
resulted O 
in O 
constitutive O 
pag B-DNA 
activation O 
( O 
phenotype O 
PhoPc B-protein 
) O 
, O 
had O 
no O 
effect O 
on O 
defensin B-protein 
resistance O 
, O 
even O 
though O 
they O 
rendered O 
the O 
organism O 
avirulent O 
and O 
deficient O 
in O 
survival O 
within O 
macrophages B-cell_type 
. O 

The O 
virulence O 
defect O 
conferred O 
by O 
mutations O 
in O 
the O 
phoP B-DNA 
- B-DNA 
phoQ I-DNA 
two O 
- O 
component O 
regulatory O 
system O 
is O 
not O 
completely O 
explained O 
by O 
alterations O 
in O 
resistance O 
to O 
cationic B-protein 
proteins I-protein 
and O 
involves O 
the O 
control O 
of O 
other O 
proteins O 
necessary O 
for O 
S O 
. O 
typhimurium O 
survival O 
within O 
macrophages B-cell_type 
. O 

Stimulation O 
of O 
a O 
human B-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
clone I-cell_line 
with O 
anti B-protein 
- I-protein 
CD3 I-protein 
or O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
induces O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
but O 
not O 
human O 
immunodeficiency O 
virus O 
1 O 
enhancer O 
- O 
dependent O 
transcription O 
. O 

The O 
expression O 
of O 
transiently O 
transfected O 
expression O 
vectors O 
under O 
the O 
control O 
of O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
of O 
the O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
or O 
its O 
enhancer B-DNA 
sequence I-DNA 
and O 
the O 
translocation O 
of O 
the O 
HIV B-protein 
enhancer I-protein 
- I-protein 
binding I-protein 
protein I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
were O 
analyzed O 
in O 
two O 
human O 
T B-cell_line 
- I-cell_line 
cell I-cell_line 
clones I-cell_line 
stimulated O 
through O 
their O 
T B-protein 
- I-protein 
cell I-protein 
receptor I-protein 
complex I-protein 
or O 
by O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
or O 
phorbol O 
12 O 
- O 
myristate O 
13 O 
- O 
acetate O 
. O 

We O 
found O 
a O 
dissociation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
from O 
transactivation O 
of O 
either O 
the O 
HIV B-DNA 
LTR I-DNA 
or O 
the O 
HIV B-DNA 
enhancer I-DNA 
. O 

Interleukin B-protein 
2 I-protein 
induced O 
proliferation O 
but O 
not O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
or O 
LTR B-DNA 
transactivation O 
. O 

Phorbol O 
ester O 
or O 
specific O 
antigen O 
recognition O 
induced O 
HIV B-DNA 
LTR I-DNA 
transactivation O 
, O 
whereas O 
stimulation O 
with O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
or O 
antibody O 
to O 
CD3 B-protein 
did O 
not O 
. O 

The O 
two O 
latter O 
signals O 
were O 
nevertheless O 
able O 
to O 
induce O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
with O 
a O 
pattern O 
in O 
the O 
band O 
- O 
shift O 
assay O 
indistinguishable O 
from O 
that O 
observed O 
using O 
phorbol O 
ester O 
. O 

Our O 
finding O 
that O 
induction O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
by O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
or O 
antibody B-protein 
to I-protein 
CD3 I-protein 
is O 
not O 
sufficient O 
to O 
induce O 
HIV B-DNA 
enhancer I-DNA 
- O 
dependent O 
transcription O 
in O 
cloned B-cell_line 
T I-cell_line 
cells I-cell_line 
contrasts O 
with O 
results O 
obtained O 
in O 
most O 
lymphoblastoid B-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
and O 
indicates O 
that O 
normal O 
T B-cell_type 
lymphocytes B-cell_type I-cell_type 
differ O 
from O 
tumoral B-cell_type 
T I-cell_type 
cells I-cell_type 
in O 
terms O 
of O 
requirements O 
for O 
HIV B-DNA 
LTR I-DNA 
activation O 
. O 

Furthermore O 
, O 
our O 
results O 
suggest O 
that O 
events O 
linked O 
to O 
T O 
- O 
cell O 
activation O 
, O 
in O 
addition O 
to O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
translocation O 
per O 
se O 
, O 
induce O 
functional O 
interactions O 
of O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
complex I-protein 
with O 
the O 
HIV B-DNA 
enhancer I-DNA 
. O 

Decreased O 
concentration O 
of O 
1 B-protein 
, I-protein 
25 I-protein 
- I-protein 
dihydroxyvitamin I-protein 
D3 I-protein 
receptors I-protein 
in O 
peripheral B-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
of O 
patients O 
with O 
X O 
- O 
linked O 
hypophosphatemic O 
rickets O 
: O 
effect O 
of O 
phosphate O 
supplementation O 
. O 

Abnormal O 
renal O 
tubular O 
phosphate O 
transport O 
is O 
considered O 
to O 
be O 
the O 
primary O 
defect O 
in O 
X O 
- O 
linked O 
hypophosphatemic O 
rickets O 
( O 
XLH O 
) O 
. O 

However O 
, O 
the O 
resistance O 
to O 
vitamin O 
D O 
treatment O 
in O 
XLH O 
cannot O 
be O 
explained O 
by O 
hypophosphatemia O 
alone O 
. O 

Since O 
most O 
of O 
the O 
actions O 
of O 
vitamin O 
D O 
are O 
mediated O 
by O 
its O 
receptors O 
( O 
VDR B-protein 
) O 
, O 
abnormalities O 
of O 
VDR B-protein 
have O 
been O 
postulated O 
in O 
XLH O 
. O 

In O 
order O 
to O 
investigate O 
this O 
possibility O 
, O 
we O 
measured O 
the O 
concentration O 
of O 
VDR B-protein 
in O 
PHA B-cell_line 
- I-cell_line 
activated I-cell_line 
peripheral B-cell_type I-cell_line 
mononuclear I-cell_type I-cell_line 
cells I-cell_type I-cell_line 
from O 
10 O 
XLH O 
patients O 
. O 

Patients O 
without O 
phosphate O 
supplementation O 
showed O 
significantly O 
lower O 
concentration O 
( O 
21 O 
. O 
7 O 
+ O 
/ O 
- O 
5 O 
. O 
1 O 
fmol O 
/ O 
mg O 
protein O 
, O 
mean O 
+ O 
/ O 
- O 
SEM O 
) O 
compared O 
to O 
the O 
normal O 
controls O 
( O 
60 O 
. O 
7 O 
+ O 
/ O 
- O 
4 O 
. O 
0 O 
) O 
. O 

On O 
the O 
contrary O 
, O 
there O 
was O 
no O 
significant O 
difference O 
between O 
the O 
phosphate O 
- O 
supplemented O 
patients O 
( O 
58 O 
. O 
3 O 
+ O 
/ O 
- O 
2 O 
. O 
7 O 
) O 
and O 
controls O 
. O 

There O 
was O 
a O 
significant O 
positive O 
correlation O 
between O 
VDR B-protein 
concentration O 
and O 
serum O 
phosphate O 
( O 
P O 
less O 
than O 
0 O 
. O 
05 O 
) O 
. O 

In O 
two O 
patients O 
, O 
VDR B-protein 
was O 
increased O 
after O 
daily O 
phosphate O 
supplementation O 
was O 
started O 
. O 

These O 
results O 
indicate O 
that O 
a O 
decreased O 
concentration O 
of O 
VDR B-protein 
secondary O 
to O 
persistent O 
hypophosphatemia O 
is O 
one O 
of O 
the O 
causes O 
of O 
vitamin O 
D O 
resistance O 
in O 
XLH O 
. O 

Two O 
distinct O 
forms O 
of O 
active B-protein 
transcription I-protein 
factor I-protein 
CREB I-protein 
( O 
cAMP B-protein 
response I-protein 
element I-protein 
binding I-protein 
protein I-protein 
) O 
. O 

Mammalian B-cell_type 
cells I-cell_type 
express O 
two O 
distinct O 
forms O 
of O 
transcription B-protein 
factor I-protein 
CREB B-protein I-protein 
( O 
cAMP B-protein 
response I-protein 
element I-protein 
binding I-protein 
protein I-protein 
) O 
that O 
are O 
apparently O 
the O 
products O 
of O 
alternative O 
splicing O 
of O 
the O 
CREB B-protein B-RNA 
gene I-RNA 
transcript I-RNA 
. O 

The O 
two O 
proteins O 
differ O 
by O 
a O 
14 B-protein 
- I-protein 
amino I-protein 
acid I-protein 
serine I-protein 
- I-protein 
rich I-protein 
insertion I-protein 
present O 
in O 
one O 
of O 
the O 
CREB B-protein B-protein 
isoforms I-protein 
. O 

We O 
show O 
that O 
both O 
CREB B-protein B-protein 
isoforms I-protein 
are O 
expressed O 
in O 
many B-cell_type 
cell I-cell_type 
types I-cell_type 
and O 
mammalian O 
species O 
. O 

Both O 
encode O 
proteins O 
that O 
bind O 
specifically O 
to O 
a O 
cAMP B-DNA 
response I-DNA 
element I-DNA 
in I-DNA 
vitro I-DNA 
. O 

As O 
expected O 
for O 
proteins O 
of O 
this O 
class O 
, O 
the O 
CREB B-protein B-protein 
proteins I-protein 
bind O 
DNA O 
as O 
dimers O 
. O 

Both O 
proteins O 
impart O 
cAMP O 
- O 
regulated O 
transcriptional O 
activity O 
to O 
a O 
heterologous B-DNA 
DNA I-DNA 
- I-DNA 
binding I-DNA 
domain I-DNA 
, O 
showing O 
that O 
cAMP O 
directly O 
modulates O 
the O 
transcriptional O 
stimulatory O 
activity O 
of O 
CREB B-protein 
. O 

The O 
presence O 
of O 
multiple O 
CREB B-protein B-protein 
isoforms I-protein 
with O 
identical O 
DNA O 
- O 
binding O 
specificities O 
but O 
differences O 
in O 
the O 
presumed O 
regulatory B-protein 
domain I-protein 
raises O 
the O 
possibility O 
that O 
CREB B-protein B-protein 
proteins I-protein 
may O 
be O 
able O 
to O 
integrate O 
distinct O 
regulatory O 
signals O 
at O 
the O 
level O 
of O 
gene O 
transcription O 
. O 

Human B-protein 
immunodeficiency I-protein 
virus I-protein 
vpr I-protein 
product I-protein 
is O 
a O 
virion B-protein 
- I-protein 
associated I-protein 
regulatory I-protein 
protein I-protein 
. O 

The O 
vpr B-protein 
product I-protein 
of O 
the O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
acts O 
in O 
trans O 
to O 
accelerate O 
virus O 
replication O 
and O 
cytopathic O 
effect O 
in O 
T B-cell_type 
cells I-cell_type 
. O 

Here O 
it O 
is O 
shown O 
that O 
the O 
HIV O 
- O 
1 O 
viral O 
particle O 
contains O 
multiple O 
copies O 
of O 
the O 
vpr B-protein 
protein I-protein 
. O 

The O 
vpr B-protein 
product I-protein 
is O 
the O 
first O 
regulatory O 
protein O 
of O 
HIV O 
- O 
1 O 
to O 
be O 
found O 
in O 
the O 
virus O 
particle O 
. O 

This O 
observation O 
raises O 
the O 
possibility O 
that O 
vpr B-DNA 
acts O 
to O 
facilitate O 
the O 
early O 
steps O 
of O 
infection O 
before O 
de O 
novo O 
viral O 
protein O 
synthesis O 
occurs O 
. O 

A O 
novel O 
B B-protein 
- I-protein 
cell I-protein 
lineage I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
present O 
at O 
early O 
but O 
not O 
late O 
stages O 
of O 
differentiation B-protein 
. O 

A O 
novel O 
B B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
, O 
BSAP B-protein 
, O 
was O 
identified O 
as O 
a O 
mammalian B-protein 
homolog I-protein 
of O 
the O 
sea B-protein 
urchin I-protein 
protein I-protein 
TSAP B-protein 
, O 
which O 
interacts O 
with O 
the O 
promoters B-DNA 
of O 
four O 
tissue O 
- O 
specific O 
late O 
histone O 
H2A O 
- O 
2 O 
and O 
H2B O 
- O 
2 O 
genes O 
. O 

As O 
shown O 
by O 
mobility O 
- O 
shift O 
, O 
methylation O 
interference O 
, O 
and O 
mutational O 
analyses O 
, O 
the O 
mammalian B-protein 
protein I-protein 
BSAP B-protein 
recognizes O 
all O 
four O 
sea B-DNA 
urchin I-DNA 
binding I-DNA 
sites I-DNA 
in O 
a O 
manner O 
indistinguishable O 
from O 
TSAP B-protein 
; O 
however O 
, O 
the O 
two O 
proteins O 
differ O 
in O 
molecular O 
weight O 
. O 

BSAP B-protein 
is O 
exclusively O 
restricted O 
to O 
the O 
B O 
- O 
cell O 
lineage O 
of O 
lymphoid O 
differentiation O 
. O 

Its O 
expression O 
appears O 
to O 
be O 
activated O 
during O 
pro O 
- O 
B O 
- O 
cell O 
development O 
, O 
is O 
abundant O 
at O 
the O 
pre O 
- O 
B O 
- O 
and O 
mature O 
B O 
- O 
cell O 
stages O 
, O 
but O 
is O 
absent O 
in O 
terminally B-cell_type 
differentiated I-cell_type 
plasma I-cell_type 
cells I-cell_type 
. O 

Moreover O 
, O 
BSAP B-protein 
is O 
clearly O 
a O 
B B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
, O 
as O 
a O 
wild B-DNA 
- I-DNA 
type I-DNA 
but O 
not O 
a O 
mutant B-DNA 
TSAP B-protein I-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
of O 
the O 
sea O 
urchin O 
functions O 
only O 
in O 
transfected B-cell_line 
B I-cell_line 
cells I-cell_line 
as O 
an O 
upstream B-DNA 
promoter I-DNA 
element I-DNA 
. O 

Competition O 
experiments O 
did O 
not O 
reveal O 
any O 
high B-DNA 
- I-DNA 
affinity I-DNA 
binding I-DNA 
site I-DNA 
for O 
BSAP B-protein 
in O 
known O 
regulatory B-DNA 
regions I-DNA 
of O 
immunoglobulin O 
and O 
class O 
II O 
major O 
histocompatibility O 
( O 
MHC O 
) O 
genes O 
, O 
suggesting O 
that O 
BSAP B-protein 
is O 
a O 
regulator O 
of O 
a O 
different O 
set O 
of O 
B B-DNA 
- I-DNA 
lymphoid I-DNA 
- I-DNA 
specific I-DNA 
genes I-DNA 
. O 

Octamer B-protein 
transcription I-protein 
factors I-protein 
and O 
the O 
cell B-DNA 
type I-DNA 
- I-DNA 
specificity I-DNA 
of I-DNA 
immunoglobulin I-DNA 
gene I-DNA 
expression O 
. O 

Antibodies B-protein 
are O 
produced O 
exclusively O 
in O 
B B-cell_type 
lymphocytes B-cell_type I-cell_type 
. O 

The O 
expression O 
of O 
the O 
antibody B-DNA 
- I-DNA 
encoding I-DNA 
genes I-DNA 
, O 
the O 
immunoglobulin B-DNA 
( I-DNA 
Ig I-DNA 
) I-DNA 
genes I-DNA 
, O 
is O 
also O 
restricted O 
to O 
B B-cell_type 
cells I-cell_type 
. O 

The O 
octamer B-DNA 
sequence I-DNA 
ATGCAAAT O 
is O 
present O 
in O 
the O 
promoter B-DNA 
and O 
the O 
enhancer B-DNA 
of O 
Ig B-DNA 
genes I-DNA 
, O 
and O 
plays O 
an O 
important O 
role O 
in O 
its O 
tissue O 
- O 
specific O 
expression O 
. O 

This O 
sequence B-DNA 
motif I-DNA 
is O 
a O 
binding O 
site O 
for O 
nuclear B-protein 
proteins I-protein 
, O 
the O 
so O 
- O 
called O 
octamer B-protein 
transcription I-protein 
factors I-protein 
( O 
Oct B-protein 
or O 
OTF B-protein 
factors I-protein 
) O 
. O 

The O 
Oct B-protein 
- I-protein 
1 I-protein 
protein I-protein 
is O 
present O 
in O 
all O 
cell O 
types O 
analyzed O 
so O 
far O 
, O 
whereas O 
Oct B-protein 
- I-protein 
2A I-protein 
and O 
Oct B-protein 
- I-protein 
2B I-protein 
are O 
found O 
mainly O 
in O 
B B-cell_type 
lymphocytes B-cell_type I-cell_type 
. O 

All O 
three O 
proteins O 
show O 
the O 
same O 
sequence O 
specificity O 
and O 
binding O 
affinity O 
. O 

It O 
appears O 
that O 
the O 
B O 
cell O 
- O 
specific O 
expression O 
of O 
Ig B-DNA 
genes I-DNA 
is O 
mediated O 
at O 
least O 
in O 
part O 
by O 
cell O 
type B-protein 
- I-protein 
specific I-protein 
Oct I-protein 
factors I-protein 
, O 
and O 
that O 
there O 
are O 
both O 
quantitative O 
and O 
qualitative O 
differences O 
between O 
Oct B-protein 
- I-protein 
1 I-protein 
and O 
Oct B-protein 
- I-protein 
2 I-protein 
factors I-protein 
. O 

Recently O 
, O 
a O 
number O 
of O 
other O 
octamer B-protein 
factor I-protein 
variants I-protein 
were O 
identified O 
. O 

Many O 
of O 
these O 
may O 
be O 
created O 
by O 
alternative O 
splicing O 
of O 
a O 
primary B-RNA 
transcript I-RNA 
of O 
one O 
Oct O 
factor O 
gene O 
and O 
may O 
serve O 
a O 
specific O 
function O 
in O 
the O 
fine O 
tuning O 
of O 
gene O 
expression O 
. O 

A O 
factor O 
known O 
to O 
bind O 
to O 
endogenous B-DNA 
Ig I-DNA 
heavy I-DNA 
chain I-DNA 
enhancer I-DNA 
only O 
in O 
lymphocytes B-cell_type 
is O 
a O 
ubiquitously B-protein 
active I-protein 
transcription I-protein 
factor I-protein 
. O 

The O 
transcriptional B-DNA 
enhancer I-DNA 
located O 
in O 
the O 
first O 
intron O 
of O 
the O 
immunoglobulin B-DNA 
heavy I-DNA 
chain I-DNA 
constant I-DNA 
region I-DNA 
is O 
a O 
major O 
determinant O 
of O 
B O 
- O 
cell O 
- O 
specific O 
expression O 
of O 
immunoglobulin B-DNA 
genes I-DNA 
. O 

Like O 
other O 
enhancers B-DNA 
, O 
the O 
Ig B-DNA 
heavy I-DNA 
chain I-DNA 
enhancer I-DNA 
contains O 
several O 
short O 
sequence B-DNA 
motifs I-DNA 
that O 
bind O 
specific B-protein 
transcription I-protein 
factors I-protein 
. O 

Each O 
binding B-DNA 
site I-DNA 
contributes O 
to O 
the O 
overall O 
activity O 
of O 
the O 
enhancer B-DNA 
, O 
however O 
no O 
single O 
element O 
seems O 
absolutely O 
required O 
for O 
activity O 
. O 

For O 
a O 
better O 
understanding O 
of O 
the O 
Ig B-DNA B-DNA 
heavy I-DNA I-DNA 
chain I-DNA I-DNA 
enhancer I-DNA I-DNA 
components I-DNA 
, O 
we O 
have O 
cloned O 
and O 
analyzed O 
individual O 
sequence B-DNA 
elements I-DNA 
. O 

We O 
find O 
that O 
the O 
factor O 
that O 
binds O 
to O 
the O 
E3 B-DNA 
enhancer I-DNA 
motif I-DNA 
, O 
CATGTGGC O 
, O 
is O 
a O 
ubiquitous B-protein 
transcription I-protein 
factor I-protein 
. O 

It O 
is O 
present O 
in O 
an O 
active O 
form O 
in O 
both O 
B B-cell_type 
cells I-cell_type 
and O 
non B-cell_type 
- I-cell_type 
B B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
, O 
where O 
it O 
can O 
mediate O 
transcriptional O 
activation O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

However O 
, O 
despite O 
its O 
ability O 
to O 
activate O 
transcription O 
of O 
a O 
transfected B-DNA 
reporter I-DNA 
gene I-DNA 
, O 
the O 
factor O 
is O 
apparently O 
unable O 
to O 
bind O 
to O 
the O 
endogenous B-DNA 
Ig B-DNA I-DNA 
heavy I-DNA I-DNA 
chain I-DNA I-DNA 
enhancer I-DNA I-DNA 
in O 
non B-cell_type 
- I-cell_type 
lymphoid B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
: O 
In O 
previous O 
experiments O 
by O 
others O 
, O 
the O 
characteristic O 
in O 
vivo O 
footprint O 
of O 
this O 
factor O 
, O 
designated O 
NF B-protein 
- I-protein 
muE3 I-protein 
, O 
was O 
detected O 
in O 
B B-cell_type 
cells I-cell_type 
but O 
not O 
in O 
non B-cell_type 
- I-cell_type 
B I-cell_type 
cells I-cell_type 
. O 

From O 
this O 
and O 
other O 
findings O 
the O 
picture O 
emerges O 
that O 
there O 
are O 
at O 
least O 
three O 
categories O 
of O 
factors O 
which O 
mediate O 
cell O 
- O 
type O 
- O 
specific O 
transcription O 
in O 
B B-cell_type 
lymphocytes B-cell_type I-cell_type 
: O 
( O 
a O 
) O 
cell B-protein 
- I-protein 
specific I-protein 
factors I-protein 
such O 
as O 
Oct B-protein 
- I-protein 
2A I-protein 
and O 
Oct B-protein 
- I-protein 
2B I-protein 
that O 
are O 
not O 
expressed O 
in O 
most O 
other O 
cell O 
types O 
: O 
( O 
b O 
) O 
ubiquitous B-protein 
factors I-protein 
such O 
as O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
that O 
are O 
constitutively O 
active O 
in O 
B B-cell_type 
cells I-cell_type 
but O 
are O 
sequestered O 
in O 
an O 
inactive O 
form O 
in O 
other O 
cells O 
; O 
( O 
c O 
) O 
ubiquitously B-protein 
active I-protein 
factors I-protein 
, O 
exemplified O 
by O 
the O 
one O 
binding O 
to O 
the O 
E3 B-DNA 
sequence I-DNA 
motif I-DNA 
. O 

This O 
factor O 
is O 
present O 
in O 
an O 
active O 
form O 
in O 
a O 
variety O 
of O 
cell O 
types O 
but O 
is O 
apparently O 
unable O 
to O 
bind O 
to O 
the O 
endogenous B-DNA 
Ig B-DNA I-DNA 
heavy I-DNA I-DNA 
chain I-DNA I-DNA 
enhancer I-DNA I-DNA 
in O 
non B-cell_type 
- I-cell_type 
B I-cell_type 
cells I-cell_type 
, O 
perhaps O 
due O 
to O 
a O 
non O 
- O 
permissive O 
chromatin B-DNA 
structure O 
of O 
the O 
Ig B-DNA 
heavy I-DNA 
chain I-DNA 
locus I-DNA 
. O 

[ O 
Endocrine O 
status O 
changes O 
in O 
children O 
with O 
bronchial O 
asthma O 
] O 
. O 

A O 
study O 
was O 
made O 
of O 
adrenocortical O 
function O 
by O 
measuring O 
blood O 
plasma O 
cortisol O 
concentration O 
and O 
amount O 
of O 
glucocorticoid B-protein 
receptors I-protein 
in O 
lymphocytes B-cell_type 
as O 
well O 
as O 
thyroid O 
function O 
by O 
measuring O 
blood O 
plasma O 
triidothyronine O 
and O 
thyroxine O 
concentration O 
in O 
58 O 
bronchial O 
asthma O 
children O 
aged O 
1 O 
to O 
14 O 
years O 
. O 

The O 
authors O 
revealed O 
alterations O 
in O 
the O 
functional O 
activity O 
of O 
the O 
indicated O 
endocrine O 
glands O 
depending O 
on O 
the O 
intensity O 
of O 
bronchial O 
patency O 
disorders O 
and O 
the O 
nature O 
of O 
the O 
therapeutic O 
measures O 
carried O 
out O 
. O 

TAR B-DNA 
independent O 
activation O 
of O 
the O 
human O 
immunodeficiency O 
virus O 
in O 
phorbol O 
ester O 
stimulated O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

Multiple B-DNA 
regulatory I-DNA 
elements I-DNA 
in O 
the O 
human O 
immunodeficiency O 
virus O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
HIV B-DNA 
LTR I-DNA 
) O 
are O 
required O 
for O 
activation O 
of O 
HIV O 
gene O 
expression O 
. O 

Previous O 
transfection O 
studies O 
of O 
HIV B-DNA B-DNA 
LTR I-DNA I-DNA 
constructs I-DNA 
linked O 
to O 
the O 
chloramphenicol B-DNA 
acetyltransferase I-DNA 
gene I-DNA 
indicated O 
that O 
multiple O 
regulatory B-DNA 
regions I-DNA 
including O 
the O 
enhancer B-DNA 
, O 
SP1 B-DNA 
, O 
TATA B-DNA 
and O 
TAR B-DNA 
regions I-DNA 
were O 
important O 
for O 
HIV O 
gene O 
expression O 
. O 

To O 
characterize O 
these O 
regulatory B-DNA 
elements I-DNA 
further O 
, O 
mutations O 
in O 
these O 
regions O 
were O 
inserted O 
into O 
both O 
the O 
5 O 
' O 
and O 
3 O 
' O 
HIV B-DNA 
LTRs I-DNA 
and O 
infectious O 
proviral O 
constructs O 
were O 
assembled O 
. O 

These O 
constructs O 
were O 
transfected O 
into O 
either O 
HeLa B-cell_line 
cells I-cell_line 
, O 
Jurkat B-cell_line 
cells I-cell_line 
or O 
U937 B-cell_line 
cells I-cell_line 
in O 
both O 
the O 
presence O 
and O 
absence O 
of O 
phorbol O 
esters O 
which O 
have O 
previously O 
been O 
demonstrated O 
to O 
activate O 
HIV O 
gene O 
expression O 
. O 

Viral O 
gene O 
expression O 
was O 
assayed O 
by O 
the O 
level O 
of O 
p24 B-protein 
gag I-protein 
protein I-protein 
released O 
from O 
cultures O 
transfected O 
with O 
the O 
proviral O 
constructs O 
. O 

Results O 
in O 
all O 
cell O 
lines O 
indicated O 
that O 
mutations O 
of O 
the O 
SP1 B-DNA 
, O 
TATA B-DNA 
and O 
the O 
TAR B-DNA 
loop I-DNA 
and O 
stem B-DNA 
secondary I-DNA 
structure I-DNA 
resulted O 
in O 
marked O 
decreases O 
in O 
gene O 
expression O 
while O 
mutations O 
of O 
the O 
enhancer B-DNA 
motif I-DNA 
or O 
TAR B-DNA 
primary I-DNA 
sequence I-DNA 
resulted O 
in O 
only O 
slight O 
decreases O 
. O 

However O 
, O 
viruses O 
containing O 
mutations O 
in O 
either O 
the O 
TAR B-DNA 
loop I-DNA 
sequences I-DNA 
or O 
stem B-DNA 
secondary I-DNA 
structure I-DNA 
which O 
were O 
very O 
defective O 
for O 
gene O 
expression O 
in O 
untreated O 
Jurkat B-cell_line 
cells I-cell_line 
, O 
gave O 
nearly O 
wild O 
- O 
type O 
levels O 
of O 
gene O 
expression O 
in O 
phorbol O 
ester O 
- O 
treated O 
Jurkat B-cell_line 
cells I-cell_line 
but O 
not O 
in O 
phorbol B-cell_line 
ester I-cell_line 
- I-cell_line 
treated I-cell_line 
HeLa I-cell_line 
or O 
U937 B-cell_line 
cells I-cell_line 
. O 

High O 
level O 
gene O 
expression O 
of O 
these O 
TAR B-DNA 
mutant I-DNA 
constructs I-DNA 
in O 
phorbol O 
ester O 
- O 
treated O 
Jurkat B-cell_line 
cells I-cell_line 
was O 
eliminated O 
by O 
second O 
site O 
mutations O 
in O 
the O 
enhancer B-DNA 
region I-DNA 
or O 
by O 
disruption O 
of O 
the O 
tat B-DNA 
gene I-DNA 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
250 O 
WORDS O 
) O 
. O 

A O 
case O 
of O 
hypersensitivity O 
to O 
thyroid O 
hormones O 
with O 
normally O 
functioning O 
thyroid O 
gland O 
and O 
increased O 
nuclear O 
triiodothyronine B-protein 
receptors I-protein 
. O 

A O 
52 O 
- O 
year O 
- O 
old O 
male O 
presented O 
himself O 
with O 
tachycardia O 
crises O 
which O 
appeared O 
first O 
during O 
childhood O 
, O 
increased O 
in O 
frequency O 
without O 
goiter O 
or O 
exophthalmos O 
. O 

Cardiac O 
and O 
adrenergic O 
diseases O 
were O 
excluded O 
. O 

The O 
thyroid O 
function O 
was O 
normal O 
regarding O 
T4 O 
, O 
free O 
T4 O 
and O 
T3 O 
, O 
TBG O 
, O 
radioiodine O 
uptake O 
, O 
TSH O 
and O 
T3 O 
suppressibility O 
; O 
however O 
the O 
TSH O 
response O 
to O 
TRH O 
was O 
decreased O 
. O 

The O 
lymphocyte B-protein 
nuclear I-protein 
T3 I-protein 
receptor I-protein 
was O 
found O 
with O 
an O 
affinity O 
close O 
to O 
that O 
of O 
normal O 
volunteers O 
( O 
Ka O 
: O 
1 O 
. O 
42 O 
x O 
10 O 
( O 
10 O 
) O 
M O 
- O 
1 O 
vs O 
1 O 
. O 
95 O 
+ O 
/ O 
- O 
0 O 
. O 
35 O 
x O 
10 O 
( O 
10 O 
) O 
M O 
- O 
1 O 
) O 
and O 
a O 
binding O 
capacity O 
markedly O 
increased O 
( O 
9 O 
. O 
9 O 
vs O 
3 O 
. O 
7 O 
+ O 
/ O 
- O 
0 O 
. O 
4 O 
fmol O 
T3 O 
/ O 
100 O 
micrograms O 
DNA O 
) O 
. O 

Pindolol O 
was O 
inefficient O 
on O 
the O 
dysrhythmia O 
which O 
disappeared O 
with O 
carbimazole O 
and O 
relapsed O 
after O 
withdrawal O 
of O 
the O 
antithyroid O 
drug O 
. O 

Under O 
carbimazole O 
, O 
the O 
plasma O 
T4 O 
markedly O 
decreased O 
( O 
27 O 
. O 
7 O 
+ O 
/ O 
- O 
3 O 
. O 
6 O 
nmol O 
/ O 
l O 
) O 
but O 
the O 
patient O 
remained O 
euthyroid O 
. O 

The O 
clinical O 
course O 
and O 
the O 
laboratory O 
data O 
suggest O 
that O 
the O 
tachycardia O 
crises O 
are O 
the O 
consequence O 
of O 
a O 
hypersensitivity O 
of O 
the O 
heart O 
to O 
thyroid O 
hormones O 
, O 
associated O 
with O 
an O 
increased O 
number O 
of O 
T3 B-protein 
nuclear I-protein 
receptor I-protein 
sites O 
in O 
lymphocytes B-cell_type 
. O 

Induction O 
of O 
immediate B-DNA 
early I-DNA 
response I-DNA 
genes I-DNA 
by O 
macrophage B-protein 
colony I-protein 
- I-protein 
stimulating I-protein 
factor I-protein 
in O 
normal B-cell_type 
human I-cell_type 
monocytes I-cell_type 
. O 

A O 
group O 
of O 
coordinately O 
induced O 
protooncogenes B-DNA 
, O 
cytoskeletal O 
, O 
and O 
extracellular O 
matrix O 
genes O 
have O 
been O 
termed O 
immediate B-DNA 
early I-DNA 
response I-DNA 
genes I-DNA 
, O 
and O 
their O 
induction O 
has O 
been O 
associated O 
with O 
growth B-protein 
factor I-protein 
- O 
stimulated O 
cell O 
proliferation O 
. O 

We O 
have O 
investigated O 
the O 
induction O 
of O 
these O 
genes O 
by O 
macrophage B-protein 
- I-protein 
CSF I-protein 
( O 
M B-protein 
- I-protein 
CSF I-protein 
) O 
in O 
human B-cell_type 
monocytes I-cell_type 
that O 
do O 
not O 
proliferate O 
in O 
response O 
to O 
M B-protein 
- I-protein 
CSF I-protein 
but O 
require O 
the O 
factor O 
for O 
optimal O 
cell O 
differentiation O 
. O 

Normal O 
human B-cell_type 
monocytes I-cell_type 
were O 
isolated O 
, O 
carefully O 
washed O 
, O 
and O 
incubated O 
for O 
36 O 
to O 
48 O 
h O 
in O 
fetal O 
bovine O 
serum O 
- O 
containing O 
medium O 
. O 

At O 
the O 
end O 
of O 
this O 
incubation O 
the O 
resting B-cell_type 
cells I-cell_type 
were O 
stimulated O 
with O 
M B-protein 
- I-protein 
CSF I-protein 
, O 
and O 
RNA B-RNA 
was O 
isolated O 
for O 
analysis O 
by O 
Northern O 
blotting O 
. O 

RNA B-RNA 
from O 
control O 
resting B-cell_type 
cells I-cell_type 
contained O 
low O 
to O 
undetectable O 
levels O 
of O 
c B-RNA 
- I-RNA 
jun I-RNA 
, O 
fibronectin B-RNA 
receptor I-RNA 
, O 
and O 
actin B-RNA 
mRNA I-RNA 
. O 

Within O 
15 O 
to O 
30 O 
min O 
of O 
addition O 
of O 
M B-protein 
- I-protein 
CSF I-protein 
, O 
however O 
, O 
there O 
was O 
a O 
dramatic O 
coordinate O 
induction O 
of O 
these O 
genes O 
. O 

The O 
c B-DNA 
- I-DNA 
jun I-DNA 
gene I-DNA 
expression O 
was O 
very O 
transient O 
and O 
was O 
not O 
detectable O 
by O 
60 O 
min O 
after O 
M B-protein 
- I-protein 
CSF I-protein 
addition O 
. O 

In O 
contrast O 
, O 
the O 
expression O 
of O 
actin O 
and O 
fibronectin O 
receptor O 
mRNA O 
was O 
more O 
sustained O 
, O 
and O 
the O 
expression O 
of O 
these O 
genes O 
remained O 
elevated O 
at O 
24 O 
to O 
48 O 
h O 
after O 
M B-protein 
- I-protein 
CSF I-protein 
addition O 
. O 

We O 
also O 
observed O 
the O 
induction O 
of O 
the O 
myelomonocytic B-protein B-DNA 
specific I-protein I-DNA 
tyrosine I-protein I-DNA 
kinase I-protein I-DNA 
hck I-DNA 
gene I-DNA 
simultaneously O 
with O 
the O 
other O 
immediate B-DNA 
early I-DNA 
response I-DNA 
genes I-DNA 
. O 

The O 
protein O 
synthesis O 
inhibitor O 
cycloheximide O 
did O 
not O 
block O 
the O 
induction O 
of O 
any O 
of O 
these O 
genes O 
, O 
and O 
in O 
fact O 
, O 
super O 
- O 
induced O 
the O 
expression O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
and O 
hck B-DNA 
. O 

Nuclear O 
run O 
on O 
transcription O 
of O 
the O 
c B-DNA 
- I-DNA 
jun I-DNA 
, O 
hck B-DNA 
, O 
and O 
actin B-DNA 
genes I-DNA 
. O 

Therefore O 
, O 
in O 
normal B-cell_type 
human B-cell_type I-cell_type 
monocytes I-cell_type I-cell_type 
M B-protein 
- I-protein 
CSF I-protein 
induces O 
immediate B-DNA 
early I-DNA 
response I-DNA 
genes I-DNA 
without O 
inducing O 
cell O 
proliferation O 
. O 

These O 
genes O 
may O 
then O 
play O 
a O 
role O 
in O 
altering O 
the O 
physiologic O 
status O 
of O 
the O 
cells O 
in O 
response O 
to O 
CSF B-protein 
. O 

Inducible O 
nuclear B-protein 
factor I-protein 
binding O 
to O 
the O 
kappa B-DNA 
B I-DNA 
elements I-DNA 
of O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
enhancer I-DNA 
in O 
T B-cell_type 
cells I-cell_type 
can O 
be O 
blocked O 
by O 
cyclosporin O 
A O 
in O 
a O 
signal O 
- O 
dependent O 
manner O 
. O 

Cyclosporin O 
A O 
( O 
CsA O 
) O 
is O 
thought O 
to O 
exert O 
its O 
immunosuppressive O 
effects O 
by O 
inhibiting O 
the O 
expression O 
of O 
a O 
distinct O 
set O 
of O 
lymphokine B-DNA 
genes I-DNA 
which O 
are O 
induced O 
upon O 
T O 
- O 
cell O 
activation O 
, O 
among O 
them O 
the O 
gene O 
coding O 
for O 
interleukin B-protein 
- I-protein 
2 I-protein 
. O 

In O 
addition O 
, O 
the O 
activation O 
of O 
the O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
is O 
partially O 
suppressed O 
. O 

To O 
better O 
understand O 
the O 
molecular O 
mechanisms O 
underlying O 
suppression O 
by O 
CsA O 
, O 
we O 
have O 
investigated O 
the O 
effects O 
of O 
this O 
drug O 
on O 
transcription B-protein 
factors I-protein 
in O 
T B-cell_type 
cells I-cell_type 
. O 

Here O 
we O 
report O 
that O 
the O 
formation O 
of O 
two O 
distinct O 
mitogen B-protein 
- I-protein 
inducible I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
complexes I-protein 
, O 
the O 
kappa B-protein 
B I-protein 
complex I-protein 
within O 
the O 
HIV B-DNA 
enhancer I-DNA 
and O 
the O 
NFAT B-protein 
- I-protein 
1 I-protein 
complex I-protein 
within O 
the O 
interleukin B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
enhancer I-DNA 
, O 
is O 
inhibited O 
in O 
the O 
presence O 
of O 
CsA O 
. O 

The O 
kappa O 
B O 
- O 
binding O 
activity O 
with O 
the O 
HIV B-DNA 
enhancer I-DNA 
is O 
inhibited O 
only O 
if O 
it O 
is O 
activated O 
via O 
the O 
mitogen B-protein 
phytohemagglutinin B-protein 
whereas O 
phorbol O 
myristate O 
acetate O 
- O 
mediated O 
activation O 
is O 
completely O 
insensitive O 
to O 
the O 
drug O 
. O 

This O 
suggests O 
a O 
model O 
in O 
which O 
functionally O 
indistinguishable O 
kappa B-protein 
B I-protein 
complexes I-protein 
can O 
be O 
activated O 
via O 
two O 
separate O 
pathways O 
of O 
signal O 
transduction O 
distinguishable O 
by O 
CsA O 
. O 

Purification O 
of O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
, O 
a O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
that O 
activates O 
the O 
T B-DNA 
- I-DNA 
cell I-DNA 
receptor I-DNA 
C I-DNA 
alpha I-DNA 
gene I-DNA 
enhancer I-DNA 
in O 
a O 
context O 
- O 
dependent O 
manner O 
. O 

The O 
differentiation O 
of O 
T B-cell_type 
cells I-cell_type 
into O 
functionally O 
diverse O 
subpopulations O 
is O 
controlled O 
in O 
part O 
, O 
by O 
transcriptional O 
activation O 
and O 
silencing O 
; O 
however O 
, O 
little O 
is O 
known O 
in O 
detail O 
about O 
the O 
proteins O 
that O 
influence O 
this O 
developmental O 
process O 
. O 

We O 
have O 
purified O 
a O 
new O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
factor I-protein 
, O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
, O 
that O 
is O 
implicated O 
in O 
the O 
activation O 
of O 
genes O 
encoding O 
a O 
major O 
component O 
of O 
the O 
human B-protein 
T I-protein 
- I-protein 
cell I-protein 
receptor I-protein 
( O 
TCR B-protein 
) O 
. O 

TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
, O 
originally O 
identified O 
and O 
purified O 
through O 
its O 
binding O 
sites O 
on O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
promoter I-DNA 
, O 
was O 
found O 
to O 
bind O 
to O 
the O 
TCR B-protein B-DNA 
alpha I-DNA 
enhancer I-DNA 
and O 
to O 
promoters B-DNA 
for O 
several O 
genes B-DNA 
expressed O 
at O 
significantly O 
earlier O 
stages O 
of O 
T O 
- O 
cell O 
development O 
than O 
the O 
TCR B-protein B-DNA 
alpha I-DNA 
gene I-DNA 
( O 
e O 
. O 
g O 
. O 
, O 
p56lck B-DNA 
and O 
CD3 B-DNA 
delta I-DNA 
) O 
. O 

Sequences O 
related O 
to O 
the O 
TCF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
alpha I-protein I-DNA 
binding I-DNA 
motif I-DNA 
( O 
5 O 
' O 
- O 
GGCACCCTTTGA O 
- O 
3 O 
' O 
) O 
are O 
also O 
found O 
in O 
the O 
human B-DNA 
TCR B-protein B-DNA I-DNA 
delta I-DNA I-DNA 
( O 
and O 
possibly O 
TCR B-protein B-DNA 
beta I-DNA 
) O 
enhancers B-DNA 
. O 

Southwestern O 
and O 
gel O 
renaturation O 
experiments O 
with O 
the O 
use O 
of O 
purified O 
protein O 
fractions O 
revealed O 
that O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
activity O 
is O 
derived O 
from O 
a O 
family O 
of O 
57 B-protein 
- I-protein 
to I-protein 
53 I-protein 
- I-protein 
kD I-protein 
proteins I-protein 
that O 
are O 
abundantly O 
expressed O 
in O 
mature O 
and O 
immature O 
T O 
- O 
cell O 
lines O 
( O 
Jurkat B-cell_line 
, O 
CCRF B-cell_line 
- I-cell_line 
CEM I-cell_line 
) O 
and O 
not O 
in O 
mature B-cell_line 
B I-cell_line 
cells I-cell_line 
( O 
JY B-cell_line 
, O 
Namalwa B-cell_line 
) O 
or O 
nonlymphoid B-cell_line 
( I-cell_line 
HeLa I-cell_line 
) I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

A O 
small O 
95 O 
- O 
bp O 
fragment O 
of O 
the O 
TCR B-protein B-DNA 
alpha I-DNA 
control I-DNA 
region I-DNA 
that O 
contains O 
the O 
TCF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
alpha I-protein I-DNA 
binding I-DNA 
site I-DNA 
juxtaposed O 
between O 
a O 
cAMP B-DNA 
- I-DNA 
response I-DNA 
element I-DNA 
( O 
the O 
CRE B-DNA 
or O 
T B-DNA 
alpha I-DNA 
1 I-DNA 
motif I-DNA 
) O 
and O 
the O 
binding B-DNA 
site I-DNA 
for O 
a O 
distinct O 
lymphoid B-protein 
- I-protein 
specific I-protein 
protein I-protein 
( O 
TCF B-protein 
- I-protein 
2 I-protein 
alpha I-protein 
) O 
behaved O 
as O 
a O 
potent O 
T B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
enhancer I-DNA 
in O 
vivo O 
. O 

Tandem O 
copies O 
of O 
this O 
enhancer O 
functioned O 
synergistically O 
in O 
mature B-cell_line 
( I-cell_line 
Jurkat I-cell_line 
) I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
as O 
well O 
as O 
resting O 
and O 
activated O 
immature B-cell_line 
( I-cell_line 
CCRF I-cell_line 
- I-cell_line 
CEM I-cell_line 
) I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Mutation O 
of O 
the O 
TCF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
alpha I-protein I-DNA 
binding I-DNA 
site I-DNA 
diminished O 
enhancer O 
activity O 
and O 
disrupted O 
the O 
synergism O 
observed O 
in O 
vivo O 
between O 
tandem B-DNA 
enhancer I-DNA 
repeats I-DNA 
. O 

The O 
TCF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
alpha I-protein I-DNA 
binding I-DNA 
site I-DNA 
was O 
also O 
required O 
for O 
TCR B-protein 
alpha O 
enhancer O 
activity O 
in O 
transcriptionally O 
active O 
extracts O 
from O 
Jurkat B-cell_line 
but O 
not O 
HeLa B-cell_line 
cells I-cell_line 
, O 
confirming O 
that O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
is O 
a O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
. O 

Curiously O 
, O 
the O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
binding O 
element O 
was O 
inactive O 
in O 
vivo O 
when O 
removed O 
from O 
its O 
neighboring O 
elements O 
on O 
the O 
TCR B-protein B-DNA 
alpha I-DNA 
enhancer I-DNA 
and O 
positioned O 
in O 
one O 
or O 
more O 
copies O 
upstream O 
of O 
a O 
heterologous B-DNA 
promoter I-DNA 
. O 

Thus O 
, O 
the O 
transcriptional O 
activity O 
of O 
TCF B-protein 
- I-protein 
1 I-protein 
alpha I-protein 
appears O 
to O 
depend O 
on O 
the O 
TCF B-protein 
- I-protein 
2 I-protein 
alpha I-protein 
and O 
T B-protein 
alpha I-protein 
1 I-protein 
( O 
CREB B-protein 
) O 
transcription B-protein 
factors I-protein 
and O 
the O 
context O 
of O 
its O 
binding O 
site O 
within O 
the O 
TCR B-protein B-DNA 
alpha I-DNA 
enhancer I-DNA 
. O 

Tandem B-DNA 
AP I-DNA 
- I-DNA 
1 I-DNA 
- I-DNA 
binding I-DNA 
sites I-DNA 
within O 
the O 
human B-DNA 
beta I-DNA 
- I-DNA 
globin I-DNA 
dominant I-DNA 
control I-DNA 
region I-DNA 
function O 
as O 
an O 
inducible B-DNA 
enhancer I-DNA 
in O 
erythroid B-cell_type 
cells I-cell_type 
. O 

A O 
powerful O 
enhancer O 
has O 
been O 
mapped O 
to O 
an O 
18 B-DNA 
- I-DNA 
bp I-DNA 
DNA I-DNA 
segment I-DNA 
located O 
11 O 
kb O 
5 O 
' O 
to O 
the O 
human B-DNA 
epsilon I-DNA 
- I-DNA 
globin I-DNA 
gene I-DNA 
within O 
the O 
dominant B-DNA 
control I-DNA 
or O 
locus B-DNA 
- I-DNA 
activating I-DNA 
region I-DNA 
. O 

This O 
enhancer B-DNA 
is O 
inducible O 
in O 
K562 B-cell_line 
human I-cell_line 
erythroleukemia I-cell_line 
cells I-cell_line 
, O 
increasing O 
linked O 
gamma B-DNA 
- I-DNA 
globin I-DNA 
promoter I-DNA 
/ B-protein 
luciferase I-protein 
gene O 
expression O 
to O 
170 O 
- O 
fold O 
over O 
an O 
enhancerless B-DNA 
construct I-DNA 
. O 

The O 
enhancer B-DNA 
consists O 
of O 
tandem B-DNA 
AP I-DNA 
- I-DNA 
1 I-DNA 
- I-DNA 
binding I-DNA 
sites I-DNA 
, O 
phased O 
10 O 
bp O 
apart O 
, O 
which O 
are O 
both O 
required O 
for O 
full O 
activity O 
. O 

DNA O 
- O 
protein O 
binding O 
assays O 
with O 
nuclear O 
extracts O 
from O 
induced O 
cells O 
demonstrate O 
a O 
high B-protein 
molecular I-protein 
weight I-protein 
complex I-protein 
on O 
the O 
enhancer B-DNA 
. O 

The O 
formation O 
of O 
this O 
complex O 
also O 
requires O 
both O 
AP B-DNA 
- I-DNA 
1 I-DNA 
sites I-DNA 
and O 
correlates O 
with O 
maximal O 
enhancer B-DNA 
activity O 
. O 

Induction O 
of O 
the O 
enhancer B-DNA 
may O 
have O 
a O 
role O 
in O 
the O 
increase O 
in O 
globin B-DNA 
gene I-DNA 
transcription O 
that O 
characterizes O 
erythroid O 
maturation O 
. O 

Enhancer O 
activity O 
appears O 
to O 
be O 
mediated O 
by O 
the O 
binding O 
of O 
a O 
complex O 
of O 
proteins O 
from O 
the O 
jun B-DNA 
and I-DNA 
fos I-DNA 
families I-DNA 
to O 
tandem B-DNA 
AP I-DNA 
- I-DNA 
1 I-DNA 
consensus I-DNA 
sequences I-DNA 
. O 

Identification O 
of O 
a O 
novel B-protein 
factor I-protein 
that O 
interacts O 
with O 
an O 
immunoglobulin B-DNA 
heavy I-DNA 
- I-DNA 
chain I-DNA 
promoter I-DNA 
and O 
stimulates O 
transcription O 
in O 
conjunction O 
with O 
the O 
lymphoid B-protein 
cell I-protein 
- I-protein 
specific I-protein 
factor I-protein 
OTF2 B-protein 
. O 

The O 
tissue O 
- O 
specific O 
expression O 
of O 
the O 
MOPC B-DNA 
141 I-DNA 
immunoglobulin I-DNA 
heavy I-DNA 
- I-DNA 
chain I-DNA 
gene I-DNA 
was O 
studied O 
by O 
using O 
in O 
vitro O 
transcription O 
. O 

B O 
- O 
cell O 
- O 
specific O 
transcription O 
of O 
this O 
gene O 
was O 
dependent O 
on O 
the O 
octamer B-DNA 
element I-DNA 
5 O 
' O 
- O 
ATGCAAAG O 
- O 
3 O 
' O 
, O 
located O 
in O 
the O 
upstream B-DNA 
region I-DNA 
of O 
this O 
promoter B-DNA 
and O 
in O 
the O 
promoters B-DNA 
of O 
all O 
other O 
immunoglobulin O 
heavy O 
- O 
and O 
light O 
- O 
chain O 
genes O 
. O 

The O 
interaction O 
of O 
purified O 
octamer B-protein 
transcription B-protein I-protein 
factors I-protein I-protein 
1 O 
and O 
2 O 
( O 
OTF1 B-protein 
and O 
OTF2 B-protein 
) O 
with O 
the O 
MOPC B-DNA 
141 I-DNA 
promoter I-DNA 
was O 
studied O 
by O 
using O 
electrophoretic O 
mobility O 
shift O 
assays O 
and O 
DNase B-protein 
I I-protein 
footprinting O 
. O 

Purified O 
OTF1 B-protein 
from O 
HeLa B-cell_line 
cells I-cell_line 
and O 
OTF1 B-protein 
and O 
OTF2 B-protein 
from O 
B B-cell_type 
cells I-cell_type 
bound O 
to O 
identical O 
sequences O 
within O 
the O 
heavy B-DNA 
- I-DNA 
chain I-DNA 
promoter I-DNA 
. O 

The O 
OTF O 
interactions O 
we O 
observed O 
extended O 
over O 
the O 
heptamer B-DNA 
element I-DNA 
5 O 
' O 
- O 
CTCAGGA O 
- O 
3 O 
' O 
, O 
and O 
it O 
seems O 
likely O 
that O 
the O 
binding O 
of O 
the O 
purified B-protein 
factors I-protein 
involves O 
cooperation O 
between O 
octamer O 
and O 
heptamer O 
sites O 
in O 
this O 
promoter B-DNA 
. O 

In O 
addition O 
to O 
these O 
elements O 
, O 
we O 
identified O 
a O 
second O 
regulatory B-DNA 
element I-DNA 
, O 
the O 
N B-DNA 
element I-DNA 
with O 
the O 
sequence O 
5 O 
' O 
- O 
GGAACCTCCCCC O 
- O 
3 O 
' O 
. O 

The O 
N B-DNA 
element I-DNA 
could O 
independently O 
mediate O 
low O 
levels O 
of O 
transcription O 
in O 
both O 
B O 
- O 
cell O 
and O 
HeLa O 
- O 
cell O 
extracts O 
, O 
and O 
, O 
in O 
conjunction O 
with O 
the O 
octamer B-DNA 
element I-DNA 
, O 
it O 
can O 
promote O 
high O 
levels O 
of O 
transcription O 
in O 
B O 
- O 
cell O 
extracts O 
. O 

The O 
N B-DNA 
element I-DNA 
bound O 
a O 
transcription B-protein 
factor I-protein 
, O 
NTF B-protein 
, O 
that O 
is O 
ubiquitous O 
in O 
cell B-protein 
- I-protein 
type I-protein 
distribution I-protein 
, O 
and O 
NTF B-protein 
was O 
distinct O 
from O 
any O 
of O 
the O 
previously B-protein 
described I-protein 
proteins I-protein 
that O 
bind O 
to O 
similar O 
sequences O 
. O 

Based O 
on O 
these O 
results O 
, O 
we O 
propose O 
that O 
NTF B-protein 
and O 
OTF2 B-protein 
interactions O 
( O 
both O 
with O 
their O 
cognate B-DNA 
DNA I-DNA 
elements I-DNA 
and O 
possibly O 
at O 
the O 
protein O 
- O 
protein O 
level O 
) O 
may O 
be O 
critical O 
to O 
B O 
- O 
cell O 
- O 
specific O 
expression O 
and O 
that O 
these O 
interactions O 
provide O 
additional O 
pathways O 
for O 
regulating O 
gene O 
expression O 
. O 

NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
as O 
inducible O 
transcriptional B-protein 
activator I-protein 
of O 
the O 
granulocyte B-DNA 
- I-DNA 
macrophage I-DNA 
colony I-DNA 
- I-DNA 
stimulating I-DNA 
factor I-DNA 
gene I-DNA 
. O 

The O 
expression O 
of O 
the O 
gene O 
encoding O 
the O 
granulocyte B-protein 
- I-protein 
macrophage B-protein I-protein 
colony I-protein I-protein 
- I-protein I-protein 
stimulating I-protein I-protein 
factor I-protein I-protein 
( O 
GM B-protein 
- I-protein 
CSF I-protein 
) O 
is O 
induced O 
upon O 
activation O 
of O 
T B-cell_type 
cells I-cell_type 
with O 
phytohemagglutinin B-protein 
and O 
active O 
phorbolester O 
and O 
upon O 
expression O 
of O 
tax1 B-protein 
, O 
a O 
transactivating B-protein 
protein I-protein 
of O 
the O 
human O 
T O 
- O 
cell O 
leukemia O 
virus O 
type O 
I O 
. O 

The O 
same O 
agents O 
induce O 
transcription O 
from O 
the O 
interleukin O 
- O 
2 O 
receptor O 
alpha O 
- O 
chain O 
and O 
interleukin O 
- O 
2 O 
genes O 
, O 
depending O 
on O 
promoter B-DNA 
elements I-DNA 
that O 
bind O 
the O 
inducible B-protein 
transcription I-protein 
factor I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
( O 
or O 
an O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
- I-protein 
like I-protein 
factor I-protein 
) O 
. O 

We O 
therefore O 
tested O 
the O 
possibility O 
that O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
gene I-DNA 
is O 
also O 
regulated O 
by O 
a O 
cognate O 
motif O 
for O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
transcription I-protein 
factor I-protein 
. O 

A O 
recent O 
functional O 
analysis O 
by O 
Miyatake O 
et O 
al O 
. O 
( O 
S O 
. O 
Miyatake O 
, O 
M O 
. O 
Seiki O 
, O 
M O 
. O 
Yoshida O 
, O 
and O 
K O 
. O 
Arai O 
, O 
Mol O 
. O 
Cell O 
. O 
Biol O 
. O 
8 O 
: O 
5581 O 
- O 
5587 O 
, O 
1988 O 
) O 
described O 
a O 
short B-DNA 
promoter I-DNA 
region I-DNA 
in O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
gene I-DNA 
that O 
conferred O 
strong O 
inducibility O 
by O 
T O 
- O 
cell O 
- O 
activating O 
signals O 
and O 
tax1 B-protein 
, O 
but O 
no O 
NF B-protein B-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
- I-DNA 
binding I-DNA 
motifs I-DNA 
were O 
identified O 
. O 

Using O 
electrophoretic O 
mobility O 
shift O 
assays O 
, O 
we O 
showed O 
binding O 
of O 
purified O 
human B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
and O 
of O 
the O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activated O 
in O 
Jurkat B-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
to O 
an O 
oligonucleotide O 
comprising O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
promoter I-DNA 
element I-DNA 
responsible O 
for O 
mediating O 
responsiveness O 
to O 
T O 
- O 
cell O 
- O 
activating O 
signals O 
and O 
tax1 B-protein 
. O 

As O 
shown O 
by O 
a O 
methylation O 
interference O 
analysis O 
and O 
oligonucleotide O 
competition O 
experiments O 
, O 
purified O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binds O 
at O 
positions B-DNA 
- I-DNA 
82 I-DNA 
to I-DNA 
- I-DNA 
91 I-DNA 
( O 
GGGAACTACC O 
) O 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
promoter I-DNA 
sequence O 
with O 
an O 
affinity O 
similar O 
to O 
that O 
with O 
which O 
it O 
binds O 
to O 
the O 
biologically B-DNA 
functional I-DNA 
kappa I-DNA 
B I-DNA 
motif I-DNA 
in O 
the O 
beta B-DNA 
interferon I-DNA 
promoter I-DNA 
( O 
GGGAAATTCC O 
) O 
. O 

Two O 
kappa B-DNA 
B I-DNA 
- I-DNA 
like I-DNA 
motifs I-DNA 
at O 
positions B-DNA 
- I-DNA 
98 I-DNA 
to I-DNA 
- I-DNA 
108 I-DNA 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
promoter I-DNA 
were O 
also O 
recognized O 
but O 
with O 
much O 
lower O 
affinities O 
. O 

Our O 
data O 
provide O 
strong O 
evidence O 
that O 
the O 
expression O 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
gene I-DNA 
following O 
T O 
- O 
cell O 
activation O 
is O 
controlled O 
by O 
binding O 
of O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
transcription I-protein 
factor I-protein 
to O 
a O 
high B-DNA 
- I-DNA 
affinity I-DNA 
binding I-DNA 
site I-DNA 
in O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
promoter I-DNA 
. O 

Effects O 
of O 
mitogenic O 
agents O 
upon O 
glucocorticoid O 
action O 
in O 
human B-cell_type 
tonsillar I-cell_type 
T I-cell_type 
- I-cell_type 
lymphocytes B-cell_type I-cell_type 
. O 

The O 
treatment O 
of O 
human B-cell_type 
tonsillar I-cell_type 
T I-cell_type 
- I-cell_type 
lymphocytes B-cell_type I-cell_type 
with O 
4 O 
- O 
phorbol O 
12 O 
- O 
myristate O 
13 O 
- O 
acetate O 
( O 
PMA O 
) O 
, O 
resulted O 
in O 
about O 
two O 
fold O 
increase O 
in O 
glucocorticoid B-protein 
receptor I-protein 
( O 
GR B-protein 
) O 
number O 
, O 
without O 
any O 
significant O 
change O 
in O 
the O 
receptor O 
affinity O 
. O 

This O 
increase O 
disappeared O 
in O 
the O 
presence O 
of O 
cycloheximide O 
. O 

Alone O 
, O 
PMA O 
and O 
calcium O 
ionophore O 
A23187 O 
did O 
not O 
affect O 
, O 
but O 
together O 
stimulated O 
, O 
like O 
phytohaemagglutinin B-protein 
( O 
PHA B-protein 
) O 
, O 
leucine O 
and O 
, O 
in O 
particular O 
, O 
thymidine O 
incorporation O 
. O 

PMA O 
enhanced O 
slightly O 
the O 
stimulatory O 
effect O 
of O 
PHA B-protein 
. O 

Alone O 
, O 
these O 
agents O 
failed O 
to O 
alter O 
the O 
suppressive O 
effect O 
of O 
dexamethasone O 
on O 
thymidine O 
and O 
leucine O 
incorporation O 
; O 
however O 
, O 
PMA O 
- O 
A23187 O 
and O 
PMA O 
- B-protein 
PHA I-protein 
combinations O 
appeared O 
to O 
antagonize O 
the O 
suppression O 
by O 
dexamethasone O 
. O 

To O 
be O 
or O 
not O 
to O 
be O 
a O 
responder O 
in O 
T O 
- O 
cell O 
responses O 
: O 
ubiquitous O 
oligopeptides O 
in O 
all O 
proteins O 
. O 

Amino O 
acid O 
sequences O 
of O 
all O 
proteins O 
are O 
essays O 
written O 
in O 
the O 
same O 
language O 
. O 

Accordingly O 
, O 
the O 
same O 
set O 
of O 
words O 
and O 
phrases O 
( O 
oligopeptides O 
) O 
appear O 
in O 
totally O 
unrelated B-protein 
proteins I-protein 
. O 

The O 
reason O 
that O 
only O 
certain O 
individuals O 
of O 
particular O 
major B-protein 
histocompatibility I-protein 
complex I-protein 
( I-protein 
MHC I-protein 
) I-protein 
haplotypes I-protein 
can O 
mount O 
T O 
- O 
cell O 
responses O 
against O 
a O 
given O 
antigen O 
of O 
pathogens O 
is O 
found O 
in O 
the O 
fact O 
that O 
T B-protein 
- I-protein 
cell I-protein 
receptors I-protein 
are O 
designed O 
to O 
recognize O 
18 O 
- O 
20 O 
residue O 
- O 
long O 
peptide O 
fragments O 
sandwiched O 
between O 
two O 
alpha B-protein 
- I-protein 
helices I-protein 
of O 
class B-protein 
I I-protein 
or O 
class B-protein 
II I-protein 
MHC I-protein 
molecules I-protein 
. O 

At O 
this O 
range O 
of O 
peptide O 
lengths O 
, O 
most O 
would O 
appear O 
as O 
self O 
, O 
while O 
nonselfness O 
of O 
the O 
remainders O 
are O 
destined O 
to O 
be O 
quite O 
ambiguous O 
, O 
hence O 
creating O 
responders O 
and O 
nonresponders O 
. O 

Two O 
distinct O 
signal O 
transmission O 
pathways O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
are O 
inhibited O 
by O 
complexes O 
formed O 
between O 
an O 
immunophilin B-protein 
and O 
either O 
FK506 O 
or O 
rapamycin O 
. O 

Proliferation O 
and O 
immunologic O 
function O 
of O 
T B-cell_type 
lymphocytes I-cell_type 
are O 
initiated O 
by O 
signals O 
from O 
the O 
antigen B-protein 
receptor I-protein 
that O 
are O 
inhibited O 
by O 
the O 
immunosuppressant O 
FK506 O 
but O 
not O 
by O 
its O 
structural O 
analog O 
, O 
rapamycin O 
. O 

On O 
the O 
other O 
hand O 
, O 
interleukin B-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
- O 
induced O 
signals O 
are O 
blocked O 
by O 
rapamycin O 
but O 
not O 
by O 
FK506 O 
. O 

Remarkably O 
, O 
these O 
two O 
drugs O 
inhibit O 
each O 
other O 
' O 
s O 
actions O 
, O 
raising O 
the O 
possibility O 
that O 
both O 
act O 
by O 
means O 
of O 
a O 
common O 
immunophilin B-protein 
( O 
immunosuppressant B-protein 
binding I-protein 
protein I-protein 
) O 
. O 

We O 
find O 
that O 
the O 
dissociation O 
constant O 
of O 
rapamycin O 
to O 
the O 
FK506 B-protein 
binding I-protein 
protein I-protein 
FKBP B-protein 
( O 
Kd O 
= O 
0 O 
. O 
2 O 
nM O 
) O 
is O 
close O 
to O 
the O 
dissociation O 
constant O 
of O 
FK506 O 
to O 
FKBP B-protein 
( O 
Kd O 
= O 
0 O 
. O 
4 O 
nM O 
) O 
and O 
to O 
their O 
effective O 
biologic O 
inhibitory O 
concentrations O 
. O 

However O 
, O 
an O 
excess O 
of O 
rapamycin O 
is O 
needed O 
to O 
revert O 
FK506 O 
- O 
mediated O 
inhibition O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
production O 
, O 
apoptosis O 
, O 
and O 
transcriptional O 
activation O 
of O 
NF B-protein 
- I-protein 
AT I-protein 
, O 
a O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
necessary O 
for O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
gene I-DNA 
activation O 
. O 

Similarly O 
, O 
an O 
excess O 
of O 
FK506 O 
is O 
needed O 
to O 
revert O 
rapamycin O 
- O 
mediated O 
inhibition O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
proliferation O 
. O 

The O 
drug O 
concentrations O 
required O 
for O 
antagonism O 
may O 
be O 
explained O 
by O 
the O 
relative O 
affinity O 
of O 
the O 
drugs O 
to O 
, O 
and O 
by O 
the O 
abundance O 
of O 
, O 
the O 
immunophilin B-protein 
FKBP B-protein 
. O 

FKBP B-protein 
has O 
been O 
shown O 
to O 
catalyze O 
the O 
interconversion O 
of O 
the O 
cis O 
- O 
and O 
trans O 
- O 
rotamers O 
of O 
the O 
peptidyl B-protein 
- I-protein 
prolyl I-protein 
amide I-protein 
bond I-protein 
of O 
peptide O 
substrates O 
; O 
here O 
we O 
show O 
that O 
rapamycin O 
, O 
like O 
FK506 O 
, O 
is O 
a O 
potent O 
inhibitor O 
of O 
the O 
rotamase O 
activity O 
of O 
FKBP B-protein 
( O 
Ki O 
= O 
0 O 
. O 
2 O 
nM O 
) O 
. O 

Neither O 
FKBP B-protein 
binding O 
nor O 
inhibition O 
of O 
rotamase O 
activity O 
of O 
FKBP B-protein 
alone O 
is O 
sufficient O 
to O 
explain O 
the O 
biologic O 
actions O 
of O 
these O 
drugs O 
. O 

Rather O 
, O 
these O 
findings O 
suggest O 
that O 
immunophilin B-protein 
bound O 
to O 
FK506 O 
interferes O 
with O 
antigen B-protein 
receptor I-protein 
- O 
induced O 
signals O 
, O 
while O 
rapamycin O 
bound O 
to O 
the O 
immunophilin B-protein 
interferes O 
with O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
signals O 
. O 

Adherence O 
- O 
dependent O 
increase O 
in O 
human B-RNA 
monocyte I-RNA 
PDGF I-RNA 
( I-RNA 
B I-RNA 
) I-RNA 
mRNA I-RNA 
is O 
associated O 
with O 
increases O 
in O 
c O 
- O 
fos O 
, O 
c O 
- O 
jun O 
, O 
and O 
EGR2 O 
mRNA O 
. O 

Adherence O 
is O 
an O 
important O 
initial O 
step O 
in O 
the O 
transition O 
of O 
a O 
circulating B-cell_type 
monocyte I-cell_type 
to O 
a O 
tissue B-cell_type 
macrophage I-cell_type 
. O 

This O 
differentiation O 
is O 
accompanied O 
by O 
an O 
augmented O 
capacity O 
to O 
generate O 
growth B-protein 
factors I-protein 
. O 

We O 
hypothesized O 
that O 
adherence O 
itself O 
might O 
be O 
an O 
important O 
trigger O 
for O 
a O 
sequence O 
of O 
gene O 
activation O 
culminating O 
in O 
cells O 
with O 
increased O 
mRNA B-RNA 
encoding O 
profibrotic O 
growth B-protein 
factors I-protein 
such O 
as O 
platelet B-protein 
- I-protein 
derived I-protein 
growth I-protein 
factor I-protein 
B I-protein 
subunit I-protein 
( O 
PDGF B-protein 
[ I-protein 
B I-protein 
] I-protein 
) O 
and O 
transforming B-protein 
growth I-protein 
factor I-protein 
- I-protein 
beta I-protein 
( O 
TGF B-protein 
- I-protein 
beta I-protein 
) O 
. O 

After O 
in O 
vitro O 
adherence O 
, O 
human O 
monocytes O 
had O 
a O 
biphasic O 
increase O 
in O 
PDGF B-protein B-RNA 
( I-protein I-RNA 
B I-protein I-RNA 
) I-protein I-RNA 
mRNA I-RNA 
with O 
peaks O 
at O 
6 O 
h O 
and O 
13 O 
d O 
. O 

No O 
increase O 
in O 
TGF B-protein B-RNA 
- I-protein I-RNA 
beta I-protein I-RNA 
mRNA I-RNA 
was O 
observed O 
. O 

The O 
6 O 
- O 
h O 
increase O 
in O 
PDGF B-protein B-RNA 
( I-protein I-RNA 
B I-protein I-RNA 
) I-protein I-RNA 
mRNA I-RNA 
was O 
adherence O 
dependent O 
, O 
and O 
in O 
addition O 
, O 
was O 
abrogated O 
when O 
the O 
cytoskeletal O 
integrity O 
was O 
compromised O 
by O 
cytochalasin O 
D O 
. O 

The O 
6 O 
- O 
h O 
increase O 
in O 
PDGF B-protein B-RNA 
( I-protein I-RNA 
B I-protein I-RNA 
) I-protein I-RNA 
mRNA I-RNA 
was O 
unaltered O 
by O 
adherence O 
in O 
the O 
presence O 
of O 
the O 
monocyte O 
stimulus O 
lipopolysaccharide O 
. O 

Adherence O 
to O 
either O 
fibronectin O 
or O 
collagen O 
- O 
coated O 
plastic O 
had O 
little O 
consistent O 
effect O 
on O 
PDGF B-protein B-RNA 
( I-protein I-RNA 
B I-protein I-RNA 
) I-protein I-RNA 
mRNA I-RNA 
accumulation O 
. O 

The O 
increased O 
PDGF B-protein B-RNA 
( I-protein I-RNA 
B I-protein I-RNA 
) I-protein I-RNA 
mRNA I-RNA 
observed O 
in O 
adherent B-cell_type 
monocytes I-cell_type 
was O 
accompanied O 
by O 
increases O 
in O 
mRNAs B-RNA 
of O 
the O 
early B-DNA 
growth I-DNA 
response I-DNA 
genes I-DNA 
c B-DNA 
- I-DNA 
fos I-DNA 
( O 
maximal O 
at O 
20 O 
min O 
) O 
, O 
c O 
- O 
jun O 
, O 
and O 
EGR2 O 
( O 
maximal O 
at O 
6 O 
- O 
24 O 
h O 
) O 
. O 

The O 
increase O 
in O 
c O 
- O 
jun O 
and O 
EGR2 O 
, O 
but O 
not O 
c B-DNA 
- I-DNA 
fos I-DNA 
, O 
mRNA O 
was O 
also O 
abrogated O 
by O 
cytochalasin O 
D O 
. O 

These O 
observations O 
suggest O 
that O 
adherence O 
results O 
in O 
increases O 
of O 
c O 
- O 
fos O 
, O 
c O 
- O 
jun O 
, O 
EGR2 O 
, O 
and O 
PDGF O 
( O 
B O 
) O 
mRNA O 
. O 

In O 
addition O 
, O 
the O 
increases O 
in O 
c B-DNA 
- I-DNA 
jun I-DNA 
, O 
EGR2 B-DNA 
, O 
and O 
PDGF B-protein 
( I-protein 
B I-protein 
) I-protein 
may O 
depend O 
on O 
cytoskeletal O 
rearrangement O 
. O 

Modulation O 
of O 
these O 
events O 
at O 
the O 
time O 
of O 
adherence O 
offers O 
a O 
mechanism O 
by O 
which O 
differential O 
priming O 
of O 
the O 
cells O 
may O 
be O 
accomplished O 
. O 

Single O 
cell O 
assay O 
of O 
a O 
transcription B-protein 
factor I-protein 
reveals O 
a O 
threshold O 
in O 
transcription O 
activated O 
by O 
signals O 
emanating O 
from O 
the O 
T B-protein 
- I-protein 
cell I-protein 
antigen I-protein 
receptor I-protein 
. O 

Stimulation O 
of O 
T B-cell_type 
lymphocytes I-cell_type 
through O 
their O 
antigen B-protein 
receptor I-protein 
leads O 
to O 
the O 
appearance O 
of O 
several O 
transcription B-protein 
factors I-protein 
, O 
including O 
NF B-protein 
- I-protein 
AT I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
which O 
are O 
involved O 
in O 
regulating O 
genes O 
required O 
for O 
immunologic O 
activation O 
. O 

To O 
investigate O 
the O 
activity O 
of O 
a O 
single O 
transcription B-protein 
factor I-protein 
in O 
individual B-cell_type 
viable I-cell_type 
cells I-cell_type 
, O 
we O 
have O 
applied O 
an O 
assay O 
that O 
uses O 
the O 
fluorescence O 
- O 
activated O 
cell O 
sorter O 
to O 
quantitate O 
beta B-protein 
- I-protein 
galactosidase I-protein 
( O 
beta B-protein 
- I-protein 
gal I-protein 
) O 
. O 

We O 
have O 
analyzed O 
the O 
distribution O 
of O 
NF B-protein 
- I-protein 
AT I-protein 
transcriptional O 
activity O 
among O 
T B-cell_type 
cells I-cell_type 
undergoing O 
activation O 
by O 
using O 
a O 
construct O 
in O 
which O 
three O 
tandem O 
copies O 
of O 
the O 
NF B-protein B-DNA 
- I-protein I-DNA 
AT I-protein I-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
directs O 
transcription O 
of O 
the O 
lacZ B-DNA 
gene I-DNA 
. O 

Unexpectedly O 
, O 
stimulation O 
of O 
cloned B-cell_line 
stably I-cell_line 
transfected I-cell_line 
Jurkat I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
leads O 
to O 
a O 
bimodal O 
pattern O 
of O 
beta O 
- O 
gal O 
expression O 
in O 
which O 
some O 
cells O 
express O 
no O 
beta B-protein 
- I-protein 
gal I-protein 
and O 
others O 
express O 
high O 
levels O 
. O 

This O 
expression O 
pattern O 
cannot O 
be O 
accounted O 
for O 
by O 
cell O 
- O 
cycle O 
position O 
or O 
heritable O 
variation O 
. O 

Further O 
results O 
, O 
in O 
which O 
beta B-protein 
- I-protein 
gal I-protein 
activity O 
is O 
correlated O 
with O 
NF B-protein 
- I-protein 
AT I-protein 
- O 
binding O 
activity O 
, O 
indicate O 
that O 
the O 
concentration O 
of O 
NF B-protein 
- I-protein 
AT I-protein 
must O 
exceed O 
a O 
critical O 
threshold O 
before O 
transcription O 
initiates O 
. O 

This O 
threshold O 
likely O 
reflects O 
the O 
NF B-protein 
- I-protein 
AT I-protein 
concentration O 
- O 
dependent O 
assembly O 
of O 
transcription B-protein 
complexes I-protein 
at O 
the O 
promoter B-DNA 
. O 

Similar O 
constructs O 
controlled O 
by O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
or O 
the O 
entire O 
interleukin B-DNA 
- I-DNA 
2 I-DNA 
enhancer I-DNA 
show O 
bimodal O 
expression O 
patterns O 
during O 
induction O 
, O 
suggesting O 
that O 
thresholds O 
set O 
by O 
the O 
concentration O 
of O 
transcription B-protein 
factors I-protein 
may O 
be O 
a O 
common O 
property O 
of O 
inducible B-DNA 
genes I-DNA 
. O 

The O 
Epstein B-DNA 
- I-DNA 
Barr I-DNA 
virus I-DNA 
( I-DNA 
EBV I-DNA 
) I-DNA 
BMRF1 I-DNA 
promoter I-DNA 
for O 
early B-protein 
antigen I-protein 
( O 
EA B-protein 
- I-protein 
D I-protein 
) O 
is O 
regulated O 
by O 
the O 
EBV B-protein 
transactivators I-protein 
, O 
BRLF1 B-protein 
and O 
BZLF1 B-protein 
, O 
in O 
a O 
cell O 
- O 
specific O 
manner O 
. O 

The O 
Epstein B-protein 
- I-protein 
Barr I-protein 
virus I-protein 
early B-protein I-protein 
antigen I-protein I-protein 
diffuse I-protein 
component I-protein 
( O 
EA B-protein 
- I-protein 
D I-protein 
) O 
is O 
essential O 
for O 
Epstein O 
- O 
Barr O 
virus B-DNA 
DNA I-DNA 
polymerase O 
activity O 
, O 
and O 
its O 
activity O 
is O 
suppressed O 
during O 
latent O 
infection O 
. O 

We O 
investigated O 
the O 
regulation O 
of O 
the O 
promoter B-DNA 
( O 
BMRF1 B-DNA 
) O 
for O 
this O 
early O 
gene O 
by O 
studying O 
its O 
responsiveness O 
in O 
vitro O 
to O 
two O 
immediate B-protein 
- I-protein 
early I-protein 
viral I-protein 
transactivators I-protein 
, O 
BZLF1 B-protein 
( O 
Z B-protein 
) O 
and O 
BRLF1 B-protein 
( O 
R B-protein 
) O 
, O 
focusing O 
on O 
the O 
differences O 
in O 
response O 
in O 
lymphoid B-cell_type 
cells I-cell_type 
and O 
epithelial B-cell_type 
cells I-cell_type 
. O 

In O 
lymphoid B-cell_type 
cells I-cell_type 
, O 
Z B-protein 
or O 
R B-protein 
alone O 
produced O 
only O 
small O 
increases O 
in O 
EA B-protein B-DNA 
- I-protein I-DNA 
D I-protein I-DNA 
promoter I-DNA 
activity O 
, O 
whereas O 
both O 
transactivators B-protein 
together O 
produced O 
a O 
large O 
stimulatory O 
effect O 
. O 

In O 
epithelial B-cell_type 
cells I-cell_type 
, O 
the O 
Z B-protein 
transactivator I-protein 
alone O 
produced O 
maximal O 
stimulation O 
of O 
the O 
EA B-protein B-DNA 
- I-protein I-DNA 
D I-protein I-DNA 
promoter I-DNA 
; O 
the O 
effect O 
of O 
R B-protein 
and O 
Z B-protein 
together O 
was O 
no O 
greater O 
than O 
that O 
of O 
Z B-protein 
alone O 
. O 

Deletional O 
analysis O 
and O 
site O 
- O 
directed O 
mutagenesis O 
of O 
the O 
EA B-protein B-DNA 
- I-protein I-DNA 
D I-protein I-DNA 
promoter I-DNA 
demonstrated O 
that O 
in O 
epithelial B-cell_type 
cells I-cell_type 
the O 
potential O 
AP B-DNA 
- I-DNA 
1 I-DNA 
binding I-DNA 
site I-DNA 
plays O 
an O 
essential O 
role O 
in O 
Z B-protein 
responsiveness O 
, O 
although O 
sequences O 
further O 
upstream O 
are O 
also O 
important O 
. O 

In O 
lymphoid B-cell_type 
cells I-cell_type 
, O 
only O 
the O 
upstream B-DNA 
sequences I-DNA 
are O 
required O 
for O 
transactivation O 
by O 
the O 
Z B-protein 
/ I-protein 
R I-protein 
combination O 
, O 
and O 
the O 
AP B-protein 
- I-protein 
1 I-protein 
site I-protein 
is O 
dispensable O 
. O 

These O 
data O 
suggest O 
that O 
EA B-protein B-DNA 
- I-protein I-DNA 
D I-protein I-DNA 
( I-DNA 
BMRF1 B-DNA I-DNA 
) I-DNA 
promoter I-DNA 
regulation O 
by O 
Z B-protein 
and O 
R B-protein 
is O 
cell O 
type O 
specific O 
and O 
appears O 
to O 
involve O 
different O 
mechanisms O 
in O 
each O 
cell O 
type O 
. O 

Complementary B-DNA 
DNA I-DNA 
encoding O 
the O 
human B-protein 
T I-protein 
- I-protein 
cell I-protein 
FK506 I-protein 
- I-protein 
binding I-protein 
protein I-protein 
, O 
a O 
peptidylprolyl B-protein 
cis I-protein 
- I-protein 
trans I-protein 
isomerase I-protein 
distinct O 
from O 
cyclophilin B-protein 
. O 

The O 
recently O 
discovered O 
macrolide O 
FK506 O 
has O 
been O 
demonstrated O 
to O 
have O 
potent O 
immunosuppressive O 
activity O 
at O 
concentrations O 
100 O 
- O 
fold O 
lower O 
than O 
cyclosporin O 
A O 
, O 
a O 
cyclic O 
undecapeptide O 
that O 
is O 
used O 
to O 
prevent O 
rejection O 
after O 
transplantation O 
of O 
bone O 
marrow O 
and O 
organs O 
, O 
such O 
as O 
kidney O 
, O 
heart O 
, O 
and O 
liver O 
. O 

After O 
the O 
recent O 
discovery O 
that O 
the O 
cyclosporin B-protein 
A I-protein 
- I-protein 
binding I-protein 
protein I-protein 
cyclophilin B-protein 
is O 
identical O 
to O 
peptidylprolyl B-protein 
cis I-protein 
- I-protein 
trans I-protein 
isomerase I-protein 
, O 
a O 
cellular B-protein 
binding I-protein 
protein I-protein 
for O 
FK506 O 
was O 
found O 
to O 
be O 
distinct O 
from O 
cyclophilin B-protein 
but O 
to O 
have O 
the O 
same O 
enzymatic O 
activity O 
. O 

In O 
this O 
study O 
, O 
we O 
isolated O 
a O 
cDNA B-DNA 
coding O 
for O 
FK506 O 
- O 
binding O 
protein O 
( O 
FKBP B-protein 
) O 
from O 
human O 
peripheral O 
blood O 
T B-cell_type 
cells I-cell_type 
by O 
using O 
mixed O 
20 O 
- O 
mer O 
oligonucleotide O 
probes O 
synthesized O 
on O 
the O 
basis O 
of O 
the O 
sequence O 
, O 
Glu O 
- O 
Asp O 
- O 
Gly O 
- O 
Lys O 
- O 
Lys O 
- O 
Phe O 
- O 
Asp O 
, O 
reported O 
for O 
bovine B-protein 
FKBP B-protein I-protein 
. O 

The O 
DNA O 
isolated O 
contained O 
an O 
open O 
reading O 
frame O 
encoding O 
108 O 
amino O 
acid O 
residues O 
. O 

The O 
first O 
40 O 
residues O 
of O 
the O 
deduced O 
amino B-protein 
acid I-protein 
sequence I-protein 
were O 
identical O 
to O 
those O 
of O 
the O 
reported O 
amino O 
- O 
terminal O 
sequence O 
of O 
bovine O 
FKBP B-protein 
, O 
indicating O 
that O 
the O 
DNA O 
sequence O 
isolated O 
represents O 
the O 
gene O 
coding O 
for O 
FKBP B-protein 
. O 

Computer O 
- O 
assisted O 
analysis O 
of O 
the O 
deduced O 
amino O 
acid O 
sequence O 
indicates O 
that O 
FKBP B-protein 
exhibits O 
no O 
internal O 
homology O 
and O 
does O 
not O 
have O 
significant O 
sequence O 
similarity O 
to O 
any O 
other O 
amino O 
acid O 
sequences O 
of O 
known O 
proteins O 
, O 
including O 
cyclophilin B-protein 
. O 

This O 
result O 
suggests O 
that O 
two O 
catalytically O 
similar O 
proteins O 
, O 
cyclophilin B-protein 
and O 
FKBP B-protein 
, O 
evolved O 
independently O 
. O 

In O 
Northern O 
blot O 
analysis O 
, O 
mRNA B-RNA 
species I-RNA 
of O 
approximately O 
1 O 
. O 
8 O 
kilobases O 
that O 
hybridized O 
with O 
human B-DNA 
FKBP B-protein I-DNA 
cDNA I-DNA 
were O 
detected O 
in O 
poly B-RNA 
( I-RNA 
A I-RNA 
) I-RNA 
+ I-RNA 
RNAs I-RNA 
from O 
brain O 
, O 
lung O 
, O 
liver O 
, O 
and O 
placental B-cell_type 
cells I-cell_type 
and O 
leukocytes B-cell_type 
. O 

Induction O 
of O 
Jurkat B-cell_line 
leukemic I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
with O 
phorbol O 
12 O 
- O 
myristate O 
13 O 
- O 
acetate O 
and O 
ionomycin O 
did O 
not O 
affect O 
the O 
level O 
of O 
FKBP B-protein B-RNA 
mRNA I-RNA 
. O 

Southern O 
blot O 
analysis O 
of O 
human B-DNA 
genomic I-DNA 
DNA I-DNA 
digested O 
with O 
different O 
restriction B-protein 
enzymes I-protein 
suggests O 
the O 
existence O 
of O 
only O 
a O 
few O 
copies O 
of O 
the O 
DNA O 
sequence O 
encoding O 
FKBP B-protein 
. O 

This O 
is O 
in O 
contrast O 
to O 
the O 
result O 
that O 
as O 
many O 
as O 
20 O 
copies O 
of O 
the O 
cyclophilin B-protein B-DNA 
gene I-DNA 
and O 
possible O 
pseudogenes O 
may O 
be O 
present O 
in O 
the O 
mammalian B-DNA 
genome I-DNA 
. O 

Involvement O 
of O 
a O 
second O 
lymphoid B-DNA 
- I-DNA 
specific I-DNA 
enhancer I-DNA 
element I-DNA 
in O 
the O 
regulation O 
of O 
immunoglobulin B-DNA 
heavy I-DNA 
- I-DNA 
chain I-DNA 
gene I-DNA 
expression O 
. O 

To O 
determine O 
whether O 
enhancer B-DNA 
elements I-DNA 
in O 
addition O 
to O 
the O 
highly O 
conserved O 
octamer B-DNA 
( I-DNA 
OCTA I-DNA 
) I-DNA 
- I-DNA 
nucleotide I-DNA 
motif I-DNA 
are O 
important O 
for O 
lymphoid O 
- O 
specific O 
expression O 
of O 
the O 
immunoglobulin B-DNA 
heavy I-DNA 
- I-DNA 
chain I-DNA 
( I-DNA 
IgH I-DNA 
) I-DNA 
gene I-DNA 
, O 
we O 
have O 
investigated O 
the O 
effect O 
of O 
mutating O 
the O 
binding B-DNA 
site I-DNA 
for O 
a O 
putative B-protein 
additional I-protein 
lymphoid I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
, O 
designated O 
NF B-protein 
- I-protein 
microB I-protein 
, O 
in O 
the O 
murine B-DNA 
IgH I-DNA 
enhancer I-DNA 
. O 

We O 
demonstrate O 
that O 
the O 
NF B-DNA 
- I-DNA 
microB I-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
plays O 
a O 
critical O 
role O 
in O 
the O 
IgH B-DNA 
enhancer I-DNA 
, O 
because O 
mutation O 
of O 
the O 
microB O 
DNA O 
motif O 
decreased O 
transcriptional O 
activity O 
of O 
the O 
IgH B-DNA 
enhancer I-DNA 
in O 
cells O 
of O 
the O 
B B-cell_type 
- I-cell_type 
cell I-cell_type 
lineage I-cell_type 
but O 
not O 
in O 
nonlymphoid B-cell_type 
cells I-cell_type 
. O 

This O 
effect O 
was O 
comparable O 
to O 
or O 
even O 
stronger O 
than O 
the O 
effect O 
of O 
a O 
mutation O 
in O 
the O 
OCTA B-DNA 
site I-DNA 
. O 

Moreover O 
, O 
combined O 
mutation O 
of O 
both O 
microB B-DNA 
and O 
OCTA B-DNA 
sites I-DNA 
further O 
reduced O 
enhancer O 
activity O 
in O 
lymphoid B-cell_type 
cells I-cell_type 
. O 

Interestingly O 
, O 
alteration O 
of O 
either O 
the O 
microB B-DNA 
or O 
E3 B-DNA 
site I-DNA 
in O 
a O 
70 B-DNA 
- I-DNA 
base I-DNA 
- I-DNA 
pair I-DNA 
fragment I-DNA 
of O 
the O 
IgH B-DNA 
enhancer I-DNA 
that O 
lacks O 
the O 
binding O 
site O 
for O 
OCTA O 
abolished O 
enhancer O 
activity O 
in O 
lymphoid B-cell_type 
cells I-cell_type 
completely O 
. O 

Nevertheless O 
, O 
a O 
multimer O 
of O 
the O 
microB B-DNA B-DNA 
motif I-DNA 
alone O 
showed O 
no O 
enhancer O 
activity O 
. O 

DNase O 
footprinting O 
analysis O 
corroborated O 
the O 
functional O 
data O 
showing O 
that O 
a O 
lymphoid B-protein 
- I-protein 
specific I-protein 
protein I-protein 
binds O 
to O 
the O 
microB B-DNA B-DNA 
DNA I-DNA 
motif I-DNA 
. O 

Our O 
results O 
suggest O 
that O 
the O 
microB B-DNA B-DNA 
element I-DNA 
is O 
a O 
new O 
crucial O 
element O 
important O 
for O 
lymphoid O 
- O 
specific O 
expression O 
of O 
the O 
IgH O 
gene O 
but O 
that O 
interaction O 
with O 
another O 
enhancer B-DNA 
element I-DNA 
is O 
essential O 
for O 
its O 
activity O 
. O 

Stimulation O 
of O 
the O 
human O 
immunodeficiency O 
virus O 
type O 
2 O 
( O 
HIV O 
- O 
2 O 
) O 
gene O 
expression O 
by O 
the O 
cytomegalovirus O 
and O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
transactivator I-DNA 
gene I-DNA 
. O 

Human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
often O 
causes O 
latent O 
infection O 
. O 

Transactivation O 
by O 
some O 
DNA O 
viruses O 
has O 
been O 
implicated O 
in O 
inducing O 
HIV O 
- O 
1 O 
replication O 
and O 
pathogenesis O 
. O 

The O 
transactivator B-DNA 
( I-DNA 
IE I-DNA 
- I-DNA 
2 I-DNA 
) I-DNA 
gene I-DNA 
of O 
the O 
human O 
cytomegalovirus O 
( O 
CMV O 
) O 
can O 
enhance O 
HIV O 
- O 
2 O 
as O 
well O 
as O 
HIV O 
- O 
1 O 
gene O 
expression O 
in O 
vitro O 
. O 

This O 
inducer O 
can O 
act O 
in O 
concert O 
with O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
tat I-DNA 
gene I-DNA 
and O 
T O 
- O 
cell O 
activation O 
in O 
enhancing O 
gene O 
expression O 
in O 
human B-cell_type 
CD4 I-cell_type 
+ I-cell_type 
lymphocytes I-cell_type 
. O 

While O 
the O 
HIV O 
- O 
2 O 
and O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
tat I-DNA 
genes I-DNA 
and O 
T B-protein 
- I-protein 
cell I-protein 
activators I-protein 
apparently O 
employ O 
independent O 
modes O 
of O 
action O 
, O 
the O 
CMV B-DNA 
transactivator I-DNA 
in O 
combination O 
with O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
tat I-DNA 
or O 
T B-protein 
- I-protein 
cell I-protein 
activators I-protein 
may O 
employ O 
a O 
gene O 
activation O 
pathway O 
with O 
some O 
common O 
and O 
some O 
distinct O 
components O 
. O 

Both O 
HIV O 
- O 
2 O 
and O 
CMV B-DNA 
transactivators B-protein I-DNA 
enhance O 
HIV O 
- O 
2 O 
gene O 
expression O 
by O 
transcriptional O 
activation O 
involving O 
transcript O 
initiation O 
as O 
well O 
as O 
elongation O 
, O 
with O 
CMV B-DNA 
transactivator B-protein I-DNA 
affecting O 
elongation O 
more O 
than O 
the O 
initiation O 
. O 

A O 
significant O 
proportion O 
of O 
transcripts B-RNA 
appear O 
to O 
terminate O 
prematurely O 
in O 
the O 
absence O 
of O 
transactivators B-protein 
. O 

Deletion O 
mutation O 
analysis O 
of O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
suggests O 
that O 
the O 
element O 
that O 
responds O 
to O 
CMV O 
transactivation O 
in O 
human B-cell_type 
CD4 I-cell_type 
+ I-cell_type 
lymphocytes I-cell_type 
is O 
either O 
a O 
diffuse O 
one O 
or O 
located O 
downstream O 
of O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
enhancer I-DNA 
element I-DNA 
. O 

Quantitative O 
immunohistochemical O 
analysis O 
of O 
mononuclear B-cell_type 
infiltrates I-cell_type 
in O 
breast O 
carcinomas O 
- O 
- O 
correlation O 
with O 
tumour O 
differentiation O 
. O 

Inflammatory B-cell_type 
infiltrates I-cell_type 
were O 
analysed O 
in O 
tissue O 
sections O 
of O 
76 O 
breast O 
carcinomas O 
by O 
counting O 
the O 
percentage O 
of O 
macrophages B-cell_type 
, O 
IgA O 
+ O 
and O 
IgG O 
+ O 
plasma O 
cells O 
, O 
T B-cell_type 
cells I-cell_type 
with O 
their O 
subpopulations O 
, O 
and O 
natural B-cell_type 
killer I-cell_type 
cells I-cell_type 
, O 
and O 
by O 
measuring O 
postcapillary O 
venules O 
( O 
PCVs O 
, O 
found O 
in O 
12 O 
cases O 
) O 
within O 
the O 
infiltrates O 
. O 

These O 
parameters O 
were O 
correlated O 
with O 
nuclear O 
grade O 
and O 
biochemically O 
determined O 
hormone O 
receptor O 
status O 
, O 
known O 
markers O 
of O 
tumour O 
differentiation O 
. O 

A O 
direct O 
correlation O 
was O 
found O 
between O 
the O 
extent O 
of O 
inflammation O 
and O 
nuclear O 
grade O 
( O 
P O 
less O 
than O 
0 O 
. O 
0001 O 
) O 
, O 
and O 
an O 
inverse O 
correlation O 
between O 
inflammation O 
and O 
oestrogen B-protein 
receptor I-protein 
( O 
OR B-protein 
) O 
positivity O 
( O 
P O 
less O 
than O 
0 O 
. O 
05 O 
) O 
as O 
well O 
as O 
inflammation O 
and O 
progesterone B-protein 
receptor I-protein 
( O 
PR B-protein 
) O 
positivity O 
( O 
P O 
less O 
than O 
0 O 
. O 
05 O 
) O 
. O 

The O 
percentage O 
of O 
the O 
OKT8 B-cell_line 
+ I-cell_line 
suppressor I-cell_line 
/ I-cell_line 
cytotoxic I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
increased O 
when O 
the O 
inflammation O 
expanded O 
from O 
scanty O 
to O 
moderate O 
( O 
P O 
less O 
than O 
0 O 
. O 
02 O 
) O 
. O 

The O 
diameter O 
of O 
the O 
PCVs O 
also O 
increased O 
with O 
increasing O 
inflammatory O 
infiltrate O 
( O 
P O 
less O 
than O 
0 O 
. O 
02 O 
) O 
. O 

In O 
addition O 
, O 
a O 
direct O 
correlation O 
exists O 
between O 
the O 
diameter O 
of O 
the O 
PCVs O 
and O 
both O 
the O 
percentage O 
of O 
the O 
OKT8 B-cell_line 
+ I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
( O 
P O 
less O 
than O 
0 O 
. O 
04 O 
) O 
and O 
the O 
Leu O 
- O 
7 O 
+ O 
natural B-cell_type 
killer I-cell_type 
cells I-cell_type 
( O 
P O 
less O 
than O 
0 O 
. O 
03 O 
) O 
. O 

Reactivity O 
of O 
lymphocytes B-cell_line 
to O 
a O 
progesterone B-protein 
receptor I-protein 
- I-protein 
specific I-protein 
monoclonal I-protein 
antibody I-protein 
. O 

In O 
this O 
study O 
we O 
present O 
evidence O 
for O 
reactivity O 
of O 
pregnancy B-cell_type 
lymphocytes B-cell_line I-cell_type 
, O 
but O 
not O 
nonpregnancy B-cell_type 
lymphocytes B-cell_line I-cell_type 
, O 
with O 
the O 
progesterone B-protein 
receptor I-protein 
- I-protein 
specific I-protein 
monoclonal I-protein 
antibody I-protein 
mPRI B-protein 
. O 

Using O 
an O 
avidin B-protein 
- B-protein 
biotin I-protein 
peroxidase I-protein 
detection O 
system O 
, O 
we O 
found O 
a O 
nuclear O 
staining O 
in O 
14 O 
. O 
6 O 
+ O 
/ O 
- O 
3 O 
. O 
7 O 
% O 
( O 
mean O 
+ O 
/ O 
- O 
SEM O 
, O 
N O 
= O 
27 O 
) O 
of O 
pregnancy B-cell_type 
lymphocytes B-cell_line I-cell_type 
, O 
while O 
only O 
0 O 
. O 
47 O 
+ O 
/ O 
- O 
0 O 
. O 
33 O 
% O 
( O 
mean O 
+ O 
/ O 
- O 
SEM O 
, O 
N O 
= O 
15 O 
) O 
of O 
nonpregnancy B-cell_type 
lymphocytes B-cell_line I-cell_type 
reacted O 
with O 
the O 
antibody O 
. O 

To O 
characterize O 
the O 
receptor O 
- O 
bearing O 
subset O 
, O 
CD8 O 
+ O 
and O 
CD4 O 
+ O 
cells O 
were O 
depleted O 
by O 
complement O 
- O 
dependent O 
lysis O 
. O 

Depletion O 
of O 
CD8 B-cell_line 
+ I-cell_line 
cells I-cell_line 
was O 
accompanied O 
by O 
62 O 
+ O 
/ O 
- O 
18 O 
% O 
loss O 
of O 
progesterone B-protein B-cell_line 
receptor I-protein I-cell_line 
- I-cell_line 
bearing I-cell_line 
cells I-cell_line 
, O 
while O 
depletion O 
of O 
CD4 B-cell_line 
+ I-cell_line 
cells I-cell_line 
resulted O 
in O 
a O 
twofold O 
increase O 
in O 
the O 
number O 
of O 
positively O 
staining O 
lymphocytes B-cell_line 
. O 

In O 
nonpregnancy B-cell_line 
lymphocytes B-cell_line I-cell_line 
a O 
3 O 
- O 
day O 
PHA B-protein 
treatment O 
, O 
as O 
well O 
as O 
allogeneic O 
stimulation O 
, O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
the O 
number O 
of O 
receptor B-cell_type 
- I-cell_type 
containing I-cell_type 
cells I-cell_type 
. O 

These O 
results O 
suggest O 
that O 
pregnancy O 
, O 
but O 
not O 
nonpregnancy O 
, O 
lymphocytes B-cell_line 
contain O 
progesterone B-protein 
binding I-protein 
structures I-protein 
, O 
and O 
that O 
these O 
are O 
inducible O 
by O 
mitogenic O 
or O 
alloantigenic O 
stimuli O 
. O 

Activation O 
of O 
human B-cell_line 
CD4 I-cell_line 
T I-cell_line 
lymphocytes I-cell_line 
. O 

Interaction O 
of O 
fibronectin B-protein 
with O 
VLA B-protein 
- I-protein 
5 I-protein 
receptor I-protein 
on O 
CD4 B-cell_line 
cells I-cell_line 
induces O 
the O 
AP B-protein 
- I-protein 
1 I-protein 
transcription I-protein 
factor I-protein 
. O 

Fibronectin B-protein 
synergized O 
with O 
anti B-protein 
- I-protein 
CD3 I-protein 
antibody I-protein 
to O 
promote O 
CD4 B-protein 
cell O 
proliferation O 
in O 
a O 
serum O 
- O 
free O 
culture O 
system O 
whereas O 
no O 
proliferation O 
was O 
observed O 
when O 
CD4 B-cell_line 
cells I-cell_line 
were O 
cultured O 
with O 
anti B-protein 
- I-protein 
CD3 I-protein 
alone O 
or O 
fibronectin B-protein 
alone O 
. O 

In O 
addition O 
, O 
anti B-protein 
- I-protein 
CD29 I-protein 
( O 
integrin B-protein 
beta I-protein 
1 I-protein 
) O 
as O 
well O 
as O 
anti B-protein 
- I-protein 
VLA I-protein 
- I-protein 
5 I-protein 
( O 
human B-protein 
fibronectin B-protein I-protein 
receptor I-protein 
) O 
antibodies O 
blocked O 
this O 
CD4 B-cell_line 
cell I-cell_line 
activation O 
in O 
this O 
system O 
. O 

Although O 
anti B-protein 
- I-protein 
CD3 I-protein 
alone O 
or O 
fibronectin B-protein 
alone O 
cannot O 
induce O 
IL B-protein 
- I-protein 
2 I-protein 
message O 
by O 
CD4 B-cell_line 
cells I-cell_line 
, O 
the O 
combination O 
of O 
anti B-protein 
- I-protein 
CD3 I-protein 
plus O 
fibronectin B-protein 
induced O 
IL B-protein 
- I-protein 
2 I-protein 
message O 
by O 
CD4 B-cell_line 
cells I-cell_line 
. O 

In O 
an O 
analysis O 
of O 
the O 
molecular O 
mechanism O 
by O 
which O 
IL B-protein 
- I-protein 
2 I-protein 
message O 
was O 
generated O 
, O 
we O 
showed O 
that O 
a O 
fibronectin B-protein 
- O 
VLA O 
- O 
5 O 
fibronectin B-protein B-protein 
receptor I-protein 
interaction O 
may O 
contribute O 
an O 
independent O 
signal O 
distinct O 
from O 
the O 
CD3 B-protein 
pathway O 
of O 
activation O 
by O 
the O 
induction O 
of O 
an O 
AP B-protein 
- I-protein 
1 I-protein 
transcriptional I-protein 
factor I-protein 
. O 

Thus O 
the O 
VLA B-protein 
- I-protein 
5 I-protein 
fibronectin B-protein I-protein 
receptor I-protein 
on O 
CD4 B-cell_line 
cells I-cell_line 
can O 
play O 
a O 
complementary O 
role O 
in O 
CD3 B-protein 
- O 
TCR B-protein 
- O 
mediated O 
signal O 
transduction O 
through O 
its O 
interaction O 
with O 
fibronectin B-protein 
. O 

Glucocorticoid B-protein 
receptors I-protein 
on O 
mononuclear B-cell_type 
leukocytes I-cell_type 
in O 
Alzheimer O 
' O 
s O 
disease O 
. O 

Several O 
lines O 
of O 
evidence O 
suggest O 
disturbances O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
( O 
HPA O 
) O 
system O 
in O 
Alzheimer O 
' O 
s O 
disease O 
( O 
AD O 
) O 
. O 

In O 
an O 
exploration O 
of O 
the O 
potential O 
role O 
of O 
the O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
in O 
AD O 
, O 
GR O 
density O 
and O 
affinity O 
were O 
assessed O 
on O 
mononuclear B-cell_type 
leukocytes I-cell_type 
of O 
12 O 
AD O 
patients O 
and O 
12 O 
healthy O 
controls O 
. O 

GR O 
binding O 
characteristics O 
did O 
not O 
differ O 
between O 
patients O 
and O 
controls O 
or O 
between O 
patients O 
subdivided O 
according O 
to O 
diagnosis O 
or O 
associated O 
clinical O 
features O 
. O 

These O 
data O 
suggest O 
that O 
the O 
abnormalities O 
of O 
the O 
HPA O 
system O 
in O 
AD O 
are O 
not O 
related O 
to O 
a O 
GR B-protein 
deficiency O 
. O 

Oncogene O 
amplification O 
correlates O 
with O 
dense O 
lymphocyte O 
infiltration O 
in O 
human O 
breast O 
cancers O 
: O 
a O 
role O 
for O 
hematopoietic B-protein 
growth I-protein 
factor I-protein 
release O 
by O 
tumor B-cell_type 
cells I-cell_type 
? O 
. O 

One O 
hundred O 
six O 
primary O 
breast O 
cancer O 
samples O 
were O 
analysed O 
for O 
c O 
- O 
erbB2 O 
, O 
int O 
- O 
2 O 
, O 
and O 
c O 
- O 
myc O 
gene O 
amplification O 
. O 

Surgically O 
confirmed O 
nodal O 
involvement O 
was O 
observed O 
in O 
42 O 
% O 
. O 

Level O 
of O 
gene O 
amplification O 
was O 
studied O 
by O 
Southern O 
and O 
/ O 
or O 
slot O 
blot O 
techniques O 
. O 

Amplified O 
c B-DNA 
- I-DNA 
erbB2 I-DNA 
gene I-DNA 
sequences I-DNA 
were O 
present O 
in O 
21 O 
. O 
5 O 
% O 
of O 
all O 
samples O 
. O 

Int B-DNA 
- I-DNA 
2 I-DNA 
was O 
amplified O 
in O 
13 O 
. O 
1 O 
% O 
and O 
c B-DNA 
- I-DNA 
myc I-DNA 
was O 
amplified O 
in O 
10 O 
. O 
3 O 
% O 
. O 

In O 
a O 
non O 
- O 
parametric O 
test O 
( O 
Kruskal O 
- O 
Wallis O 
) O 
a O 
strong O 
negative O 
association O 
was O 
found O 
between O 
high O 
levels O 
of O 
c B-DNA 
- I-DNA 
erbB2 I-DNA 
amplification O 
and O 
absence O 
of O 
estrogen O 
receptor O 
( O 
ER O 
) O 
( O 
P O 
= O 
. O 
0009 O 
) O 
or O 
progesterone B-protein 
receptor I-protein 
( O 
PR B-protein 
) O 
( O 
P O 
= O 
. O 
011 O 
) O 
expression O 
. O 

No O 
correlations O 
were O 
found O 
between O 
all O 
or O 
high O 
levels O 
of O 
amplification O 
of O 
each O 
oncogene O 
separately O 
or O 
combined O 
with O 
T O 
, O 
N O 
, O 
grade O 
, O 
multifocality O 
of O 
tumor O 
, O 
or O 
associated O 
carcinoma O 
in O 
situ O 
. O 

There O 
was O 
a O 
trend O 
approaching O 
statistical O 
significance O 
for O 
patients O 
with O 
c B-DNA 
- I-DNA 
erbB2 I-DNA 
amplifications O 
to O 
have O 
positive O 
lymph O 
nodes O 
at O 
surgery O 
( O 
P O 
= O 
0 O 
. O 
09 O 
) O 
. O 

A O 
somewhat O 
surprising O 
finding O 
however O 
was O 
a O 
very O 
strong O 
association O 
between O 
oncogene B-DNA 
amplification O 
and O 
dense O 
lymphocyte O 
infiltration O 
of O 
the O 
tumor O 
( O 
P O 
= O 
. O 
05 O 
) O 
. O 
This O 
correlation O 
is O 
even O 
stronger O 
when O 
only O 
high O 
levels O 
of O 
amplification O 
are O 
considered O 
, O 
either O 
for O 
each O 
oncogene O 
separately O 
( O 
P O 
= O 
. O 
0048 O 
) O 
or O 
in O 
combination O 
( O 
P O 
= O 
. O 
0007 O 
) O 
. O 

We O 
propose O 
that O 
malignant O 
cell O 
cytokine B-protein 
production O 
may O 
help O 
explain O 
this O 
observation O 
. O 

Suppression O 
of O 
signals O 
required O 
for O 
activation O 
of O 
transcription B-protein 
factor I-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
in O 
cells O 
constitutively O 
expressing O 
the O 
HTLV B-protein 
- I-protein 
I I-protein 
Tax I-protein 
protein I-protein 
. O 

Transient O 
short O 
- O 
term O 
expression O 
of O 
the O 
Tax B-protein 
protein I-protein 
of O 
human O 
T O 
- O 
cell O 
leukemia O 
virus O 
type O 
- O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
leads O 
to O 
activation O 
of O 
the O 
pleiotropic O 
transcription B-protein 
factor I-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
. O 

Consistent O 
with O 
findings O 
obtained O 
with O 
transient O 
expression O 
assays O 
, O 
we O 
observed O 
marked O 
accumulation O 
of O 
the O 
transcription B-protein 
factor I-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
in O 
the O 
nucleus O 
of O 
Namalwa B-cell_line 
B I-cell_line 
lymphoid I-cell_line 
cells I-cell_line 
, O 
which O 
constitutively O 
express O 
Tax B-protein 
. O 

In O 
contrast O 
, O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activity O 
was O 
not O 
detected O 
in O 
the O 
nucleus O 
following O 
long O 
- O 
term O 
expression O 
of O 
Tax B-protein 
in O 
Jurkat B-cell_line 
T I-cell_line 
lymphocytes I-cell_line 
. O 

The O 
ability O 
of O 
both O 
mitogens O 
and O 
cytokines B-protein 
to O 
activate O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
was O 
also O 
blocked O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
constitutively O 
expressing O 
Tax B-protein 
. O 

However O 
, O 
the O 
activation O 
of O 
other O 
mitogen B-protein 
- I-protein 
inducible I-protein 
transcription I-protein 
factors I-protein 
, O 
such O 
as O 
Fos B-protein 
and O 
Jun B-protein 
, O 
was O 
unaffected O 
. O 

Thus O 
, O 
depending O 
on O 
the O 
cellular O 
environment O 
, O 
the O 
short O 
- O 
and O 
long O 
- O 
term O 
effects O 
of O 
Tax B-protein 
expression O 
can O 
be O 
quite O 
different O 
. O 

Consequently O 
, O 
one O 
function O 
of O 
Tax B-protein 
in O 
cells O 
infected O 
with O 
HTLV O 
- O 
I O 
might O 
involve O 
cell O 
- O 
type O 
- O 
specific O 
suppression O 
, O 
as O 
opposed O 
to O 
activation O 
, O 
of O 
distinct O 
signal O 
pathways O 
. O 

The O 
cells O 
lines O 
described O 
here O 
should O 
be O 
useful O 
for O 
the O 
delineation O 
of O 
signaling O 
pathways O 
utilized O 
in O 
the O 
selective O 
regulation O 
of O 
gene O 
expression O 
. O 

Interferon B-protein 
- I-protein 
gamma I-protein 
and O 
the O 
sexual O 
dimorphism O 
of O 
autoimmunity O 
. O 

The O 
sexual O 
difference O 
in O 
the O 
incidence O 
of O 
autoimmune O 
diseases O 
has O 
remained O 
an O 
enigma O 
for O 
many O 
years O 
. O 

In O 
the O 
examination O 
of O 
the O 
induction O 
of O 
autoimmunity O 
in O 
transgenic O 
mice O 
, O 
evidence O 
has O 
been O 
obtained O 
further O 
implicating O 
the O 
lymphokine B-protein 
interferon B-protein 
- I-protein 
gamma I-protein 
in O 
the O 
etiology O 
of O 
autoimmunity O 
. O 

Sex O 
steroid O 
regulation O 
of O 
the O 
production O 
of O 
this O 
molecule O 
, O 
as O 
well O 
as O 
other O 
cytokines B-protein 
, O 
may O 
help O 
explain O 
the O 
gender O 
- O 
specific O 
differences O 
in O 
the O 
immune O 
system O 
, O 
including O 
autoimmunity O 
. O 

Cloning O 
of O 
a O 
transcriptionally B-protein 
active I-protein 
human B-protein I-protein 
TATA I-protein I-protein 
binding I-protein I-protein 
factor I-protein I-protein 
. O 

Transcription B-protein 
factor I-protein 
IID I-protein 
( O 
TFIID B-protein 
) O 
binds O 
to O 
the O 
TATA B-DNA 
box I-DNA 
promoter I-DNA 
element I-DNA 
and O 
regulates O 
the O 
expression O 
of O 
most O 
eukaryotic B-DNA 
genes I-DNA 
transcribed O 
by O 
RNA B-protein 
polymerase I-protein 
II I-protein 
. O 

Complementary B-DNA 
DNA I-DNA 
( O 
cDNA B-DNA 
) O 
encoding O 
a O 
human B-protein 
TFIID B-protein I-protein 
protein I-protein 
has O 
been O 
cloned O 
. O 

The O 
human B-protein 
TFIID B-protein I-protein 
polypeptide I-protein 
has O 
339 O 
amino O 
acids O 
and O 
a O 
molecular O 
size O 
of O 
37 O 
, O 
745 O 
daltons O 
. O 

The O 
carboxyl B-protein 
- I-protein 
terminal I-protein 
181 I-protein 
amino I-protein 
acids I-protein 
of O 
the O 
human B-protein 
TFIID B-protein I-protein 
protein I-protein 
shares O 
80 O 
% O 
identity O 
with O 
the O 
TFIID B-protein 
protein O 
from O 
Saccharomyces O 
cerevisiae O 
. O 

The O 
amino B-protein 
terminus I-protein 
contains O 
an O 
unusual O 
repeat O 
of O 
38 O 
consecutive O 
glutamine O 
residues O 
and O 
an O 
X B-protein 
- I-protein 
Thr I-protein 
- I-protein 
Pro I-protein 
repeat I-protein 
. O 

Expression O 
of O 
DNA B-DNA 
in O 
reticulocyte O 
lysates O 
or O 
in O 
Escherichia O 
coli O 
yielded O 
a O 
protein O 
that O 
was O 
competent O 
for O 
both O 
DNA O 
binding O 
and O 
transcription O 
activation O 
. O 

A O 
novel O 
T B-protein 
- I-protein 
cell I-protein 
trans I-protein 
- I-protein 
activator I-protein 
that O 
recognizes O 
a O 
phorbol B-DNA 
ester I-DNA 
- I-DNA 
inducible I-DNA 
element I-DNA 
of O 
the O 
interleukin B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
. O 

The O 
interleukin B-protein B-DNA 
2 I-protein I-DNA 
( I-DNA 
IL B-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
) I-DNA 
gene I-DNA 
promoter I-DNA 
is O 
recognized O 
by O 
several O 
cell O 
- O 
type O 
- O 
specific O 
and O 
ubiquitous O 
transcriptional O 
regulators O 
that O 
integrate O 
information O 
transmitted O 
by O 
various O 
signaling O 
systems O 
leading O 
to O 
IL B-protein 
- I-protein 
2 I-protein 
production O 
and O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
activation O 
. O 

Using O 
a O 
combination O 
of O 
transfection O 
, O 
protein O 
- O 
DNA O 
binding O 
, O 
and O 
in O 
vitro O 
transcription O 
methods O 
, O 
we O 
have O 
discovered O 
the O 
novel B-protein 
T I-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcriptional I-protein 
activator I-protein 
TCF B-protein 
- I-protein 
1 I-protein 
( O 
for O 
T B-protein 
- I-protein 
Cell I-protein 
Factor I-protein 
- I-protein 
1 I-protein 
) O 
, O 
which O 
recognizes O 
a O 
T B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
response I-DNA 
element I-DNA 
( O 
TCE B-DNA 
) O 
located O 
within O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
. O 

Although O 
the O 
TCE B-DNA 
is O 
similar O 
in O 
sequence O 
to O 
a O 
consensus B-DNA 
NF B-protein B-DNA I-DNA 
kappa I-protein I-DNA I-DNA 
B I-protein I-DNA I-DNA 
site I-DNA I-DNA 
, O 
several O 
criteria O 
indicate O 
that O 
TCF B-protein 
- I-protein 
1 I-protein 
is O 
distinct O 
from O 
NF B-protein 
kappa I-protein 
B I-protein 
. O 

However O 
, O 
like O 
NF B-protein 
kappa I-protein 
B I-protein 
, O 
TCF B-protein 
- I-protein 
1 I-protein 
activity O 
is O 
induced O 
by O 
phorbol O 
esters O 
and O 
other O 
T O 
- O 
cell O 
activators O 
. O 

Risk O 
factors O 
for O 
breast O 
recurrence O 
in O 
premenopausal O 
and O 
postmenopausal O 
patients O 
with O 
ductal O 
cancers O 
treated O 
by O 
conservation O 
therapy O 
. O 

Risk O 
factors O 
for O 
local O 
failure O 
were O 
evaluated O 
for O 
496 O 
clinical O 
Stage O 
I O 
- O 
II O 
patients O 
with O 
infiltrating O 
ductal O 
carcinomas O 
( O 
median O 
follow O 
- O 
up O 
, O 
71 O 
months O 
) O 
treated O 
by O 
conservative O 
surgery O 
and O 
radiotherapy O 
. O 

Monofactorial O 
analysis O 
identified O 
the O 
following O 
factors O 
to O 
be O 
correlated O 
with O 
increased O 
risk O 
: O 
moderate O 
/ O 
marked O 
mononuclear O 
cell O 
reaction O 
( O 
MCR O 
) O 
, O 
high O 
histologic O 
grade O 
( O 
G O 
) O 
, O 
extensive O 
intraductal O 
component O 
( O 
EIC O 
) O 
, O 
tumor O 
necrosis O 
, O 
macroscopic O 
multiplicity O 
, O 
estrogen B-protein 
receptor I-protein 
negativity O 
, O 
anatomic O 
tumor O 
size O 
, O 
age O 
younger O 
than O 
40 O 
years O 
, O 
and O 
vascular O 
invasion O 
. O 

Only O 
MCR O 
, O 
G O 
, O 
and O 
EIC O 
proved O 
significant O 
in O 
Cox O 
multivariate O 
analysis O 
. O 

These O 
risk O 
factors O 
were O 
highly O 
age O 
dependent O 
, O 
with O 
EIC O 
markedly O 
more O 
prevalent O 
in O 
women O 
younger O 
than O 
50 O 
, O 
MCR O 
and O 
G O 
in O 
women O 
younger O 
than O 
40 O 
. O 

Separate O 
Cox O 
analysis O 
for O 
premenopausal O 
patients O 
showed O 
that O 
MCR O 
/ O 
EIC O 
determined O 
risk O 
independent O 
of O 
resection O 
margins O 
: O 
tumors O 
with O 
MCR O 
had O 
a O 
28 O 
% O 
, O 
and O 
with O 
EIC O 
a O 
22 O 
% O 
probability O 
of O 
recurring O 
locally O 
by O 
5 O 
years O 
. O 

Premenopausal O 
patients O 
with O 
neither O 
risk O 
factor O 
had O 
a O 
very O 
low O 
failure O 
rate O 
( O 
2 O 
. O 
6 O 
% O 
at O 
5 O 
years O 
) O 
, O 
regardless O 
of O 
age O 
. O 

For O 
postmenopausal O 
patients O 
risk O 
of O 
breast O 
recurrence O 
was O 
determined O 
both O 
by O 
adequacy O 
of O 
resection O 
margins O 
and O 
grade O 
, O 
with O 
a O 
high O 
local O 
failure O 
rate O 
for O 
patients O 
having O 
G3 O 
tumors O 
with O 
positive O 
or O 
indeterminate O 
margins O 
( O 
31 O 
% O 
at O 
5 O 
years O 
) O 
. O 

The O 
authors O 
conclude O 
that O 
the O 
microscopic O 
examination O 
is O 
the O 
only O 
useful O 
tool O 
for O 
assessing O 
the O 
risk O 
of O 
local O 
failure O 
, O 
which O 
is O 
quite O 
low O 
for O 
the O 
majority O 
of O 
patients O 
treated O 
with O 
breast O 
conservation O 
. O 

High O 
- O 
risk O 
patients O 
can O 
be O 
recognized O 
morphologically O 
. O 

The O 
age O 
dependence O 
of O 
morphologic O 
risk O 
factors O 
appears O 
to O 
explain O 
the O 
high O 
local O 
failure O 
rate O 
seen O 
in O 
patients O 
younger O 
than O 
40 O 
. O 

Tax B-protein 
- O 
independent O 
binding O 
of O 
multiple O 
cellular B-protein 
factors I-protein 
to O 
Tax B-protein B-DNA 
- I-DNA 
response I-DNA 
element I-DNA 
DNA I-DNA 
of O 
HTLV O 
- O 
I O 
. O 

The O 
human B-DNA 
T I-DNA 
- I-DNA 
cell I-DNA 
leukemia I-DNA 
virus I-DNA 
type I-DNA 
I I-DNA 
( I-DNA 
HTLV I-DNA 
- I-DNA 
I I-DNA 
) I-DNA 
promoter I-DNA 
contains O 
three O 
copies O 
of O 
imperfect O 
repeats O 
of O 
a O 
21 O 
- O 
base O 
pair O 
sequence O 
designated O 
here O 
as O 
TRE B-DNA 
( O 
Tax B-protein B-DNA 
- I-DNA 
response I-DNA 
element I-DNA 
) O 
that O 
is O 
responsive O 
to O 
the O 
virally B-protein 
encoded I-protein 
transactivator I-protein 
protein I-protein 
Tax B-protein 
. O 

We O 
have O 
identified O 
and O 
separated O 
four O 
nuclear B-protein 
proteins I-protein 
from O 
C81 O 
- O 
66 O 
- O 
45 O 
cells O 
, O 
an O 
HTLV B-cell_line 
- I-cell_line 
I I-cell_line 
immortalized I-cell_line 
Tax B-protein I-cell_line 
- I-cell_line 
expressing I-cell_line 
human I-cell_line 
T I-cell_line 
- I-cell_line 
lymphocyte I-cell_line 
line I-cell_line 
( O 
Salahuddin O 
et O 
al O 
. O 
, O 
1983 O 
) O 
, O 
that O 
interact O 
with O 
the O 
TRE B-DNA B-DNA 
- I-DNA 
DNA I-DNA 
, O 
none O 
of O 
which O 
are O 
identical O 
with O 
the O 
Tax B-protein B-protein 
- I-protein 
protein I-protein 
. O 

The O 
proteins O 
identified O 
have O 
molecular O 
weights O 
of O 
about O 
32 O 
, O 
36 O 
to O 
42 O 
, O 
50 O 
and O 
110 O 
kD O 
. O 

Four O 
different O 
methods O 
were O 
used O 
to O 
identify O 
the O 
proteins O 
. O 

First O 
, O 
from O 
different O 
cell O 
lines O 
three O 
or O 
all O 
four O 
of O 
the O 
nuclear B-protein 
proteins I-protein 
were O 
specifically O 
cross O 
- O 
linked O 
by O 
UV O 
irradiation O 
to O 
the O 
radioactively O 
labeled O 
TRE B-DNA B-DNA 
- I-DNA 
DNA I-DNA 
fragment I-DNA 
. O 

Second O 
, O 
TRE B-DNA B-protein 
- I-protein 
DNA I-protein 
binding I-protein 
proteins I-protein 
sedimented O 
through O 
a O 
glycerol O 
density O 
gradient O 
at O 
rates O 
corresponding O 
to O 
proteins O 
of O 
native O 
molecular O 
weights O 
of O 
35 O 
to O 
50 O 
kD O 
and O 
110 O 
kD O 
. O 

Third O 
, O 
only O 
the O 
50 B-protein 
kD I-protein 
protein I-protein 
was O 
retained O 
on O 
a O 
biotinylated O 
DNA O 
- O 
streptavidin O 
matrix O 
when O 
the O 
DNA O 
fragment O 
contained O 
the O 
TRE B-DNA B-DNA 
- I-DNA 
DNA I-DNA 
. O 

Fourth O 
, O 
extensive O 
purification O 
by O 
several O 
cycles O 
of O 
TRE B-DNA 
- O 
DNA O 
affinity O 
chromatography O 
resulted O 
in O 
the O 
32 O 
, O 
36 O 
to O 
42 O 
and O 
110 O 
kD O 
proteins O 
and O 
to O 
less O 
extent O 
the O 
50 B-protein 
kD I-protein 
factor I-protein 
. O 

Two O 
abundant O 
proteins O 
of O 
75 O 
and O 
80 O 
kD O 
were O 
competed O 
out O 
by O 
poly O 
[ O 
d O 
( O 
I O 
- O 
C O 
) O 
] O 
in O 
all O 
reactions O 
. O 

The O 
cAMP B-DNA 
- I-DNA 
response I-DNA 
element I-DNA 
CRE B-DNA 
, O 
TGACGTCA O 
, O 
present O 
in O 
the O 
21 B-DNA 
base I-DNA 
- I-DNA 
pair I-DNA 
sequence I-DNA 
, O 
appears O 
to O 
be O 
essential O 
for O 
specific O 
protein O 
- O 
TRE B-DNA 
- O 
DNA O 
interactions O 
because O 
mutation O 
of O 
the O 
two O 
G O 
' O 
s O 
destroys O 
this O 
complex O 
. O 

This O 
result O 
suggests O 
that O 
the O 
cAMP B-protein 
response I-protein 
element I-protein 
binding I-protein 
protein I-protein 
, O 
CREB B-protein 
, O 
is O 
involved O 
in O 
the O 
protein B-protein 
- I-protein 
TRE B-DNA I-protein 
- I-protein 
DNA I-protein 
complex I-protein 
and O 
in O 
mediating O 
the O 
Tax B-protein 
response O 
. O 

Two O 
distinct O 
transcription B-protein 
factors I-protein 
that O 
bind O 
the O 
immunoglobulin B-DNA 
enhancer I-DNA 
microE5 B-DNA 
/ I-DNA 
kappa I-DNA 
2 I-DNA 
motif I-DNA 
. O 

Activity O 
of O 
the O 
immunoglobulin O 
heavy O 
and O 
kappa O 
light O 
chain O 
gene O 
enhancers O 
depends O 
on O 
a O 
complex O 
interplay O 
of O 
ubiquitous B-protein 
and O 
developmentally B-protein 
regulated I-protein 
proteins I-protein 
. O 

Two O 
complementary B-DNA 
DNAs I-DNA 
were O 
isolated O 
that O 
encode O 
proteins O 
, O 
denoted O 
ITF B-protein 
- I-protein 
1 I-protein 
and O 
ITF B-protein 
- I-protein 
2 I-protein 
, O 
that O 
are O 
expressed O 
in O 
a O 
variety O 
of O 
cell O 
types O 
and O 
bind O 
the O 
microE5 B-DNA 
/ I-DNA 
kappa I-DNA 
2 I-DNA 
motif I-DNA 
found O 
in O 
both O 
heavy O 
and O 
kappa O 
light O 
chain O 
enhancers O 
. O 

The O 
complementary B-DNA 
DNAs I-DNA 
are O 
the O 
products O 
of O 
distinct O 
genes O 
, O 
yet O 
both O 
ITF B-protein 
- I-protein 
1 I-protein 
and O 
ITF B-protein 
- I-protein 
2 I-protein 
are O 
structurally O 
and O 
functionally O 
similar O 
. O 

The O 
two O 
proteins O 
interact O 
with O 
one O 
another O 
through O 
their O 
putative O 
helix B-protein 
- I-protein 
loop I-protein 
- I-protein 
helix I-protein 
motifs I-protein 
and O 
each O 
possesses O 
a O 
distinct O 
domain O 
that O 
dictates O 
transcription O 
activation O 
. O 

Elevated O 
glucocorticoid B-protein 
receptor I-protein 
concentrations O 
before O 
and O 
after O 
glucocorticoid O 
therapy O 
in O 
peripheral B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
of O 
patients O 
with O 
atopic O 
dermatitis O 
. O 

The O 
number O 
and O 
affinity O 
of O 
glucocorticoid O 
binding O 
sites O 
in O 
peripheral B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
of O 
patients O 
with O 
atopic O 
dermatitis O 
( O 
AD O 
) O 
and O 
healthy O 
controls O 
were O 
determined O 
under O 
baseline O 
conditions O 
and O 
after O 
a O 
defined O 
oral O 
glucocorticoid O 
treatment O 
. O 

Patients O 
with O 
AD O 
( O 
n O 
= O 
15 O 
) O 
exhibited O 
significantly O 
more O 
glucocorticoid B-protein 
receptors I-protein 
( O 
GR B-protein 
) O 
per O 
cell O 
than O 
the O 
control O 
group O 
( O 
n O 
= O 
22 O 
) O 
, O 
while O 
the O 
GR B-protein 
affinity O 
did O 
not O 
differ O 
. O 

Methylprednisolone O 
treatment O 
resulted O 
in O 
a O 
significant O 
reduction O 
of O 
the O 
GR B-protein 
sites O 
per O 
cell O 
in O 
the O 
steroid O 
- O 
treated O 
control O 
group O 
( O 
n O 
= O 
10 O 
) O 
in O 
contrast O 
to O 
the O 
patients O 
. O 

The O 
dissociation O 
constant O 
was O 
not O 
affected O 
by O 
methylprednisolone O 
treatment O 
in O 
either O 
group O 
. O 

In O 
view O 
of O 
the O 
therapeutic O 
efficiency O 
of O 
glucocorticoids O 
in O 
AD O 
and O 
findings O 
of O 
abnormal O 
cAMP O 
and O 
cAMP O 
- O 
phosphodiesterase O 
activity O 
, O 
the O 
elevated O 
GR B-protein 
concentrations O 
in O 
AD O 
lend O 
support O 
to O 
the O 
hypothesis O 
of O 
a O 
compensatory O 
GR B-protein 
upregulation O 
due O 
to O 
an O 
insufficient O 
action O 
of O 
endogenous O 
cortisol O 
or O 
to O 
altered O 
cAMP O 
- O 
induced O 
GR B-protein 
expression O 
. O 

The O 
actions O 
of O 
cyclosporin O 
A O 
and O 
FK506 O 
suggest O 
a O 
novel O 
step O 
in O 
the O 
activation O 
of O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

Cyclosporin O 
A O 
and O 
FK506 O 
are O 
immunosuppressive O 
compounds O 
that O 
have O 
similar O 
inhibitory O 
effects O 
on O 
the O 
expression O 
of O 
several O 
lymphokines B-protein 
produced O 
by O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

Despite O 
their O 
similar O 
effects O 
the O 
drugs O 
bind O 
to O 
two O 
different O 
cytosolic B-protein 
protein I-protein 
, O 
cyclophilin B-protein 
and O 
FKBP B-protein 
respectively O 
, O 
which O 
raises O 
the O 
possibility O 
that O 
they O 
have O 
different O 
modes O 
of O 
action O 
. O 

Using O 
constructs O 
in O 
which O 
mRNA B-RNA 
production O 
controlled O 
by O 
a O 
specific O 
transcription B-protein 
factor I-protein 
could O 
be O 
readily O 
measured O 
we O 
found O 
that O 
both O 
cyclosporin O 
A O 
and O 
FK506 O 
completely O 
inhibited O 
transcription O 
activated O 
by O 
NF B-protein 
- I-protein 
AT I-protein 
, O 
NFIL2 B-protein 
A I-protein 
, O 
NFIL2 B-protein 
B I-protein 
and O 
partially O 
inhibited O 
transcription O 
activated O 
by O 
NF B-protein 
kappa I-protein 
B I-protein 
. O 

Cyclosporin O 
A O 
and O 
FK506 O 
inhibited O 
only O 
transcriptional O 
activation O 
that O 
was O 
dependent O 
on O 
Ca2 O 
+ O 
mobilization O 
. O 

However O 
, O 
cyclosporin O 
A O 
and O 
FK506 O 
did O 
not O 
inhibit O 
Ca2 O 
+ O 
mobilization O 
dependent O 
expression O 
of O 
c B-RNA 
- I-RNA 
fos I-RNA 
mRNA I-RNA 
indicating O 
that O 
only O 
a O 
subset O 
of O 
signalling O 
pathways O 
regulated O 
by O 
Ca2 O 
+ O 
is O 
sensitive O 
to O 
these O 
drugs O 
. O 

Furthermore O 
, O 
we O 
did O 
not O 
observe O 
any O 
qualitative O 
differences O 
between O 
the O 
effect O 
of O 
cyclosporin O 
A O 
and O 
FK506 O 
on O 
six O 
different O 
transcription B-protein 
factors I-protein 
which O 
suggests O 
that O 
these O 
drugs O 
may O 
interfere O 
with O 
the O 
activity O 
of O 
a O 
novel O 
Ca2 O 
+ O 
dependent O 
step O 
that O 
regulates O 
several O 
transcription B-protein 
factors I-protein 
. O 

The O 
internal O 
methionine O 
codons O 
of O 
human B-DNA 
T I-DNA 
- I-DNA 
cell I-DNA 
leukemia I-DNA 
virus I-DNA 
type I-DNA 
II I-DNA 
rex I-DNA 
gene I-DNA 
are O 
not O 
required O 
for O 
p24rex B-protein 
production O 
or O 
virus O 
replication O 
and O 
transformation O 
. O 

Human O 
T O 
- O 
cell O 
leukemia O 
virus O 
types O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
and O 
II O 
( O 
HTLV O 
- O 
II O 
) O 
have O 
two O 
nonstructural B-DNA 
trans I-DNA 
- I-DNA 
acting I-DNA 
regulatory I-DNA 
genes I-DNA 
, O 
tax B-DNA 
and O 
rex B-DNA 
, O 
located O 
in O 
the O 
3 B-DNA 
' I-DNA 
region I-DNA 
of O 
the O 
viral B-DNA 
genome I-DNA 
. O 

The O 
tax B-DNA B-protein 
gene I-protein 
product I-protein 
( O 
HTLV O 
- O 
I O 
p40tax B-DNA 
and O 
HTLV O 
- O 
II O 
p37tax B-DNA 
) O 
is O 
the O 
transcriptional O 
activator O 
of O 
the O 
viral B-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
. O 

The O 
rex B-DNA 
gene I-DNA 
encodes O 
two O 
protein O 
products O 
, O 
p27rex B-protein 
/ B-protein 
p21rex I-protein 
and O 
p26rex B-protein 
/ B-protein 
p24rex I-protein 
in O 
HTLV O 
- O 
I O 
and O 
HTLV O 
- O 
II O 
, O 
respectively O 
. O 

Rex B-protein 
acts O 
posttranscriptionally O 
to O 
facilitate O 
accumulation O 
of O 
full O 
- O 
length O 
gag B-protein 
/ I-protein 
pol I-protein 
and O 
singly O 
spliced O 
env B-RNA 
mRNA I-RNA 
in O 
the O 
cytoplasm O 
of O 
HTLV B-cell_type 
- I-cell_type 
infected I-cell_type 
cells I-cell_type 
. O 

Previous O 
studies O 
showed O 
that O 
the O 
first O 
ATG O 
of O 
the O 
rex B-DNA B-DNA 
gene I-DNA 
is O 
critical O 
for O 
Rex B-protein 
production O 
and O 
function O 
. O 

The O 
importance O 
of O 
the O 
internal O 
ATGs O 
to O 
Rex B-protein 
function O 
is O 
not O 
known O 
. O 

However O 
, O 
in O 
vitro O 
mutagenesis O 
of O 
the O 
HTLV O 
- O 
I O 
rex B-DNA B-DNA 
gene I-DNA 
has O 
provided O 
indirect O 
evidence O 
which O 
suggests O 
that O 
p21rex B-protein 
, O 
and O 
by O 
analogy O 
HTLV O 
- O 
II O 
p24rex B-protein 
, O 
results O 
from O 
initiation O 
at O 
an O 
internal O 
AUG O 
of O 
the O 
tax B-DNA B-RNA 
/ B-DNA I-RNA 
rex I-DNA I-RNA 
mRNA I-RNA 
. O 

By O 
using O 
an O 
infectious O 
molecular O 
clone O 
of O 
HTLV O 
- O 
II O 
, O 
we O 
investigated O 
the O 
importance O 
of O 
the O 
internal O 
ATGs O 
of O 
the O 
rex B-DNA B-DNA 
gene I-DNA 
on O 
Rex B-protein 
protein O 
production O 
and O 
function O 
. O 

Our O 
results O 
indicate O 
that O 
p24rex B-protein 
of O 
HTLV O 
- O 
II O 
is O 
not O 
initiated O 
at O 
an O 
internal O 
AUG O 
and O 
that O 
the O 
internal O 
methionine O 
codons O 
are O 
not O 
crucial O 
to O 
the O 
function O 
of O 
the O 
rex B-DNA 
gene I-DNA 
and O 
, O 
ultimately O 
, O 
the O 
transforming O 
properties O 
of O 
the O 
virus O 
. O 

Astrocytes B-cell_type 
and O 
glioblastoma B-cell_type 
cells I-cell_type 
express O 
novel O 
octamer B-protein 
- I-protein 
DNA I-protein 
binding I-protein 
proteins I-protein 
distinct O 
from O 
the O 
ubiquitous B-protein 
Oct I-protein 
- I-protein 
1 I-protein 
and O 
B B-protein 
cell I-protein 
type I-protein 
Oct I-protein 
- I-protein 
2 I-protein 
proteins I-protein 
. O 

The O 
' B-DNA 
octamer I-DNA 
' I-DNA 
sequence I-DNA 
, O 
ATGCAAAT O 
or O 
its O 
complement O 
ATTTGCAT O 
, O 
is O 
a O 
key O 
element O 
for O 
the O 
transcriptional O 
regulation O 
of O 
immunoglobulin B-DNA 
genes I-DNA 
in O 
B B-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
as O 
well O 
as O 
a O 
number O 
of O 
housekeeping B-DNA 
genes I-DNA 
in O 
all O 
cell O 
types O 
. O 

In O 
lymphocytes B-cell_type 
, O 
the O 
octamer B-protein 
- I-protein 
binding I-protein 
protein I-protein 
Oct B-protein 
- I-protein 
2A I-protein 
and O 
variants O 
thereof O 
are O 
thought O 
to O 
contribute O 
to O 
the O 
B B-DNA 
- I-DNA 
cell I-DNA 
specific I-DNA 
gene I-DNA 
expression O 
, O 
while O 
the O 
ubiquitous O 
protein O 
Oct O 
- O 
1 O 
seems O 
to O 
control O 
general O 
octamer B-DNA 
site I-DNA 
- O 
dependent O 
transcription O 
. O 

Various O 
other O 
genes O 
, O 
for O 
example O 
interleukin O 
- O 
1 O 
and O 
MHC O 
class O 
II O 
genes O 
, O 
contain O 
an O 
octamer B-DNA 
sequence I-DNA 
in O 
the O 
promoter B-DNA 
and O 
are O 
expressed O 
in O 
cells O 
of O 
both O 
the O 
immune O 
and O 
nervous O 
systems O 
. O 

This O 
prompted O 
us O 
to O 
analyze O 
the O 
octamer B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
in O 
the O 
latter O 
cells O 
. O 

Using O 
the O 
electrophoretic O 
mobility O 
shift O 
assay O 
, O 
at O 
least O 
six O 
novel O 
octamer B-protein 
binding I-protein 
proteins I-protein 
were O 
detected O 
in O 
nuclear O 
extracts O 
of O 
cultured B-cell_type 
mouse I-cell_type 
astrocytes I-cell_type 
. O 

These O 
proteins O 
are O 
differentially O 
expressed O 
in O 
human O 
glioblastoma O 
and O 
neuroblastoma O 
cell O 
lines O 
. O 

The O 
nervous B-protein 
system I-protein 
- I-protein 
derived I-protein 
( I-protein 
N I-protein 
- I-protein 
Oct I-protein 
) I-protein 
proteins I-protein 
bound O 
to O 
the O 
octamer B-DNA 
DNA I-DNA 
sequence I-DNA 
in O 
a O 
manner O 
which O 
is O 
indistinguishable O 
from O 
the O 
Oct B-protein 
- I-protein 
1 I-protein 
and O 
Oct B-protein 
- I-protein 
2A I-protein 
proteins I-protein 
. O 

The O 
relationship O 
of O 
the O 
N B-protein 
- I-protein 
Oct I-protein 
proteins I-protein 
to O 
Oct B-protein 
- I-protein 
1 I-protein 
and O 
Oct B-protein 
- I-protein 
2A I-protein 
was O 
analyzed O 
by O 
proteolytic O 
clipping O 
bandshift O 
assays O 
and O 
by O 
their O 
reactivity O 
towards O 
antisera O 
raised O 
against O 
recombinant O 
Oct B-protein 
- I-protein 
1 I-protein 
and O 
Oct B-protein 
- I-protein 
2A I-protein 
proteins O 
. O 

On O 
the O 
basis O 
of O 
these O 
assays O 
, O 
all O 
N B-protein 
- I-protein 
Oct I-protein 
- I-protein 
factors I-protein 
were O 
found O 
to O 
be O 
distinct O 
from O 
the O 
ubiquitous B-protein 
Oct B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
and O 
the O 
lymphoid B-protein 
- I-protein 
specific I-protein 
Oct B-protein I-protein 
- I-protein I-protein 
2A I-protein I-protein 
proteins O 
. O 

In O 
melanoma B-cell_type 
cells I-cell_type 
that O 
contain O 
the O 
N B-protein 
- I-protein 
Oct I-protein 
- I-protein 
3 I-protein 
factor I-protein 
, O 
a O 
transfected O 
lymphocyte O 
- O 
specific O 
promoter O 
was O 
neither O 
activated O 
nor O 
was O 
it O 
repressed O 
upon O 
contransfection O 
with O 
an O 
Oct B-protein B-DNA 
- I-protein I-DNA 
2A I-protein I-DNA 
expression I-DNA 
vector I-DNA 
. O 

We O 
therefore O 
speculate O 
that O 
N B-protein 
- I-protein 
Oct I-protein 
- I-protein 
3 I-protein 
and O 
other O 
N B-protein 
- I-protein 
Oct I-protein 
factors I-protein 
have O 
a O 
specific O 
role O 
in O 
gene O 
expression O 
in O 
cells O 
of O 
the O 
nervous O 
system O 
. O 

Detection O 
in O 
non B-cell_type 
- I-cell_type 
erythroid I-cell_type 
cells I-cell_type 
of O 
a O 
factor O 
with O 
the O 
binding O 
characteristics O 
of O 
the O 
erythroid B-protein 
cell I-protein 
transcription I-protein 
factor I-protein 
EF1 B-protein 
. O 

The O 
erythroid B-protein 
transcription I-protein 
factor I-protein 
erythroid B-protein 
factor I-protein 
- I-protein 
1 I-protein 
( O 
EF1 B-protein 
) O 
plays O 
a O 
critical O 
role O 
in O 
the O 
transcription O 
of O 
erythroid B-DNA 
- I-DNA 
specific I-DNA 
genes I-DNA 
. O 

Here O 
we O 
report O 
the O 
presence O 
of O 
a O 
factor O 
with O 
the O 
mobility O 
and O 
sequence O 
- O 
specific O 
DNA O 
- O 
binding O 
characteristics O 
of O 
EF1 B-protein 
at O 
low O 
abundance O 
in O 
a O 
wide O 
variety O 
of O 
non B-cell_type 
- I-cell_type 
erythroid I-cell_type 
cell I-cell_type 
types I-cell_type 
. O 

This O 
is O 
the O 
first O 
report O 
of O 
an O 
EF1 B-protein 
- O 
like O 
activity O 
in O 
non B-cell_type 
- I-cell_type 
erythroid I-cell_type 
cells I-cell_type 
and O 
indicates O 
that O 
this O 
factor O 
may O 
play O 
a O 
role O 
in O 
the O 
regulation O 
of O 
genes B-DNA 
expressed O 
in O 
such O 
cells O 
. O 

Protein O 
kinase O 
inhibitor O 
H O 
- O 
7 O 
blocks O 
accumulation O 
of O 
unspliced B-RNA 
mRNA I-RNA 
of O 
human O 
T O 
- O 
cell O 
leukemia O 
virus O 
type O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
. O 

Rex B-protein 
, O 
the O 
post B-protein 
- I-protein 
transcriptional I-protein 
regulator I-protein 
of O 
human O 
T O 
- O 
cell O 
leukemia O 
virus O 
type O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
, O 
is O 
known O 
to O 
induce O 
accumulation O 
of O 
the O 
unspliced B-RNA 
viral I-RNA 
gag I-RNA 
- I-RNA 
pol I-RNA 
mRNA I-RNA 
. O 

Rex B-protein 
is O 
a O 
phosphoprotein B-protein 
found O 
in O 
the O 
cell O 
nucleolus O 
, O 
whose O 
function O 
may O 
be O 
regulated O 
by O 
its O 
localization O 
and O 
phosphorylation O 
. O 

We O 
have O 
examined O 
the O 
role O 
of O 
phosphorylation O 
on O 
Rex B-protein 
function O 
by O 
using O 
a O 
protein O 
kinase O 
inhibitor O 
, O 
H O 
- O 
7 O 
[ O 
1 O 
- O 
( O 
5 O 
- O 
isoquinolinyl O 
- O 
sulfonyl O 
) O 
- O 
2 O 
- O 
methylpiperazine O 
] O 
. O 

Treatment O 
of O 
an O 
HTLV B-cell_line 
- I-cell_line 
I I-cell_line 
infected I-cell_line 
human I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
with O 
H O 
- O 
7 O 
blocked O 
specifically O 
accumulation O 
of O 
the O 
unspliced B-RNA 
gag I-RNA 
- I-RNA 
pol I-RNA 
mRNA I-RNA 
, O 
resulting O 
in O 
the O 
decreased O 
Gag B-protein 
protein I-protein 
synthesis O 
that O 
corresponds O 
with O 
the O 
decreased O 
in O 
vivo O 
phosphorylation O 
of O 
Rex B-protein 
. O 

In O 
contrast O 
, O 
other O 
viral O 
and O 
cellular O 
products O 
have O 
not O 
been O 
influenced O 
by O 
the O 
level O 
of O 
H O 
- O 
7 O 
used O 
. O 

Therefore O 
, O 
the O 
phosphorylation O 
of O 
Rex B-protein 
is O 
required O 
for O 
the O 
viral O 
RNA O 
partition O 
of O 
HTLV O 
- O 
I O 
. O 

Increased O 
glucocorticoid O 
responsiveness O 
of O 
CD4 B-cell_line 
+ I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
clonal I-cell_line 
lines I-cell_line 
grown O 
in O 
serum O 
- O 
free O 
media O 
. O 

CEM B-cell_line 
- I-cell_line 
C7 I-cell_line 
, O 
a O 
human B-cell_line 
leukemic I-cell_line 
CD4 I-cell_line 
+ I-cell_line 
T I-cell_line 
- I-cell_line 
lymphocyte I-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
three O 
of O 
its O 
subclones O 
, O 
CEM B-cell_line 
- I-cell_line 
4R4 I-cell_line 
, O 
CEM B-cell_line 
- I-cell_line 
3R43 I-cell_line 
, O 
and O 
ICR B-cell_line 
- I-cell_line 
27 I-cell_line 
, O 
previously O 
cultured O 
in O 
a O 
medium O 
supplemented O 
with O 
5 O 
to O 
10 O 
% O 
fetal O 
bovine O 
serum O 
, O 
have O 
been O 
adapted O 
to O 
serum O 
- O 
free O 
media O 
. O 

The O 
best O 
medium O 
of O 
those O 
tested O 
was O 
RPMI O 
1640 O 
supplemented O 
with O 
5 O 
micrograms O 
/ O 
ml O 
each O 
transferrin B-protein 
and O 
insulin B-protein 
+ O 
5 O 
ng O 
/ O 
ml O 
sodium O 
selenite O 
+ O 
/ O 
- O 
0 O 
. O 
1 O 
% O 
bovine B-protein 
serum I-protein 
albumin I-protein 
. O 

While O 
growing O 
either O 
with O 
or O 
without O 
albumin O 
, O 
the O 
several O 
clonal B-cell_line 
lines I-cell_line 
of O 
CEM B-cell_line 
cells O 
displayed O 
growth O 
similar O 
to O 
serum O 
- O 
supplemented O 
cultures O 
. O 

Cell O 
proliferation O 
of O 
CEM B-cell_line 
- I-cell_line 
C7 I-cell_line 
cells O 
cultured O 
in O 
both O 
serum O 
- O 
free O 
media O 
has O 
been O 
sustained O 
for O 
3 O 
mo O 
. O 

with O 
culture O 
doubling O 
times O 
of O 
about O 
25 O 
h O 
for O 
both O 
serum O 
- O 
supplemented O 
and O 
serum O 
- O 
free O 
cultures O 
( O 
viability O 
greater O 
than O 
or O 
equal O 
to O 
90 O 
% O 
) O 
. O 

Cell O 
morphology O 
remained O 
essentially O 
the O 
same O 
in O 
serum O 
- O 
free O 
or O 
serum O 
containing O 
media O 
. O 

The O 
expression O 
of O 
CD4 B-protein 
, O 
a O 
marker O 
for O 
T B-cell_type 
- I-cell_type 
derived I-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
, O 
was O 
not O 
significantly O 
different O 
in O 
serum O 
- O 
free O 
medium O 
. O 

When O 
grown O 
in O 
serum O 
- O 
free O 
medium O 
, O 
CEM B-cell_line 
- I-cell_line 
C7 I-cell_line 
cells O 
exhibited O 
increased O 
steroid O 
responsiveness O 
as O 
evidenced O 
by O 
increased O 
glucocorticoid B-protein 
receptor I-protein 
binding O 
sites O 
, O 
increased O 
induction O 
of O 
glutamine B-protein 
synthetase I-protein 
, O 
and O 
cell O 
lysis O 
at O 
lower O 
concentrations O 
of O 
steroid O 
. O 

Receptor O 
mutant O 
subclones O 
of O 
CEM B-cell_line 
- I-cell_line 
C7 I-cell_line 
, O 
which O 
are O 
proven O 
to O 
be O 
completely O 
unresponsive O 
to O 
micromolar O 
concentrations O 
of O 
dexamethasone O 
when O 
grown O 
in O 
serum O 
- O 
supplemented O 
medium O 
, O 
become O 
partially O 
sensitive O 
to O 
the O 
hormone O 
after O 
growth O 
in O 
defined O 
medium O 
. O 

The O 
increased O 
sensitivity O 
of O 
CEM B-cell_line B-cell_line 
- I-cell_line I-cell_line 
C7 I-cell_line I-cell_line 
cells I-cell_line 
and O 
its O 
subclones O 
to O 
dexamethasone O 
in O 
serum O 
- O 
free O 
medium O 
returned O 
to O 
previous O 
levels O 
when O 
these O 
cells O 
were O 
recultured O 
in O 
serum O 
- O 
containing O 
medium O 
. O 

Our O 
results O 
suggest O 
that O 
substances O 
in O 
serum O 
influence O 
steroid O 
effects O 
on O 
these O 
cells O 
and O 
that O 
the O 
molecular O 
details O 
of O 
glucocorticoid O 
hormone O 
action O 
may O 
be O 
pursued O 
more O 
precisely O 
in O 
a O 
clearly O 
defined O 
culture O 
medium O 
. O 

[ O 
Glucocorticoid B-protein 
receptors I-protein 
on O 
human O 
peripheral O 
mononuclear O 
and O 
polymorphonuclear O 
leucocytes O 
: O 
changes O 
in O 
patients O 
with O 
yang O 
- O 
deficiency O 
] O 
. O 

It O 
was O 
found O 
that O 
, O 
in O 
former O 
works O 
, O 
the O 
glucocorticoid B-protein 
receptors I-protein 
( O 
GCR B-protein 
) O 
on O 
peripheral B-cell_type 
mixed I-cell_type 
leucocytes I-cell_type 
in O 
patients O 
with O 
Yang O 
- O 
deficiency O 
were O 
decreased O 
. O 

In O 
this O 
work O 
, O 
the O 
mixed B-cell_type 
leucocytes I-cell_type 
were O 
further O 
separated O 
into O 
mononuclear O 
( O 
MNL O 
) O 
and O 
polymorphonuclear O 
( O 
PML O 
) O 
leucocytes O 
, O 
and O 
GCR B-protein 
were O 
determined O 
in O 
each O 
part O 
of O 
leucocytes B-cell_type 
. O 

GCR B-protein 
on O 
MNL B-cell_type 
and O 
PML B-cell_type 
in O 
6 O 
Yang O 
deficient O 
patients O 
were O 
3473 O 
+ O 
/ O 
- O 
413 O 
and O 
4433 O 
+ O 
/ O 
- O 
651 O 
sites O 
/ O 
cell O 
respectively O 
, O 
statistically O 
significant O 
from O 
the O 
normal O 
control O 
group O 
( O 
4462 O 
+ O 
/ O 
- O 
962 O 
and O 
5622 O 
+ O 
/ O 
- O 
782 O 
sites O 
/ O 
cell O 
respectively O 
, O 
P O 
less O 
than O 
0 O 
. O 
05 O 
) O 
. O 

GCR B-protein 
on O 
MNL B-cell_type 
, O 
PML B-cell_type 
and O 
mixed B-cell_type 
leucocytes I-cell_type 
in O 
5 O 
patients O 
were O 
determined O 
simultaneously O 
, O 
and O 
all O 
lowered O 
from O 
the O 
control O 
group O 
. O 

The O 
results O 
were O 
3369 O 
+ O 
/ O 
- O 
370 O 
, O 
4986 O 
+ O 
/ O 
- O 
419 O 
and O 
4524 O 
+ O 
/ O 
- O 
852 O 
sites O 
/ O 
cell O 
respectively O 
, O 
with O 
the O 
lowest O 
GCR B-protein 
on O 
MNL B-cell_type 
and O 
highest O 
on O 
PML B-cell_type 
. O 

The O 
ubiquitous B-protein 
octamer I-protein 
- I-protein 
binding I-protein 
protein I-protein 
( O 
s O 
) O 
is O 
sufficient O 
for O 
transcription O 
of O 
immunoglobulin B-DNA 
genes I-DNA 
. O 

All O 
immunoglobulin B-DNA 
genes I-DNA 
contain O 
a O 
conserved O 
octanucleotide B-DNA 
promoter I-DNA 
element I-DNA 
, O 
ATGCAAAT O 
, O 
which O 
has O 
been O 
shown O 
to O 
be O 
required O 
for O 
their O 
normal O 
B O 
- O 
cell O 
- O 
specific O 
transcription O 
. O 

Proteins O 
that O 
bind O 
this O 
octamer O 
have O 
been O 
purified O 
, O 
and O 
cDNAs B-DNA 
encoding O 
octamer B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
have O 
been O 
cloned O 
. O 

Some O 
of O 
these O 
proteins O 
( O 
referred O 
to O 
as O 
OTF B-protein 
- I-protein 
2 I-protein 
) O 
are O 
lymphoid O 
specific O 
, O 
whereas O 
at O 
least O 
one O 
other O 
, O 
and O 
possibly O 
more O 
( O 
referred O 
to O 
as O 
OTF B-protein 
- I-protein 
1 I-protein 
) O 
, O 
is O 
found O 
ubiquitously O 
in O 
all O 
cell O 
types O 
. O 

The O 
exact O 
role O 
of O 
these O 
different O 
proteins O 
in O 
directing O 
the O 
tissue O 
- O 
specific O 
expression O 
of O 
immunoglobulin B-DNA 
genes I-DNA 
is O 
unclear O 
. O 

We O 
have O 
identified O 
two O 
human B-cell_line 
pre I-cell_line 
- I-cell_line 
B I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
that O 
contain O 
extremely O 
low O 
levels O 
of O 
OTF B-protein 
- I-protein 
2 I-protein 
yet O 
still O 
express O 
high O 
levels O 
of O 
steady B-RNA 
- I-RNA 
state I-RNA 
immunoglobulin B-protein I-RNA 
heavy I-protein I-RNA 
- I-protein I-RNA 
chain I-protein I-RNA 
mRNA I-RNA 
in O 
vivo O 
and O 
efficiently O 
transcribe O 
an O 
immunoglobulin B-DNA 
gene I-DNA 
in O 
vitro O 
. O 

Addition O 
of O 
a O 
highly O 
enriched O 
preparation O 
of O 
OTF B-protein 
- I-protein 
1 I-protein 
made O 
from O 
one O 
of O 
these O 
pre B-cell_line 
- I-cell_line 
B I-cell_line 
cells I-cell_line 
or O 
from O 
HeLa B-cell_line 
cells I-cell_line 
specifically O 
stimulated O 
in O 
vitro O 
transcription O 
of O 
an O 
immunoglobulin B-DNA 
gene I-DNA 
. O 

Furthermore O 
, O 
OFT O 
- O 
1 O 
appeared O 
to O 
have O 
approximately O 
the O 
same O 
transactivation O 
ability O 
as O 
OTF B-protein 
- I-protein 
2 I-protein 
when O 
normalized O 
for O 
binding O 
activity O 
. O 

These O 
results O 
suggest O 
that O 
OTF B-protein 
- I-protein 
1 I-protein 
, O 
without O 
OTF B-protein 
- I-protein 
2 I-protein 
, O 
is O 
sufficient O 
for O 
transcription O 
of O 
immunoglobulin B-DNA 
genes I-DNA 
and O 
that O 
OTF B-protein 
- I-protein 
2 I-protein 
alone O 
is O 
not O 
responsible O 
for O 
the O 
B O 
- O 
cell O 
- O 
specific O 
regulation O 
of O 
immunoglobulin B-DNA 
gene I-DNA 
expression O 
. O 

Effects O 
of O 
aldosterone O 
on O 
intralymphocytic O 
sodium O 
and O 
potassium O 
in O 
patients O 
with O 
essential O 
hypertension O 
. O 

In O 
vitro O 
binding O 
of O 
aldosterone O 
to O 
mineralocorticoid B-protein 
receptors I-protein 
on O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
( O 
HML B-cell_type 
) O 
and O 
its O 
effects O 
on O 
the O 
intracellular O 
sodium O 
and O 
potassium O 
concentrations O 
of O 
HML B-cell_type 
have O 
already O 
been O 
described O 
. O 

In O 
the O 
present O 
paper O 
this O 
easily O 
accessible O 
human O 
cell O 
model O 
was O 
investigated O 
in O 
13 O 
patients O 
with O 
essential O 
hypertension O 
. O 

In O 
only O 
four O 
patients O 
sodium O 
in O 
HML B-cell_type 
without O 
incubation O 
was O 
elevated O 
compared O 
with O 
the O 
range O 
for O 
normal O 
persons O 
. O 

A O 
decrease O 
of O 
intracellular O 
sodium O 
or O 
potassium O 
occurred O 
during O 
incubation O 
without O 
aldosterone O 
( O 
P O 
less O 
than O 
0 O 
. O 
02 O 
) O 
. O 

The O 
addition O 
of O 
1 O 
. O 
4 O 
nM O 
aldosterone O 
did O 
not O 
prevent O 
this O 
loss O 
of O 
electrolytes O 
as O 
observed O 
in O 
normal O 
persons O 
. O 

Plasma B-protein 
renin I-protein 
activity O 
and O 
aldosterone O 
were O 
not O 
correlated O 
with O 
the O 
electrolyte O 
response O 
and O 
were O 
within O 
the O 
normal O 
limits O 
. O 

The O 
number O 
of O 
mineralocorticoid B-protein 
receptors I-protein 
/ O 
cell O 
were O 
within O 
or O 
close O 
to O 
the O 
normal O 
range O 
( O 
n O 
= O 
9 O 
) O 
. O 

The O 
independence O 
of O 
intracellular O 
electrolytes O 
from O 
aldosterone O 
despite O 
a O 
normal O 
number O 
of O 
mineralocorticoid B-protein 
receptors I-protein 
may O 
reflect O 
an O 
impairment O 
of O 
the O 
mineralocorticoid O 
effector O 
mechanism O 
in O 
the O 
HML B-cell_type 
of O 
patients O 
with O 
essential O 
hypertension O 
. O 

[ O 
Differential O 
diagnostic O 
value O 
of O 
receptors O 
of O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
calcitriol O 
) O 
determination O 
in O 
lymphocytes B-cell_type 
of O 
children O 
with O 
rickets O 
and O 
rickets O 
- O 
like O 
diseases O 
] O 
. O 

The O 
authors O 
provide O 
the O 
results O 
of O 
studying O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
calcitriol O 
) O 
in O 
lymphocytes B-cell_type 
of O 
children O 
with O 
rickets O 
and O 
rickets O 
- O 
like O 
diseases O 
. O 

It O 
is O 
proposed O 
that O 
the O 
character O 
of O 
their O 
expression O 
under O 
the O 
influence O 
of O 
vitamin O 
D O 
may O 
be O 
used O 
with O 
differential O 
diagnostic O 
purposes O 
in O 
view O 
. O 

Regulation O 
of O 
gene O 
expression O 
with O 
double O 
- O 
stranded O 
phosphorothioate O 
oligonucleotides O 
. O 

Alteration O 
of O 
gene O 
transcription O 
by O 
inhibition O 
of O 
specific O 
transcriptional B-protein 
regulatory I-protein 
proteins I-protein 
is O 
necessary O 
for O 
determining O 
how O 
these O 
factors O 
participate O 
in O 
cellular O 
differentiation O 
. O 

The O 
functions O 
of O 
these O 
proteins O 
can O 
be O 
antagonized O 
by O 
several O 
methods O 
, O 
each O 
with O 
specific O 
limitations O 
. O 

Inhibition O 
of O 
sequence B-protein 
- I-protein 
specific I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
was O 
achieved O 
with O 
double O 
- O 
stranded O 
( O 
ds O 
) O 
phosphorothioate O 
oligonucleotides O 
that O 
contained O 
octamer O 
or O 
kappa O 
B O 
consensus O 
sequences O 
. O 

The O 
phosphorothioate O 
oligonucleotides O 
specifically O 
bound O 
either O 
octamer B-protein 
transcription I-protein 
factor I-protein 
or O 
nuclear B-protein 
factor I-protein 
( I-protein 
NF I-protein 
) I-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

The O 
modified O 
oligonucleotides O 
accumulated O 
in O 
cells O 
more O 
effectively O 
than O 
standard O 
ds O 
oligonucleotides O 
and O 
modulated O 
gene O 
expression O 
in O 
a O 
specific O 
manner O 
. O 

Octamer O 
- O 
dependent O 
activation O 
of O 
a O 
reporter B-DNA 
plasmid I-DNA 
or O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
- O 
dependent O 
activation O 
of O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
( I-DNA 
HIV I-DNA 
) I-DNA 
enhancer I-DNA 
was O 
inhibited O 
when O 
the O 
appropriate O 
phosphorothioate O 
oligonucleotide O 
was O 
added O 
to O 
a O 
transiently B-cell_line 
transfected I-cell_line 
B I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

Addition O 
of O 
phosphorothioate O 
oligonucleotides O 
that O 
contained O 
the O 
octamer B-DNA 
consensus I-DNA 
to O 
Jurkat B-cell_line 
T I-cell_line 
leukemia I-cell_line 
cells I-cell_line 
inhibited O 
interleukin B-protein 
- I-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
secretion O 
to O 
a O 
degree O 
similar O 
to O 
that O 
observed O 
with O 
a O 
mutated B-DNA 
octamer I-DNA 
site I-DNA 
in O 
the O 
IL B-DNA 
- I-DNA 
2 I-DNA 
enhancer I-DNA 
. O 

The O 
ds O 
phosphorothioate O 
oligonucleotides O 
probably O 
compete O 
for O 
binding O 
of O 
specific O 
transcription O 
factors O 
and O 
may O 
provide O 
anti O 
- O 
viral O 
, O 
immunosuppressive O 
, O 
or O 
other O 
therapeutic O 
effects O 
. O 

[ O 
Effect O 
of O 
the O 
regimen O 
of O 
kidney O 
- O 
tonifying O 
and O 
qi O 
- O 
invigorating O 
on O 
aging O 
changes O 
of O 
glucocorticoid B-protein 
receptor I-protein 
] O 
. O 

The O 
plasma O 
cortisol O 
concentration O 
and O 
the O 
sites O 
of O 
glucocorticoid B-protein 
receptor I-protein 
( O 
GCR B-protein 
) O 
in O 
the O 
peripheral B-cell_type 
lymphocytes B-cell_type I-cell_type 
were O 
measured O 
in O 
32 O 
healthy O 
aged O 
persons O 
and O 
13 O 
young O 
adults O 
. O 

In O 
animal O 
experiment O 
, O 
GCR B-protein 
of O 
spleen B-cell_type 
lymphocytic I-cell_type 
cell I-cell_type 
was O 
also O 
measured O 
in O 
18 O 
aged O 
rats O 
and O 
9 O 
young O 
rats O 
. O 

The O 
results O 
showed O 
that O 
GCR B-protein 
was O 
significantly O 
lower O 
in O 
the O 
aged O 
persons O 
or O 
rats O 
than O 
that O 
in O 
the O 
young O 
while O 
the O 
plasma O 
cortisol O 
level O 
didn O 
' O 
t O 
change O 
with O 
aging O 
. O 

So O 
we O 
think O 
that O 
GCR B-protein 
is O 
more O 
sensitive O 
than O 
the O 
plasma O 
cortisol O 
level O 
to O 
reflect O 
the O 
aging O 
change O 
of O 
the O 
adrenal O 
cortex O 
function O 
. O 

After O 
the O 
treatment O 
with O 
the O 
regimen O 
of O 
Kidney O 
- O 
tonifying O 
and O 
Qi O 
- O 
invigorating O 
, O 
the O 
GCR B-protein 
of O 
the O 
aged O 
persons O 
and O 
rats O 
was O 
enhanced O 
, O 
and O 
in O 
this O 
way O 
, O 
the O 
function O 
of O 
the O 
aged O 
adrenal O 
cortex O 
was O 
improved O 
. O 

Interferon O 
affects O 
nuclear B-protein 
proteins I-protein 
in O 
cells O 
of O 
clinically O 
sensitive O 
chronic O 
myelogenous O 
leukemia O 
patients O 
. O 

Cytoplasmic O 
protein O 
extracts O 
from O 
chronic B-cell_type 
myelogenous I-cell_type 
leukemia I-cell_type 
( I-cell_type 
CML I-cell_type 
) I-cell_type 
cells I-cell_type 
contained O 
an O 
activity O 
that O 
altered O 
the O 
electrophoretic O 
mobility O 
of O 
complexes O 
formed O 
between O 
nuclear B-protein 
proteins I-protein 
and O 
the O 
transcriptional O 
enhancers O 
of O 
interferon O 
( O 
IFN O 
) O 
- O 
inducible O 
genes O 
. O 

Exposure O 
of O 
CML B-cell_type 
cells I-cell_type 
to O 
IFN B-protein 
- I-protein 
alpha I-protein 
diminished O 
the O 
effect O 
of O 
the O 
CML B-protein 
cytoplasmic I-protein 
proteins I-protein 
on O 
these O 
nuclear B-protein 
protein I-protein 
- I-protein 
DNA I-protein 
complexes I-protein 
. O 

The O 
presence O 
of O 
clinical O 
responsiveness O 
to O 
IFN B-protein 
- I-protein 
alpha I-protein 
correlated O 
with O 
the O 
sensitivity O 
to O 
the O 
IFN B-protein 
- O 
induced O 
change O 
in O 
the O 
electrophoretic O 
mobility O 
of O 
nuclear B-protein 
protein I-protein 
- I-protein 
DNA I-protein 
complexes I-protein 
. O 

These O 
data O 
suggest O 
that O 
the O 
action O 
of O 
IFN B-protein 
- I-protein 
alpha I-protein 
in O 
CML O 
may O 
be O 
linked O 
to O 
a O 
pathway O 
that O 
can O 
result O 
in O 
posttranslational O 
modification O 
of O 
nuclear B-protein 
proteins I-protein 
. O 

Epstein B-protein 
- I-protein 
Barr I-protein 
virus I-protein 
nuclear I-protein 
antigen I-protein 
2 I-protein 
transactivates O 
latent B-protein 
membrane I-protein 
protein I-protein 
LMP1 B-protein 
. O 

Several O 
lines O 
of O 
evidence O 
are O 
compatible O 
with O 
the O 
hypothesis O 
that O 
Epstein B-protein 
- I-protein 
Barr I-protein 
virus I-protein 
( I-protein 
EBV I-protein 
) I-protein 
nuclear I-protein 
antigen I-protein 
2 I-protein 
( O 
EBNA B-protein 
- I-protein 
2 I-protein 
) O 
or O 
leader B-protein 
protein I-protein 
( O 
EBNA B-protein 
- I-protein 
LP I-protein 
) O 
affects O 
expression O 
of O 
the O 
EBV B-protein 
latent I-protein 
infection I-protein 
membrane I-protein 
protein I-protein 
LMP1 B-protein 
. O 

We O 
now O 
demonstrate O 
the O 
following O 
. O 

( O 
i O 
) O 
Acute O 
transfection O 
and O 
expression O 
of O 
EBNA B-protein 
- I-protein 
2 I-protein 
under O 
control O 
of O 
simian O 
virus O 
40 O 
or O 
Moloney O 
murine O 
leukemia O 
virus O 
promoters O 
resulted O 
in O 
increased O 
LMP1 B-protein 
expression O 
in O 
P3HR B-cell_line 
- I-cell_line 
1 I-cell_line 
- I-cell_line 
infected I-cell_line 
Burkitt I-cell_line 
' I-cell_line 
s I-cell_line 
lymphoma I-cell_line 
cells I-cell_line 
and O 
the O 
P3HR B-cell_line 
- I-cell_line 
1 I-cell_line 
or O 
Daudi B-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

( O 
ii O 
) O 
Transfection O 
and O 
expression O 
of O 
EBNA B-protein 
- I-protein 
LP I-protein 
alone O 
had O 
no O 
effect O 
on O 
LMP1 B-protein 
expression O 
and O 
did O 
not O 
act O 
synergistically O 
with O 
EBNA B-protein 
- I-protein 
2 I-protein 
to O 
affect O 
LMP1 B-protein 
expression O 
. O 

( O 
iii O 
) O 
LMP1 B-protein 
expression O 
in O 
Daudi B-cell_line 
and O 
P3HR B-cell_line 
- I-cell_line 
1 I-cell_line 
- I-cell_line 
infected I-cell_line 
cells I-cell_line 
was O 
controlled O 
at O 
the O 
mRNA B-RNA 
level O 
, O 
and O 
EBNA B-protein 
- I-protein 
2 I-protein 
expression O 
in O 
Daudi B-cell_line 
cells I-cell_line 
increased O 
LMP1 B-protein B-RNA 
mRNA I-RNA 
. O 

( O 
iv O 
) O 
No O 
other O 
EBV B-DNA 
genes I-DNA 
were O 
required O 
for O 
EBNA B-protein 
- I-protein 
2 I-protein 
transactivation O 
of O 
LMP1 B-protein 
since O 
cotransfection O 
of O 
recombinant B-DNA 
EBNA B-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
expression I-DNA 
vectors I-DNA 
and O 
genomic O 
LMP1 B-protein B-DNA 
DNA I-DNA 
fragments I-DNA 
enhanced O 
LMP1 B-protein 
expression O 
in O 
the O 
EBV B-cell_line 
- I-cell_line 
negative I-cell_line 
B I-cell_line 
- I-cell_line 
lymphoma I-cell_line 
cell I-cell_line 
lines I-cell_line 
BJAB B-cell_line 
, O 
Louckes B-cell_line 
, O 
and O 
BL30 B-cell_line 
. O 

( O 
v O 
) O 
An O 
EBNA B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
was O 
found O 
within O 
the O 
- B-DNA 
512 I-DNA 
to I-DNA 
+ I-DNA 
40 I-DNA 
LMP1 B-protein B-DNA I-DNA 
DNA I-DNA I-DNA 
since O 
this O 
DNA O 
linked O 
to O 
a O 
chloramphenicol B-protein B-DNA 
acetyltransferase I-protein I-DNA 
reporter I-DNA 
gene I-DNA 
was O 
transactivated O 
by O 
cotransfection O 
with O 
an O 
EBNA B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
expression I-DNA 
vector I-DNA 
. O 

( O 
vi O 
) O 
The O 
EBV O 
type O 
2 O 
EBNA B-protein 
- I-protein 
2 I-protein 
transactivated O 
LMP1 B-protein 
as O 
well O 
as O 
the O 
EBV O 
type O 
1 O 
EBNA B-protein 
- I-protein 
2 I-protein 
. O 

( O 
vii O 
) O 
Two O 
deletions O 
within O 
the O 
EBNA B-protein 
- I-protein 
2 I-protein 
gene O 
which O 
rendered O 
EBV O 
transformation O 
incompetent O 
did O 
not O 
transactivate O 
LMP1 B-protein 
, O 
whereas O 
a O 
transformation B-DNA 
- I-DNA 
competent I-DNA 
EBNA B-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
deletion I-DNA 
mutant I-DNA 
did O 
transactivate O 
LMP1 B-protein 
. O 

LMP1 B-protein 
is O 
a O 
potent O 
effector O 
of O 
B O 
- O 
lymphocyte O 
activation O 
and O 
can O 
act O 
synergistically O 
with O 
EBNA B-protein 
- I-protein 
2 I-protein 
to O 
induce O 
cellular O 
CD23 O 
gene O 
expression O 
. O 

Thus O 
, O 
EBNA B-protein 
- I-protein 
2 I-protein 
transactivation O 
of O 
LMP1 B-protein 
amplifies O 
the O 
biological O 
impact O 
of O 
EBNA B-protein 
- I-protein 
2 I-protein 
and O 
underscores O 
its O 
central O 
role O 
in O 
EBV O 
- O 
induced O 
growth O 
transformation O 
. O 

The O 
expression O 
of O 
c B-DNA 
- I-DNA 
fos I-DNA 
, O 
c B-DNA 
- I-DNA 
jun I-DNA 
, O 
and O 
c B-DNA 
- I-DNA 
myc I-DNA 
genes I-DNA 
is O 
regulated O 
by O 
heat O 
shock O 
in O 
human B-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
. O 

The O 
effect O 
of O 
heat O 
shock O 
on O 
the O 
expression O 
of O 
the O 
nuclear B-DNA 
protooncogenes I-DNA 
c B-DNA 
- I-DNA 
fos I-DNA 
, O 
c B-DNA 
- I-DNA 
jun I-DNA 
, O 
and O 
c B-DNA 
- I-DNA 
myc I-DNA 
was O 
studied O 
in O 
human B-cell_type 
lymphoid I-cell_type 
cells I-cell_type 
. O 

Heat O 
shock O 
caused O 
an O 
increase O 
in O 
c O 
- O 
fos O 
and O 
c O 
- O 
jun O 
mRNA O 
levels O 
and O 
a O 
decrease O 
in O 
c B-DNA B-RNA 
- I-DNA I-RNA 
myc I-DNA I-RNA 
mRNA I-RNA 
levels O 
in O 
pre O 
- O 
B O 
( O 
Hyon O 
) O 
and O 
T O 
( O 
DND O 
- O 
41 O 
) O 
cell O 
lines O 
as O 
well O 
as O 
in O 
freshly O 
isolated O 
normal O 
human O 
thymocytes O 
. O 

The O 
changes O 
in O 
the O 
mRNA O 
levels O 
of O 
these O 
protooncogenes B-DNA 
in O 
Hyon B-cell_line 
cells I-cell_line 
were O 
most O 
pronounced O 
at O 
42 O 
and O 
43 O 
degrees O 
C O 
; O 
kinetic O 
analysis O 
demonstrated O 
that O 
the O 
changes O 
could O 
be O 
detected O 
within O 
30 O 
min O 
of O 
heat O 
shock O 
. O 

Altered O 
transcription O 
of O 
c B-DNA 
- I-DNA 
fos I-DNA 
and O 
c B-DNA B-DNA 
- I-DNA I-DNA 
myc I-DNA I-DNA 
genes I-DNA 
was O 
the O 
primary O 
effect O 
of O 
heat O 
shock O 
. O 

Secondarily O 
, O 
heat O 
shock O 
of O 
Hyon B-cell_line 
cells I-cell_line 
stabilized O 
the O 
c B-DNA B-RNA 
- I-DNA I-RNA 
myc I-DNA I-RNA 
mRNA I-RNA 
level O 
by O 
increasing O 
its O 
half O 
- O 
life O 
from O 
24 O 
to O 
45 O 
min O 
. O 

The O 
overall O 
effect O 
of O 
heat O 
shock O 
on O 
c B-DNA B-RNA 
- I-DNA I-RNA 
myc I-DNA I-RNA 
mRNA I-RNA 
level O 
, O 
however O 
, O 
was O 
a O 
marked O 
inhibition O 
of O 
its O 
transcription O 
. O 

These O 
results O 
demonstrate O 
that O 
the O 
transcription O 
of O 
nuclear B-DNA 
protooncogenes B-DNA I-DNA 
is O 
regulated O 
by O 
heat O 
shock O 
indicating O 
a O 
role O 
for O 
nuclear B-DNA 
protooncogenes B-DNA I-DNA 
in O 
the O 
stress O 
response O 
of O 
lymphoid B-cell_type 
cells I-cell_type 
. O 

Mapping O 
of O 
B B-protein 
- I-protein 
cell I-protein 
epitopes I-protein 
of O 
the O 
human B-protein 
hepatitis I-protein 
B I-protein 
virus I-protein 
X I-protein 
protein I-protein 
. O 

The O 
immune O 
response O 
to O 
the O 
X B-protein 
protein I-protein 
of O 
human O 
hepatitis O 
B O 
virus O 
( O 
HBV O 
) O 
was O 
studied O 
by O 
epitope O 
mapping O 
by O 
using O 
a O 
set O 
of O 
MS2 B-protein 
- I-protein 
HBx I-protein 
fusion I-protein 
proteins I-protein 
and O 
synthetic O 
peptides O 
. O 

Antibodies O 
in O 
sera O 
of O 
patients O 
with O 
acute O 
and O 
chronic O 
HBV O 
infection O 
showed O 
a O 
multispecific O 
immune O 
response O 
. O 

Each O 
serum O 
contained O 
antibodies B-protein 
to O 
a O 
different O 
set O 
of O 
epitopes B-protein 
, O 
which O 
taken O 
together O 
cover O 
most O 
of O 
the O 
HBx B-protein 
sequence I-protein 
. O 

Some O 
of O 
the O 
epitopes O 
were O 
detectable O 
only O 
by O 
immunoblotting O 
with O 
fusion B-protein 
proteins I-protein 
; O 
others O 
were O 
detectable O 
only O 
by O 
an O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
with O 
synthetic O 
peptides O 
. O 

The O 
carboxy B-protein 
- I-protein 
terminal I-protein 
half I-protein 
of O 
the O 
HBx B-protein B-protein 
protein I-protein 
was O 
preferentially O 
recognized O 
by O 
antibodies B-protein 
from O 
patients O 
with O 
chronic O 
hepatitis O 
and O 
contained O 
a O 
short O 
immunodominant B-protein 
antigenic I-protein 
region I-protein 
with O 
at O 
least O 
two O 
major O 
nonoverlapping B-protein 
epitopes I-protein 
. O 

Anti O 
- O 
HBx B-protein 
antibody O 
titers O 
as O 
revealed O 
by O 
peptide O 
ELISAs O 
were O 
highest O 
and O 
most O 
frequent O 
in O 
patients O 
with O 
chronic O 
hepatitis O 
and O 
usually O 
low O 
in O 
acutely O 
infected O 
patients O 
and O 
asymptomatic O 
carriers O 
. O 

The O 
data O 
demonstrate O 
a O 
remarkable O 
qualitative O 
and O 
quantitative O 
heterogeneity O 
of O 
the O 
humoral O 
HBx B-protein 
immune O 
response O 
which O 
can O 
be O 
monitored O 
by O 
HBx B-protein 
- O 
specific O 
peptide O 
ELISAs O 
. O 

Such O 
tests O 
may O 
become O 
useful O 
diagnostic O 
tools O 
. O 

[ O 
The O 
inhibitory O 
effect O 
of O 
hydrocortisone O 
on O 
the O 
chemotactic O 
migration O 
of O 
human B-cell_type 
leukocytes I-cell_type 
] O 
. O 

Random O 
migration O 
( O 
RM O 
) O 
and O 
chemotactic O 
migration O 
( O 
ChtM O 
) O 
of O 
human B-cell_type 
leukocytes I-cell_type 
to O 
yeast O 
activated O 
serum O 
were O 
studied O 
with O 
the O 
modified O 
Boyden O 
chamber O 
method O 
. O 

Both O 
RM O 
and O 
ChtM O 
showed O 
circadian O 
rhythm O 
. O 

Leukocytes B-cell_type 
migrated O 
most O 
rapidly O 
at O 
night O 
. O 

The O 
difference O 
between O 
the O 
peak O 
( O 
0 O 
: O 
00 O 
) O 
and O 
trough O 
values O 
( O 
8 O 
: O 
00 O 
) O 
of O 
RM O 
and O 
ChtM O 
was O 
significant O 
statistically O 
( O 
P O 
less O 
than O 
0 O 
. O 
01 O 
) O 
. O 

ChtM O 
was O 
inhibited O 
by O 
hydrocortisone O 
( O 
F O 
) O 
of O 
physiological O 
concentration O 
( O 
10 O 
( O 
- O 
9 O 
) O 
- O 
10 O 
( O 
- O 
7 O 
) O 
mol O 
/ O 
L O 
) O 
which O 
was O 
dose O 
- O 
dependent O 
and O 
completely O 
antagonized O 
by O 
the O 
competitive O 
antagonist O 
, O 
RU38486 O 
. O 

The O 
inhibitory O 
effect O 
was O 
much O 
more O 
evident O 
with O 
higher O 
dose O 
( O 
more O 
than O 
10 O 
( O 
- O 
5 O 
) O 
mol O 
/ O 
L O 
) O 
and O 
it O 
was O 
also O 
reversed O 
by O 
RU38486 O 
, O 
but O 
only O 
partially O 
. O 

It O 
is O 
suggested O 
that O 
glucocorticoids O 
( O 
GC O 
) O 
may O 
be O 
a O 
physiological O 
regulator O 
of O 
the O 
activity O 
of O 
leukocytes B-cell_type 
and O 
its O 
inhibitory O 
action O 
on O 
ChtM O 
may O 
be O 
involved O 
in O 
antiinflammatory O 
mechanisms O 
of O 
GC O 
of O 
pharmacological O 
doses O 
. O 

The O 
action O 
of O 
physiological O 
and O 
pharmacological O 
concentration O 
of O 
GC O 
may O 
be O 
mediated O 
by O 
low B-protein 
affinity I-protein 
specific I-protein 
binding I-protein 
sites I-protein 
of O 
glucocorticoid B-protein 
receptors I-protein 
. O 

Heterogeneity O 
of O 
antigen B-protein 
molecules I-protein 
recognized O 
by O 
anti B-protein 
- I-protein 
tax1 I-protein 
monoclonal I-protein 
antibody I-protein 
Lt B-protein 
- I-protein 
4 I-protein 
in O 
cell O 
lines O 
bearing O 
human O 
T O 
cell O 
leukemia O 
virus O 
type O 
I O 
and O 
related O 
retroviruses O 
. O 

Using O 
a O 
monoclonal B-protein 
antibody I-protein 
, O 
Lt B-protein 
- I-protein 
4 I-protein 
, O 
directed O 
against O 
human B-protein B-protein 
T I-protein I-protein 
cell I-protein I-protein 
leukemia I-protein I-protein 
virus I-protein I-protein 
type I-protein I-protein 
I I-protein I-protein 
( I-protein I-protein 
HTLV I-protein I-protein 
- I-protein I-protein 
I I-protein I-protein 
) I-protein I-protein 
trans I-protein I-protein 
- I-protein I-protein 
activator I-protein I-protein 
( I-protein 
tax1 B-protein I-protein 
) I-protein 
antigen I-protein 
, O 
we O 
examined O 
the O 
expression O 
of O 
tax1 B-protein 
and O 
related O 
antigens B-protein 
in O 
a O 
variety O 
of O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
bearing O 
HTLV O 
- O 
I O 
and O 
related O 
retroviruses O 
, O 
simian O 
T O 
cell O 
leukemia O 
virus O 
type O 
I O 
( O 
STLV O 
- O 
I O 
) O 
and O 
HTLV O 
- O 
II O 
, O 
by O 
immunofluorescence O 
and O 
immunoblot O 
assays O 
. O 

Lt B-protein 
- I-protein 
4 I-protein 
reacted O 
with O 
all O 
HTLV B-cell_line 
- I-cell_line 
I I-cell_line 
- I-cell_line 
bearing I-cell_line 
cell I-cell_line 
lines I-cell_line 
tested O 
and O 
five O 
out O 
of O 
eight O 
simian B-cell_line 
cell I-cell_line 
lines I-cell_line 
bearing O 
STLV O 
- O 
I O 
, O 
but O 
not O 
with O 
an O 
HTLV B-cell_line 
- I-cell_line 
II I-cell_line 
- I-cell_line 
bearing I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

Lt B-protein 
- I-protein 
4 I-protein 
detected O 
40 O 
kd O 
tax1 B-protein B-protein 
antigen I-protein 
molecules I-protein 
in O 
most O 
HTLV B-cell_line 
- I-cell_line 
I I-cell_line 
- I-cell_line 
bearing I-cell_line 
cell I-cell_line 
lines I-cell_line 
except O 
one O 
cell O 
line O 
that O 
expressed O 
39 B-protein 
kd I-protein 
tax1 B-protein I-protein 
antigen I-protein 
. O 

In O 
the O 
STLV O 
- O 
I O 
- O 
bearing O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
tax1 B-protein B-protein 
- I-protein 
related I-protein 
antigen I-protein 
molecules I-protein 
detected O 
by O 
Lt B-protein 
- I-protein 
4 I-protein 
were O 
heterogeneous O 
, O 
having O 
molecular O 
weights O 
in O 
the O 
range O 
of O 
36 O 
- O 
41 O 
kd O 
. O 

Characterization O 
of O 
the O 
human B-DNA B-protein 
immunodeficiency I-DNA I-protein 
virus I-DNA I-protein 
type I-DNA I-protein 
1 I-DNA I-protein 
enhancer I-DNA I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
from O 
the O 
human B-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
Jurkat B-cell_line 
. O 

The O 
transcription O 
of O 
the O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
is O 
under O 
the O 
control O 
of O 
cellular B-protein 
proteins I-protein 
that O 
bind O 
to O 
the O 
viral B-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
. O 

Among O 
the O 
protein O 
- O 
binding O 
regions O 
of O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
LTR I-DNA 
is O 
the O 
transcription B-DNA 
- I-DNA 
enhancer I-DNA 
region I-DNA 
. O 

We O 
show O 
that O 
at O 
least O 
one O 
inducible B-protein 
, O 
C1 B-protein 
, O 
and O 
one O 
constitutive B-protein 
, I-protein 
C2 B-protein I-protein 
, I-protein 
protein I-protein 
can O 
bind O 
to O 
the O 
HIV B-DNA 
enhancer I-DNA 
in O 
Jurkat B-cell_line 
cells I-cell_line 
. O 

The O 
two O 
proteins O 
differ O 
in O 
their O 
surface O 
charge O 
, O 
since O 
they O 
are O 
separable O 
by O 
anion O 
- O 
exchange O 
chromatography O 
. O 

Bivalent O 
cations O 
such O 
as O 
Mg2 O 
+ O 
and O 
Zn2 O 
+ O 
differentially O 
affect O 
their O 
binding O 
to O 
oligonucleotides O 
which O 
contain O 
the O 
HIV B-DNA 
- I-DNA 
enhancer I-DNA 
domain I-DNA 
. O 

Both O 
C1 B-protein 
and O 
C2 B-protein 
proteins I-protein 
also O 
bind O 
to O 
a O 
similar O 
sequence O 
found O 
in O 
the O 
interleukin B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
2 I-protein I-protein I-DNA 
- I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
- I-protein I-DNA 
subunit I-protein I-DNA 
enhancer I-DNA 
. O 

The O 
inducible B-protein 
C1 B-protein I-protein 
protein I-protein 
was O 
partially O 
purified O 
by O 
three O 
chromatographic O 
steps O 
and O 
characterized O 
by O 
u O 
. O 
v O 
. O 
cross O 
- O 
linking O 
as O 
a O 
47 B-protein 
kDa I-protein 
protein I-protein 
. O 

Differences O 
in O 
transcriptional B-DNA 
enhancers I-DNA 
of O 
HIV O 
- O 
1 O 
and O 
HIV O 
- O 
2 O 
. O 

Response O 
to O 
T B-cell_type 
cell I-cell_type 
activation O 
signals O 
. O 

T B-cell_type 
cell I-cell_type 
activation O 
results O 
in O 
high O 
levels O 
of O 
HIV O 
replication O 
and O 
is O 
thought O 
to O 
be O 
one O 
mechanism O 
leading O 
to O 
the O 
conversion O 
from O 
latent O 
to O 
active O 
viral O 
infection O 
. O 

In O 
HIV O 
- O 
1 O 
, O 
the O 
sequences O 
that O 
respond O 
to O 
these O 
signaling O 
events O 
are O 
found O 
in O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
and O 
comprise O 
the O 
transcriptional B-DNA 
enhancer I-DNA 
, O 
which O 
contains O 
two O 
conserved B-DNA 
binding I-DNA 
sites I-DNA 
for O 
the O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
kappa I-protein 
B I-protein 
) O 
. O 

The O 
corresponding O 
region O 
in O 
the O 
second O 
AIDS O 
retrovirus O 
, O 
HIV O 
- O 
2 O 
, O 
contains O 
a O 
conserved O 
and O 
a O 
divergent O 
NF B-protein B-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
binding I-DNA 
site I-DNA 
. O 

We O 
demonstrate O 
that O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
LTR I-DNA 
responds O 
better O 
than O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
LTR I-DNA 
to O 
T O 
cell O 
activation O 
signals O 
. O 

These O 
qualitative O 
differences O 
in O 
the O 
response O 
to O 
T B-cell_type 
cell I-cell_type 
activation O 
are O 
reproduced O 
not O 
only O 
when O 
HIV O 
- O 
1 O 
or O 
HIV O 
- O 
2 O 
enhancers O 
are O 
placed O 
upstream O 
of O 
a O 
heterologous B-DNA 
promoter I-DNA 
but O 
also O 
when O 
these O 
enhancers B-DNA 
are O 
switched O 
between O 
their O 
respective O 
LTR B-DNA 
. O 

In O 
electrophoretic O 
mobility O 
shift O 
assays O 
, O 
NF B-protein 
kappa I-protein 
B I-protein 
binds O 
to O 
both O 
conserved O 
sites O 
in O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
transcriptional I-DNA 
enhancer I-DNA 
and O 
only O 
to O 
the O 
single O 
conserved O 
site O 
in O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
transcriptional I-DNA 
enhancer I-DNA 
. O 

Instead O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
, O 
the O 
activator B-protein 
protein I-protein 
3 I-protein 
binds O 
to O 
the O 
divergent O 
site O 
in O 
HIV O 
- O 
2 O 
. O 

In O 
conclusion O 
, O 
HIV O 
- O 
1 O 
and O 
HIV O 
- O 
2 O 
are O 
differentially O 
regulated O 
by O 
T O 
cell O 
activation O 
signals O 
, O 
and O 
this O 
difference O 
may O 
account O 
for O 
the O 
longer O 
period O 
of O 
viral O 
latency O 
observed O 
with O 
HIV O 
- O 
2 O 
than O 
with O 
HIV O 
- O 
1 O 
infection O 
. O 

NF B-protein 
- I-protein 
X2 I-protein 
that O 
binds O 
to O 
the O 
DRA B-DNA 
X2 I-DNA 
- I-DNA 
box I-DNA 
is O 
activator B-protein 
protein I-protein 
1 I-protein 
. O 

Expression O 
cloning O 
of O 
c B-protein 
- I-protein 
Jun I-protein 
. O 

Human B-protein 
class I-protein 
II I-protein 
MHC I-protein 
Ag I-protein 
are O 
a O 
family O 
of O 
cell B-protein 
surface I-protein 
glycoproteins I-protein 
. O 

Their O 
constitutive O 
expression O 
is O 
limited O 
to O 
B B-cell_type 
lymphocytes I-cell_type 
and O 
thymic B-cell_type 
epithelial I-cell_type 
cells I-cell_type 
. O 

In O 
many O 
other O 
cells O 
their O 
expression O 
can O 
be O 
induced O 
by O 
IFN B-protein 
- I-protein 
gamma I-protein 
. O 

Conserved O 
upstream O 
promoter O 
sequences O 
regulate O 
this O 
tissue O 
- O 
specific O 
expression O 
of O 
class B-DNA 
II I-DNA 
genes I-DNA 
. O 

In O 
the O 
DRA B-DNA 
promoter I-DNA 
, O 
one O 
of O 
these O 
cis B-DNA 
- I-DNA 
acting I-DNA 
regulatory I-DNA 
motifs I-DNA 
is O 
the O 
X2 B-DNA 
- I-DNA 
box I-DNA 
to O 
which O 
nuclear B-protein 
factor I-protein 
X2 I-protein 
( O 
NF B-protein 
- I-protein 
X2 I-protein 
) O 
binds O 
. O 

Here O 
, O 
we O 
present O 
the O 
isolation O 
and O 
characterization O 
of O 
the O 
full B-DNA 
- I-DNA 
length I-DNA 
cDNA I-DNA 
clone I-DNA 
encoding O 
NF B-protein 
- I-protein 
X2 I-protein 
. O 

This O 
cDNA B-DNA 
clone I-DNA 
was O 
isolated O 
by O 
expression O 
cDNA B-DNA 
cloning O 
, O 
and O 
encodes O 
the O 
human B-protein 
c B-protein I-protein 
- I-protein I-protein 
Jun I-protein I-protein 
protein I-protein 
, O 
which O 
together O 
with O 
c B-protein 
- I-protein 
Fos I-protein 
forms O 
the O 
heterodimeric B-protein 
activator I-protein 
protein I-protein 
- I-protein 
1 I-protein 
transcription I-protein 
complex I-protein 
. O 

Whereas O 
c B-protein B-protein 
- I-protein I-protein 
Fos I-protein I-protein 
/ B-protein I-protein 
c I-protein I-protein 
- I-protein I-protein 
Jun I-protein I-protein 
heterodimers I-protein 
do O 
not O 
exist O 
in O 
B B-cell_line 
cells I-cell_line 
, O 
they O 
form O 
and O 
bind O 
to O 
the O 
X2 B-DNA 
- I-DNA 
box I-DNA 
in O 
class B-cell_line 
II I-cell_line 
nonexpressing I-cell_line 
cells I-cell_line 
. O 

Thus O 
, O 
c B-protein B-protein 
- I-protein I-protein 
Fos I-protein I-protein 
/ B-protein I-protein 
c I-protein I-protein 
- I-protein I-protein 
Jun I-protein I-protein 
heterodimers I-protein 
might O 
contribute O 
to O 
the O 
repression O 
of O 
DRA B-DNA 
gene I-DNA 
expression O 
. O 

Synthesis O 
of O 
4 O 
, O 
19 O 
- O 
disubstituted O 
derivatives O 
of O 
DOC O 
. O 

Radioreceptor O 
assay O 
of O 
some O 
corticosteroid O 
derivatives O 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
. O 

Several O 
new O 
4 O 
, O 
19 O 
- O 
substituted O 
steroids O 
and O 
previously O 
synthesized O 
corticosteroids O 
were O 
assayed O 
for O 
affinity O 
to O 
type B-protein 
1 I-protein 
receptors I-protein 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
. O 

11 O 
beta O 
, O 
19 O 
- O 
epoxy O 
- O 
4 O 
, O 
21 O 
- O 
dihydroxypregn O 
- O 
4 O 
- O 
ene O 
- O 
3 O 
, O 
20 O 
- O 
dione O 
( O 
2 O 
) O 
was O 
hydrogenated O 
with O 
Pd O 
- O 
C O 
to O 
yield O 
a O 
mixture O 
of O 
all O 
four O 
dihydro O 
derivatives O 
5 O 
, O 
accompanied O 
by O 
4 O 
, O 
21 O 
- O 
diacetoxy O 
- O 
11 O 
beta O 
, O 
19 O 
- O 
epoxy O 
- O 
3 O 
- O 
hydroxypregnan O 
- O 
20 O 
- O 
one O 
( O 
6 O 
) O 
and O 
21 O 
- O 
acetoxy O 
- O 
11 O 
beta O 
, O 
19 O 
- O 
epoxy O 
- O 
4 O 
- O 
hydroxypregnane O 
- O 
3 O 
, O 
20 O 
- O 
dione O 
( O 
7 O 
) O 
. O 

With O 
hot O 
acetic O 
+ O 
p O 
- O 
toluenesulfonic O 
acid O 
5 O 
underwent O 
rearrangement O 
to O 
21 O 
- O 
acetoxy O 
- O 
11 O 
beta O 
, O 
19 O 
- O 
epoxypregn O 
- O 
5 O 
- O 
ene O 
- O 
4 O 
, O 
20 O 
- O 
dione O 
( O 
8 O 
) O 
Pd O 
- O 
C O 
hydrogenation O 
of O 
3 O 
, O 
21 O 
- O 
diacetoxy O 
- O 
5 O 
beta O 
, O 
19 O 
- O 
cyclopregna O 
- O 
2 O 
, O 
9 O 
( O 
11 O 
) O 
- O 
diene O 
- O 
4 O 
, O 
20 O 
- O 
dione O 
( O 
10 O 
) O 
gave O 
3 O 
, O 
21 O 
- O 
diacetoxy O 
- O 
5 O 
beta O 
, O 
19 O 
- O 
cyclopregn O 
- O 
5 O 
- O 
ene O 
- O 
4 O 
, O 
20 O 
- O 
dione O 
( O 
11 O 
) O 
and O 
the O 
9 O 
, O 
11 O 
- O 
dihydro O 
derivative O 
of O 
the O 
latter O 
. O 

Treatment O 
of O 
10 O 
with O 
warm O 
HCl O 
furnished O 
19 O 
- O 
chloro O 
- O 
4 O 
, O 
21 O 
- O 
dihydroxypregna O 
- O 
4 O 
, O 
9 O 
( O 
11 O 
) O 
- O 
diene O 
- O 
3 O 
, O 
20 O 
- O 
dione O 
( O 
13 O 
) O 
. O 

Pd O 
- O 
C O 
hydrogenation O 
of O 
its O 
diacetate O 
14 O 
afforded O 
the O 
4 O 
, O 
5 O 
- O 
dihydro O 
derivative O 
18 O 
, O 
19 O 
- O 
chloro O 
- O 
21 O 
- O 
acetoxypregn O 
- O 
9 O 
( O 
11 O 
) O 
- O 
en O 
- O 
20 O 
- O 
one O 
( O 
15 O 
) O 
, O 
its O 
4 O 
- O 
acetoxy O 
derivative O 
16 O 
and O 
the O 
3 O 
, O 
4 O 
- O 
diacetoxy O 
derivative O 
17 O 
. O 

When O 
tested O 
in O 
a O 
radioreceptor O 
assay O 
in O 
human B-cell_type 
mononuclear I-cell_type 
leukocytes I-cell_type 
the O 
synthesized O 
compounds O 
showed O 
only O 
low O 
relative O 
binding O 
affinities O 
( O 
RBA O 
) O 
to O 
type B-protein 
1 I-protein 
receptor I-protein 
, O 
the O 
highest O 
being O 
0 O 
. O 
72 O 
% O 
for O 
13 O 
( O 
aldosterone O 
= O 
100 O 
% O 
) O 
. O 

For O 
comparison O 
, O 
other O 
RBA O 
in O 
this O 
system O 
were O 
: O 
19 O 
- O 
noraldosterone O 
, O 
20 O 
% O 
; O 
18 O 
- O 
deoxyaldosterone O 
, O 
5 O 
. O 
8 O 
% O 
; O 
18 O 
- O 
deoxy O 
- O 
19 O 
- O 
noraldosterone O 
, O 
4 O 
. O 
7 O 
% O 
; O 
18 O 
, O 
21 O 
- O 
anhydroaldosterone O 
, O 
0 O 
. O 
37 O 
% O 
; O 
17 O 
- O 
isoaldosterone O 
, O 
7 O 
. O 
6 O 
% O 
and O 
apoaldosterone O 
, O 
4 O 
. O 
3 O 
% O 
. O 

Cell O 
type O 
specificity O 
and O 
activation O 
requirements O 
for O 
NFAT B-protein 
- I-protein 
1 I-protein 
( O 
nuclear B-protein 
factor I-protein 
of O 
activated B-cell_type 
T I-cell_type 
- I-cell_type 
cells I-cell_type 
) O 
transcriptional O 
activity O 
determined O 
by O 
a O 
new O 
method O 
using O 
transgenic O 
mice O 
to O 
assay O 
transcriptional O 
activity O 
of O 
an O 
individual O 
nuclear B-protein 
factor I-protein 
. O 

Nuclear B-protein 
factor I-protein 
of O 
activated B-cell_type 
T I-cell_type 
- I-cell_type 
cells I-cell_type 
( O 
NFAT B-protein 
- I-protein 
1 I-protein 
) O 
is O 
a O 
transcription B-protein 
factor I-protein 
which O 
is O 
considered O 
to O 
be O 
an O 
important O 
regulator O 
in O 
early O 
T O 
- O 
cell O 
activation O 
. O 

We O 
have O 
developed O 
a O 
system O 
to O 
monitor O 
the O 
transcriptional O 
activity O 
of O 
NFAT B-protein 
- I-protein 
1 I-protein 
at O 
the O 
single O 
cell O 
level O 
in O 
whole O 
animals O 
. O 

The O 
system O 
is O 
based O 
on O 
the O 
use O 
of O 
an O 
oligomerized O 
NFAT B-protein 
- I-protein 
1 I-protein 
binding O 
motif O 
that O 
directs O 
transcription B-protein 
of I-protein 
SV40 I-protein 
T I-protein 
- I-protein 
antigen I-protein 
in O 
transgenic O 
mice O 
. O 

This O 
report O 
represents O 
the O 
first O 
demonstration O 
that O 
a O 
multimerized O 
short O 
binding O 
motif O 
can O 
function O 
appropriately O 
in O 
transgenic O 
mice O 
. O 

NFAT B-protein 
- I-protein 
1 I-protein 
activity O 
had O 
previously O 
been O 
thought O 
to O 
be O 
confined O 
to O 
activated B-cell_type 
T I-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
upon O 
release O 
of O 
intracellular B-cell_type 
calcium I-cell_type 
. O 

By O 
targeting O 
NFAT B-protein 
- I-protein 
1 I-protein 
- O 
dependent O 
gene O 
expression O 
in O 
transgenic O 
mice O 
we O 
discovered O 
new O 
sites O 
of O 
NFAT B-protein 
- I-protein 
1 I-protein 
activity O 
. O 

Besides O 
in O 
T B-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
NFAT B-protein 
- I-protein 
1 I-protein 
activity O 
could O 
also O 
be O 
induced O 
in O 
T B-cell_type 
- I-cell_type 
lymphocyte I-cell_type 
- I-cell_type 
depleted I-cell_type 
spleen I-cell_type 
cells I-cell_type 
and O 
purified B-cell_type 
B I-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
and O 
requires O 
agents O 
that O 
both O 
release O 
intracellular O 
calcium O 
and O 
activate O 
protein B-protein 
kinase I-protein 
C I-protein 
. O 

A O 
difference O 
in O 
the O 
time O 
course O 
of O 
appearance O 
of O 
NFAT B-protein 
- I-protein 
1 I-protein 
activity O 
between O 
T B-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
and O 
non B-cell_type 
- I-cell_type 
T I-cell_type 
- I-cell_type 
lymphocytes I-cell_type 
was O 
revealed O 
. O 

Constitutive O 
expression O 
was O 
observed O 
in O 
a O 
small O 
population O 
of O 
cells O 
in O 
the O 
dermis O 
and O 
some O 
mice O 
have O 
developed O 
skin O 
lesions O 
. O 

Interestingly O 
, O 
the O 
tissue O 
pattern O 
of O 
expression O 
of O 
the O 
NFAT B-protein 
- I-protein 
1 I-protein 
activity O 
resembles O 
the O 
expression O 
pattern O 
described O 
for O 
HIV O 
- O 
LTR O 
/ O 
tat O 
transgenic O 
mice O 
( O 
Vogel O 
, O 
J O 
. O 
, O 
Hinrichs O 
, O 
S O 
. O 
H O 
. O 
, O 
Reynolds O 
, O 
R O 
. O 
K O 
. O 
, O 
Luciw O 
, O 
P O 
. O 
A O 
. O 
, O 
and O 
Jay O 
, O 
G O 
. O 
( O 
1988 O 
) O 
Nature O 
335 O 
, O 
606 O 
- O 
611 O 
) O 
. O 

This O 
similarity O 
in O 
expression O 
and O 
the O 
fact O 
that O 
NFAT B-protein 
- I-protein 
1 I-protein 
has O 
been O 
shown O 
to O 
bind O 
functional B-DNA 
sequences I-DNA 
in O 
HIV B-DNA 
- I-DNA 
LTR I-DNA 
suggest O 
a O 
role O 
for O 
NFAT B-protein 
- I-protein 
1 I-protein 
in O 
dermal O 
activation O 
of O 
the O 
HIV B-DNA 
- I-DNA 
LTR I-DNA 
. O 

A O 
novel O 
T B-protein 
- I-protein 
cell I-protein 
protein I-protein 
which O 
recognizes O 
a O 
palindromic B-DNA 
sequence I-DNA 
in O 
the O 
negative B-DNA 
regulatory I-DNA 
element I-DNA 
of O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
. O 

Two O 
major B-DNA 
protein I-DNA 
- I-DNA 
binding I-DNA 
sites I-DNA 
within O 
the O 
negative B-DNA 
regulatory I-DNA 
element I-DNA 
of O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
type I-DNA 
1 I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
have O 
been O 
identified O 
. O 

One O 
( O 
site B-DNA 
B I-DNA 
) O 
contained O 
a O 
palindromic B-DNA 
sequence I-DNA 
with O 
homology O 
to O 
steroid B-DNA 
/ I-DNA 
thyroid I-DNA 
hormone I-DNA 
response I-DNA 
elements I-DNA 
but O 
was O 
distinct O 
from O 
previously O 
described O 
binding O 
sites O 
of O 
this O 
class O 
. O 

A O 
novel O 
T B-protein 
- I-protein 
cell I-protein 
protein I-protein 
recognized O 
the O 
palindromic B-DNA 
sequence I-DNA 
within O 
site B-DNA 
B I-DNA 
and O 
also O 
bound O 
estrogen O 
- O 
or O 
thyroid O 
hormone O 
- O 
response O 
elements O 
with O 
lower O 
affinity O 
. O 

A O 
7 O 
- O 
base O 
- O 
pair O 
mutation O 
in O 
the O 
site B-DNA B-DNA 
B I-DNA I-DNA 
palindrome I-DNA 
, O 
which O 
destroyed O 
protein O 
binding O 
, O 
resulted O 
in O 
increased O 
expression O 
from O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
type I-DNA 
1 I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
in O 
T B-cell_type 
cells I-cell_type 
. O 

Progesterone O 
suppression O 
of O 
pregnancy B-cell_type 
lymphocytes I-cell_type 
is O 
not O 
mediated O 
by O 
glucocorticoid O 
effect O 
. O 

This O 
study O 
investigated O 
whether O 
the O 
suppressive O 
effect O 
of O 
progesterone O 
on O 
pregnancy B-cell_type 
lymphocytes I-cell_type 
is O 
mediated O 
by O 
specific O 
progesterone B-protein 
receptors I-protein 
. O 

The O 
effects O 
of O 
a O 
competitive O 
progesterone O 
antagonist O 
( O 
RU486 O 
) O 
and O 
a O 
specific O 
glucocorticoid B-protein 
receptor I-protein 
blocker O 
( O 
RU43044 O 
) O 
were O 
tested O 
on O 
the O 
release O 
of O 
a O 
blocking B-protein 
factor I-protein 
by O 
progesterone O 
- O 
treated O 
pregnancy B-cell_type 
lymphocytes I-cell_type 
. O 

RU O 
486 O 
tested O 
at O 
an O 
equal O 
concentration O 
as O 
progesterone O 
significantly O 
inhibited O 
the O 
production O 
of O 
the O 
blocking B-protein 
factor I-protein 
, O 
while O 
RU O 
43044 O 
was O 
without O 
effect O 
. O 

These O 
data O 
suggest O 
that O 
in O 
pregnancy O 
, O 
lymphocyte O 
progesterone O 
acts O 
on O 
specific O 
progesterone B-protein 
receptors I-protein 
and O 
glucocorticoid B-protein 
binding I-protein 
sites I-protein 
are O 
not O 
involved O 
. O 

The O 
56 B-protein 
- I-protein 
59 I-protein 
- I-protein 
kilodalton I-protein 
protein I-protein 
identified O 
in O 
untransformed B-protein 
steroid I-protein 
receptor I-protein 
complexes I-protein 
is O 
a O 
unique B-protein 
protein I-protein 
that O 
exists O 
in O 
cytosol O 
in O 
a O 
complex O 
with O 
both O 
the O 
70 O 
- O 
and O 
90 O 
- O 
kilodalton O 
heat O 
shock O 
proteins O 
. O 

It O 
has O 
previously O 
been O 
shown O 
that O 
9S B-protein 
, O 
untransformed O 
progestin O 
, O 
estrogen O 
, O 
androgen O 
, O 
and O 
glucocorticoid O 
receptor O 
complexes O 
in O 
rabbit O 
uterine O 
and O 
liver O 
cytosols O 
contain O 
a O 
59 B-protein 
- I-protein 
kDa I-protein 
protein I-protein 
[ O 
Tai O 
, O 
P O 
. O 
K O 
. O 
, O 
Maeda O 
, O 
Y O 
. O 
, O 
Nakao O 
, O 
K O 
. O 
, O 
Wakim O 
, O 
N O 
. O 
G O 
. O 
, O 
Duhring O 
, O 
J O 
. O 
L O 
. O 
, O 
& O 
Faber O 
, O 
L O 
. O 
E O 
. O 
( O 
1986 O 
) O 
Biochemistry O 
25 O 
, O 
5269 O 
- O 
5275 O 
] O 
. O 

In O 
this O 
work O 
we O 
show O 
that O 
the O 
monoclonal B-protein 
antibody I-protein 
KN I-protein 
382 I-protein 
/ I-protein 
EC1 I-protein 
raised O 
against O 
the O 
rabbit B-protein 
59 I-protein 
- I-protein 
kDa I-protein 
protein I-protein 
reacts O 
with O 
9S B-protein 
, O 
untransformed B-protein 
glucocorticoid I-protein 
receptor I-protein 
complexes I-protein 
in O 
cytosol O 
prepared O 
from O 
human B-cell_line 
IM I-cell_line 
- I-cell_line 
9 I-cell_line 
lymphocytes I-cell_line 
but O 
not O 
with O 
4S B-protein 
salt I-protein 
- I-protein 
transformed I-protein 
receptors I-protein 
. O 

The O 
human O 
protein O 
recognized O 
by O 
the O 
EC1 B-protein 
antibody I-protein 
is O 
a O 
56 B-protein 
- I-protein 
kDa I-protein 
protein I-protein 
( O 
p56 B-protein 
) O 
of O 
moderate O 
abundance O 
located O 
predominantly O 
in O 
the O 
cytoplasm O 
by O 
indirect O 
immunofluorescence O 
. O 

There O 
are O 
at O 
least O 
six O 
isomorphs B-protein 
of O 
p56 B-protein 
by O 
two O 
- O 
dimensional O 
gel O 
analysis O 
. O 

N O 
- O 
Terminal O 
sequencing O 
( O 
20 O 
amino O 
acids O 
) O 
shows O 
that O 
p56 B-protein 
is O 
a O 
unique B-protein 
human I-protein 
protein I-protein 
. O 

When O 
p56 B-protein 
is O 
immunoadsorbed O 
from O 
IM B-cell_line 
- I-cell_line 
9 I-cell_line 
cell I-cell_line 
cytosol O 
, O 
both O 
the O 
70 O 
- O 
and O 
90 O 
- O 
kDa O 
heat O 
shock O 
proteins O 
are O 
coadsorbed O 
in O 
an O 
immune O 
- O 
specific O 
manner O 
. O 

Neither O 
heat B-protein 
shock I-protein 
protein I-protein 
reacts O 
directly O 
with O 
the O 
EC1 B-protein 
antibody I-protein 
. O 

We O 
conclude O 
that O 
p56 B-protein 
exists O 
in O 
cytosol O 
in O 
a O 
higher O 
order O 
complex O 
containing O 
hsp70 B-protein 
and O 
hsp90 B-protein 
, O 
both O 
of O 
which O 
in O 
turn O 
have O 
been O 
found O 
to O 
be O 
associated O 
with O 
untransformed B-protein 
steroid I-protein 
receptors I-protein 
. O 

Sequence O 
- O 
specific O 
DNA O 
binding O 
of O 
the O 
proto B-protein 
- I-protein 
oncoprotein I-protein 
ets B-protein 
- I-protein 
1 I-protein 
defines O 
a O 
transcriptional B-DNA 
activator I-DNA 
sequence I-DNA 
within O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
of O 
the O 
Moloney O 
murine O 
sarcoma O 
virus O 
. O 

The O 
ets B-DNA 
proto I-DNA 
- I-DNA 
oncogene I-DNA 
family I-DNA 
is O 
a O 
group O 
of O 
sequence B-DNA 
- I-DNA 
related I-DNA 
genes I-DNA 
whose O 
normal O 
cellular O 
function O 
is O 
unknown O 
. O 

In O 
a O 
study O 
of O 
cellular B-protein 
proteins I-protein 
involved O 
in O 
the O 
transcriptional O 
regulation O 
of O 
murine O 
retroviruses O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
, O 
we O 
have O 
discovered O 
that O 
a O 
member O 
of O 
the O 
ets B-DNA 
gene I-DNA 
family I-DNA 
encodes O 
a O 
sequence B-protein 
- I-protein 
specific I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
protein I-protein 
. O 

A O 
mouse B-DNA 
ets B-protein I-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
cDNA I-DNA 
clone I-DNA 
was O 
obtained O 
by O 
screening O 
a O 
mouse B-DNA 
thymus I-DNA 
cDNA I-DNA 
expression I-DNA 
library I-DNA 
with O 
a O 
double B-DNA 
- I-DNA 
stranded I-DNA 
oligonucleotide I-DNA 
probe I-DNA 
representing O 
20 O 
bp O 
of O 
the O 
Moloney O 
murine O 
sarcoma O 
virus O 
( O 
MSV O 
) O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
. O 

The O 
cDNA B-DNA 
sequence I-DNA 
has O 
an O 
813 B-DNA 
- I-DNA 
bp I-DNA 
open I-DNA 
reading I-DNA 
frame I-DNA 
( O 
ORF B-DNA 
) O 
whose O 
predicted O 
amino B-protein 
acid I-protein 
sequence I-protein 
is O 
97 O 
. O 
6 O 
% O 
identical O 
to O 
the O 
272 B-protein 
carboxy I-protein 
- I-protein 
terminal I-protein 
amino I-protein 
acids I-protein 
of O 
the O 
human B-protein 
ets B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
. O 

The O 
ORF B-DNA 
was O 
expressed O 
in O 
bacteria O 
, O 
and O 
the O 
30 B-protein 
- I-protein 
kD I-protein 
protein I-protein 
product I-protein 
was O 
shown O 
to O 
bind O 
DNA B-DNA 
in O 
a O 
sequence O 
- O 
specific O 
manner O 
by O 
mobility O 
- O 
shift O 
assays O 
, O 
Southwestern O 
blot O 
analysis O 
, O 
and O 
methylation O 
interference O 
. O 

A O 
mutant B-DNA 
LTR I-DNA 
containing O 
four O 
base O 
pair O 
substitutions O 
in O 
the O 
ets B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
binding I-DNA 
site I-DNA 
was O 
constructed O 
and O 
was O 
shown O 
to O 
have O 
reduced O 
binding O 
in O 
vitro O 
. O 

Transcriptional O 
efficiency O 
of O 
the O 
MSV B-DNA 
LTR I-DNA 
promoter I-DNA 
containing O 
this O 
disrupted O 
ets B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
binding I-DNA 
site I-DNA 
was O 
compared O 
to O 
the O 
activity O 
of O 
a O 
wild B-DNA 
- I-DNA 
type I-DNA 
promoter I-DNA 
in O 
mouse B-cell_type 
T B-cell_type I-cell_type 
lymphocytes I-cell_type I-cell_type 
in O 
culture O 
, O 
and O 
15 O 
- O 
to O 
20 O 
- O 
fold O 
reduction O 
in O 
expression O 
of O 
a O 
reporter B-DNA 
gene I-DNA 
was O 
observed O 
. O 

We O 
propose O 
that O 
ets B-protein 
- I-protein 
1 I-protein 
functions O 
as O 
a O 
transcriptional O 
activator O 
of O 
mammalian O 
type O 
- O 
C O 
retroviruses O 
and O 
speculate O 
that O 
ets B-DNA 
- I-DNA 
related I-DNA 
genes I-DNA 
constitute O 
a O 
new O 
group O 
of O 
eukaryotic B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
. O 

Type B-protein 
II I-protein 
estrogen I-protein 
binding I-protein 
sites I-protein 
in O 
human B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
: O 
variations O 
during O 
the O 
menstrual O 
cycle O 
. O 

We O 
have O 
previously O 
reported O 
that O 
human B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
( O 
PBMC B-cell_type 
) O 
contain O 
type O 
II B-protein 
estrogen I-protein 
binding I-protein 
sites I-protein 
( O 
type B-protein 
II I-protein 
EBS I-protein 
) O 
. O 

In O 
this O 
study O 
, O 
the O 
fluctuations O 
of O 
type B-protein 
II I-protein 
EBS I-protein 
during O 
the O 
menstrual O 
cycle O 
were O 
analyzed O 
in O 
6 O 
normally O 
menstruating O 
women O 
. O 

Approximately O 
3 O 
times O 
higher O 
levels O 
of O 
type B-protein 
II I-protein 
EBS I-protein 
were O 
found O 
in O 
the O 
periovulatory O 
period O 
with O 
respect O 
to O 
both O 
follicular O 
and O 
luteal O 
phases O 
. O 

In O 
postmenopausal O 
women O 
the O 
mean O 
type B-protein 
II I-protein 
EBS I-protein 
levels O 
were O 
similar O 
to O 
those O 
observed O 
in O 
the O 
follicular O 
phase O 
of O 
the O 
cycle O 
. O 

However O 
, O 
in O 
3 O 
postmenopausal O 
patients O 
a O 
short O 
course O 
of O 
estrogen O 
or O 
tamoxifen O 
resulted O 
in O 
a O 
marked O 
increase O 
of O 
type B-protein 
II I-protein 
EBS I-protein 
levels O 
. O 

Tamoxifen O 
was O 
also O 
found O 
to O 
compete O 
with O 
17 O 
beta O 
- O 
estradiol O 
for O 
type B-protein 
II I-protein 
EBS I-protein 
in O 
PBMC B-cell_type 
, O 
although O 
to O 
a O 
lesser O 
extent O 
than O 
diethylstilbestrol O 
. O 

Mononuclear B-cell_type 
leukocyte I-cell_type 
glucocorticoid B-protein 
receptor I-protein 
binding O 
characteristics O 
and O 
down O 
- O 
regulation O 
in O 
major O 
depression O 
. O 

Some O 
patients O 
with O 
major O 
depressive O 
disorder O 
( O 
MDD O 
) O 
have O 
elevated O 
plasma O 
cortisol O 
concentrations O 
and O 
show O 
failure O 
to O 
suppress O 
cortisol O 
secretion O 
upon O 
administration O 
of O 
dexamethasone O 
( O 
DEX O 
) O 
, O 
yet O 
they O 
do O 
not O 
have O 
Cushingoid O 
features O 
. O 

To O 
study O 
whether O 
this O 
represents O 
glucocorticoid O 
( O 
GC O 
) O 
resistance O 
, O 
[ O 
3H O 
] O 
- O 
DEX O 
- O 
binding O 
assays O 
were O 
used O 
to O 
measure O 
, O 
in O 
vitro O 
, O 
the O 
GC B-protein 
receptor I-protein 
affinity O 
( O 
1 O 
/ O 
Kd O 
) O 
and O 
number O 
( O 
Bmax O 
) O 
in O 
mononuclear B-cell_type 
leukocytes I-cell_type 
of O 
11 O 
MDD O 
patients O 
and O 
15 O 
control O 
subjects O 
. O 

No O 
receptor O 
abnormalities O 
were O 
detected O 
in O 
the O 
MDD O 
group O 
; O 
thus O 
any O 
cellular O 
defect O 
leading O 
to O 
a O 
lack O 
of O 
responsiveness O 
to O 
GC O 
in O 
the O 
MDD O 
patients O 
, O 
if O 
present O 
, O 
probably O 
lies O 
beyond O 
the O 
initial O 
receptor O 
binding O 
. O 

DEX O 
( O 
1 O 
. O 
0 O 
mg O 
orally O 
) O 
was O 
administered O 
to O 
study O 
in O 
vivo B-protein 
GC I-protein 
receptor I-protein 
down O 
- O 
regulation O 
. O 

Compared O 
to O 
the O 
control O 
group O 
, O 
fewer O 
depressed O 
subjects O 
down O 
- O 
regulated O 
Bmax O 
after O 
DEX O 
. O 

By O 
paired O 
t O 
- O 
test O 
, O 
Bmax O 
decreased O 
significantly O 
in O 
the O 
control O 
group O 
but O 
not O 
in O 
the O 
depressed O 
group O 
. O 

Receptor O 
number O 
on O 
the O 
control O 
day O 
did O 
not O 
correlate O 
significantly O 
with O 
the O 
degree O 
of O 
receptor O 
down O 
- O 
regulation O 
, O 
severity O 
of O 
depression O 
or O 
cortisol O 
concentrations O 
across O 
all O 
the O 
subjects O 
. O 

These O 
results O 
do O 
not O 
lend O 
support O 
to O 
previous O 
reports O 
suggesting O 
that O 
GC O 
resistance O 
in O 
MDD O 
results O 
from O 
a O 
GC O 
receptor O 
- O 
binding O 
abnormality O 
, O 
and O 
they O 
emphasize O 
the O 
importance O 
of O 
considering O 
receptor O 
studies O 
in O 
the O 
context O 
of O 
GC O 
- O 
mediated O 
cell O 
processes O 
in O 
order O 
to O 
identify O 
the O 
exact O 
cellular O 
defect O 
( O 
s O 
) O 
leading O 
to O 
GC O 
resistance O 
. O 

Ras B-protein 
- I-protein 
related I-protein 
GTP I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
and O 
leukocyte B-cell_type 
signal O 
transduction O 
. O 

Many O 
aspects O 
of O 
leukocyte B-cell_type 
function O 
are O 
regulated O 
by O 
both O 
heterotrimeric B-protein 
and O 
Ras B-protein 
- I-protein 
related I-protein 
GTP I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
, O 
but O 
there O 
is O 
little O 
definite O 
information O 
about O 
their O 
roles O 
in O 
the O 
specialized O 
processes O 
utilized O 
by O 
leukocytes B-cell_type 
for O 
cell O 
killing O 
. O 

Recent O 
progress O 
in O 
understanding O 
the O 
regulation O 
of O 
the O 
phagocyte B-protein 
NADPH I-protein 
oxidase I-protein 
by O 
the O 
Rac B-protein 
GTP I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
provides O 
a O 
basis O 
for O 
defining O 
the O 
operational O 
characteristics O 
of O 
one O 
such O 
phagocyte O 
system O 
. O 

It O 
is O 
clear O 
from O 
various O 
studies O 
that O 
the O 
activity O 
of O 
the O 
NADPH B-protein 
oxidase I-protein 
can O 
be O 
modulated O 
through O 
the O 
regulation O 
of O 
the O 
GTP B-protein 
- I-protein 
GDP I-protein 
state I-protein 
of O 
Rac B-protein 
. O 

Proteins O 
exist O 
in O 
leukocytes B-cell_type 
able O 
to O 
modify O 
GTP B-protein 
- I-protein 
binding I-protein 
protein I-protein 
function O 
in O 
this O 
manner O 
, O 
and O 
their O 
activity O 
may O 
be O 
regulated O 
by O 
signals O 
generated O 
on O 
phagocyte O 
stimulation O 
. O 

Proteins O 
of O 
the O 
Ras B-protein 
superfamily I-protein 
are O 
likely O 
to O 
be O 
involved O 
in O 
a O 
variety O 
of O 
normal O 
phagocyte O 
functions O 
through O 
their O 
ability O 
to O 
modulate O 
the O 
assembly O 
of O 
actin B-protein 
filaments I-protein 
, O 
direct O 
vesicle O 
trafficking O 
and O 
fusion O 
, O 
and O 
so O 
forth O 
. O 

BSAP B-protein 
: O 
a O 
key O 
regulator O 
of O 
B B-cell_type 
- I-cell_type 
cell I-cell_type 
development O 
and O 
differentiation O 
. O 

B B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
activator I-protein 
protein I-protein 
( O 
BSAP B-protein 
) O 
is O 
a O 
recently O 
identified O 
member O 
of O 
the O 
Pax B-DNA 
- I-DNA 
gene I-DNA 
family I-DNA 
of O 
transcription B-protein 
factors I-protein 
; O 
in O 
the O 
lymphoid O 
system O 
, O 
BSAP B-protein 
is O 
produced O 
only O 
in O 
B B-cell_type 
cells I-cell_type 
. O 

Here O 
, O 
Markus O 
Neurath O 
, O 
Eckhard O 
Stuber O 
and O 
Warren O 
Strober O 
describe O 
the O 
molecular O 
structure O 
of O 
BSAP B-protein 
and O 
focus O 
on O 
the O 
ability O 
of O 
this O 
protein O 
to O 
regulate O 
the O 
expression O 
of O 
B B-DNA 
- I-DNA 
cell I-DNA 
- I-DNA 
specific I-DNA 
genes I-DNA 
. O 

They O 
propose O 
that O 
BSAP B-protein 
is O 
a O 
key B-protein 
protein I-protein 
of O 
B B-cell_type 
cells I-cell_type 
and O 
that O 
it O 
not O 
only O 
influence O 
B O 
- O 
cell O 
development O 
but O 
also O 
influences O 
the O 
balance O 
between O 
B O 
- O 
cell O 
proliferation O 
and O 
immunoglobulin B-protein 
secretion O 
at O 
later O 
stages O 
of O 
B O 
- O 
cell O 
differentiation O 
. O 

Down O 
- O 
regulation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
protein I-protein 
levels O 
in O 
activated O 
human O 
lymphocytes O 
by O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
[ O 
published O 
erratum O 
appears O 
in O 
Proc O 
Natl O 
Acad O 
Sci O 
U O 
S O 
A O 
1996 O 
Jan O 
9 O 
; O 
93 O 
( O 
1 O 
) O 
: O 
524 O 
] O 
. O 

The O 
effect O 
of O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
[ O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2 O 
) O 
D3 O 
] O 
, O 
a O 
steroid O 
hormone O 
with O 
immunomodulating O 
properties O 
, O 
on O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
) O 
proteins O 
was O 
examined O 
in O 
in B-cell_line 
vitro I-cell_line 
activated I-cell_line 
normal I-cell_line 
human B-cell_type I-cell_line 
lymphocytes I-cell_type I-cell_line 
by O 
Western O 
blot O 
analysis O 
. O 

Over O 
a O 
72 O 
- O 
hr O 
period O 
of O 
activation O 
, O 
the O 
expression O 
of O 
the O 
50 B-protein 
- I-protein 
kDa I-protein 
NF I-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
p50 B-protein 
, O 
and O 
its O 
precursor O 
, O 
p105 B-protein 
, O 
was O 
increased O 
progressively O 
. O 

When O 
cells O 
were O 
activated O 
in O 
the O 
presence O 
of O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
, O 
the O 
levels O 
of O 
the O 
mature O 
protein O 
as O 
well O 
as O 
its O 
precursor O 
were O 
decreased O 
. O 

The O 
effect O 
of O 
the O 
hormone O 
on O 
the O 
levels O 
of O 
p50 B-protein 
was O 
demonstrable O 
in O 
the O 
cytosolic O 
and O 
nuclear O 
compartments O 
; O 
it O 
required O 
between O 
4 O 
and O 
8 O 
hr O 
and O 
was O 
specific O 
, O 
as O 
25 O 
- O 
hydroxyvitamin O 
D3 O 
and O 
24 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
were O 
ineffective O 
. O 

Besides O 
p50 B-protein 
, O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
decreased O 
the O 
levels O 
of O 
another O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
protein I-protein 
, O 
namely O 
c B-protein 
- I-protein 
rel I-protein 
. O 

In O 
addition O 
, O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
decreased O 
the O 
abundance O 
of O 
a O 
specific B-protein 
DNA I-protein 
- I-protein 
protein I-protein 
complex I-protein 
formed O 
upon O 
incubation O 
of O 
nuclear O 
extracts O 
from O 
activated O 
lymphocytes O 
with O 
a O 
labeled O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
DNA I-protein 
binding I-protein 
motif I-protein 
. O 

Further O 
, O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
inhibited O 
the O 
transcriptional O 
activity O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
Jurkat B-cell_line 
cells I-cell_line 
transiently O 
transfected O 
with O 
a O 
construct B-DNA 
containing O 
four O 
tandem B-DNA 
repeats I-DNA 
of O 
the O 
NF B-protein B-DNA 
- I-protein I-DNA 
kappa I-protein I-DNA 
B I-protein I-DNA 
binding I-DNA 
sequence I-DNA 
of O 
the O 
immunoglobulin B-DNA 
kappa I-DNA 
light I-DNA 
chain I-DNA 
gene I-DNA 
linked O 
to O 
the O 
chloramphenicol B-protein B-DNA 
acetyltransferase I-protein I-DNA 
reporter I-DNA 
gene I-DNA 
. O 

These O 
observations O 
demonstrate O 
directly O 
that O 
there O 
is O 
de O 
novo O 
synthesis O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
during O 
human O 
lymphocyte O 
activation O 
and O 
suggest O 
that O 
this O 
process O 
is O 
hormonally O 
regulated O 
. O 

The O 
myeloid B-DNA 
zinc I-DNA 
finger I-DNA 
gene I-DNA 
, O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
, O 
regulates O 
the O 
CD34 B-DNA 
promoter I-DNA 
in O 
vitro O 
. O 

MZF B-DNA 
- I-DNA 
1 I-DNA 
is O 
a O 
C2H2 B-DNA 
zinc I-DNA 
finger I-DNA 
gene I-DNA 
encoding O 
a O 
putative B-protein 
transcriptional I-protein 
regulator I-protein 
of O 
myeloid O 
differentiation O 
. O 

The O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
protein O 
contains O 
13 O 
C2H2 B-protein 
zinc I-protein 
fingers I-protein 
arranged O 
in O 
bipartite O 
DNA B-protein 
binding I-protein 
domains I-protein 
containing O 
zinc B-protein 
fingers I-protein 
through O 
4 O 
and O 
, O 
in O 
the O 
carboxy B-protein 
- I-protein 
terminus I-protein 
, O 
5 O 
through O 
13 O 
. O 

We O 
previously O 
identified O 
the O 
DNA B-DNA 
consensus I-DNA 
binding I-DNA 
site I-DNA 
recognized O 
by O 
the O 
two O 
DNA B-protein 
binding I-protein 
domains I-protein 
. O 

To O 
assess O 
the O 
transcription O 
regulatory O 
function O 
of O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
, O 
the O 
full O 
- O 
length O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
coding O 
region O 
was O 
fused O 
to O 
the O 
DNA B-protein 
binding I-protein 
domain I-protein 
of O 
the O 
yeast B-protein 
transactivator I-protein 
GAL4 B-protein I-protein 
. O 

The O 
expression O 
vector O 
was O 
cotransfected O 
with O 
the O 
chloramphenicol B-protein B-DNA 
acetyl I-protein I-DNA 
transferase I-protein I-DNA 
( I-DNA 
CAT I-DNA 
) I-DNA 
reporter I-DNA 
gene I-DNA 
regulated O 
by O 
the O 
thymidine B-protein B-DNA 
kinase I-protein I-DNA 
promoter I-DNA 
containing O 
GAL4 B-protein B-DNA 
DNA I-DNA 
binding I-DNA 
sites I-DNA 
into O 
NIH B-cell_line 
3T3 I-cell_line 
, O 
293 B-cell_line 
, O 
K562 B-cell_line 
, O 
and O 
Jurkat B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

MZF B-DNA 
- I-DNA 
1 I-DNA 
represses O 
CAT B-DNA 
reporter I-DNA 
gene I-DNA 
expression O 
via O 
GAL4 B-protein 
binding O 
sites O 
in O 
the O 
nonhematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
NIH B-cell_line 
3T3 I-cell_line 
and O 
293 B-cell_line 
. O 

In O 
contrast O 
, O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
activates O 
CAT B-DNA 
reporter I-DNA 
gene I-DNA 
expression O 
in O 
the O 
hematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
K562 B-cell_line 
and O 
Jurkat B-cell_line 
. O 

The O 
MZF B-DNA B-DNA 
- I-DNA I-DNA 
1 I-DNA I-DNA 
binding I-DNA 
sites I-DNA 
are O 
present O 
in O 
the O 
promoters B-DNA 
of O 
several O 
genes B-DNA 
expressed O 
during O 
myeloid O 
differentiation O 
, O 
including O 
the O 
CD34 B-DNA 
promoter I-DNA 
. O 

MZF B-DNA 
- I-DNA 
1 I-DNA 
transcriptional O 
regulation O 
of O 
this O 
physiologically B-DNA 
relevant I-DNA 
promoter I-DNA 
was O 
assessed O 
in O 
both O 
hematopoietic B-cell_line 
and O 
nonhematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Recombinant B-protein 
MZF B-DNA I-protein 
- I-DNA I-protein 
1 I-DNA I-protein 
protein I-protein 
specifically O 
binds O 
to O 
the O 
consensus B-DNA 
binding I-DNA 
sites I-DNA 
in O 
the O 
CD34 B-DNA 
promoter I-DNA 
in O 
mobility O 
shift O 
assays O 
. O 

MZF B-DNA 
- I-DNA 
1 I-DNA 
expression O 
vectors O 
were O 
cotransfected O 
with O 
the O 
luciferase B-DNA 
reporter I-DNA 
plasmids I-DNA 
regulated O 
by O 
the O 
CD34 B-DNA 
promoter I-DNA 
into O 
both O 
nonhematopoietic O 
and O 
hematopoietic O 
cell O 
lines O 
. O 

As O 
with O 
the O 
heterologous O 
DNA B-protein 
binding I-protein 
domain I-protein 
, O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
represses O 
reporter B-DNA 
gene I-DNA 
expression O 
in O 
nonhematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
and O 
activates O 
expression O 
in O 
hematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Activation O 
of O 
CD34 B-protein 
expression O 
in O 
hematopoietic B-cell_line 
cell I-cell_line 
lines I-cell_line 
is O 
dependent O 
on O 
the O 
presence O 
of O 
intact O 
MZF B-DNA B-DNA 
- I-DNA I-DNA 
1 I-DNA I-DNA 
binding I-DNA 
sites I-DNA 
. O 

The O 
cell O 
type O 
- O 
specific O 
regulation O 
of O 
the O 
CD34 B-DNA 
promoter I-DNA 
by O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
suggests O 
the O 
presence O 
of O 
tissue O 
- O 
specific O 
regulators O 
/ O 
adapters O 
or O 
differential O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
modifications O 
that O 
determine O 
MZF B-DNA 
- I-DNA 
1 I-DNA 
transcriptional O 
regulatory O 
function O 
. O 

The O 
murine O 
BCL6 B-DNA 
gene I-DNA 
is O 
induced O 
in O 
activated B-cell_type 
lymphocytes I-cell_type 
as O 
an O 
immediate B-DNA 
early I-DNA 
gene I-DNA 
. O 

The O 
chromosomal O 
translocation O 
involving O 
3q27 B-DNA 
is O 
often O 
detected O 
in O 
human B-cell_type 
B I-cell_type 
- I-cell_type 
cell I-cell_type 
lymphomas I-cell_type 
, O 
especially O 
diffuse O 
lymphomas O 
with O 
a O 
large O 
- O 
cell O 
component O 
. O 

The O 
BCL6 B-DNA 
gene I-DNA 
has O 
been O 
isolated O 
from O 
the O 
chromosomal O 
breakpoint O 
in O 
these O 
lymphomas O 
. O 

Here O 
we O 
cloned O 
the O 
murine B-protein B-DNA 
BCL6 I-protein I-DNA 
( I-DNA 
mBCL6 I-DNA 
) I-DNA 
cDNA I-DNA 
from O 
the O 
muscle B-DNA 
cDNA I-DNA 
library I-DNA 
using O 
the O 
human B-protein B-DNA 
BCL6 I-protein I-DNA 
( I-DNA 
hBCL6 I-DNA 
) I-DNA 
cDNA I-DNA 
as O 
a O 
probe O 
. O 

The O 
predicted O 
amino O 
acid O 
sequence O 
was O 
95 O 
% O 
identical O 
to O 
that O 
of O 
hBCL6 B-protein 
. O 

It O 
contains O 
six O 
repeats O 
of O 
the O 
Kruppel B-protein 
- I-protein 
like I-protein 
zinc I-protein 
- I-protein 
finger I-protein 
motif I-protein 
that O 
are O 
completely O 
identical O 
to O 
those O 
of O 
hBCL6 B-protein 
, O 
indicating O 
that O 
the O 
BCL6 B-DNA 
gene I-DNA 
is O 
well O 
conserved O 
between O 
humans O 
and O 
mice O 
. O 

Expression O 
of O 
the O 
mBCL6 B-DNA 
gene I-DNA 
was O 
ubiquitously O 
detected O 
in O 
adult O 
mouse O 
tissues O 
including O 
lymphatic O 
organs O 
. O 

Furthermore O 
, O 
it O 
was O 
induced O 
in O 
lymphocytes B-cell_type 
activated O 
with O 
phorbol O 
ester O 
and O 
Ca2 O 
+ O 
ionophore O 
within O 
30 O 
min O 
after O 
stimulation O 
. O 

This O 
induction O 
was O 
not O 
inhibited O 
by O 
treatment O 
of O 
the O 
cells O 
with O 
a O 
protein O 
synthesis O 
inhibitor O 
, O 
cycloheximide O 
. O 

These O 
results O 
suggest O 
that O 
BCL6 B-protein 
plays O 
a O 
role O 
in O 
activated B-cell_type 
lymphocytes B-cell_type I-cell_type 
as O 
an O 
immediate O 
early O 
gene O 
. O 

The O 
role O 
of O 
BSAP B-protein 
( O 
Pax B-protein 
- I-protein 
5 I-protein 
) O 
in O 
B O 
- O 
cell O 
development O 
. O 

The O 
hierarchy O 
of O 
transcriptional O 
control O 
in O 
B O 
- O 
cell O 
development O 
has O 
recently O 
been O 
analyzed O 
by O 
targeted O 
gene O 
inactivation O 
in O 
the O 
mouse O 
. O 

In O 
this O 
manner O 
, O 
the O 
paired B-DNA 
box I-DNA 
containing I-DNA 
gene I-DNA 
Pax B-DNA 
- I-DNA 
5 I-DNA 
, O 
encoding O 
the O 
B B-protein 
cell I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
BSAP B-protein 
, O 
has O 
been O 
shown O 
to O 
play O 
a O 
key O 
role O 
in O 
early O 
B O 
lymphopoiesis O 
. O 

Other O 
experimental O 
strategies O 
have O 
implicated O 
BSAP B-protein 
in O 
the O 
control O 
of O 
cell O 
proliferation O 
, O 
isotype O 
switching O 
and O 
transcription O 
of O 
the O 
immunoglobulin B-protein B-DNA 
heavy I-protein I-DNA 
- I-protein I-DNA 
chain I-protein I-DNA 
gene I-DNA 
at O 
late O 
stages O 
of O 
B O 
- O 
cell O 
differentiation O 
. O 

The O 
DNA O 
- O 
binding O 
properties O 
of O 
two B-protein 
heat I-protein 
shock I-protein 
factors I-protein 
, O 
HSF1 B-protein 
and O 
HSF3 B-protein 
, O 
are O 
induced O 
in O 
the O 
avian B-cell_line 
erythroblast I-cell_line 
cell I-cell_line 
line I-cell_line 
HD6 B-cell_line 
. O 

Avian O 
cells O 
express O 
three O 
heat B-protein B-DNA 
shock I-protein I-DNA 
transcription I-protein I-DNA 
factor I-protein I-DNA 
( I-DNA 
HSF B-protein I-DNA 
) I-DNA 
genes I-DNA 
corresponding O 
to O 
a O 
novel B-protein 
factor I-protein 
, O 
HSF3 B-protein 
, O 
and O 
homologs O 
of O 
mouse O 
and O 
human O 
HSF1 B-protein 
and O 
HSF2 B-protein 
. O 

Analysis O 
of O 
the O 
biochemical O 
and O 
cell O 
biological O 
properties O 
of O 
these O 
HSFs B-protein 
reveals O 
that O 
HSF3 B-protein 
has O 
properties O 
in O 
common O 
with O 
both O 
HSF1 B-protein 
and O 
HSF2 B-protein 
and O 
yet O 
has O 
features O 
which O 
are O 
distinct O 
from O 
both O 
. O 

HSF3 B-protein 
is O 
constitutively O 
expressed O 
in O 
the O 
erythroblast B-cell_line 
cell I-cell_line 
line I-cell_line 
HD6 I-cell_line 
, O 
the O 
lymphoblast B-cell_line 
cell I-cell_line 
line I-cell_line 
MSB I-cell_line 
, O 
and O 
embryo B-cell_line 
fibroblasts I-cell_line 
, O 
and O 
yet O 
its O 
DNA O 
- O 
binding O 
activity O 
is O 
induced O 
only O 
upon O 
exposure O 
of O 
HD6 O 
cells O 
to O 
heat O 
shock O 
. O 

Acquisition O 
of O 
HSF3 B-protein 
DNA O 
- O 
binding O 
activity O 
in O 
HD6 B-cell_line 
cells I-cell_line 
is O 
accompanied O 
by O 
oligomerization O 
from O 
a O 
non B-protein 
- I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
dimer I-protein 
to O 
a O 
DNA B-protein 
- I-protein 
binding I-protein 
trimer I-protein 
, O 
whereas O 
the O 
effect O 
of O 
heat O 
shock O 
on O 
HSF1 B-protein 
is O 
oligomerization O 
of O 
an O 
inert B-protein 
monomer I-protein 
to O 
a O 
DNA B-protein 
- I-protein 
binding I-protein 
trimer I-protein 
. O 

Induction O 
of O 
HSF3 B-protein 
DNA O 
- O 
binding O 
activity O 
is O 
delayed O 
compared O 
with O 
that O 
of O 
HSF1 B-protein 
. O 

As O 
occurs O 
for O 
HSF1 B-protein 
, O 
heat O 
shock O 
leads O 
to O 
the O 
translocation O 
of O 
HSF3 B-protein 
to O 
the O 
nucleus O 
. O 

HSF O 
exhibits O 
the O 
properties O 
of O 
a O 
transcriptional B-protein 
activator I-protein 
, O 
as O 
judged O 
from O 
the O 
stimulatory O 
activity O 
of O 
transiently B-protein 
overexpressed I-protein 
HSF3 B-protein I-protein 
measured O 
by O 
using O 
a O 
heat B-DNA 
shock I-DNA 
element I-DNA 
- I-DNA 
containing I-DNA 
reporter I-DNA 
construct I-DNA 
and O 
as O 
independently O 
assayed O 
by O 
the O 
activity O 
of O 
a O 
chimeric B-protein 
GAL4 B-protein I-protein 
- B-protein I-protein 
HSF3 I-protein I-protein 
protein I-protein 
on O 
a O 
GAL4 B-protein B-DNA 
reporter I-DNA 
construct I-DNA 
. O 

These O 
results O 
reveal O 
that O 
HSF3 B-protein 
is O 
negatively O 
regulated O 
in O 
avian B-cell_type 
cells I-cell_type 
and O 
acquires O 
DNA O 
- O 
binding O 
activity O 
in O 
certain O 
cells O 
upon O 
heat O 
shock O 
. O 

Direct O 
demonstration O 
of O 
NFATp B-protein 
dephosphorylation O 
and O 
nuclear O 
localization O 
in O 
activated B-cell_line 
HT B-cell_line I-cell_line 
- I-cell_line I-cell_line 
2 I-cell_line I-cell_line 
cells I-cell_line I-cell_line 
using O 
a O 
specific O 
NFATp B-protein B-protein 
polyclonal I-protein 
antibody I-protein 
. O 

Nuclear B-protein 
factor I-protein 
of I-protein 
activated I-protein 
T I-protein 
cells I-protein 
( O 
NFAT B-protein 
) O 
regulates O 
transcription O 
of O 
a O 
number O 
of O 
cytokine B-protein 
genes I-protein 
, O 
and O 
NFAT B-protein 
DNA O 
binding O 
activity O 
is O 
stimulated O 
following O 
T O 
cell O 
activation O 
. O 

Several O 
lines O 
of O 
evidence O 
have O 
suggested O 
that O 
NFAT B-protein 
is O 
a O 
substrate O 
for O 
calcineurin B-protein 
, O 
a O 
serine B-protein 
/ I-protein 
threonine I-protein 
phosphatase I-protein 
. O 

Using O 
a O 
polyclonal O 
antibody O 
to O 
murine B-protein 
NFATp B-protein I-protein 
, O 
Western O 
blot O 
analysis O 
of O 
various O 
mouse O 
tissues O 
demonstrated O 
that O 
the O 
110 O 
- O 
130 O 
- O 
kDa O 
NFATp B-protein B-protein 
protein I-protein 
was O 
highly O 
expressed O 
in O 
thymus O 
and O 
spleen O 
. O 

Treatment O 
of O 
immunoprecipitated O 
NFATp B-protein 
from O 
untreated O 
HT B-cell_line 
- I-cell_line 
2 I-cell_line 
cells I-cell_line 
with O 
calcineurin B-protein 
resulted O 
in O 
the O 
dephosphorylation O 
of O 
NFATp B-protein 
, O 
demonstrating O 
that O 
NFATp B-protein 
is O 
an O 
in O 
vitro O 
substrate O 
for O 
calcineurin B-protein 
. O 

NFATp B-protein 
immunoprecipitated O 
from O 
32P B-cell_line 
- I-cell_line 
labeled I-cell_line 
HT B-cell_line I-cell_line 
- I-cell_line I-cell_line 
2 I-cell_line I-cell_line 
cells I-cell_line I-cell_line 
migrated O 
as O 
an O 
approximately O 
120 O 
- O 
kDa O 
protein O 
that O 
was O 
localized O 
to O 
the O 
cytosol O 
of O 
the O 
cells O 
. O 

Treatment O 
of O 
the O 
cells O 
with O 
ionomycin O 
resulted O 
in O 
a O 
decrease O 
in O 
the O 
molecular O 
weight O 
of O 
NFATp B-protein 
and O 
a O 
loss O 
of O 
32P O 
, O 
consistent O 
with O 
NFATp B-protein 
dephosphorylation O 
. O 

The O 
dephosphorylation O 
of O 
NFATp B-protein 
was O 
accompanied O 
by O 
localization O 
of O 
the O 
protein O 
to O 
the O 
nuclear O 
fraction O 
. O 

Both O 
of O 
these O 
events O 
were O 
blocked O 
by O 
preincubation O 
of O 
the O 
cells O 
with O 
FK506 O 
, O 
a O 
calcineurin B-protein 
inhibitor O 
, O 
consistent O 
with O 
the O 
hypothesis O 
that O 
NFATp B-protein 
is O 
a O 
calcineurin B-protein 
substrate O 
in O 
cells O 
. O 

Activation O 
and O 
expression O 
of O 
the O 
nuclear B-protein 
factors I-protein 
of O 
activated B-cell_type 
T I-cell_type 
cells I-cell_type 
, O 
NFATp B-protein 
and O 
NFATc B-protein 
, O 
in O 
human B-cell_type 
natural I-cell_type 
killer I-cell_type 
cells I-cell_type 
: O 
regulation O 
upon O 
CD16 B-protein 
ligand O 
binding O 
. O 

The O 
putative O 
factors O 
that O 
couple O 
the O 
signal O 
transduction O 
from O 
surface O 
receptors O 
to O 
the O 
activation O 
of O 
cytokine B-protein 
synthesis O 
in O 
natural B-cell_type 
killer I-cell_type 
( I-cell_type 
NK I-cell_type 
) I-cell_type 
cells I-cell_type 
have O 
not O 
been O 
elucidated O 
. O 

We O 
report O 
here O 
that O 
the O 
nuclear B-protein 
factor I-protein 
of O 
activated B-cell_type 
T I-cell_type 
cells I-cell_type 
( O 
NFATp B-protein 
) O 
, O 
a O 
cyclosporin B-protein 
A I-protein 
( I-protein 
CsA I-protein 
) I-protein 
- I-protein 
sensitive I-protein 
factor I-protein 
that O 
regulates O 
the O 
transcription O 
of O 
several O 
cytokines B-protein 
, O 
mediates O 
CD16 B-protein 
- O 
induced O 
activation O 
of O 
cytokine B-protein 
genes I-protein 
in O 
human B-cell_type 
NK I-cell_type 
cells I-cell_type 
. O 

CD16 B-protein 
( O 
Fc B-protein 
gamma I-protein 
RIIIA I-protein 
) O 
- O 
induced O 
expression O 
of O 
cytokine B-RNA 
mRNA I-RNA 
in O 
NK B-cell_type 
cells I-cell_type 
occurs O 
via O 
a O 
CsA O 
- O 
sensitive O 
and O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
mechanism O 
. O 

Stimulation O 
of O 
NK B-cell_type 
cells I-cell_type 
with O 
CD16 B-protein 
ligands O 
induces O 
NFAT B-protein 
- O 
like O 
DNA O 
binding O 
activity O 
in O 
the O 
nuclear O 
extracts O 
from O 
these O 
cells O 
, O 
as O 
detected O 
in O 
electrophoretic O 
mobility O 
shift O 
assays O 
. O 

This O 
occurs O 
with O 
fast O 
kinetics O 
after O 
stimulation O 
, O 
via O 
a O 
CsA O 
- O 
sensitive O 
and O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
mechanism O 
that O 
does O 
not O 
require O 
de O 
novo O 
protein O 
synthesis O 
. O 

NK B-protein 
cell I-protein 
NFAT I-protein 
is O 
present O 
in O 
the O 
cytosol O 
of O 
nonstimulated B-cell_type 
cells I-cell_type 
, O 
migrates O 
to O 
the O 
nucleus O 
upon O 
stimulation O 
, O 
and O 
can O 
associate O 
with O 
AP B-protein 
- I-protein 
1 I-protein 
. O 

Two O 
distinct O 
molecules O 
, O 
NFATp B-protein 
and O 
NFATc B-protein 
, O 
have O 
been O 
reported O 
to O 
mediate O 
NFAT B-protein 
activity O 
. O 

The O 
results O 
of O 
supershift O 
assays O 
using O 
NFATp O 
- O 
and O 
NFATc O 
- O 
specific O 
antibodies O 
indicate O 
that O 
NK O 
cell O 
activation O 
early O 
after O 
CD16 B-protein 
ligand O 
binding O 
involves O 
primarily O 
, O 
if O 
not O 
exclusively O 
, O 
NFATp B-protein 
, O 
and O 
Western O 
blot O 
analysis O 
shows O 
that O 
this O 
has O 
the O 
same O 
electrophoretic O 
mobility O 
( O 
approximately O 
120 O 
kD O 
) O 
as O 
that O 
of O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

NK B-cell_type 
cells I-cell_type 
do O 
not O 
express O 
NFATc B-protein 
constitutively O 
, O 
but O 
NFATc B-protein B-RNA 
mRNA I-RNA 
accumulation O 
is O 
induced O 
in O 
these O 
cells O 
within O 
2 O 
h O 
of O 
stimulation O 
with O 
CD16 O 
ligands O 
. O 

However O 
, O 
supershift O 
assays O 
using O 
the O 
available O 
mAb B-protein 
recognizing O 
the O 
T B-protein 
cell I-protein 
NFATc B-protein I-protein 
revealed O 
no O 
detectable O 
NFATc B-protein 
protein O 
in O 
nuclear O 
and O 
cytoplasmic O 
extracts O 
from O 
CD16 O 
- O 
or O 
phorbol B-cell_line 
ester I-cell_line 
- I-cell_line 
stimulated I-cell_line 
cells I-cell_line 
at O 
any O 
time O 
tested O 
, O 
up O 
to O 
4 O 
h O 
. O 

These O 
results O 
provide O 
the O 
first O 
direct O 
evidence O 
that O 
both O 
CsA O 
- O 
sensitive O 
transcription B-protein 
factors I-protein 
, O 
NFATp B-protein 
and O 
NFATc B-protein 
, O 
are O 
expressed O 
in O 
human O 
NK B-cell_type 
cells I-cell_type 
, O 
and O 
that O 
their O 
activation O 
and O 
/ O 
or O 
expression O 
can O 
be O 
regulated O 
in O 
primary O 
cells O 
by O 
a O 
single O 
stimulus O 
, O 
that O 
, O 
in O 
the O 
case O 
of O 
CD16 O 
in O 
NK B-cell_type 
cells I-cell_type 
, O 
results O 
in O 
early O 
activation O 
of O 
NFATp B-protein 
and O 
subsequently O 
induced O 
expression O 
of O 
NFATc B-protein B-RNA 
mRNA I-RNA 
. O 

Interleukin O 
2 O 
signaling O 
involves O 
the O 
phosphorylation O 
of O 
Stat B-protein 
proteins I-protein 
. O 

One O 
of O 
the O 
most O 
important O 
cytokines B-protein 
involved O 
in O 
immune O 
response O 
regulation O 
is O 
interleukin O 
2 O 
( O 
IL O 
- O 
2 O 
) O 
, O 
a O 
potent O 
activator O 
of O 
the O 
proliferation O 
and O 
function O 
of O 
T B-cell_type 
lymphocytes B-cell_type I-cell_type 
and O 
natural B-cell_type 
killer I-cell_type 
cells I-cell_type 
. O 

The O 
mechanisms O 
by O 
which O 
the O 
effects O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
are O 
propagated O 
within O 
cells O 
are O 
not O 
understood O 
. O 

While O 
the O 
binding O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
to O 
its O 
receptor O 
was O 
recently O 
shown O 
to O 
lead O 
to O 
the O 
activation O 
of O 
two O 
kinases B-protein 
, O 
Jak B-protein 
- I-protein 
1 I-protein 
and O 
Jak B-protein 
- I-protein 
3 I-protein 
, O 
subsequent O 
steps O 
in O 
the O 
signaling O 
pathway O 
to O 
the O 
nucleus O 
that O 
lead O 
to O 
the O 
activation O 
of O 
specific O 
genes O 
had O 
not O 
been O 
characterized O 
. O 

Since O 
many O 
cytokines B-protein 
that O 
activate O 
Jak B-protein 
kinases B-protein I-protein 
also O 
lead O 
to O 
the O 
tyrosine O 
phosphorylation O 
and O 
activation O 
of O 
members O 
of O 
the O 
Stat B-protein 
family I-protein 
of O 
transcription B-protein 
factors I-protein 
, O 
the O 
ability O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
to O 
trigger O 
Stat O 
phosphorylation O 
was O 
examined O 
. O 

Exposure O 
of O 
activated O 
human O 
T B-cell_type 
lymphocytes I-cell_type 
or O 
of O 
a O 
natural B-cell_type B-cell_line 
killer I-cell_type I-cell_line 
cell I-cell_type I-cell_line 
line I-cell_line 
( O 
NKL B-cell_line 
) O 
to O 
IL B-protein 
- I-protein 
2 I-protein 
leads O 
to O 
the O 
phosphorylation O 
of O 
Stat1 B-protein 
alpha I-protein 
, O 
Stat1 B-protein 
beta I-protein 
, O 
and O 
Stat3 B-protein 
, O 
as O 
well O 
as O 
of O 
two O 
Stat B-protein 
- I-protein 
related I-protein 
proteins I-protein 
, O 
p94 B-protein 
and O 
p95 B-protein 
. O 

p94 B-protein 
and O 
p95 B-protein 
share O 
homology O 
with O 
Stat1 B-protein 
at O 
the O 
phosphorylation B-protein 
site I-protein 
and O 
in O 
the O 
Src B-protein 
homology I-protein 
2 I-protein 
( I-protein 
SH2 I-protein 
) I-protein 
domain I-protein 
, O 
but O 
otherwise O 
are O 
immunologically O 
distinct O 
from O 
Stat1 B-protein 
. O 

These O 
Stat B-protein 
proteins I-protein 
were O 
found O 
to O 
translocate O 
to O 
the O 
nucleus O 
and O 
to O 
bind O 
to O 
a O 
specific B-DNA 
DNA I-DNA 
sequence I-DNA 
. O 

These O 
findings O 
suggest O 
a O 
mechanism O 
by O 
which O 
IL B-protein 
- I-protein 
2 I-protein 
binding O 
to O 
its O 
receptor O 
may O 
activate O 
specific B-DNA 
genes I-DNA 
involved O 
in O 
immune O 
cell O 
function O 
. O 

Expression O 
of O 
c B-DNA 
- I-DNA 
fos I-DNA 
correlates O 
with O 
IFN B-protein 
- I-protein 
alpha I-protein 
responsiveness O 
in O 
Philadelphia O 
chromosome O 
positive O 
chronic O 
myelogenous O 
leukemia O 
. O 

This O 
study O 
evaluates O 
( O 
i O 
) O 
constitutive O 
levels O 
of O 
oncogene B-DNA 
and O 
p53 B-RNA 
transcripts I-RNA 
in O 
chronic O 
phase O 
CML O 
patients O 
and O 
( O 
ii O 
) O 
their O 
modulations O 
subsequent O 
to O 
in O 
vivo O 
therapy O 
with O 
rIFN B-protein 
- I-protein 
alpha I-protein 
2c I-protein 
. O 

Peripheral B-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
( O 
pbmc B-cell_type 
) O 
and O 
bone B-cell_type 
marrow I-cell_type 
cells I-cell_type 
of O 
26 O 
patients O 
were O 
examined O 
for O 
c O 
- O 
fos O 
, O 
c O 
- O 
myc O 
, O 
p53 O 
and O 
the O 
hybrid O 
bcr O 
/ O 
abl O 
mRNA O 
levels O 
. O 

Results O 
indicated O 
that O 
( O 
i O 
) O 
constitutive O 
c B-RNA 
- I-RNA 
fos I-RNA 
transcript I-RNA 
levels O 
are O 
significantly O 
higher O 
in O 
patients O 
subsequently O 
responding O 
to O 
IFN B-protein 
- I-protein 
alpha I-protein 
therapy O 
( O 
p O 
< O 
0 O 
. O 
01 O 
) O 
and O 
positively O 
correlated O 
with O 
the O 
proportion O 
of O 
lymphocytes B-cell_type 
( O 
r O 
= O 
0 O 
. O 
6895 O 
, O 
p O 
< O 
0 O 
. O 
01 O 
) O 
and O 
negatively O 
with O 
the O 
proportion O 
of O 
immature B-cell_type 
cells I-cell_type 
( O 
r O 
= O 
- O 
0 O 
. O 
568 O 
, O 
p O 
< O 
0 O 
. O 
01 O 
) O 
contained O 
in O 
the O 
pbmc B-cell_type 
preparations O 
tested O 
, O 
( O 
ii O 
) O 
constitutive B-RNA 
mRNA I-RNA 
levels O 
of O 
the O 
hybrid B-DNA 
bcr I-DNA 
/ I-DNA 
abl I-DNA 
, O 
c B-DNA 
- I-DNA 
myc I-DNA 
and O 
p53 B-DNA 
are O 
positively O 
correlated O 
with O 
each O 
other O 
, O 
but O 
failed O 
to O 
relate O 
to O 
disease O 
parameters O 
, O 
and O 
( O 
iii O 
) O 
acute O 
and O 
chronic O 
in O 
vivo O 
exposure O 
to O 
IFN B-protein 
- I-protein 
alpha I-protein 
is O 
accompanied O 
by O 
upregulation O 
of O 
c O 
- O 
fos O 
and O 
downregulation O 
of O 
c B-RNA 
- I-RNA 
myc I-RNA 
mRNA I-RNA 
levels O 
in O 
responder O 
patients O 
. O 

Menopause O 
is O 
associated O 
with O 
a O 
significant O 
increase O 
in O 
blood O 
monocyte O 
number O 
and O 
a O 
relative O 
decrease O 
in O 
the O 
expression O 
of O 
estrogen B-protein 
receptors I-protein 
in O 
human B-cell_type 
peripheral I-cell_type 
monocytes I-cell_type 
. O 

PROBLEM O 
: O 
The O 
clinical O 
significance O 
of O 
the O 
differential O 
expression O 
of O 
estrogen B-protein 
receptor I-protein 
( O 
ER B-protein 
) O 
in O 
human B-cell_type 
monocytes I-cell_type 
was O 
evaluated O 
. O 

METHOD O 
: O 
Two O 
color O 
flow O 
cytometry O 
analysis O 
was O 
used O 
on O 
peripheral O 
blood O 
samples O 
of O 
young O 
and O 
postmenopausal O 
females O 
and O 
postmenopausal O 
females O 
treated O 
with O 
estrogen O 
replacement O 
therapy O 
. O 

In O 
addition O 
, O 
the O 
monocyte O 
and O 
lymphocyte O 
counts O 
and O 
the O 
blood O 
estrogen O 
levels O 
of O 
each O 
patient O 
were O 
determine O 
. O 

RESULTS O 
: O 
During O 
menopause O 
there O 
is O 
a O 
significant O 
decrease O 
in O 
the O 
percentage O 
of O 
ER B-protein B-cell_type 
positive I-cell_type 
monocytes I-cell_type 
, O 
and O 
an O 
increase O 
in O 
blood B-cell_type 
monocyte B-cell_type I-cell_type 
number O 
, O 
which O 
declines O 
following O 
estrogen O 
replacement O 
therapy O 
to O 
values O 
of O 
the O 
young O 
. O 

CONCLUSIONS O 
: O 
These O 
findings O 
suggest O 
that O 
estrogen O 
modulates O 
the O 
monocyte B-cell_type 
numbers O 
and O 
its O 
effects O 
may O 
be O 
mediated O 
through O 
the O 
ER B-protein 
in O 
the O 
monocytes B-cell_type 
. O 

Staphylococcal B-protein 
enterotoxins I-protein 
modulate O 
interleukin B-protein 
2 I-protein 
receptor I-protein 
expression O 
and O 
ligand O 
- O 
induced O 
tyrosine O 
phosphorylation O 
of O 
the O 
Janus B-protein 
protein I-protein 
- I-protein 
tyrosine I-protein 
kinase I-protein 
3 I-protein 
( O 
Jak3 B-protein 
) O 
and O 
signal B-protein 
transducers I-protein 
and I-protein 
activators I-protein 
of I-protein 
transcription I-protein 
( O 
Stat B-protein 
proteins I-protein 
) O 
. O 

Staphylococcal B-protein 
enterotoxins I-protein 
( O 
SE B-protein 
) O 
stimulate O 
T B-cell_type 
cells I-cell_type 
expressing O 
the O 
appropriate O 
variable B-protein B-protein 
region I-protein I-protein 
beta I-protein I-protein 
chain I-protein I-protein 
of I-protein 
( I-protein 
V B-protein I-protein 
beta I-protein I-protein 
) I-protein 
T I-protein 
- I-protein 
cell I-protein 
receptors I-protein 
and O 
have O 
been O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
several O 
autoimmune O 
diseases O 
. O 

Depending O 
on O 
costimulatory O 
signals O 
, O 
SE B-protein 
induce O 
either O 
proliferation O 
or O 
anergy O 
in O 
T B-cell_type 
cells I-cell_type 
. O 

In O 
addition O 
, O 
SE B-protein 
can O 
induce O 
an O 
interleukin B-protein 
- I-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
nonresponsive O 
state O 
and O 
apoptosis O 
. O 

Here O 
, O 
we O 
show O 
that O 
SE B-protein 
induce O 
dynamic O 
changes O 
in O 
the O 
expression O 
of O 
and O 
signal O 
transduction O 
through O 
the O 
IL O 
- O 
2 O 
receptor O 
( O 
IL O 
- O 
2R O 
) O 
beta O 
and O 
gamma O 
chains O 
( O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
and O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
) O 
in O 
human B-cell_line 
antigen I-cell_line 
- I-cell_line 
specific I-cell_line 
CD4 I-cell_line 
+ I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Thus O 
, O 
after O 
4 O 
hr O 
of O 
exposure O 
to O 
SEA B-protein 
and O 
SEB B-protein 
, O 
the O 
expression O 
of O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
was O 
down O 
- O 
regulated O 
, O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
was O 
slightly O 
up O 
- O 
regulated O 
, O 
while O 
IL B-protein 
- I-protein 
2R I-protein 
alpha I-protein 
remained O 
largely O 
unaffected O 
. O 

The O 
changes O 
in O 
the O 
composition O 
of O 
IL B-protein 
- I-protein 
2Rs I-protein 
were O 
accompanied O 
by O 
inhibition O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
tyrosine O 
phosphorylation O 
of O 
the O 
Janus B-protein 
protein I-protein 
- I-protein 
tyrosine I-protein 
kinase I-protein 
3 I-protein 
( O 
Jak3 B-protein 
) O 
and O 
signal B-protein 
transducers I-protein 
and I-protein 
activators I-protein 
of I-protein 
transcription I-protein 
called O 
Stat3 B-protein 
and O 
Stat5 B-protein 
. O 

In O 
parallel O 
experiments O 
, O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
driven O 
proliferation O 
was O 
inhibited O 
significantly O 
. O 

After O 
16 O 
hr O 
of O 
exposure O 
to O 
SE B-protein 
, O 
the O 
expression O 
of O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
remained O 
low O 
, O 
while O 
that O 
of O 
IL2R B-protein 
alpha I-protein 
and O 
IL2R B-protein 
gamma I-protein 
was O 
further O 
up O 
- O 
regulated O 
, O 
and O 
ligand O 
- O 
induced O 
tyrosine O 
phosphorylation O 
of O 
Jak3 B-protein 
and O 
Stat B-protein 
proteins I-protein 
was O 
partly O 
normalized O 
. O 

Yet O 
, O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
driven O 
proliferation O 
remained O 
profoundly O 
inhibited O 
, O 
suggesting O 
that O 
signaling O 
events O 
other O 
than O 
Jak3 B-protein 
/ B-protein 
Stat I-protein 
activation O 
had O 
also O 
been O 
changed O 
following O 
SE B-protein 
stimulation O 
. O 

In O 
conclusion O 
, O 
our O 
data O 
suggest O 
that O 
SE B-protein 
can O 
modulate O 
IL B-protein 
- I-protein 
2R I-protein 
expression O 
and O 
signal O 
transduction O 
involving O 
the O 
Jak B-protein 
/ I-protein 
Stat I-protein 
pathway O 
in O 
CD4 B-cell_line 
+ I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Constitutive O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
, O 
enhanced O 
granulopoiesis O 
, O 
and O 
neonatal O 
lethality O 
in O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
- O 
deficient O 
mice O 
. O 

Transcription B-protein 
factors I-protein 
belonging O 
to O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
family I-protein 
are O 
controlled O 
by O 
inhibitory B-protein 
I I-protein 
kappa I-protein 
B I-protein 
proteins I-protein 
, O 
mainly O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
and O 
I B-protein 
kappa I-protein 
B I-protein 
beta I-protein 
. O 

Apparently O 
normal O 
at O 
birth O 
, O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
- O 
/ O 
- O 
mice O 
exhibit O 
severe O 
runting O 
, O 
skin O 
defects O 
, O 
and O 
extensive O 
granulopoiesis O 
postnatally O 
, O 
typically O 
dying O 
by O 
8 O 
days O 
. O 

Hematopoietic O 
tissues O 
from O 
these O 
mice O 
display O 
elevated O 
levels O 
of O 
both O 
nuclear B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
and O 
mRNAs B-RNA 
of O 
some O 
, O 
but O 
not O 
all O 
, O 
genes O 
thought O 
to O 
be O 
regulated O 
by O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
elevation O 
results O 
in O 
these O 
phenotypic O 
abnormalities O 
because O 
mice O 
lacking O 
both O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
and O 
the O 
p50 B-protein 
subunit I-protein 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
show O 
a O 
dramatically O 
delayed O 
onset O 
of O 
abnormalities O 
. O 

In O 
contrast O 
to O 
hematopoietic B-cell_type 
cells I-cell_type 
, O 
I B-protein B-cell_line 
kappa I-protein I-cell_line 
B I-protein I-cell_line 
alpha I-protein I-cell_line 
- I-cell_line 
/ I-cell_line 
- I-cell_line 
embryonic I-cell_line 
fibroblasts I-cell_line 
show O 
minimal O 
constitutive B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
, O 
as O 
well O 
as O 
normal O 
signal O 
- O 
dependent O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
that O 
is O 
concomitant O 
with O 
I B-protein 
kappa I-protein 
B I-protein 
beta I-protein 
degradation O 
. O 

Our O 
results O 
indicate O 
that O 
I O 
kappa O 
b O 
beta O 
, O 
but O 
not O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
, O 
is O 
required O 
for O 
the O 
signal O 
- O 
dependent O 
activation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
fibroblasts B-cell_type 
. O 

However O 
, O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
is O 
required O 
for O 
the O 
postinduction O 
repression O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
fibroblasts B-cell_type 
. O 

These O 
results O 
define O 
distinct O 
roles O 
for O 
the O 
two O 
forms O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
and O 
demonstrate O 
the O 
necessity O 
for O 
stringent O 
control O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Interleukin B-protein 
- I-protein 
7 I-protein 
can O 
induce O 
the O 
activation O 
of O 
Jak B-protein 
1 I-protein 
, O 
Jak B-protein 
3 I-protein 
and O 
STAT B-protein 
5 I-protein 
proteins I-protein 
in O 
murine O 
T B-cell_type 
cells I-cell_type 
. O 

The O 
activation O 
of O 
Janus B-protein 
protein I-protein 
tyrosine I-protein 
kinases I-protein 
( O 
Jak B-protein 
) O 
and O 
STAT B-protein B-protein 
( I-protein 
signal B-protein I-protein 
transducer I-protein I-protein 
and I-protein I-protein 
activator I-protein I-protein 
of I-protein I-protein 
transcription I-protein I-protein 
) I-protein 
proteins I-protein 
has O 
recently O 
been O 
linked O 
to O 
the O 
signal O 
transduction O 
mechanism O 
of O 
several O 
cytokines B-protein 
. O 

IL B-protein 
- I-protein 
7 I-protein 
was O 
observed O 
to O 
induce O 
a O 
rapid O 
and O 
dose O 
- O 
dependent O 
tyrosine O 
phosphorylation O 
of O 
Jak B-protein 
1 I-protein 
and O 
Jak B-protein 
3 I-protein 
and O 
concomitantly O 
, O 
the O 
tyrosine O 
phosphorylation O 
and O 
DNA O 
binding O 
activity O 
of O 
multiple O 
STAT B-protein 
proteins I-protein 
. O 

The O 
STAT B-protein 
proteins I-protein 
utilized O 
by O 
IL B-protein 
- I-protein 
7 I-protein 
were O 
identical O 
to O 
those O 
induced O 
by O 
IL B-protein 
- I-protein 
2 I-protein 
and O 
could O 
be O 
identified O 
as O 
various O 
STAT B-protein 
5 I-protein 
isoforms I-protein 
. O 

Moreover O 
, O 
the O 
induction O 
of O 
both O 
Jak O 
1 O 
and O 
3 O 
, O 
and O 
STAT B-protein 
5 I-protein 
activity O 
strongly O 
correlated O 
with O 
the O 
growth O 
- O 
promoting O 
effects O 
of O 
IL B-protein 
- I-protein 
7 I-protein 
, O 
suggesting O 
that O 
this O 
signal O 
transduction O 
mechanism O 
may O 
play O 
a O 
key O 
role O 
in O 
IL B-protein 
- I-protein 
7 I-protein 
- O 
induced O 
proliferation O 
. O 

Cytokine B-protein 
- O 
modulating O 
activity O 
of O 
tepoxalin O 
, O 
a O 
new O 
potential O 
antirheumatic O 
. O 

Tepoxalin O 
is O 
a O 
new O 
dual O 
cyclooxygenase O 
/ O 
5 O 
- O 
lipoxygenase O 
anti O 
- O 
inflammatory O 
compound O 
currently O 
under O 
clinical O 
investigation O 
. O 

It O 
has O 
been O 
shown O 
to O 
possess O 
anti O 
- O 
inflammatory O 
activity O 
in O 
a O 
variety O 
of O 
animal O 
models O 
and O 
more O 
recently O 
to O 
inhibit O 
IL B-protein 
- I-protein 
2 I-protein 
induced O 
signal O 
transduction O 
. O 

The O 
current O 
study O 
was O 
conducted O 
to O 
evaluate O 
the O 
cytokine B-protein 
modulating O 
activity O 
of O 
tepoxalin O 
and O 
the O 
role O 
of O 
iron O 
in O 
these O 
effects O 
. O 

In O 
human B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
( O 
PBMC B-cell_type 
) O 
stimulated O 
with O 
OKT3 O 
/ O 
PMA O 
, O 
tepoxalin O 
inhibited O 
lymphocyte B-cell_type 
proliferation O 
with O 
an O 
IC50 O 
of O 
6 O 
microM O 
. O 

Additionally O 
, O 
it O 
inhibited O 
the O 
production O 
of O 
LTB4 B-protein 
( O 
IC50 O 
= O 
0 O 
. O 
5 O 
microM O 
) O 
and O 
the O 
cytokines B-protein 
IL B-protein 
- I-protein 
2 I-protein 
, O 
IL B-protein 
- I-protein 
6 I-protein 
and O 
TNF B-protein 
alpha I-protein 
( O 
IC50 O 
= O 
10 O 
- O 
12 O 
microM O 
) O 
. O 

Cytotoxicity O 
was O 
not O 
demonstrated O 
at O 
these O 
concentrations O 
. O 

Add O 
- O 
back O 
experiments O 
with O 
either O 
cytokines B-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
or O 
IL B-protein 
- I-protein 
6 I-protein 
) O 
, O 
LTB4 B-protein 
or O 
conditioned O 
media O 
failed O 
to O 
restore O 
the O 
proliferative O 
response O 
in O 
the O 
presence O 
of O 
tepoxalin O 
. O 

However O 
, O 
the O 
concurrent O 
addition O 
of O 
iron O 
( O 
in O 
the O 
form O 
of O 
ferrous O 
or O 
ferric O 
chloride O 
and O 
other O 
iron O 
salts O 
) O 
reversed O 
the O 
inhibition O 
of O 
proliferation O 
caused O 
by O 
tepoxalin O 
. O 

Tepoxalin O 
also O 
inhibits O 
the O 
activation O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
, O 
a O 
transcription B-protein 
factor I-protein 
which O 
acts O 
on O 
several O 
cytokine B-DNA 
genes I-DNA 
. O 

Tepoxalin O 
' O 
s O 
effect O 
on O 
NF B-protein 
kappa I-protein 
B I-protein 
is O 
also O 
reversed O 
by O 
the O 
addition O 
of O 
iron O 
salts O 
. O 

These O 
data O 
suggest O 
that O 
the O 
action O 
of O 
tepoxalin O 
to O 
inhibit O 
proliferation O 
in O 
PBMC B-cell_type 
may O 
be O 
at O 
least O 
in O 
part O 
due O 
to O 
its O 
ability O 
to O 
reduce O 
the O 
amount O 
of O 
available O 
iron O 
resulting O 
in O 
decreased O 
activation O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
and O 
subsequent O 
inhibition O 
of O 
cytokine B-protein 
production O 
. O 

N B-protein 
- I-protein 
and I-protein 
C I-protein 
- I-protein 
terminal I-protein 
sequences I-protein 
control O 
degradation O 
of O 
MAD3 B-protein 
/ I-protein 
I B-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein I-protein 
in O 
response O 
to O 
inducers O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activity O 
. O 

The O 
proteolytic O 
degradation O 
of O 
the O 
inhibitory B-protein 
protein I-protein 
MAD3 B-protein 
/ I-protein 
I B-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein I-protein 
in O 
response O 
to O 
extracellular O 
stimulation O 
is O 
a O 
prerequisite O 
step O 
in O 
the O 
activation O 
of O 
the O 
transcription B-protein 
factor I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Analysis O 
of O 
the O 
expression O 
of O 
human B-protein 
I B-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein I-protein 
protein I-protein 
in O 
stable O 
transfectants O 
of O 
mouse B-cell_line 
70Z I-cell_line 
/ I-cell_line 
3 I-cell_line 
cells I-cell_line 
shows O 
that O 
, O 
as O 
for O 
the O 
endogenous O 
murine O 
protein O 
, O 
exogenous O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
is O 
degraded O 
in O 
response O 
to O 
inducers O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activity O 
, O 
such O 
as O 
phorbol O 
myristate O 
acetate O 
or O 
lipopolysaccharide O 
. O 

In O 
addition O 
, O 
pretreatment O 
of O 
the O 
cells O 
with O 
the O 
proteasome B-protein 
inhibitor O 
N O 
- O 
Ac O 
- O 
Leu O 
- O 
Leu O 
- O 
norleucinal O 
inhibits O 
this O 
ligand O 
- O 
induced O 
degradation O 
and O 
, O 
in O 
agreement O 
with O 
previous O 
studies O 
, O 
stabilizes O 
a O 
hyperphosphorylated O 
form O 
of O 
the O 
human B-protein 
I B-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein I-protein 
protein I-protein 
. O 

By O 
expressing O 
mutant O 
forms O 
of O 
the O 
human O 
protein O 
in O 
this O 
cell B-cell_line 
line I-cell_line 
, O 
we O 
have O 
been O 
able O 
to O 
delineate O 
the O 
sequences O 
responsible O 
for O 
both O 
the O 
ligand O 
- O 
induced O 
phosphorylation O 
and O 
the O 
degradation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
. O 

Our O 
results O 
show O 
that O 
deletion O 
of O 
the O 
C B-protein 
terminus I-protein 
of O 
the O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
molecule O 
up O 
to O 
amino B-protein 
acid I-protein 
279 I-protein 
abolishes O 
constitutive O 
but O 
not O 
ligand O 
- O 
inducible O 
phosphorylation O 
and O 
inhibits O 
ligand O 
- O 
inducible O 
degradation O 
. O 

Further O 
analysis O 
reveals O 
that O 
the O 
inducible O 
phosphorylation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
maps O 
to O 
two O 
serines O 
in O 
the O 
N B-protein 
terminus I-protein 
of O 
the O 
protein O 
( O 
residues O 
32 O 
and O 
36 O 
) O 
and O 
that O 
the O 
mutation O 
of O 
either O 
residue O 
is O 
sufficient O 
to O 
abolish O 
ligand O 
- O 
induced O 
degradation O 
, O 
whereas O 
both O 
residues O 
must O 
be O 
mutated O 
to O 
abolish O 
inducible O 
phosphorylation O 
of O 
the O 
protein O 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
250 O 
WORDS O 
) O 
. O 

Microtubules B-protein 
mediate O 
cellular O 
25 O 
- O 
hydroxyvitamin O 
D3 O 
trafficking O 
and O 
the O 
genomic O 
response O 
to O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
in O 
normal O 
human B-cell_type 
monocytes I-cell_type 
. O 

The O 
genomic O 
actions O 
of O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
( O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
) O 
are O 
mediated O 
by O 
the O 
intracellular O 
vitamin B-protein 
D I-protein 
receptor I-protein 
( O 
VDR B-protein 
) O 
. O 

Although O 
immunocytochemistry O 
has O 
shown O 
that O 
disruption O 
of O 
microtubular O 
assembly O 
prevents O 
nuclear O 
access O 
of O 
the O 
sterol B-protein 
- I-protein 
VDR B-protein I-protein 
complex I-protein 
, O 
the O 
role O 
of O 
microtubules B-protein 
in O 
the O 
response O 
to O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
has O 
not O 
been O 
studied O 
in O 
viable B-cell_type 
cells I-cell_type 
. O 

Our O 
studies O 
examined O 
this O 
interaction O 
in O 
normal O 
human B-cell_type 
monocytes I-cell_type 
. O 

Monocytes O 
convert O 
25 O 
( O 
OH O 
) O 
D3 O 
to O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
and O 
to O 
24 O 
- O 
hydroxylated O 
metabolites O 
more O 
polar O 
than O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
. O 

Microtubule O 
disruption O 
totally O 
abolished O 
the O 
ability O 
of O 
exogenous O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
to O 
suppress O 
its O 
own O 
synthesis O 
and O 
to O 
induce O 
24 B-RNA 
- I-RNA 
hydroxylase I-RNA 
mRNA I-RNA 
and O 
activity O 
, O 
without O 
affecting O 
either O 
total O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
uptake O 
or O 
maximal O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
- B-protein 
VDR I-protein 
binding O 
. O 

Thus O 
, O 
intact O 
microtubules B-protein 
are O 
essential O 
for O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
- O 
dependent O 
modulation O 
of O 
gene O 
transcription O 
. O 

Interestingly O 
, O 
microtubule B-protein 
disruption O 
also O 
decreased O 
monocyte B-cell_type 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
synthesis O 
, O 
not O 
by O 
decreasing O 
the O 
Vmax O 
of O 
monocyte B-cell_type B-protein 
mitochondrial I-protein 
1 I-protein 
alpha I-protein 
- I-protein 
hydroxylase I-protein 
but O 
through O 
an O 
increase O 
in O 
the O 
Km O 
for O 
25 O 
( O 
OH O 
) O 
2D3 O 
. O 

We O 
examined O 
25 O 
( O 
OH O 
) O 
D3 O 
transport O 
. O 

Microtubule O 
disruption O 
did O 
not O 
affect O 
total O 
cellular O 
25 O 
( O 
OH O 
) O 
D3 O 
uptake O 
but O 
reduced O 
its O 
intracellular O 
trafficking O 
to O 
the O 
mitochondria O 
. O 

Thus O 
, O 
microtubules B-protein 
participate O 
in O 
intracellular O 
25 O 
( O 
OH O 
) O 
D3 O 
transport O 
, O 
and O 
their O 
integrity O 
determines O 
normal O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
synthesis O 
. O 

Relationship O 
between O 
Rap1 B-protein 
protein I-protein 
phosphorylation O 
and O 
regulation O 
of O 
Ca2 O 
+ O 
transport O 
in O 
platelets B-cell_type 
: O 
a O 
new O 
approach O 
. O 

Although O 
the O 
interrelationship O 
between O 
the O 
two O 
messengers O 
Ca2 O 
+ O 
and O 
cyclic O 
AMP O 
in O 
platelet O 
function O 
is O 
well O 
documented O 
, O 
its O 
mechanism O 
of O 
action O 
still O 
remains O 
to O 
be O 
established O 
. O 

We O 
investigated O 
here O 
the O 
question O 
of O 
the O 
regulation O 
of O 
platelet B-protein 
Ca I-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
ATPases I-protein 
by O 
cyclic O 
AMP O 
through O 
the O 
phosphorylation O 
of O 
the O 
Rap1 B-protein 
protein I-protein 
using O 
a O 
pathological O 
model O 
. O 

We O 
first O 
found O 
experimental O 
conditions O 
where O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
transport O 
by O 
platelet O 
membrane O 
vesicles O 
appeared O 
to O 
be O 
dependent O 
on O 
the O 
phosphorylation O 
of O 
the O 
Rap1 B-protein 
protein I-protein 
. O 

Then O 
, O 
we O 
studied O 
platelets B-cell_type 
of O 
patients O 
with O 
congestive O 
heart O 
failure O 
for O 
their O 
expression O 
of O 
the O 
potential O 
97 B-protein 
kDa I-protein 
Ca B-protein I-protein 
( I-protein I-protein 
2 I-protein I-protein 
+ I-protein I-protein 
) I-protein I-protein 
- I-protein I-protein 
ATPase I-protein I-protein 
target I-protein 
of O 
regulation O 
through O 
the O 
Rap1 B-protein 
protein I-protein 
as O 
well O 
as O 
the O 
phosphorylation O 
of O 
the O 
Rap1 B-protein 
protein I-protein 
using O 
the O 
catalytic B-protein 
subunit I-protein 
of O 
the O 
cyclic B-protein 
AMP I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinase I-protein 
( O 
C B-protein 
. I-protein 
Sub I-protein 
. I-protein 
) O 
. O 

In O 
the O 
first O 
patients O 
studied O 
, O 
we O 
found O 
no O 
significant O 
modification O 
in O 
the O 
expression O 
of O 
the O 
97 B-protein 
kDa I-protein 
Ca I-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
ATPase I-protein 
by O 
Western O 
blotting O 
using O 
the O 
PL B-protein 
/ I-protein 
IM I-protein 
430 I-protein 
monoclonal I-protein 
antibody I-protein 
which O 
specifically O 
recognized O 
this O 
isoform O 
. O 

In O 
contrast O 
, O 
the O 
Rap1 B-protein 
protein I-protein 
was O 
differentially O 
phosphorylated O 
when O 
using O 
15 O 
micrograms O 
/ O 
ml O 
of O 
the O 
C O 
. O 
Sub O 
. O 

These O 
results O 
allowed O 
us O 
to O 
use O 
these O 
pathological O 
platelets B-cell_type 
to O 
study O 
the O 
relationship O 
between O 
the O 
expression O 
of O 
Rap1 B-protein 
protein I-protein 
and O 
the O 
regulation O 
of O 
Ca2 O 
+ O 
transport O 
by O 
selecting O 
a O 
patient O 
with O 
severe O 
heart O 
failure O 
. O 

We O 
could O 
show O 
a O 
decrease O 
in O 
the O 
expression O 
as O 
well O 
as O 
in O 
the O 
phosphorylation O 
of O 
Rap1 B-protein 
protein I-protein 
and O 
demonstrate O 
a O 
lower O 
effect O 
of O 
C B-protein 
. I-protein 
Sub I-protein 
. I-protein 
on O 
Ca2 O 
+ O 
transport O 
. O 

Finally O 
, O 
by O 
studying O 
a O 
further O 
series O 
of O 
patients O 
, O 
we O 
could O 
confirm O 
that O 
the O 
decrease O 
in O 
Rap1 B-protein 
protein I-protein 
expression O 
in O 
heart O 
failure O 
, O 
whatever O 
its O 
extent O 
, O 
was O 
variable O 
, O 
and O 
could O 
strictly O 
correlate O 
the O 
expression O 
of O 
Rap1 B-protein 
protein I-protein 
with O 
the O 
stimulatory O 
effect O 
of O 
C B-protein 
. I-protein 
Sub I-protein 
. I-protein 
on O 
Ca2 O 
+ O 
transport O 
. O 

Besides O 
the O 
evidence O 
for O 
regulation O 
of O 
the O 
expression O 
of O 
the O 
Rap1 B-protein 
protein I-protein 
in O 
platelets B-cell_type 
from O 
patients O 
with O 
heart O 
failure O 
, O 
these O 
findings O 
constitute O 
a O 
new O 
approach O 
in O 
favour O 
of O 
the O 
regulation O 
of O 
platelet O 
Ca2 O 
+ O 
transport O 
through O 
the O 
phosphorylation O 
of O 
the O 
Rap1 B-protein 
protein I-protein 
. O 

An O 
IRF B-protein 
- I-protein 
1 I-protein 
- O 
dependent O 
pathway O 
of O 
DNA O 
damage O 
- O 
induced O 
apoptosis O 
in O 
mitogen B-cell_line 
- I-cell_line 
activated I-cell_line 
T I-cell_line 
lymphocytes I-cell_line 
. O 

Lymphocytes B-cell_line 
are O 
particularly O 
susceptible O 
to O 
DNA O 
damage O 
- O 
induced O 
apoptosis O 
, O 
a O 
response O 
which O 
may O 
serve O 
as O 
a O 
form O 
of O 
' O 
altruistic O 
suicide O 
' O 
to O 
counter O 
their O 
intrinsic O 
high O 
potential O 
for O 
mutation O 
and O 
clonal O 
expansion O 
. O 

The O 
tumour B-protein 
suppressor I-protein 
p53 I-protein 
has O 
been O 
shown O 
to O 
regulate O 
this O 
type O 
of O 
apoptosis O 
in O 
thymocytes B-cell_type 
, O 
but O 
an O 
as O 
yet O 
unknown O 
, O 
p53 B-protein 
- O 
independent O 
pathway O 
( O 
s O 
) O 
appears O 
to O 
mediate O 
the O 
same O 
event O 
in O 
mitogen B-cell_line 
- I-cell_line 
activated I-cell_line 
mature I-cell_line 
T I-cell_line 
lymphocytes I-cell_line 
. O 

Here O 
we O 
show O 
DNA O 
damage O 
- O 
induced O 
apoptosis O 
in O 
these O 
T B-cell_type 
lymphocytes I-cell_type 
is O 
dependent O 
on O 
the O 
antioncogenic B-protein 
transcription B-protein I-protein 
factor I-protein I-protein 
interferon I-protein 
regulatory I-protein 
factor I-protein 
( B-protein 
IRF I-protein 
) I-protein 
- I-protein 
1 I-protein 
. O 

Thus O 
two O 
different O 
anti B-protein 
- I-protein 
onco I-protein 
- I-protein 
genic I-protein 
transcription I-protein 
factors I-protein 
, O 
p53 B-protein 
and O 
IRF B-protein 
- I-protein 
1 I-protein 
, O 
are O 
required O 
for O 
distinct O 
apoptotic O 
pathways O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

We O 
also O 
show O 
that O 
mitogen O 
induction O 
of O 
the O 
interleukin B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
beta I-protein I-DNA 
converting I-protein I-DNA 
enzyme I-protein I-DNA 
( I-DNA 
ICE B-protein I-DNA 
) I-DNA 
gene I-DNA 
, O 
a O 
mammalian B-protein 
homologue I-protein 
of O 
the O 
Caenorhabditis B-DNA 
elegans I-DNA 
cell I-DNA 
death I-DNA 
gene I-DNA 
ced B-DNA 
- I-DNA 
3 I-DNA 
, O 
is O 
IRF B-protein 
- I-protein 
1 I-protein 
- O 
dependent O 
. O 

Ectopic O 
overexpression O 
of O 
IRF B-protein 
- I-protein 
1 I-protein 
results O 
in O 
the O 
activation O 
of O 
the O 
endogenous B-DNA 
gene I-DNA 
for O 
ICE B-protein 
and O 
enhances O 
the O 
sensitivity O 
of O 
cells O 
to O 
radiation O 
- O 
induced O 
apoptosis O 
. O 

Circadian O 
rhythm O 
of O 
glucocorticoid B-protein 
receptors I-protein 
in O 
human B-cell_type 
peripheral I-cell_type 
leukocytes I-cell_type 
and O 
their O 
reactivity O 
to O 
glucocorticoids O 
. O 

1 O 
) O 
There O 
exists O 
a O 
CR O 
of O 
GR B-protein 
in O 
human B-cell_type 
leukocytes I-cell_type 
, O 
PMN B-cell_type 
, O 
and O 
monocytes B-cell_type 
with O 
the O 
peak O 
values O 
from O 
0400 O 
to O 
0800 O 
hr O 
and O 
the O 
trough O 
values O 
between O 
2300 O 
and O 
0000 O 
hr O 
. O 

The O 
difference O 
between O 
them O 
was O 
significant O 
statistically O 
. O 

2 O 
) O 
The O 
FI O 
of O 
the O 
chemotactic O 
migration O 
rate O 
of O 
PMN B-cell_type 
by O 
cortisol O 
also O 
showed O 
diurnal O 
changes O 
which O 
were O 
synchronous O 
with O 
that O 
of O 
GR B-protein 
. O 

This O 
indicates O 
that O 
the O 
CR O 
of O 
GR B-protein 
may O 
be O 
of O 
functional O 
significance O 
. O 

3 O 
) O 
In O 
Cushing O 
' O 
s O 
syndrome O 
, O 
the O 
CR O 
of O 
GR B-protein 
was O 
normal O 
in O 
spite O 
of O 
the O 
fact O 
that O 
the O 
CR O 
of O 
plasma O 
cortisol O 
was O 
disturbed O 
. O 

This O 
indicates O 
the O 
independency O 
of O 
the O 
CR O 
of O 
GR B-protein 
from O 
that O 
of O 
cortisol O 
. O 

4 O 
) O 
In O 
apoplexy O 
caused O 
by O 
brain O 
ischemia O 
, O 
the O 
CR O 
of O 
GR B-protein 
was O 
abolished O 
in O 
patients O 
with O 
basal O 
lesions O 
but O 
preserved O 
when O 
the O 
lesions O 
were O 
located O 
in O 
the O 
cerebral O 
cortex O 
. O 

These O 
results O 
strongly O 
suggest O 
that O 
the O 
main O 
" O 
circadian O 
pacemaker O 
" O 
of O 
GR B-protein 
is O 
located O 
in O 
the O 
basal O 
brain O 
, O 
most O 
probably O 
in O 
the O 
suprachiasmatic O 
nuclei O 
as O 
has O 
been O 
suggested O 
for O 
rodents O 
. O 

B B-cell_line 
- I-cell_line 
lymphoblastoid I-cell_line 
cell I-cell_line 
lines I-cell_line 
from O 
multiple O 
sclerosis O 
patients O 
and O 
a O 
healthy O 
control O 
producing O 
a O 
putative O 
new O 
human O 
retrovirus O 
and O 
Epstein O 
- O 
Barr O 
virus O 
. O 

On O 
several O 
occasions O 
we O 
have O 
observed O 
retrovirus O 
- O 
like O 
particles O 
( O 
RVLPs O 
) O 
by O 
transmission O 
electron O 
microscopy O 
( O 
EM O 
) O 
of O 
cultured B-cell_line 
T I-cell_line 
cells I-cell_line 
from O 
a O 
patient O 
with O 
MS O 
. O 

Later O 
we O 
established O 
spontaneously O 
formed O 
B B-cell_line 
- I-cell_line 
lymphoblastoid I-cell_line 
cell I-cell_line 
lines I-cell_line 
( O 
LCLs B-cell_line 
) O 
from O 
a O 
patient O 
with O 
an O 
MS O 
- O 
like O 
disease O 
and O 
from O 
another O 
patient O 
with O 
MS O 
who O 
had O 
a O 
reactivated O 
Epstein O 
- O 
Barr O 
virus O 
( O 
EBV O 
) O 
infection O 
. O 

Both O 
LCLs B-cell_line 
were O 
found O 
by O 
EM O 
to O 
produce O 
RVLP O 
and O 
EBV O 
particles O 
. O 

Reverse O 
transcriptase O 
( O 
RT O 
) O 
assays O 
were O 
positive O 
in O 
purified O 
viral O 
material O 
from O 
both O 
LCLs B-cell_line 
. O 

To O 
substantiate O 
these O 
findings O 
we O 
initiated O 
an O 
intensified O 
culturing O 
procedure O 
and O 
were O 
able O 
to O 
establish O 
LCLs B-cell_line 
from O 
5 O 
out O 
of O 
21 O 
consecutive O 
MS O 
patients O 
and O 
1 O 
out O 
of O 
13 O 
consecutive O 
healthy O 
controls O 
. O 

All O 
LCLs B-cell_line 
were O 
found O 
to O 
produce O 
both O 
RVLP O 
and O 
EBV O 
particles O 
by O 
EM O 
. O 

Whether O 
the O 
putative O 
new O 
retrovirus O 
( O 
es O 
) O 
and O 
EBV O 
have O 
any O 
causal O 
relationship O 
to O 
MS O 
is O 
still O 
not O 
known O 
, O 
but O 
the O 
findings O 
support O 
this O 
possibility O 
. O 

Identification O 
of O 
an O 
ionomycin B-DNA 
/ I-DNA 
cyclosporin I-DNA 
A I-DNA 
- I-DNA 
responsive I-DNA 
element I-DNA 
within O 
the O 
human B-DNA 
T I-DNA 
cell I-DNA 
receptor I-DNA 
gamma I-DNA 
enhancer I-DNA 
. O 

Activation O 
through O 
the O 
Ca2 O 
+ O 
/ O 
calcineurin B-protein 
pathway O 
is O 
essential O 
to O 
the O 
transcription O 
of O 
many O 
cytokine B-DNA 
genes I-DNA 
. O 

The O 
conserved B-DNA 
cis I-DNA 
- I-DNA 
acting I-DNA 
sequence I-DNA 
, O 
GGAAAA O 
, O 
and O 
transcription B-protein 
factors I-protein 
binding O 
to O 
this O 
sequence O 
are O 
involved O 
in O 
the O 
response O 
to O 
increased O 
intracellular O 
Ca2 O 
+ O 
concentrations O 
. O 

Here O 
we O 
report O 
the O 
identification O 
and O 
importance O 
of O 
the O 
same O 
sequence O 
in O 
a O 
non B-DNA 
- I-DNA 
cytokine I-DNA 
gene I-DNA 
, O 
the O 
human B-cell_type B-protein B-DNA 
T I-cell_type I-protein I-DNA 
cell I-cell_type I-protein I-DNA 
receptor I-protein I-DNA 
gamma I-protein I-DNA 
( I-DNA 
TCRG B-protein I-DNA 
) I-DNA 
enhancer I-DNA 
. O 

Results O 
from O 
site O 
- O 
directed O 
mutations O 
and O 
electrophoretic O 
mobility O 
shift O 
assays O 
strongly O 
suggest O 
that O 
this O 
sequence O 
mediates O 
the O 
ionomycin O 
- O 
induced O 
activation O 
of O 
the O 
TCRG B-DNA 
enhancer I-DNA 
. O 

Our O 
studies O 
provide O 
an O 
explanation O 
for O 
a O 
previous O 
observation O 
that O 
TCRG B-RNA 
mRNA I-RNA 
levels O 
, O 
but O 
not O 
mRNA O 
levels O 
for O 
T O 
cell O 
receptor O 
alpha O 
and O 
- O 
beta O 
, O 
are O 
increased O 
by O 
ionomycin O 
treatment O 
. O 

Coexpression O 
of O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
/ I-protein 
Rel I-protein 
and O 
Sp1 B-protein 
transcription B-protein 
factors I-protein 
in O 
human O 
immunodeficiency O 
virus O 
1 O 
- O 
induced O 
, O 
dendritic O 
cell O 
- O 
T O 
- O 
cell O 
syncytia O 
. O 

Productive O 
infection O 
of O 
T B-cell_type 
cells I-cell_type 
with O 
human O 
immunodeficiency O 
virus O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
typically O 
requires O 
that O 
the O 
T B-cell_type 
cells I-cell_type 
be O 
stimulated O 
with O 
antigens O 
or O 
mitogens O 
. O 

This O 
requirement O 
has O 
been O 
attributed O 
to O 
the O 
activation O 
of O 
the O 
transcription B-protein 
factor I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
which O 
synergizes O 
with O 
the O 
constitutive B-protein 
transcription I-protein 
factor I-protein 
Sp1 B-protein 
to O 
drive O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
promoter I-DNA 
. O 

Recently O 
, O 
we O 
have O 
found O 
that O 
vigorous O 
replication O 
of O 
HIV O 
- O 
1 O 
takes O 
place O 
in O 
nonactivated O 
memory B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
after O 
syncytium O 
formation O 
with O 
dendritic B-cell_type 
cells I-cell_type 
( O 
DCs B-cell_type 
) O 
. O 

These O 
syncytia O 
lack O 
activated B-cell_type 
cells I-cell_type 
as O 
determined O 
by O 
an O 
absence O 
of O 
staining O 
for O 
Ki O 
- O 
67 O 
cell O 
cycle O 
antigen O 
. O 

The O 
expression O 
and O 
activity O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
Sp1 B-protein 
were O 
, O 
therefore O 
, O 
analyzed O 
in O 
isolated O 
T B-cell_type 
cells I-cell_type 
and O 
DCs B-cell_type 
from O 
humans O 
and O 
mice O 
. O 

We O 
have O 
used O 
immunolabeling O 
, O 
Western O 
blot O 
analysis O 
, O 
and O 
electrophoretic O 
mobility O 
shift O 
and O 
supershift O 
assays O 
. O 

T B-cell_type 
cells I-cell_type 
lack O 
active O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
but O 
express O 
Sp1 B-protein 
as O 
expected O 
. O 

DCs B-cell_type 
express O 
high O 
levels O 
of O 
all O 
known O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
Rel B-protein 
proteins I-protein 
, O 
with O 
activity O 
residing O 
primarily O 
within O 
RelB B-protein 
, O 
p50 B-protein 
, O 
and O 
p65 B-protein 
. O 

However O 
, O 
DCs B-cell_type 
lack O 
Sp1 B-protein 
, O 
which O 
may O 
explain O 
the O 
failure O 
of O 
HIV O 
- O 
1 O 
to O 
replicate O 
in O 
purified O 
DCs B-cell_type 
. O 

Coexpression O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
and O 
Sp1 B-protein 
occurs O 
in O 
the O 
heterologous B-cell_type 
DC I-cell_type 
- I-cell_type 
T I-cell_type 
- I-cell_type 
cell I-cell_type 
syncytia I-cell_type 
that O 
are O 
induced O 
by O 
HIV O 
- O 
1 O 
. O 

Therefore O 
, O 
HIV O 
- O 
1 O 
- O 
induced O 
cell O 
fusion O 
brings O 
together O 
factors O 
that O 
upregulate O 
virus O 
transcription O 
. O 

Since O 
DCs B-cell_type 
and O 
memory O 
T B-cell_type 
cells I-cell_type 
frequently O 
traffic O 
together O 
in O 
situ O 
, O 
these O 
unusual O 
heterologous B-cell_type 
syncytia I-cell_type 
could O 
develop O 
in O 
infected O 
individuals O 
and O 
lead O 
to O 
chronic O 
HIV O 
- O 
1 O 
replication O 
without O 
ostensible O 
immune O 
stimulation O 
. O 

Cupric O 
ion O 
blocks O 
NF B-protein 
kappa I-protein 
B I-protein 
activation O 
through O 
inhibiting O 
the O 
signal O 
- O 
induced O 
phosphorylation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
. O 

A O 
transcription B-protein 
factor I-protein 
NF B-protein 
kappa I-protein 
B I-protein 
, O 
which O 
regulates O 
expression O 
of O 
various O 
cellular O 
genes O 
involved O 
in O 
immune O 
responses O 
and O 
viral B-DNA 
genes I-DNA 
including O 
HIV O 
, O 
is O 
sequestered O 
in O 
the O 
cytoplasm O 
as O 
a O 
complex O 
with O 
an O 
inhibitory B-protein 
protein I-protein 
I I-protein 
kappa I-protein 
B I-protein 
. O 

Various O 
extracellular O 
signals O 
induce O 
phosphorylation O 
and O 
rapid O 
degradation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
to O 
release O 
NF B-protein 
kappa I-protein 
B I-protein 
. O 

Cu2 O 
+ O 
was O 
found O 
to O 
inhibit O 
the O 
activation O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
induced O 
by O 
TNF B-protein 
- I-protein 
alpha I-protein 
, O 
TPA O 
, O 
or O 
H2O2 O 
. O 

Deoxycholate O 
treatment O 
of O 
the O 
cytoplasmic O 
extract O 
prepared O 
from O 
cells O 
stimulated O 
by O 
TNF B-protein 
- I-protein 
alpha I-protein 
in O 
the O 
presence O 
of O 
Cu2 O 
+ O 
resulted O 
in O 
the O 
release O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
from O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
, O 
indicating O 
that O 
Cu2 O 
+ O 
interferes O 
with O 
the O 
dissociation O 
of O 
the O 
NF B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
- I-protein 
I I-protein 
kappa I-protein 
B I-protein 
complex I-protein 
. O 

Neither O 
phosphorylation O 
nor O 
degradation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
was O 
observed O 
upon O 
TNF B-protein 
- I-protein 
alpha I-protein 
stimulation O 
in O 
the O 
presence O 
of O 
Cu2 O 
+ O 
. O 

These O 
results O 
indicate O 
that O 
Cu2 O 
+ O 
inhibits O 
the O 
release O 
of O 
NF B-protein 
kappa I-protein 
B I-protein 
by O 
blockade O 
of O 
a O 
signal O 
leading O 
to O 
the O 
phosphorylation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
. O 

Cloning O 
a O 
cDNA B-DNA 
from O 
human O 
NK B-cell_type 
/ I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
which O 
codes O 
for O 
a O 
protein O 
with O 
high O 
proline O 
content O 
. O 

A O 
cDNA B-DNA 
clone I-DNA 
, O 
B4 B-DNA 
- I-DNA 
2 I-DNA 
, O 
was O 
isolated O 
from O 
a O 
natural B-DNA 
killer I-DNA 
( I-DNA 
NK I-DNA 
) I-DNA 
minus I-DNA 
T I-DNA 
cell I-DNA 
subtractive I-DNA 
library I-DNA 
. O 

The O 
B4 B-DNA 
- I-DNA 
2 I-DNA 
clone O 
coded O 
for O 
an O 
mRNA B-RNA 
of O 
2061 O 
bp O 
in O 
length O 
. O 

It O 
encodes O 
a O 
deduced O 
327 B-protein 
aa I-protein 
protein I-protein 
with O 
a O 
calculated O 
molecular O 
mass O 
of O 
35 O 
. O 
2 O 
kDa O 
. O 

Searching O 
of O 
B4 B-DNA B-DNA 
- I-DNA I-DNA 
2 I-DNA I-DNA 
DNA I-DNA 
and O 
protein O 
sequences O 
against O 
various O 
databases O 
revealed O 
no O 
high O 
homology O 
to O 
other O 
sequences O 
. O 

However O 
, O 
B4 B-DNA 
- I-DNA 
2 I-DNA 
has O 
an O 
unusually O 
high O 
proline O 
content O 
( O 
13 O 
% O 
) O 
, O 
contains O 
a O 
putative O 
nuclear B-protein 
targeting I-protein 
sequence I-protein 
, O 
and O 
has O 
several O 
SPXX B-protein 
motifs I-protein 
which O 
are O 
frequently O 
found O 
in O 
gene B-protein 
regulatory I-protein 
proteins I-protein 
. O 

One O 
of O 
the O 
stretches O 
of O 
prolines O 
in O 
B4 B-DNA 
- I-DNA 
2 I-DNA 
closely O 
resembles O 
the O 
ligand O 
for O 
proteins O 
with O 
SH3 B-protein 
domains I-protein 
. O 

Northern O 
hybridization O 
data O 
showed O 
that O 
B4 B-DNA 
- I-DNA 
2 I-DNA 
is O 
not O 
a O 
lymphoid B-DNA 
specific I-DNA 
gene I-DNA 
and O 
is O 
expressed O 
in O 
a O 
hepatoma B-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
also O 
weakly O 
transcribed O 
or O 
absent O 
in O 
a O 
variety O 
of O 
other O 
cells O 
. O 

A O 
polyclonal O 
antiserum O 
raised O 
against O 
recombinant B-protein 
B4 B-DNA I-protein 
- I-DNA I-protein 
2 I-DNA I-protein 
recognizes O 
a O 
32 B-protein 
- I-protein 
34 I-protein 
kDa I-protein 
protein I-protein 
in O 
lymphocytes B-cell_type 
. O 

Activation O 
of O 
JAK3 B-protein 
, O 
but O 
not O 
JAK1 B-protein 
, O 
is O 
critical O 
for O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
proliferation O 
and O 
STAT5 B-protein 
recruitment O 
by O 
a O 
COOH B-protein 
- I-protein 
terminal I-protein 
region I-protein 
of O 
the O 
IL B-protein 
- I-protein 
2 I-protein 
receptor I-protein 
beta I-protein 
- I-protein 
chain I-protein 
. O 

A O 
number O 
of O 
cytokines B-protein 
and O 
growth B-protein 
factors I-protein 
use O 
the O 
JAK B-protein 
- B-protein 
STAT I-protein 
pathway O 
to O 
signal O 
from O 
the O 
cell O 
membrane O 
to O 
the O 
nucleus O 
. O 

While O 
homodimerizing B-protein 
cytokine I-protein 
receptors I-protein 
may O 
transmit O 
signal O 
via O 
a O 
single O 
form O 
of O 
JAK B-protein 
( O 
i O 
. O 
e O 
. O 
growth B-protein 
hormone I-protein 
receptors I-protein 
) O 
, O 
several O 
multicomponent B-protein 
cytokine I-protein 
receptors I-protein 
have O 
been O 
shown O 
to O 
require O 
simultaneous O 
activation O 
of O 
pairs O 
of O 
different O 
JAK B-protein 
kinases I-protein 
( O 
i O 
. O 
e O 
. O 
interferon B-protein 
receptors I-protein 
) O 
. O 

Recent O 
evidence O 
for O 
a O 
preferential O 
coupling O 
of O 
JAK3 B-protein 
to O 
interleukin B-protein 
- I-protein 
2 I-protein 
receptor I-protein 
- I-protein 
gamma I-protein 
( O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
) O 
and O 
JAK1 B-protein 
to O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
supports O 
the O 
concept O 
of O 
heterotrans O 
- O 
activation O 
of O 
JAK1 B-protein 
and O 
JAK3 B-protein 
caused O 
by O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
heterodimerization O 
of O 
their O 
receptor O 
partners O 
. O 

The O 
present O 
study O 
verified O 
the O 
ability O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
to O 
cause O 
tyrosine O 
phosphorylation O 
and O 
activation O 
of O 
JAK1 B-protein 
and O 
JAK3 B-protein 
, O 
but O 
demonstrated O 
that O 
IL B-protein 
- I-protein 
2 I-protein 
stimulated O 
JAK3 B-protein 
to O 
a O 
significantly O 
larger O 
extent O 
than O 
JAK1 B-protein 
in O 
human B-cell_type 
T I-cell_type 
lymphocytes I-cell_type 
and O 
the O 
YT B-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

This O 
conclusion O 
was O 
based O 
upon O 
several O 
independent O 
criteria O 
, O 
including O 
more O 
vigorous O 
tyrosine O 
phosphorylation O 
of O 
JAK3 B-protein 
, O 
more O 
marked O 
enzymatic O 
activation O 
of O 
JAK3 B-protein 
as O 
well O 
as O 
higher O 
abundance O 
of O 
JAK3 B-protein 
in O 
activated O 
IL B-protein 
- I-protein 
2 I-protein 
receptor I-protein 
complexes I-protein 
. O 

Furthermore O 
, O 
when O 
human B-protein 
IL B-protein I-protein 
- I-protein I-protein 
2R I-protein I-protein 
beta I-protein 
was O 
stably O 
expressed O 
in O 
murine B-cell_line 
BA I-cell_line 
/ I-cell_line 
F3 I-cell_line 
cells I-cell_line 
, O 
robust O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
proliferation O 
and O 
JAK3 B-protein 
activation O 
occurred O 
without O 
detectable O 
involvement O 
of O 
either O 
JAK1 B-protein 
, O 
JAK2 B-protein 
or O 
TYK2 B-protein 
. O 

We O 
therefore O 
propose O 
that O 
IL B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
receptor I-protein 
signal O 
transduction O 
does O 
not O 
depend O 
on O 
equimolar O 
heterodimerization O 
of O 
JAK1 B-protein 
and O 
JAK3 B-protein 
following O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
induced O 
heterodimerization O 
of O 
IL B-protein B-protein 
- I-protein I-protein 
2R I-protein I-protein 
beta I-protein 
and O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
. O 

Nonetheless O 
, O 
a O 
membrane B-protein 
- I-protein 
proximal I-protein 
region I-protein 
of O 
human O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
( O 
Asn240 B-protein 
- I-protein 
Leu335 I-protein 
) O 
was O 
critical O 
for O 
JAK3 B-protein 
activation O 
, O 
and O 
the O 
amount O 
of O 
JAK3 B-protein 
present O 
in O 
activated O 
IL B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
receptor I-protein 
complexes I-protein 
increased O 
with O 
time O 
, O 
suggesting O 
that O 
stabilization O 
of O 
JAK3 B-protein 
binding O 
to O 
the O 
receptor B-protein 
complex I-protein 
relies O 
on O 
both O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
and O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
. O 

Moreover O 
, O 
STAT5 B-protein 
was O 
found O 
to O 
be O 
the O 
predominant O 
STAT B-protein 
transcription I-protein 
factor I-protein 
used O 
by O 
IL B-protein 
- I-protein 
2 I-protein 
in O 
human B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
, O 
and O 
specifically O 
required O 
a O 
COOH B-protein 
- I-protein 
terminal I-protein 
region I-protein 
of O 
IL B-protein 
- I-protein 
2R I-protein 
beta I-protein 
( O 
Ser386 B-protein 
- I-protein 
Val525 I-protein 
) O 
, O 
while O 
STAT5 B-protein 
recruitment O 
was O 
not O 
correlated O 
to O 
activation O 
of O 
IL B-protein 
- I-protein 
2R I-protein 
gamma I-protein 
or O 
JAK3 B-protein 
. O 

Up O 
- O 
regulation O 
of O 
high O 
- O 
affinity O 
dehydroepiandrosterone O 
binding O 
activity O 
by O 
dehydroepiandrosterone O 
in O 
activated O 
human B-cell_type 
T I-cell_type 
lymphocytes I-cell_type 
. O 

Although O 
evidence O 
indicates O 
that O 
dehydroepiandrosterone O 
( O 
DHEA O 
) O 
exerts O 
direct O 
physiological O 
effects O 
, O 
its O 
mechanism O 
of O 
action O 
remains O 
unknown O 
. O 

DHEA O 
binding O 
sites O 
were O 
examined O 
using O 
a O 
whole O 
- O 
cell O 
binding O 
assay O 
in O 
a O 
human B-cell_line 
T I-cell_line 
lymphoid I-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
PEER B-cell_line 
, O 
revealing O 
that O 
a O 
single O 
class O 
of O 
high O 
- O 
affinity O 
binding O 
sites O 
for O 
DHEA O 
( O 
dissociation O 
constant O 
= O 
7 O 
. O 
4 O 
+ O 
/ O 
- O 
0 O 
. O 
53 O 
nmol O 
/ O 
L O 
, O 
mean O 
+ O 
/ O 
- O 
SE O 
, O 
n O 
= O 
4 O 
) O 
was O 
greatly O 
increased O 
when O 
treated O 
with O 
DHEA O 
, O 
phorbol O 
- O 
12 O 
- O 
myristate O 
- O 
13 O 
- O 
acetate O 
, O 
and O 
the O 
Ca2 O 
+ O 
ionophore O 
A23187 O 
. O 

Bound O 
[ O 
3H O 
] O 
DHEA O 
was O 
displaced O 
sensitively O 
by O 
DHEA O 
and O 
secondarily O 
by O 
dihydrotestosterone O 
, O 
but O 
not O 
effectively O 
by O 
other O 
steroids O 
, O 
including O 
DHEA O 
sulfate O 
. O 

These O 
results O 
not O 
only O 
indicate O 
the O 
existence O 
of O 
a O 
DHEA B-protein 
receptor I-protein 
, O 
but O 
also O 
suggest O 
that O 
T B-cell_type 
cells I-cell_type 
become O 
susceptible O 
to O 
regulation O 
by O 
DHEA O 
during O 
the O 
process O 
of O 
signal O 
- O 
induced O 
activation O 
. O 

Ubiquitin O 
- O 
mediated O 
processing O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
transcriptional B-protein 
activator I-protein 
precursor I-protein 
p105 B-protein 
. O 

Reconstitution O 
of O 
a O 
cell O 
- O 
free O 
system O 
and O 
identification O 
of O 
the O 
ubiquitin B-protein 
- I-protein 
carrier I-protein 
protein I-protein 
, O 
E2 B-protein 
, O 
and O 
a O 
novel O 
ubiquitin B-protein 
- I-protein 
protein I-protein 
ligase I-protein 
, O 
E3 B-protein 
, O 
involved O 
in O 
conjugation O 
. O 

In O 
most O 
cases O 
, O 
the O 
transcriptional B-protein 
factor I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
is O 
a O 
heterodimer B-protein 
consisting O 
of O 
two O 
subunits O 
, O 
p50 B-protein 
and O 
p65 B-protein 
, O 
which O 
are O 
encoded O 
by O 
two O 
distinct O 
genes O 
of O 
the O 
Rel B-DNA 
family I-DNA 
. O 

p50 B-protein 
is O 
translated O 
as O 
a O 
precursor O 
of O 
105 B-protein 
kDa I-protein 
. O 

The O 
C B-protein 
- I-protein 
terminal I-protein 
domain I-protein 
of O 
the O 
precursor O 
is O 
rapidly O 
degraded O 
, O 
forming O 
the O 
mature B-protein 
p50 I-protein 
subunit I-protein 
consisted O 
of O 
the O 
N B-protein 
- I-protein 
terminal I-protein 
region I-protein 
of O 
the O 
molecule O 
. O 

The O 
mechanism O 
of O 
generation O 
of O 
p50 B-protein 
is O 
not O 
known O 
. O 

It O 
has O 
been O 
suggested O 
that O 
the O 
ubiquitin B-protein 
- B-protein 
proteasome I-protein 
system O 
is O 
involved O 
in O 
the O 
process O 
; O 
however O 
, O 
the O 
specific O 
enzymes B-protein 
involved O 
and O 
the O 
mechanism O 
of O 
limited O 
proteolysis O 
, O 
in O 
which O 
half O 
of O 
the O 
molecule O 
is O 
spared O 
, O 
have O 
been O 
obscure O 
. O 

Palombella O 
and O 
colleagues O 
( O 
Palombella O 
, O 
V O 
. O 
J O 
. O 
, O 
Rando O 
, O 
O O 
. O 
J O 
. O 
, O 
Goldberg O 
, O 
A O 
. O 
L O 
. O 
, O 
and O 
Maniatis O 
, O 
T O 
. O 
( O 
1994 O 
) O 
Cell O 
78 O 
, O 
773 O 
- O 
785 O 
) O 
have O 
shown O 
that O 
ubiquitin B-protein 
is O 
required O 
for O 
the O 
processing O 
in O 
a O 
cell O 
- O 
free O 
system O 
of O 
a O 
truncated O 
, O 
artificially O 
constructed O 
, O 
60 B-protein 
- I-protein 
kDa I-protein 
precursor I-protein 
. O 

They O 
have O 
also O 
shown O 
that O 
proteasome B-protein 
inhibitors O 
block O 
the O 
processing O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

In O 
this O 
study O 
, O 
we O 
demonstrate O 
reconstitution O 
of O 
a O 
cell O 
- O 
free O 
processing O 
system O 
and O 
demonstrate O 
directly O 
that O 
: O 
( O 
a O 
) O 
the O 
ubiquitin B-protein 
- B-protein 
proteasome I-protein 
system O 
is O 
involved O 
in O 
processing O 
of O 
the O 
intact O 
p105 B-protein 
precursor O 
, O 
( O 
b O 
) O 
conjugation O 
of O 
ubiquitin B-protein 
to O 
the O 
precursor O 
is O 
an O 
essential O 
intermediate O 
step O 
in O 
the O 
processing O 
, O 
( O 
c O 
) O 
the O 
recently O 
discovered O 
novel O 
species O 
of O 
the O 
ubiquitin B-protein B-protein 
- I-protein 
carrier I-protein 
protein I-protein 
, O 
E2 B-protein 
- I-protein 
F1 I-protein 
, O 
that O 
is O 
involved O 
in O 
the O 
conjugation O 
and O 
degradation O 
of O 
p53 B-protein 
, O 
is O 
also O 
required O 
for O 
the O 
limited O 
processing O 
of O 
the O 
p105 B-protein 
precursor I-protein 
, O 
and O 
( O 
d O 
) O 
a O 
novel O 
, O 
approximately O 
320 B-protein 
- I-protein 
kDa I-protein 
species I-protein 
of O 
ubiquitin B-protein B-protein 
- I-protein 
protein I-protein 
ligase I-protein 
, O 
is O 
involved O 
in O 
the O 
process O 
. O 

This O 
novel O 
enzyme O 
is O 
distinct O 
from O 
E6 B-protein 
- I-protein 
AP I-protein 
, O 
the O 
p53 B-protein B-protein 
- I-protein 
conjugating I-protein 
ligase I-protein 
, O 
and O 
from O 
E3 B-protein B-protein 
alpha I-protein 
, O 
the O 
" B-protein 
N I-protein 
- I-protein 
end I-protein 
rule I-protein 
" I-protein 
ligase I-protein 
. O 

Flutamide O 
in O 
the O 
treatment O 
of O 
hirsutism O 
: O 
long O 
- O 
term O 
clinical O 
effects O 
, O 
endocrine O 
changes O 
, O 
and O 
androgen B-protein 
receptor I-protein 
behavior O 
. O 

OBJECTIVE O 
: O 
To O 
investigate O 
the O 
long O 
- O 
term O 
effects O 
of O 
treatment O 
with O 
low O 
doses O 
of O 
flutamide O 
on O 
clinical O 
and O 
hormonal O 
parameters O 
, O 
as O 
well O 
as O 
on O 
the O 
androgen B-protein 
receptor I-protein 
status O 
, O 
in O 
hirsute O 
women O 
. O 

DESIGN O 
: O 
Eighteen O 
hirsute O 
patients O 
with O 
regular O 
menses O 
were O 
studied O 
basally O 
and O 
during O 
treatment O 
with O 
125 O 
mg O 
flutamide O 
, O 
three O 
times O 
per O 
day O 
for O 
12 O 
months O 
. O 

Barrier O 
or O 
intrauterine O 
contraception O 
was O 
used O 
during O 
the O 
study O 
in O 
sexually O 
active O 
women O 
. O 

Safety O 
parameters O 
were O 
assessed O 
throughout O 
the O 
study O 
. O 

Hirsutism O 
, O 
graded O 
by O 
the O 
modified O 
Ferriman O 
- O 
Gallwey O 
score O 
, O 
and O 
hormonal O 
parameters O 
were O 
evaluated O 
basally O 
and O 
at O 
4 O 
- O 
month O 
intervals O 
during O 
treatment O 
. O 

Gonadotropin O 
- O 
releasing O 
hormone O 
and O 
ACTH O 
stimulation O 
tests O 
were O 
performed O 
before O 
and O 
after O 
3 O 
to O 
4 O 
months O 
of O 
therapy O 
. O 

In O 
addition O 
, O 
the O 
concentration O 
of O 
androgen B-protein 
receptors I-protein 
in O 
mononuclear B-cell_type 
leukocytes I-cell_type 
was O 
measured O 
, O 
in O 
both O 
the O 
follicular O 
and O 
luteal O 
phases O 
of O 
the O 
menstrual O 
cycle O 
, O 
basally O 
and O 
after O 
4 O 
months O 
of O 
flutamide O 
treatment O 
. O 

RESULTS O 
: O 
Flutamide O 
was O 
well O 
tolerated O 
in O 
all O 
women O 
, O 
with O 
the O 
noticeable O 
exception O 
of O 
one O 
patient O 
who O 
presented O 
increased O 
serum B-protein 
transaminase I-protein 
after O 
8 O 
months O 
of O 
therapy B-protein 
. O 

Hirsutism O 
markedly O 
improved O 
in O 
all O 
women O 
during O 
the O 
treatment O 
( O 
Ferriman O 
- O 
Gallwey O 
score O 
after O 
1 O 
year O 
: O 
4 O 
. O 
1 O 
+ O 
/ O 
- O 
0 O 
. O 
5 O 
versus O 
14 O 
. O 
1 O 
+ O 
/ O 
- O 
0 O 
. O 
9 O 
) O 
. O 

A O 
reduction O 
of O 
serum O 
androgens O 
was O 
found O 
, O 
whereas O 
no O 
change O 
was O 
observed O 
in O 
either O 
basal O 
or O 
GnRH O 
- O 
stimulated O 
gonadotropins O 
or O 
in O 
the O 
cortisol O 
and O 
17 O 
alpha O 
- O 
hydroxyprogesterone O 
response O 
to O 
ACTH O 
. O 

Cycles O 
remained O 
ovulatory O 
. O 

Before O 
treatment O 
, O 
the O 
number O 
of O 
androgen B-protein 
receptors I-protein 
was O 
higher O 
in O 
the O 
luteal O 
than O 
in O 
the O 
follicular O 
phase O 
. O 

This O 
rhythmic O 
differentiation O 
disappeared O 
after O 
the O 
patients O 
had O 
been O 
given O 
the O 
antiandrogen O 
drug O 
. O 

CONCLUSIONS O 
: O 
Flutamide O 
is O 
effective O 
in O 
the O 
treatment O 
of O 
hirsutism O 
but O 
requires O 
constant O 
surveillance O 
of O 
liver O 
function O 
. O 

Androgen O 
receptor O 
blockade O 
might O 
be O 
potentiated O 
by O 
a O 
reduction O 
of O 
serum O 
androgens O 
. O 

Flutamide O 
affects O 
androgen B-protein 
receptor I-protein 
behavior O 
during O 
the O 
menstrual O 
cycle O 
. O 

The O 
meaning O 
of O 
this O 
finding O 
remains O 
to O 
be O 
elucidated O 
. O 

Constitutive O 
expression O 
of O 
HIV B-protein 
- I-protein 
1 I-protein 
tat I-protein 
protein I-protein 
in O 
human B-cell_line 
Jurkat B-cell_line I-cell_line 
T I-cell_line I-cell_line 
cells I-cell_line I-cell_line 
using O 
a O 
BK O 
virus O 
vector O 
. O 

The O 
production O 
and O 
characterization O 
of O 
Jurkat B-cell_line 
cell I-cell_line 
lines I-cell_line 
that O 
constitutively O 
express O 
functional O 
human O 
immune O 
deficiency O 
virus O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
tat B-protein 
protein I-protein 
, O 
using O 
a O 
BK O 
virus O 
plasmid O 
expression O 
vector O 
and O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
tat I-DNA 
cDNA I-DNA 
, O 
is O 
described O 
. O 

An O 
increased O 
growth O 
rate O 
of O 
these O 
Jurkat B-cell_line 
- I-cell_line 
tat I-cell_line 
cell I-cell_line 
lines I-cell_line 
as O 
compared O 
with O 
control B-cell_line 
cell I-cell_line 
lines I-cell_line 
was O 
observed O 
. O 

A O 
PEBP2 B-protein 
alpha I-protein 
/ I-protein 
AML I-protein 
- I-protein 
1 I-protein 
- I-protein 
related I-protein 
factor I-protein 
increases O 
osteocalcin B-DNA 
promoter I-DNA 
activity O 
through O 
its O 
binding O 
to O 
an O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
cis I-DNA 
- I-DNA 
acting I-DNA 
element I-DNA 
. O 

To O 
identify O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
cis I-DNA 
- I-DNA 
acting I-DNA 
elements I-DNA 
and O 
trans B-protein 
- I-protein 
acting I-protein 
factors I-protein 
, O 
we O 
initiated O 
an O 
analysis O 
of O 
the O 
promoter B-DNA 
of O 
a O 
mouse B-DNA 
osteocalcin I-DNA 
gene I-DNA 
, O 
an O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
gene I-DNA 
. O 

In O 
this O 
promoter O 
, O 
we O 
identified O 
two O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
cis I-DNA 
- I-DNA 
acting I-DNA 
elements I-DNA 
( O 
Ducy O 
, O 
P O 
. O 
and O 
Karsenty O 
, O 
G O 
. O 
( O 
1995 O 
) O 
Mol O 
. O 
Cell O 
. O 
Biol O 
. O 
15 O 
, O 
1858 O 
- O 
1869 O 
) O 
. O 

The O 
sequence O 
of O 
one O 
of O 
these O 
elements B-DNA 
, O 
OSE2 B-DNA 
, O 
is O 
identical O 
to O 
the O 
DNA B-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
of O 
the O 
PEBP2 B-protein 
alpha I-protein 
/ I-protein 
AML I-protein 
- I-protein 
1 I-protein 
transcription I-protein 
factors I-protein 
, O 
the O 
mammalian B-protein 
homologues I-protein 
of O 
the O 
Drosophila B-protein 
Runt I-protein 
protein I-protein 
. O 

Here O 
we O 
show O 
, O 
using O 
nuclear O 
extracts O 
, O 
recombinant B-protein 
protein I-protein 
, O 
and O 
a O 
specific O 
antiserum O 
against O 
AML B-protein 
- I-protein 
1 I-protein 
proteins I-protein 
in O 
DNA O 
- O 
binding O 
assays O 
, O 
that O 
one O 
member O 
of O 
this O 
family O 
, O 
AML B-protein 
- I-protein 
1B I-protein 
, O 
binds O 
specifically O 
to O 
OSE2 B-DNA 
and O 
is O 
immunologically O 
related O 
to O 
OSF2 B-protein 
, O 
the O 
factor O 
present O 
in O 
osteoblast O 
nuclear O 
extracts O 
that O 
binds O 
to O 
OSE2 B-DNA 
. O 

By O 
DNA O 
cotransfection O 
experiments O 
, O 
we O 
also O 
demonstrate O 
that O 
AML B-protein 
- I-protein 
1B I-protein 
can O 
increase O 
the O 
activity O 
of O 
a O 
short O 
osteocalcin B-DNA 
promoter I-DNA 
through O 
its O 
binding O 
to O 
OSE2 B-DNA 
. O 

Lastly O 
, O 
the O 
different O 
mobilities O 
of O 
osteoblast B-protein 
nuclear I-protein 
extract I-protein 
- I-protein 
DNA I-protein 
complexes I-protein 
compared O 
with O 
T B-protein 
- I-protein 
cell I-protein 
nuclear I-protein 
extract I-protein 
- I-protein 
DNA I-protein 
complexes I-protein 
, O 
along O 
with O 
the O 
inability O 
of O 
OSF2 B-protein 
to O 
be O 
upregulated O 
by O 
retinoic O 
acid O 
, O 
unlike O 
the O 
other O 
PEBP2 B-protein 
alpha I-protein 
factors I-protein 
, O 
suggest O 
that O 
OSF2 B-protein 
is O 
a O 
new O 
member O 
of O 
this O 
family O 
of O 
transcription B-protein 
factors I-protein 
. O 

Thus O 
, O 
this O 
study O 
demonstrates O 
that O 
AML B-protein 
- I-protein 
1B I-protein 
can O 
increase O 
gene O 
expression O 
of O 
an O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
gene I-DNA 
through O 
its O 
binding O 
to O 
an O 
osteoblast B-DNA 
- I-DNA 
specific I-DNA 
cis I-DNA 
- I-DNA 
acting I-DNA 
element I-DNA 
and O 
presents O 
evidence O 
that O 
OSF2 B-protein 
is O 
a O 
member O 
of O 
the O 
PEBP2 B-protein 
alpha I-protein 
/ I-protein 
AML I-protein 
- I-protein 
1 I-protein 
family I-protein 
of O 
transcription B-protein 
factors I-protein 
. O 

Initiation B-protein 
binding I-protein 
repressor I-protein 
, O 
a O 
factor O 
that O 
binds O 
to O 
the O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
of O 
the O 
histone B-protein B-DNA 
h5 I-protein I-DNA 
gene I-DNA 
, O 
is O 
a O 
glycosylated B-protein 
member I-protein 
of O 
a O 
family O 
of O 
cell B-protein 
growth I-protein 
regulators I-protein 
[ O 
corrected O 
] O 
[ O 
published O 
erratum O 
appears O 
in O 
Mol O 
Cell O 
Biol O 
1996 O 
Feb O 
; O 
16 O 
( O 
2 O 
) O 
: O 
735 O 
] O 
. O 

Initiation B-protein 
binding I-protein 
repressor I-protein 
[ O 
corrected O 
] O 
( O 
IBR B-protein 
) O 
is O 
a O 
chicken B-protein 
erythrocyte I-protein 
factor I-protein 
( O 
apparent O 
molecular O 
mass O 
, O 
70 O 
to O 
73 O 
kDa O 
) O 
that O 
binds O 
to O 
the O 
sequences O 
spanning O 
the O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
of O 
the O 
histone B-protein B-DNA 
h5 I-protein I-DNA 
gene I-DNA 
, O 
repressing O 
its O 
transcription O 
. O 

A O 
variety O 
of O 
other O 
cells O 
, O 
including O 
transformed B-cell_type 
erythroid I-cell_type 
precursors I-cell_type 
, O 
do O 
not O 
have O 
IBR B-protein 
but O 
a O 
factor O 
referred O 
to O 
as O 
IBF B-protein 
( O 
68 O 
to O 
70 O 
kDa O 
) O 
that O 
recognizes O 
the O 
same O 
IBR B-protein 
sites O 
. O 

We O 
have O 
cloned O 
the O 
IBR B-protein B-DNA 
cDNA I-DNA 
and O 
studied O 
the O 
relationship O 
of O 
IBR B-protein 
and O 
IBF B-protein 
. O 

IBR B-protein 
is O 
a O 
503 B-protein 
- I-protein 
amino I-protein 
- I-protein 
acid I-protein 
- I-protein 
long I-protein 
acidic I-protein 
protein I-protein 
which O 
is O 
99 O 
. O 
0 O 
% O 
identical O 
to O 
the O 
recently O 
reported O 
human B-protein 
NRF I-protein 
- I-protein 
1 I-protein 
/ I-protein 
alpha I-protein 
- I-protein 
Pal I-protein 
factor I-protein 
and O 
highly O 
related O 
to O 
the O 
invertebrate O 
transcription B-protein 
factors I-protein 
P3A2 B-protein 
and O 
erected B-protein 
wing I-protein 
gene I-protein 
product I-protein 
( O 
EWG B-protein 
) O 
. O 

We O 
present O 
evidence O 
that O 
IBR B-protein 
and O 
IBF B-protein 
are O 
most O 
likely O 
identical O 
proteins O 
, O 
differing O 
in O 
their O 
degree O 
of O 
glycosylation O 
. O 

We O 
have O 
analyzed O 
several O 
molecular O 
aspects O 
of O 
IBR B-protein 
/ I-protein 
F I-protein 
and O 
shown O 
that O 
the O 
factor O 
associates O 
as O 
stable O 
homodimers B-protein 
and O 
that O 
the O 
dimer B-protein 
is O 
the O 
relevant B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
species I-protein 
. O 

The O 
evolutionarily O 
conserved O 
N B-protein 
- I-protein 
terminal I-protein 
half I-protein 
of O 
IBR B-protein 
/ I-protein 
F I-protein 
harbors O 
the O 
DNA B-protein 
- I-protein 
binding I-protein 
/ I-protein 
dimerization I-protein 
domain I-protein 
( O 
outer O 
limits O 
, O 
127 O 
to O 
283 O 
) O 
, O 
one O 
or O 
several O 
casein B-protein 
kinase I-protein 
II I-protein 
sites I-protein 
( O 
37 O 
to O 
67 O 
) O 
, O 
and O 
a O 
bipartite B-protein 
nuclear I-protein 
localization I-protein 
signal I-protein 
( O 
89 O 
to O 
106 O 
) O 
which O 
appears O 
to O 
be O 
necessary O 
for O 
nuclear O 
targeting O 
. O 

Binding O 
site O 
selection O 
revealed O 
that O 
the O 
alternating B-protein 
RCGCRYGCGY I-protein 
consensus I-protein 
constitutes O 
high O 
- O 
affinity O 
IBR B-protein B-DNA 
/ I-protein I-DNA 
F I-protein I-DNA 
binding I-DNA 
sites I-DNA 
and O 
that O 
the O 
direct B-DNA 
- I-DNA 
repeat I-DNA 
palindrome I-DNA 
TGCGCATGCGCA O 
is O 
the O 
optimal B-DNA 
site I-DNA 
. O 

A O 
survey O 
of O 
genes B-DNA 
potentially O 
regulated O 
by O 
this O 
family O 
of O 
factors B-protein 
primarily O 
revealed O 
genes B-DNA 
involved O 
in O 
growth O 
- O 
related O 
metabolism O 
. O 

Triggering O 
of O 
the O 
human O 
interleukin O 
- O 
6 O 
gene O 
by O 
interferon O 
- O 
gamma O 
and O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
in O 
monocytic O 
cells O 
involves O 
cooperation O 
between O 
interferon B-protein 
regulatory I-protein 
factor I-protein 
- I-protein 
1 I-protein 
, O 
NF B-protein 
kappa I-protein 
B I-protein 
, O 
and O 
Sp1 B-protein 
transcription B-protein 
factors I-protein 
. O 

We O 
investigated O 
the O 
molecular O 
basis O 
of O 
the O 
synergistic O 
induction O 
by O 
interferon B-protein 
- I-protein 
gamma I-protein 
( O 
IFN B-protein 
- I-protein 
gamma I-protein 
) O 
/ O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
- I-protein 
alpha I-protein 
( O 
TNF B-protein 
- I-protein 
alpha I-protein 
) O 
of O 
human B-DNA 
interleukin I-DNA 
- I-DNA 
6 I-DNA 
( I-DNA 
IL I-DNA 
- I-DNA 
6 I-DNA 
) I-DNA 
gene I-DNA 
in O 
THP B-cell_type 
- I-cell_type 
1 I-cell_type 
monocytic I-cell_type 
cells I-cell_type 
, O 
and O 
compared O 
it O 
with O 
the O 
basis O 
of O 
this O 
induction O 
by O 
lipopolysaccharide O 
( O 
LPS O 
) O 
. O 

Functional O 
studies O 
with O 
IL B-DNA 
- I-DNA 
6 I-DNA 
promoter I-DNA 
demonstrated O 
that O 
three O 
regions O 
are O 
the O 
targets O 
of O 
the O 
IFN B-protein 
- I-protein 
gamma I-protein 
and O 
/ O 
or O 
TNF B-protein 
- I-protein 
alpha I-protein 
action O 
, O 
whereas O 
only O 
one O 
of O 
these O 
regions O 
seemed O 
to O 
be O 
implicated O 
in O 
LPS O 
activation O 
. O 

The O 
three O 
regions O 
concerned O 
are O 
: O 
1 O 
) O 
a O 
region O 
between O 
- O 
73 O 
and O 
- O 
36 O 
, O 
which O 
is O 
the O 
minimal B-DNA 
element I-DNA 
inducible O 
by O 
LPS O 
or O 
TNF B-protein 
- I-protein 
alpha I-protein 
; O 
2 O 
) O 
an O 
element O 
located O 
between O 
- O 
181 O 
and O 
- O 
73 O 
, O 
which O 
appeared O 
to O 
regulate O 
the O 
response O 
to O 
IFN B-protein 
- I-protein 
gamma I-protein 
and O 
TNF B-protein 
- I-protein 
alpha I-protein 
negatively O 
; O 
and O 
3 O 
) O 
a O 
distal B-DNA 
element I-DNA 
upstream I-DNA 
of O 
- O 
224 O 
, O 
which O 
was O 
inducible O 
by O 
IFN B-protein 
- I-protein 
gamma I-protein 
alone O 
. O 

LPS O 
signaling O 
was O 
found O 
to O 
involve O 
NF B-protein 
kappa I-protein 
B I-protein 
activation O 
by O 
the O 
p50 B-protein 
/ I-protein 
p65 I-protein 
heterodimers I-protein 
. O 

Synergistic O 
induction O 
of O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
6 I-protein I-DNA 
gene I-DNA 
by O 
IFN B-protein 
- I-protein 
gamma I-protein 
and O 
TNF B-protein 
- I-protein 
alpha I-protein 
, O 
in O 
monocytic B-cell_type 
cells I-cell_type 
, O 
involved O 
cooperation O 
between O 
the O 
IRF B-protein 
- I-protein 
1 I-protein 
and O 
NF B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
p65 B-protein I-protein 
homodimers I-protein 
with O 
concomitant O 
removal O 
of O 
the O 
negative O 
effect O 
of O 
the O 
retinoblastoma B-DNA 
control I-DNA 
element I-DNA 
present O 
in O 
the O 
IL B-DNA 
- I-DNA 
6 I-DNA 
promoter I-DNA 
. O 

This O 
removal O 
occurred O 
by O 
activation O 
of O 
the O 
constitutive B-protein 
Sp1 B-protein I-protein 
factor I-protein 
, O 
whose O 
increased O 
binding O 
activity O 
and O 
phosphorylation O 
were O 
mediated O 
by O 
IFN B-protein 
- I-protein 
gamma I-protein 
. O 

Mutation O 
of O 
Jak3 B-protein 
in O 
a O 
patient O 
with O 
SCID O 
: O 
essential O 
role O 
of O 
Jak3 B-protein 
in O 
lymphoid O 
development O 
. O 

Males O 
with O 
X O 
- O 
linked O 
severe O 
combined O 
immunodeficiency O 
( O 
XSCID O 
) O 
have O 
defects O 
in O 
the O 
common O 
cytokine B-protein B-DNA 
receptor I-protein I-DNA 
gamma I-protein I-DNA 
chain I-protein I-DNA 
( I-DNA 
gamma B-protein I-DNA 
c I-protein I-DNA 
) I-DNA 
gene I-DNA 
that O 
encodes O 
a O 
shared O 
, O 
essential O 
component O 
of O 
the O 
receptors O 
of O 
interleukin B-protein 
- I-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
, O 
IL B-protein 
- I-protein 
4 I-protein 
, O 
IL B-protein 
- I-protein 
7 I-protein 
, O 
IL B-protein 
- I-protein 
9 I-protein 
, O 
and O 
IL B-protein 
- I-protein 
15 I-protein 
. O 

The O 
Janus B-protein 
family I-protein 
tyrosine I-protein 
kinase I-protein 
Jak3 B-protein 
is O 
the O 
only O 
signaling O 
molecule O 
known O 
to O 
be O 
associated O 
with O 
gamma B-protein 
c I-protein 
, O 
so O 
it O 
was O 
hypothesized O 
that O 
defects O 
in O 
Jak3 B-protein 
might O 
cause O 
an O 
XSCID O 
- O 
like O 
phenotype O 
. O 

A O 
girl O 
with O 
immunological O 
features O 
indistinguishable O 
from O 
those O 
of O 
XSCID O 
was O 
therefore O 
selected O 
for O 
analysis O 
. O 

An O 
Epstein B-cell_line 
- I-cell_line 
Barr I-cell_line 
virus I-cell_line 
( I-cell_line 
EBV I-cell_line 
) I-cell_line 
- I-cell_line 
transformed I-cell_line 
cell I-cell_line 
line I-cell_line 
derived O 
from O 
her O 
lymphocytes B-cell_type 
had O 
normal O 
gamma B-protein 
c I-protein 
expression O 
but O 
lacked O 
Jak3 B-protein B-protein 
protein I-protein 
and O 
had O 
greatly O 
diminished O 
Jak3 B-protein B-RNA 
messenger I-RNA 
RNA I-RNA 
. O 

Sequencing O 
revealed O 
a O 
different O 
mutation O 
on O 
each O 
allele O 
: O 
a O 
single O 
nucleotide O 
insertion O 
resulting O 
in O 
a O 
frame O 
shift O 
and O 
premature O 
termination O 
in O 
the O 
Jak3 B-protein B-protein 
JH4 I-protein 
domain I-protein 
and O 
a O 
nonsense O 
mutation O 
in O 
the O 
Jak3 B-protein 
JH2 O 
domain O 
. O 

The O 
lack O 
of O 
Jak3 B-protein 
expression O 
correlated O 
with O 
impaired O 
B O 
cell O 
signaling O 
, O 
as O 
demonstrated O 
by O 
the O 
inability O 
of O 
IL B-protein 
- I-protein 
4 I-protein 
to O 
activate O 
Stat6 B-protein 
in O 
the O 
EBV B-cell_line 
- I-cell_line 
transformed I-cell_line 
cell I-cell_line 
line I-cell_line 
from O 
the O 
patient O 
. O 
These O 
observations O 
indicate O 
that O 
the O 
functions O 
of O 
gamma B-protein 
c I-protein 
are O 
dependent O 
on O 
Jak3 B-protein 
and O 
that O 
Jak3 B-protein 
is O 
essential O 
for O 
lymphoid O 
development O 
and O 
signaling O 
. O 

Constitutive O 
overexpression O 
of O 
the O 
L B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
gene I-DNA 
in O 
fresh O 
leukemic B-cell_type 
cells I-cell_type 
of O 
adult O 
T O 
- O 
cell O 
leukemia O 
that O 
can O 
be O 
transactivated O 
by O 
human B-protein 
T I-protein 
- I-protein 
cell I-protein 
lymphotropic I-protein 
virus I-protein 
type I-protein 
1 I-protein 
Tax I-protein 
. O 

L B-protein 
- I-protein 
selectin I-protein 
is O 
an O 
adhesion O 
molecule O 
of O 
the O 
selectin O 
family O 
that O 
mediates O 
the O 
initial O 
step O 
of O 
leukocyte O 
adhesion O 
to O 
vascular O 
endothelium O 
. O 

Upon O 
cellular O 
activation O 
, O 
expression O 
of O 
the O 
L B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
gene I-DNA 
is O 
downregulated O 
at O 
both O 
the O 
protein O 
and O 
mRNA O 
levels O 
. O 

To O 
understand O 
the O 
mechanism O 
of O 
leukemic B-cell_type 
cell I-cell_type 
infiltration O 
into O 
organs O 
, O 
we O 
studied O 
the O 
expression O 
and O 
regulation O 
of O 
L B-protein B-RNA 
- I-protein I-RNA 
selectin I-protein I-RNA 
mRNA I-RNA 
in O 
fresh O 
leukemic B-cell_type 
cells I-cell_type 
of O 
adult O 
T O 
- O 
cell O 
leukemia O 
( O 
ATL O 
) O 
patients O 
and O 
investigated O 
the O 
response O 
of O 
the O 
L B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
promoter I-DNA 
to O 
human B-protein 
T I-protein 
- I-protein 
cell I-protein 
lymphotropic I-protein 
virus I-protein 
type I-protein 
1 I-protein 
( I-protein 
HTLV I-protein 
- I-protein 
1 I-protein 
) I-protein 
Tax I-protein 
, O 
which O 
is O 
a O 
viral B-protein 
transcriptional I-protein 
transactivator I-protein 
. O 

Flow O 
cytometry O 
showed O 
that O 
L B-protein 
- I-protein 
selectin I-protein 
was O 
expressed O 
on O 
fresh O 
ATL B-cell_line 
cells I-cell_line 
along O 
with O 
other O 
activation B-protein 
antigens I-protein 
. O 

Northern O 
blot O 
analysis O 
showed O 
that O 
ATL B-cell_line 
cells I-cell_line 
overexpressed O 
that O 
L B-protein B-RNA 
- I-protein I-RNA 
selectin I-protein I-RNA 
mRNA I-RNA 
and O 
that O 
the O 
level O 
was O 
aberrantly O 
upregulated O 
after O 
PMA O 
stimulation O 
. O 

Studies O 
using O 
in O 
situ O 
hybridization O 
showed O 
expression O 
of O 
the O 
L B-protein B-RNA 
- I-protein I-RNA 
selectin I-protein I-RNA 
mRNA I-RNA 
in O 
the O 
infiltrating O 
leukemic B-cell_type 
cells I-cell_type 
in O 
the O 
liver O 
of O 
two O 
ATL O 
patients O 
. O 

Intravenous O 
injection O 
of O 
a O 
rat B-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
line I-cell_line 
that O 
overexpresses O 
L B-protein 
- I-protein 
selectin I-protein 
showed O 
increased O 
organ O 
infiltration O 
. O 

The O 
induction O 
of O 
Tax B-protein 
expression O 
in O 
JPX9 B-cell_line 
cells I-cell_line 
resulted O 
in O 
about O 
a O 
twofold O 
increase O 
in O 
the O 
mRNA B-RNA 
expression O 
levels O 
compared O 
with O 
the O 
basal O 
level O 
. O 

Chloramphenicol B-protein 
acetyltransferase I-protein 
( O 
CAT B-protein 
) O 
assay O 
after O 
transient O 
cotransfection O 
showed O 
about O 
a O 
fivefold O 
transactivation O 
of O 
the O 
L B-DNA 
- I-DNA 
selectin I-DNA 
promoter I-DNA 
by O 
Tax B-protein 
. O 

The O 
serum O 
level O 
of O 
the O 
shed O 
form O 
of O 
L B-protein 
- I-protein 
selectin I-protein 
was O 
significantly O 
increased O 
in O 
ATL O 
patients O 
( O 
mean O 
+ O 
/ O 
- O 
SD O 
, O 
4 O 
, O 
215 O 
. O 
4 O 
+ O 
/ O 
- O 
4 O 
, O 
111 O 
ng O 
/ O 
mL O 
) O 
compared O 
with O 
those O 
of O 
asymptomatic O 
carriers O 
and O 
healthy O 
blood O 
donors O 
( O 
mean O 
+ O 
/ O 
- O 
SD O 
, O 
1 O 
, O 
148 O 
. O 
0 O 
+ O 
/ O 
- O 
269 O 
. O 
0 O 
ng O 
/ O 
mL O 
and O 
991 O 
. O 
9 O 
+ O 
/ O 
- O 
224 O 
ng O 
/ O 
mL O 
, O 
respectively O 
) O 
. O 

These O 
results O 
indicated O 
that O 
ATL B-cell_line 
cells I-cell_line 
constitutively O 
overexpress O 
the O 
L B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
gene I-DNA 
that O 
can O 
be O 
transactivated O 
by O 
HTLV O 
- O 
1 O 
Tax B-protein 
. O 

The O 
overexpression O 
of O 
L B-protein 
- I-protein 
selectin I-protein 
, O 
as O 
well O 
as O 
of O 
inflammatory B-protein 
cytokines I-protein 
, O 
by O 
ATL B-cell_line 
cells I-cell_line 
may O 
provide O 
a O 
basis O 
for O 
ATL B-cell_line 
cells I-cell_line 
to O 
attach O 
the O 
vascular O 
endothelium O 
, O 
leading O 
to O 
transmigration O 
and O 
organ O 
infitration O 
. O 

Human O 
herpesvirus O 
6 O 
variant O 
A O 
, O 
but O 
not O 
variant O 
B O 
, O 
infects O 
EBV B-cell_line 
- I-cell_line 
positive I-cell_line 
B I-cell_line 
lymphoid I-cell_line 
cells I-cell_line 
, O 
activating O 
the O 
latent B-DNA 
EBV I-DNA 
genome I-DNA 
through O 
a O 
BZLF B-protein 
- I-protein 
1 I-protein 
- O 
dependent O 
mechanism O 
. O 

Human O 
herpesvirus O 
6 O 
, O 
a O 
predominantly O 
T O 
lymphotropic O 
virus O 
, O 
has O 
been O 
recently O 
shown O 
to O 
infect O 
some O 
EBV B-cell_line 
- I-cell_line 
positive I-cell_line 
B I-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
and O 
to O 
induce O 
in O 
them O 
the O 
activation O 
of O 
the O 
EBV O 
lytic O 
cycle O 
. O 

Here O 
we O 
have O 
confirmed O 
and O 
extended O 
such O 
observations O 
, O 
showing O 
that O 
( O 
1 O 
) O 
this O 
phenomenon O 
is O 
restricted O 
to O 
the O 
variant O 
A O 
of O 
HHV O 
- O 
6 O 
: O 
in O 
fact O 
two O 
isolates O 
belonging O 
to O 
the O 
HHV O 
- O 
6 O 
variant O 
B O 
( O 
BA92 O 
and O 
Z29 O 
) O 
were O 
neither O 
able O 
to O 
infect O 
any O 
B B-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
independently O 
of O 
the O 
EBV O 
status O 
, O 
nor O 
to O 
induce O 
the O 
EBV O 
genome O 
expression O 
. O 

The O 
only O 
exception O 
is O 
represented O 
by O 
the O 
P3HR1 B-cell_line 
cells I-cell_line 
, O 
in O 
which O 
, O 
however O 
, O 
the O 
infection O 
by O 
the O 
variant O 
B O 
does O 
not O 
determine O 
induction O 
of O 
EBV B-protein 
antigens I-protein 
; O 
( O 
2 O 
) O 
the O 
presence O 
of O 
the O 
EBV B-DNA 
genome I-DNA 
contributes O 
to O 
the O 
susceptibility O 
of O 
the O 
B B-cell_line 
cell I-cell_line 
lines I-cell_line 
to O 
HHV O 
- O 
6 O 
infection O 
, O 
increasing O 
the O 
binding O 
sites O 
and O 
the O 
percentage O 
of O 
infectable B-cell_type 
cells I-cell_type 
, O 
as O 
detected O 
by O 
immunoelectron O 
microscopy O 
; O 
and O 
( O 
3 O 
) O 
HHV B-cell_line 
- I-cell_line 
6 I-cell_line 
infected I-cell_line 
T I-cell_line 
cells I-cell_line 
, O 
transfected O 
with O 
plasmids B-DNA 
bearing O 
the O 
promoter B-DNA 
regions I-DNA 
of O 
the O 
EBV O 
early O 
genes O 
BZLF1 B-DNA 
and O 
BMRF1 B-DNA 
, O 
show O 
a O 
strong O 
transactivation O 
of O 
these O 
promoters B-DNA 
. O 

Evidence O 
for O 
normal O 
vitamin B-protein B-RNA 
D I-protein I-RNA 
receptor I-protein I-RNA 
messenger I-RNA 
ribonucleic I-RNA 
acid I-RNA 
and O 
genotype O 
in O 
absorptive O 
hypercalciuria O 
. O 

Absorptive O 
hypercalciuria O 
( O 
a O 
stone O 
- O 
forming O 
condition O 
) O 
is O 
characterized O 
by O 
gut O 
hyperabsorption O 
of O 
calcium O 
, O 
hypercalciuria O 
, O 
and O 
reduced O 
bone O 
density O 
. O 

Inasmuch O 
as O 
these O 
features O 
implicate O 
enhanced O 
calcitriol O 
action O 
in O 
gut O 
and O 
bone O 
, O 
we O 
analyzed O 
the O 
vitamin B-protein B-DNA 
D I-protein I-DNA 
receptor I-protein I-DNA 
( I-DNA 
VDR B-protein I-DNA 
) I-DNA 
gene I-DNA 
to O 
ascertain O 
whether O 
an O 
abnormality O 
of O 
this O 
gene O 
marks O 
patients O 
with O 
intestinal O 
hyperabsorption O 
of O 
calcium O 
. O 

We O 
have O 
compared O 
the O 
frequency O 
of O 
a O 
restriction B-DNA 
fragment I-DNA 
length I-DNA 
polymorphism I-DNA 
( O 
Bsm B-DNA 
I I-DNA 
) O 
associated O 
with O 
different O 
alleles O 
of O 
the O 
VDR B-protein B-DNA 
gene I-DNA 
in O 
a O 
group O 
of O 
33 O 
well O 
characterized O 
absorptive O 
hypercalciuric O 
patients O 
and O 
a O 
group O 
of O 
36 O 
normal O 
race O 
- O 
and O 
age O 
- O 
matched O 
control O 
subjects O 
. O 

There O 
was O 
no O 
difference O 
between O 
the O 
distribution O 
of O 
the O 
VDR B-protein 
alleles O 
in O 
the O 
patient O 
population O 
when O 
compared O 
with O 
the O 
normal O 
population O 
. O 

The O 
coding O 
region O 
of O 
VDR B-protein B-RNA 
messenger I-RNA 
RNA I-RNA 
was O 
also O 
normal O 
, O 
as O 
determined O 
by O 
both O 
DNA B-DNA 
sequence I-DNA 
analysis O 
and O 
chemical O 
mismatch O 
cleavage O 
analysis O 
of O 
copy O 
DNA O 
from O 
11 O 
index O 
absorptive O 
hypercalciuric O 
patients O 
. O 

On O 
the O 
basis O 
of O 
these O 
results O 
, O 
we O 
propose O 
that O 
the O 
enhanced O 
intestinal O 
calcium O 
absorption O 
invariably O 
seen O 
in O 
absorptive O 
hypercalciuria O 
and O 
attendant O 
symptoms O 
of O 
this O 
disorder O 
are O 
not O 
attributable O 
to O 
mutations O 
of O 
the O 
VDR B-protein 
and O 
are O 
not O 
linked O 
to O 
a O 
common O 
VDR B-protein B-DNA 
genotype I-DNA 
. O 

Transcriptional O 
regulation O 
of O 
the O 
gene O 
encoding O 
the O 
human B-protein 
C I-protein 
- I-protein 
type I-protein 
lectin I-protein 
leukocyte I-protein 
receptor I-protein 
AIM B-protein 
/ I-protein 
CD69 I-protein 
and O 
functional O 
characterization O 
of O 
its O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
- I-protein 
alpha I-protein 
- O 
responsive O 
elements B-DNA 
. O 

The O 
human B-protein 
activation I-protein 
antigen I-protein 
CD69 B-protein 
is O 
a O 
member O 
of O 
the O 
C B-protein 
- I-protein 
type I-protein 
animal I-protein 
lectin I-protein 
superfamily I-protein 
that O 
functions O 
as O 
a O 
signal B-protein 
- I-protein 
transmitting I-protein 
receptor I-protein 
. O 

Although O 
the O 
expression O 
of O 
CD69 B-protein 
can O 
be O 
induced O 
in O 
vitro O 
on O 
cells O 
of O 
most O 
hematopoietic O 
lineages O 
with O 
a O 
wide O 
variety O 
of O 
stimuli O 
, O 
in O 
vivo O 
it O 
is O 
mainly O 
expressed O 
by O 
T B-cell_type 
- I-cell_type 
lymphocytes B-cell_type I-cell_type 
located O 
in O 
the O 
inflammatory O 
infiltrates O 
of O 
several O 
human O 
diseases O 
. O 

To O 
elucidate O 
the O 
mechanisms O 
that O 
regulate O 
the O 
constitutive O 
and O 
inducible O 
expression O 
of O 
CD69 B-protein 
by O 
leukocytes B-cell_type 
, O 
we O 
isolated O 
the O 
promoter B-DNA 
region I-DNA 
of O 
the O 
CD69 B-protein 
gene O 
and O 
carried O 
out O 
its O 
functional O 
characterization O 
. O 

Sequence O 
analysis O 
of O 
the O 
5 B-DNA 
' I-DNA 
- I-DNA 
flanking I-DNA 
region I-DNA 
of O 
the O 
CD69 B-protein B-DNA 
gene I-DNA 
revealed O 
the O 
presence O 
of O 
a O 
potential O 
TATA B-DNA 
element I-DNA 
30 B-DNA 
base I-DNA 
pairs I-DNA 
upstream I-DNA 
of O 
the O 
major O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
and O 
several O 
putative O 
binding O 
sequences O 
for O 
inducible O 
transcription B-protein 
factors I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
Egr B-protein 
- I-protein 
1 I-protein 
, O 
AP B-protein 
- I-protein 
1 I-protein 
) O 
, O 
which O 
might O 
mediate O 
the O 
inducible O 
expression O 
of O 
this O 
gene O 
. O 

Transient O 
expression O 
of O 
CD69 B-protein B-DNA 
promoter I-DNA 
- I-DNA 
based I-DNA 
reporter I-DNA 
gene I-DNA 
constructs I-DNA 
in O 
K562 B-cell_line 
cells I-cell_line 
indicated O 
that O 
the O 
proximal B-DNA 
promoter B-DNA I-DNA 
region I-DNA I-DNA 
spanning O 
positions O 
- O 
78 O 
to O 
+ O 
16 O 
contained O 
the O 
cis B-DNA 
- I-DNA 
acting I-DNA 
sequences I-DNA 
necessary O 
for O 
basal O 
and O 
phorbol O 
12 O 
- O 
myristate O 
13 O 
- O 
acetate O 
- O 
inducible O 
transcription O 
of O 
the O 
CD69 B-protein B-DNA 
gene I-DNA 
. O 

Removal O 
of O 
the O 
upstream O 
sequences O 
located O 
between O 
positions O 
- O 
78 O 
and O 
- O 
38 O 
resulted O 
in O 
decreased O 
promoter O 
strength O 
and O 
abolished O 
the O 
response O 
to O 
phorbol O 
12 O 
- O 
myristate O 
13 O 
- O 
acetate O 
. O 

We O 
also O 
found O 
that O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
- I-protein 
alpha I-protein 
( O 
TNF B-protein 
- I-protein 
alpha I-protein 
) O 
is O 
capable O 
of O 
inducing O 
the O 
surface O 
expression O 
of O 
the O 
CD69 B-protein 
molecule O 
as O 
well O 
as O 
the O 
promoter O 
activity O 
of O 
fusion O 
plasmids O 
that O 
contain O 
5 O 
' O 
- O 
flanking O 
sequences O 
of O 
the O 
CD69 B-protein 
gene O 
, O 
suggesting O 
that O 
this O 
cytokine O 
may O 
regulate O 
in O 
vivo O 
the O 
expression O 
of O 
CD69 B-protein 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
250 O 
WORDS O 
) O 
. O 

Characterization O 
of O 
5 B-DNA 
' I-DNA 
end I-DNA 
of I-DNA 
human B-DNA I-DNA 
thromboxane I-DNA I-DNA 
receptor I-DNA I-DNA 
gene I-DNA I-DNA 
. O 

Organizational O 
analysis O 
and O 
mapping O 
of O 
protein B-DNA 
kinase I-DNA 
C I-DNA 
- I-DNA 
- I-DNA 
responsive I-DNA 
elements B-DNA I-DNA 
regulating O 
expression O 
in O 
platelets B-cell_type 
. O 

Platelet B-cell_type B-protein 
thromboxane I-protein 
receptors I-protein 
are O 
acutely O 
and O 
reversibly O 
upregulated O 
after O 
acute O 
myocardial O 
infarction O 
. O 

To O 
determine O 
if O 
platelet O 
thromboxane B-protein 
receptors I-protein 
are O 
under O 
transcriptional O 
control O 
, O 
we O 
isolated O 
and O 
characterized O 
human B-DNA 
genomic I-DNA 
DNA I-DNA 
clones I-DNA 
containing O 
the O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
region I-DNA 
of O 
the O 
thromboxane B-DNA 
receptor I-DNA 
gene I-DNA 
. O 

The O 
exon B-DNA 
- I-DNA 
intron I-DNA 
structure I-DNA 
of O 
the O 
5 B-DNA 
' I-DNA 
portion I-DNA 
of O 
the O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
was O 
determined O 
initially O 
by O 
comparing O 
the O 
nucleotide B-DNA 
sequence I-DNA 
of O 
the O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
genomic I-DNA 
clone I-DNA 
with O 
that O 
of O 
a O 
novel B-DNA 
human I-DNA 
uterine I-DNA 
thromboxane B-protein I-DNA 
receptor I-protein I-DNA 
cDNA I-DNA 
that O 
extended O 
the O 
mRNA B-RNA 
141 B-DNA 
bp I-DNA 
further I-DNA 
upstream I-DNA 
than O 
the O 
previously B-DNA 
identified I-DNA 
human I-DNA 
placental I-DNA 
cDNA I-DNA 
. O 

A O 
major O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
was O 
located O 
in O 
three O 
human O 
tissues O 
approximately O 
560 B-DNA 
bp I-DNA 
upstream I-DNA 
from O 
the O 
translation B-DNA 
initiation I-DNA 
codon I-DNA 
and O 
380 B-DNA 
bp I-DNA 
upstream I-DNA 
from O 
any O 
previously O 
identified O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
. O 

The O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
has O 
neither O 
a O 
TATA B-DNA 
nor O 
a O 
CAAT B-DNA 
consensus I-DNA 
site I-DNA 
. O 

Promoter O 
function O 
of O 
the O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
region I-DNA 
of O 
the O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
was O 
evaluated O 
by O 
transfection O 
of O 
thromboxane B-protein B-DNA B-DNA 
receptor I-protein I-DNA I-DNA 
gene I-DNA I-DNA 
promoter I-DNA 
/ I-DNA 
chloramphenicol B-protein I-DNA 
acetyltransferase I-protein I-DNA 
( I-DNA 
CAT B-protein I-DNA 
) I-DNA 
chimera I-DNA 
plasmids I-DNA 
into O 
platelet O 
- O 
like O 
K562 B-cell_line 
cells I-cell_line 
. O 

Thromboxane O 
receptor B-DNA 
promoter I-DNA 
activity O 
, O 
as O 
assessed O 
by O 
CAT B-protein 
expression O 
, O 
was O 
relatively O 
weak O 
but O 
was O 
significantly O 
enhanced O 
by O 
phorbol O 
ester O 
treatment O 
. O 

Functional O 
analysis O 
of O 
5 B-DNA 
' I-DNA 
deletion I-DNA 
constructs I-DNA 
in O 
transfected O 
K562 B-cell_line 
cells I-cell_line 
and O 
gel O 
mobility O 
shift O 
localized O 
the O 
major O 
phorbol O 
ester O 
- O 
responsive O 
motifs O 
in O 
the O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
promoter O 
to O 
a O 
cluster O 
of O 
activator B-protein B-DNA 
protein I-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
( I-DNA 
AP B-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
) I-DNA 
binding I-DNA 
consensus I-DNA 
sites I-DNA 
located O 
approximately O 
1 O 
. O 
8 O 
kb O 
5 O 
' O 
from O 
the O 
transcription B-DNA 
initiation I-DNA 
site I-DNA 
. O 

These O 
studies O 
are O 
the O 
first O 
to O 
determine O 
the O 
structure O 
and O 
organization O 
of O 
the O 
5 O 
' O 
end O 
of O 
the O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
and O 
demonstrate O 
that O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
expression O 
can O 
be O 
regulated O 
by O 
activation O 
of O 
protein B-protein 
kinase I-protein 
C I-protein 
via O 
induction O 
of O 
an O 
AP B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
- I-protein 
like I-protein 
nuclear I-protein 
factor I-protein 
binding O 
to O 
upstream B-DNA 
promoter I-DNA 
elements I-DNA 
. O 

These O 
findings O 
strongly O 
suggest O 
that O 
the O 
mechanism O 
for O 
previously O 
described O 
upregulation O 
of O 
platelet B-protein 
thromboxane I-protein 
receptors I-protein 
after O 
acute O 
myocardial O 
infarction O 
is O 
increased O 
thromboxane B-protein B-DNA 
receptor I-protein I-DNA 
gene I-DNA 
transcription O 
in O 
platelet B-cell_type 
- I-cell_type 
progenitor I-cell_type 
cells I-cell_type 
. O 

Estrogen B-protein 
receptor I-protein 
concentration O 
and O 
social O 
factors O 
as O 
predictors O 
of O 
natural O 
killer O 
cell O 
activity O 
in O 
early O 
- O 
stage O 
breast O 
cancer O 
patients O 
. O 

Confirmation O 
of O 
a O 
model O 
. O 

Previous O 
work O 
of O 
ours O 
has O 
demonstrated O 
that O 
a O 
significant O 
amount O 
of O 
natural O 
killer O 
( O 
NK O 
) O 
activity O 
variance O 
after O 
surgery O 
in O 
stage O 
I O 
and O 
II O 
breast O 
cancer O 
patients O 
could O 
be O 
accounted O 
for O 
by O 
both O 
the O 
estrogen B-protein 
receptor I-protein 
( O 
ER B-protein 
) O 
status O 
of O 
the O 
tumor O 
and O 
by O 
social O 
factors O 
, O 
namely O 
, O 
perceived O 
social O 
support O 
and O 
seeking O 
social O 
support O 
as O 
a O 
general O 
coping O 
strategy O 
. O 

As O 
considerable O 
evidence O 
has O 
accumulated O 
that O 
social O 
support O 
in O 
both O 
animal O 
and O 
human O 
populations O 
may O 
have O 
survival O 
value O 
, O 
we O 
sought O 
to O 
test O 
the O 
reliability O 
of O 
this O 
regression O 
model O 
, O 
using O 
coping O 
and O 
perceived O 
support O 
factor O 
values O 
obtained O 
at O 
3 O 
months O 
after O 
surgery O 
to O 
account O 
for O 
concurrent O 
follow O 
- O 
up O 
NK O 
activity O 
in O 
this O 
serially O 
assessed O 
group O 
of O 
patients O 
. O 

It O 
was O 
found O 
that O 
the O 
most O 
significant O 
variable O 
predicting O 
NK O 
activity O 
at O 
follow O 
- O 
up O 
was O 
tumor O 
ER B-protein 
concentration O 
, O 
with O 
higher O 
NK O 
activity O 
associated O 
with O 
ER B-protein 
- O 
status O 
. O 

In O 
addition O 
, O 
seeking O 
social O 
support O 
as O 
a O 
coping O 
strategy O 
, O 
as O 
well O 
as O 
the O 
perceived O 
quality O 
of O 
support O 
, O 
also O 
entered O 
the O 
model O 
to O 
account O 
for O 
a O 
significant O 
amount O 
of O 
NK O 
activity O 
variance O 
( O 
multivariate O 
F O 
= O 
5 O 
. O 
25 O 
, O 
p O 
less O 
than O 
0 O 
. O 
001 O 
) O 
. O 

If O 
, O 
as O 
the O 
literature O 
suggests O 
, O 
NK O 
activity O 
is O 
relevant O 
to O 
breast O 
cancer O 
control O 
, O 
and O 
since O 
ER B-protein 
- O 
tumors O 
have O 
a O 
worse O 
prognosis O 
, O 
we O 
suggest O 
here O 
that O 
perhaps O 
such O 
tumors O 
are O 
resistant O 
to O 
control O 
by O 
NK B-cell_type 
cells I-cell_type 
because O 
they O 
lack O 
the O 
ability O 
to O 
attract O 
an O 
accumulation O 
of O 
effector B-cell_type 
cells I-cell_type 
to O 
the O 
tumor O 
site O 
, O 
or O 
because O 
blocking O 
factors O 
at O 
the O 
site O 
of O 
the O 
tumor O 
prevent O 
local O 
tumor O 
control O 
at O 
the O 
site O 
of O 
action O 
. O 

The O 
finding O 
related O 
to O 
social O 
support O 
also O 
replicates O 
results O 
from O 
an O 
independent O 
sample O 
of O 
breast O 
cancer O 
patients O 
. O 

This O 
finding O 
, O 
taken O 
together O 
with O 
other O 
evidence O 
that O 
this O 
social O 
variable O 
is O 
associated O 
with O 
longer O 
survival O 
in O 
breast O 
cancer O 
populations O 
, O 
underscores O 
the O 
potential O 
importance O 
of O 
this O 
social O 
support O 
variable O 
. O 

Our O 
findings O 
also O 
suggest O 
one O 
possible O 
immunological O 
variable O 
involved O 
, O 
with O 
potential O 
clinical O 
significance O 
, O 
for O 
this O 
patient O 
population O 
. O 

Solution O 
structure O 
of O 
the O 
sequence B-DNA 
- I-DNA 
specific I-DNA 
HMG I-DNA 
box I-DNA 
of O 
the O 
lymphocyte B-protein 
transcriptional I-protein 
activator I-protein 
Sox B-protein 
- I-protein 
4 I-protein 
. O 

Two O 
groups O 
of O 
HMG B-protein 
box I-protein 
proteins I-protein 
are O 
distinguished O 
. O 

Proteins O 
in O 
the O 
first O 
group O 
contain O 
multiple O 
HMG B-protein 
boxes I-protein 
, O 
are O 
non O 
- O 
sequence O 
- O 
specific O 
, O 
and O 
recognize O 
structural O 
features O 
as O 
found O 
in O 
cruciform B-DNA 
DNA I-DNA 
and O 
cross B-DNA 
- I-DNA 
over I-DNA 
DNA I-DNA 
. O 

The O 
abundant O 
chromosomal B-protein 
protein I-protein 
HMG B-protein 
- I-protein 
1 I-protein 
belongs O 
to O 
this O 
subgroup O 
. O 

Proteins O 
in O 
the O 
second O 
group O 
carry O 
a O 
single B-protein 
HMG I-protein 
box I-protein 
with O 
affinity O 
for O 
the O 
minor B-DNA 
groove I-DNA 
of O 
the O 
heptamer B-DNA 
motif I-DNA 
AACAAAG O 
or O 
variations O 
thereof O 
. O 

A O 
solution O 
structure O 
for O 
the O 
non O 
- O 
sequence O 
- O 
specific O 
C B-protein 
- I-protein 
terminal I-protein 
HMG I-protein 
box I-protein 
of O 
HMG B-protein 
- I-protein 
1 I-protein 
has O 
recently O 
been O 
proposed O 
. O 

Now O 
, O 
we O 
report O 
the O 
solution O 
structure O 
of O 
the O 
sequence B-protein 
- I-protein 
specific I-protein 
HMG I-protein 
- I-protein 
box I-protein 
of O 
the O 
SRY B-protein 
- I-protein 
related I-protein 
protein I-protein 
Sox B-protein 
- I-protein 
4 I-protein 
. O 

NMR O 
analysis O 
demonstrated O 
the O 
presence O 
of O 
three O 
alpha B-protein 
- I-protein 
helices I-protein 
( O 
Val10 B-protein 
- I-protein 
Gln22 I-protein 
, O 
Glu30 B-protein 
- I-protein 
Leu41 I-protein 
and O 
Phe50 B-protein 
- I-protein 
Tyr65 I-protein 
) O 
connected O 
by O 
loop B-protein 
regions I-protein 
( O 
Ser23 B-protein 
- I-protein 
Ala49 I-protein 
and O 
Leu42 B-protein 
- I-protein 
Pro49 I-protein 
) O 
. O 

Helices O 
I O 
and O 
II O 
are O 
positioned O 
in O 
an O 
antiparallel B-protein 
mode I-protein 
and O 
form O 
one O 
arm O 
of O 
the O 
HMG B-protein 
box I-protein 
. O 

Helix B-protein 
III I-protein 
is O 
less O 
rigid O 
, O 
makes O 
an O 
average O 
angle O 
of O 
about O 
90 O 
degrees O 
with O 
helices O 
I O 
and O 
II O 
, O 
and O 
constitutes O 
the O 
other O 
arm O 
of O 
the O 
molecule O 
. O 

As O 
in O 
HMG1B B-protein 
, O 
the O 
overall O 
structure O 
of O 
the O 
Sox B-protein 
- I-protein 
4 I-protein 
HMG B-protein 
box I-protein 
is O 
L O 
- O 
shaped O 
and O 
is O 
maintained O 
by O 
a O 
cluster O 
of O 
conserved O 
, O 
mainly O 
aromatic O 
residues O 
. O 

Nuclear B-protein 
factor I-protein 
- I-protein 
IL6 I-protein 
activates O 
the O 
human B-DNA 
IL I-DNA 
- I-DNA 
4 I-DNA 
promoter I-DNA 
in O 
T B-cell_type 
cells I-cell_type 
. O 

Positive B-DNA 
regulatory I-DNA 
element I-DNA 
I I-DNA 
( O 
PRE B-DNA 
- I-DNA 
I I-DNA 
) O 
is O 
a O 
strong O 
enhancer B-DNA 
element I-DNA 
essential O 
for O 
expression O 
of O 
the O 
human B-DNA 
IL I-DNA 
- I-DNA 
4 I-DNA 
gene I-DNA 
. O 

To O 
identify O 
transcription B-protein 
factors I-protein 
binding O 
to O 
PRE B-DNA 
- I-DNA 
I I-DNA 
, O 
we O 
screened O 
a O 
cDNA B-DNA 
expression I-DNA 
library I-DNA 
from O 
Jurkat B-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
and O 
isolated O 
a O 
cDNA B-DNA 
encoding O 
nuclear B-protein 
factor I-protein 
( B-protein 
NF I-protein 
) I-protein 
- I-protein 
IL6 I-protein 
( O 
also O 
known O 
as O 
C B-protein 
/ I-protein 
EBP I-protein 
beta I-protein 
) O 
. O 

NF B-RNA 
- I-RNA 
IL6 I-RNA 
mRNA I-RNA 
was O 
found O 
in O 
human B-cell_line 
Jurkat I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
and O 
in O 
the O 
mouse B-cell_line 
Th2 I-cell_line 
clone I-cell_line 
D10 B-cell_line 
, O 
but O 
not O 
in O 
Th1 B-cell_line 
clone I-cell_line 
29 I-cell_line 
. O 

rNF B-protein 
- I-protein 
IL6 I-protein 
expressed O 
in O 
bacteria O 
was O 
shown O 
to O 
specifically O 
bind O 
to O 
PRE B-DNA 
- I-DNA 
I I-DNA 
. O 

PRE B-DNA 
- I-DNA 
I I-DNA 
forms O 
multiple B-protein 
DNA I-protein 
- I-protein 
protein I-protein 
complexes I-protein 
with O 
nuclear O 
extracts O 
from O 
Jurkat B-cell_line 
cells I-cell_line 
. O 

Some O 
of O 
these O 
complexes O 
were O 
demonstrated O 
to O 
contain O 
NF B-protein 
- I-protein 
IL6 I-protein 
by O 
using O 
anti B-protein 
- I-protein 
C B-protein I-protein 
/ I-protein I-protein 
EBP I-protein I-protein 
beta I-protein I-protein 
Abs I-protein 
. O 

Overexpression O 
of O 
NF B-protein 
- I-protein 
IL6 I-protein 
enhanced O 
expression O 
of O 
the O 
chloramphenicol B-protein B-DNA 
acetyl I-protein I-DNA 
transferase I-protein I-DNA 
reporter I-DNA 
gene I-DNA 
linked O 
to O 
the O 
PRE B-DNA B-protein 
- I-DNA I-protein 
I I-DNA I-protein 
- I-protein 
thymidine I-protein 
kinase I-protein 
or O 
the O 
human B-protein B-DNA 
IL I-protein I-DNA 
- I-protein I-DNA 
4 I-protein I-DNA 
promoter I-DNA 
more O 
than O 
10 O 
- O 
fold O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
. O 

Promoter O 
deletion O 
studies O 
revealed O 
two O 
additional O 
NF B-protein B-DNA 
- I-protein I-DNA 
IL6 I-protein I-DNA 
binding I-DNA 
sites I-DNA 
located O 
at O 
positions O 
- O 
44 O 
to O 
- O 
36 O 
( O 
C B-protein 
/ I-protein 
EBP I-protein 
proximal I-protein 
) O 
and O 
- O 
87 O 
to O 
- O 
79 O 
( O 
C B-protein 
/ I-protein 
EBP I-protein 
medial I-protein 
) O 
, O 
respectively O 
. O 

Our O 
results O 
demonstrate O 
that O 
NF B-protein 
- I-protein 
IL6 I-protein 
is O 
involved O 
in O 
transcriptional O 
activation O 
of O 
the O 
human B-protein B-DNA 
IL I-protein I-DNA 
- I-protein I-DNA 
4 I-protein I-DNA 
promoter I-DNA 
in O 
T B-cell_type 
cells I-cell_type 
. O 

Identification O 
of O 
an O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
- I-protein 
associated I-protein 
protein I-protein 
kinase I-protein 
in O 
a O 
human B-cell_line 
monocytic I-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
determination O 
of O 
its O 
phosphorylation B-protein 
sites I-protein 
on O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
. O 

Nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
) O 
is O 
stored O 
in O 
the O 
cytoplasm O 
as O 
an O 
inactive O 
form O 
through O 
interaction O 
with O 
I B-protein 
kappa I-protein 
B I-protein 
. O 

Stimulation O 
of O 
cells O 
leads O 
to O 
a O 
rapid O 
phosphorylation O 
of O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
, O 
which O 
is O 
presumed O 
to O 
be O 
important O 
for O 
the O 
subsequent O 
degradation O 
. O 

We O 
have O 
recently O 
reported O 
the O 
establishment O 
of O 
a O 
lipopolysaccharide O 
( O 
LPS O 
) O 
- O 
dependent O 
cell O 
- O 
free O 
activation O 
system O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
association O 
with O 
the O 
induction O 
of O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
phosphorylation O 
. O 

In O 
this O 
study O 
, O 
we O 
have O 
identified O 
a O 
kinase B-protein 
in O 
cell O 
extracts O 
from O 
the O 
LPS B-cell_line 
- I-cell_line 
stimulated I-cell_line 
human I-cell_line 
monocytic I-cell_line 
cell I-cell_line 
line I-cell_line 
, O 
THP B-cell_line 
- I-cell_line 
1 I-cell_line 
, O 
that O 
specifically O 
binds O 
and O 
phosphorylates O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
. O 

LPS O 
stimulation O 
transiently O 
enhanced O 
the O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
- B-protein 
bound I-protein 
kinase I-protein 
activity O 
in O 
THP B-cell_line 
- I-cell_line 
1 I-cell_line 
cells I-cell_line 
. O 

Mutational O 
analyses O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha O 
and O 
competition O 
experiments O 
with O 
the O 
synthetic O 
peptides O 
identified O 
major O 
phosphorylation B-protein 
sites I-protein 
by O 
the O 
bound O 
kinase B-protein 
as O 
Ser O 
and O 
Thr O 
residues O 
in O 
the O 
C B-protein 
- I-protein 
terminal I-protein 
acidic I-protein 
domain I-protein 
of O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
. O 

Moreover O 
, O 
we O 
show O 
that O 
the O 
peptide O 
, O 
corresponding O 
to O 
the O 
C B-protein 
- I-protein 
terminal I-protein 
acidic I-protein 
domain I-protein 
of O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
, O 
blocked O 
the O 
LPS O 
- O 
induced O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
as O 
well O 
as O 
inducible O 
phosphorylation O 
of O 
endogenous O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
in O 
a O 
cell O 
- O 
free O 
system O 
using O 
THP B-cell_line 
- I-cell_line 
1 I-cell_line 
cells I-cell_line 
. O 

These O 
results O 
suggested O 
that O 
the O 
bound B-protein 
kinase I-protein 
is O 
involved O 
in O 
the O 
signaling O 
pathway O 
of O 
LPS O 
by O 
inducing O 
the O 
phosphorylation O 
of O 
the O 
C B-protein 
- I-protein 
terminal I-protein 
region I-protein 
of O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein 
and O 
subsequent O 
dissociation O 
of O 
the O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 
I B-protein B-protein 
kappa I-protein I-protein 
B I-protein I-protein 
alpha I-protein I-protein 
complex I-protein 
. O 

Bik B-protein 
, O 
a O 
novel O 
death B-protein 
- I-protein 
inducing I-protein 
protein I-protein 
shares O 
a O 
distinct O 
sequence O 
motif O 
with O 
Bcl B-protein 
- I-protein 
2 I-protein 
family I-protein 
proteins I-protein 
and O 
interacts O 
with O 
viral O 
and O 
cellular B-protein 
survival I-protein 
- I-protein 
promoting I-protein 
proteins I-protein 
. O 

The O 
survival O 
- O 
promoting O 
activity O 
of O 
the O 
Bcl B-protein 
- I-protein 
2 I-protein 
family I-protein 
of O 
proteins O 
appears O 
to O 
be O 
modulated O 
by O 
interactions O 
between O 
various O 
cellular B-protein 
proteins I-protein 
. O 

We O 
have O 
identified O 
a O 
novel O 
cellular B-protein 
protein I-protein 
, O 
Bik B-protein 
, O 
that O 
interacts O 
with O 
the O 
cellular B-protein 
survival I-protein 
- I-protein 
promoting I-protein 
proteins I-protein 
, O 
Bcl B-protein 
- I-protein 
2 I-protein 
and O 
Bcl B-protein 
- I-protein 
xL I-protein 
, O 
as O 
well O 
as O 
the O 
viral B-protein 
survival I-protein 
- I-protein 
promoting I-protein 
proteins I-protein 
, O 
Epstein B-protein 
Barr I-protein 
virus I-protein 
- I-protein 
BHRF1 I-protein 
and O 
adenovirus B-protein 
E1B I-protein 
- I-protein 
19 I-protein 
kDa I-protein 
. O 

In O 
transient O 
transfection O 
assays O 
, O 
Bik B-protein 
promotes O 
cell O 
death O 
in O 
a O 
manner O 
similar O 
to O 
the O 
death B-protein 
- I-protein 
promoting I-protein 
members I-protein 
of O 
the O 
Bcl B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
family I-protein 
, O 
Bax B-protein 
and O 
Bak B-protein 
. O 

This O 
death O 
- O 
promoting O 
activity O 
of O 
Bik B-protein 
can O 
be O 
suppressed O 
by O 
coexpression O 
of O 
Bcl B-protein 
- I-protein 
2 I-protein 
, O 
Bcl B-protein 
- I-protein 
XL I-protein 
, O 
EBV B-protein 
- I-protein 
BHRF1 I-protein 
and O 
E1B B-protein 
- I-protein 
19 I-protein 
kDa I-protein 
proteins O 
suggesting O 
that O 
Bik B-protein 
may O 
be O 
a O 
common O 
target O 
for O 
both O 
cellular O 
and O 
viral O 
anti O 
- O 
apoptotic O 
proteins O 
. O 

While O 
Bik B-protein 
does O 
not O 
show O 
overt O 
homology O 
to O 
the O 
BH1 B-protein 
and O 
BH2 B-protein 
conserved O 
domains O 
characteristic O 
of O 
the O 
Bcl B-protein 
- I-protein 
2 I-protein 
family I-protein 
, O 
it O 
does O 
share O 
a O 
9 O 
amino B-protein 
acid I-protein 
domain I-protein 
( O 
BH3 B-protein 
) O 
with O 
Bax B-protein 
and O 
Bak B-protein 
which O 
may O 
be O 
a O 
critical O 
determinant O 
for O 
the O 
death O 
- O 
promoting O 
activity O 
of O 
these O 
proteins O 
. O 

The O 
human B-DNA 
TCF I-DNA 
- I-DNA 
1 I-DNA 
gene I-DNA 
encodes O 
a O 
nuclear B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
protein I-protein 
uniquely O 
expressed O 
in O 
normal O 
and O 
neoplastic O 
T O 
- O 
lineage O 
lymphocytes O 
. O 

The O 
TCF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
gene I-DNA 
encodes O 
a O 
putative B-protein 
transcription I-protein 
factor I-protein 
with O 
affinity O 
for O 
a O 
sequence B-DNA 
motif I-DNA 
occurring O 
in O 
a O 
number O 
of O 
T B-DNA 
- I-DNA 
cell I-DNA 
enhancers I-DNA 
. O 

TCF B-protein B-RNA 
- I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
was O 
originally O 
found O 
to O 
be O 
expressed O 
in O 
a O 
T O 
cell O 
- O 
specific O 
fashion O 
within O 
a O 
set O 
of O 
human B-cell_line 
and O 
mouse B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

In O 
contrast O 
, O 
expression O 
reportedly O 
occurs O 
in O 
multiple O 
nonlymphoid O 
tissues O 
during O 
murine O 
embryogenesis O 
. O 

We O 
have O 
now O 
raised O 
a O 
monoclonal B-protein 
antibody I-protein 
to O 
document O 
expression O 
and O 
biochemistry O 
of O 
the O 
human B-protein 
TCF B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
. O 

As O 
expected O 
, O 
the O 
TCF B-protein 
- I-protein 
1 I-protein 
protein I-protein 
was O 
detectable O 
only O 
in O 
cell B-cell_line 
lines I-cell_line 
of I-cell_line 
T I-cell_line 
lineage I-cell_line 
. O 

Its O 
expression O 
was O 
always O 
restricted O 
to O 
the O 
nucleus O 
. O 

Immunohistochemistry O 
on O 
a O 
panel O 
of O 
human O 
tissues O 
revealed O 
that O 
the O 
TCF B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
was O 
found O 
exclusively O 
in O 
thymocytes O 
and O 
in O 
CD3 B-cell_line 
+ I-cell_line 
T B-cell_type I-cell_line 
cells I-cell_type I-cell_line 
in O 
peripheral O 
lymphoid O 
tissues O 
. O 

Western O 
blotting O 
yielded O 
a O 
set O 
of O 
bands O 
ranging O 
from O 
25 O 
kD O 
to O 
55 O 
kD O 
, O 
resulting O 
from O 
extensive O 
alternative O 
splicing O 
. O 

The O 
TCF B-protein 
- I-protein 
1 I-protein 
protein O 
was O 
detectable O 
in O 
all O 
samples O 
of O 
a O 
set O 
of O 
22 O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
malignancies I-cell_type 
of O 
various O 
stages O 
of O 
maturation O 
, O 
but O 
was O 
absent O 
from O 
a O 
large O 
number O 
of O 
other O 
hematologic B-cell_type 
neoplasms I-cell_type 
. O 

These O 
observations O 
imply O 
a O 
T O 
cell O 
- O 
specific O 
function O 
for O 
TCF B-protein 
- I-protein 
1 I-protein 
, O 
a O 
notion O 
corroborated O 
by O 
recent O 
observations O 
on O 
Tcf O 
- O 
1 O 
knock O 
- O 
out O 
mice O 
. O 

In O 
addition O 
, O 
these O 
results O 
indicate O 
that O 
nuclear O 
TCF B-protein 
- I-protein 
1 I-protein 
expression O 
can O 
serve O 
as O 
a O 
pan O 
- O 
T O 
- O 
lineage O 
marker O 
in O 
the O 
diagnosis O 
of O 
lymphoid O 
malignancies O 
. O 

Cross O 
- O 
linking O 
of O 
Fc B-protein 
gamma I-protein 
receptors I-protein 
activates O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
- O 
driven O 
transcription O 
in O 
human B-cell_type 
monocytes I-cell_type 
. O 

Elevation O 
of O 
the O 
levels O 
of O 
circulating B-protein 
immune I-protein 
complexes I-protein 
frequently O 
accompanies O 
HIV O 
- O 
1 O 
infection O 
and O 
is O 
a O 
prognostic O 
indicator O 
of O 
clinical O 
progression O 
from O 
asymptomatic O 
infection O 
to O 
AIDS O 
. O 

Here O 
we O 
report O 
that O 
cross O 
- O 
linking O 
of O 
Fc B-protein 
gamma I-protein 
RI I-protein 
or O 
Fc B-protein 
gamma I-protein 
RII I-protein 
by O 
adherent B-protein 
human I-protein 
IgG I-protein 
or O 
by O 
specific O 
anti B-protein 
- I-protein 
Fc I-protein 
gamma I-protein 
R I-protein 
mAb I-protein 
activates O 
HIV O 
- O 
1 O 
gene O 
expression O 
in O 
the O 
human B-cell_line 
monocytic I-cell_line 
cell I-cell_line 
line I-cell_line 
BF24 B-cell_line 
and O 
increased O 
HIV B-RNA 
RNA I-RNA 
expression O 
in O 
monocytes B-cell_type 
from O 
HIV O 
infected O 
patients O 
as O 
assayed O 
by O 
reverse O 
transcription O 
- O 
PCR O 
. O 

In O 
THP B-cell_line B-cell_line 
- I-cell_line I-cell_line 
1 I-cell_line I-cell_line 
cells I-cell_line 
, O 
Fc B-protein 
gamma I-protein 
R I-protein 
cross O 
- O 
linking O 
induced O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
which O 
is O 
known O 
to O 
bind O 
to O 
the O 
regulatory B-DNA 
region I-DNA 
of O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
of O 
HIV O 
- O 
1 O 
and O 
to O 
activate O 
HIV O 
- O 
1 O 
transcription O 
. O 
Anti B-protein 
- I-protein 
TNF I-protein 
- I-protein 
alpha I-protein 
antibody I-protein 
but O 
not O 
anti B-protein 
- I-protein 
IL I-protein 
- I-protein 
1 I-protein 
beta I-protein 
antibody I-protein 
strongly O 
inhibited O 
both O 
the O 
induction O 
of O 
HIV O 
- O 
1 O 
- O 
LTR B-DNA 
- O 
driven O 
transcription O 
and O 
the O 
induction O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
by O 
Fc B-protein 
gamma I-protein 
R I-protein 
cross O 
- O 
linking O 
. O 

These O 
results O 
indicate O 
that O 
Fc B-protein 
gamma I-protein 
R I-protein 
can O 
mediate O 
a O 
TNF B-protein 
- I-protein 
alpha I-protein 
- O 
dependent O 
induction O 
of O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
gene I-DNA 
transcription O 
and O 
suggest O 
that O 
immune B-protein 
complexes I-protein 
may O 
contribute O 
to O 
the O 
pathophysiology O 
of O 
HIV O 
- O 
1 O 
infection O 
by O 
augmenting O 
viral O 
replication O 
in O 
monocytes B-cell_type 
. O 

Signalling O 
via O 
CD28 B-protein 
of O 
human B-cell_line 
naive I-cell_line 
neonatal I-cell_line 
T I-cell_line 
lymphocytes I-cell_line 
. O 

Accessory O 
molecules O 
play O 
a O 
crucial O 
role O 
in O 
the O 
development O 
of O 
the O 
T O 
cell O 
response O 
to O 
antigenic O 
challenge O 
. O 

We O 
have O 
examined O 
the O 
role O 
of O 
CD28 B-protein 
in O 
modulating O 
the O 
' O 
naive O 
' O 
neonatal O 
T O 
cell O 
response O 
to O 
anti B-protein 
- I-protein 
CD2 I-protein 
- O 
mediated O 
activation O 
. O 

To O 
compare O 
the O 
role O 
of O 
CD28 B-protein 
, O 
neonatal B-cell_type 
and O 
adult B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
were O 
stimulated O 
with O 
a O 
pair O 
of O 
mitogenic B-protein 
anti I-protein 
- I-protein 
CD2 I-protein 
antibodies I-protein 
in O 
the O 
presence O 
or O 
absence O 
of O 
anti B-protein 
- I-protein 
CD28 B-protein I-protein 
MoAb I-protein 
. O 

With O 
anti B-protein 
- I-protein 
CD2 I-protein 
alone O 
, O 
neonatal B-cell_type 
T I-cell_type 
cells I-cell_type 
proliferated O 
slightly O 
but O 
produced O 
no O 
detectable O 
IL B-protein 
- I-protein 
2 I-protein 
, O 
whereas O 
adult O 
T B-cell_type 
cells I-cell_type 
proliferated O 
vigorously O 
, O 
with O 
significant O 
IL B-protein 
- I-protein 
2 I-protein 
production O 
. O 

Costimulation O 
with O 
anti B-protein 
- I-protein 
CD28 B-protein I-protein 
MoAb I-protein 
greatly O 
enhanced O 
the O 
proliferative O 
response O 
of O 
neonatal B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
to O 
levels O 
equivalent O 
to O 
those O 
of O 
adult B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
, O 
whereas O 
adult B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
showed O 
only O 
slight O 
increases O 
. O 

Although O 
IL B-protein 
- I-protein 
2 I-protein 
secretion O 
was O 
increased O 
in O 
the O 
presence O 
of O 
anti B-protein 
- I-protein 
CD28 B-protein I-protein 
MoAb I-protein 
, O 
neonatal B-cell_type 
T I-cell_type 
cell I-cell_type 
IL B-protein 
- I-protein 
2 I-protein 
production O 
remained O 
lower O 
than O 
in O 
adults O 
. O 

In O 
contrast O 
, O 
enhancement O 
of O 
IL B-protein B-RNA 
- I-protein I-RNA 
2 I-protein I-RNA 
mRNA I-RNA 
expression O 
in O 
neonates O 
was O 
similar O 
to O 
adult O 
levels O 
. O 

Anti O 
- O 
CD28 B-protein B-protein 
MoAb I-protein 
costimulation O 
increased O 
NF B-protein 
kappa I-protein 
B I-protein 
levels O 
in O 
neonates O 
, O 
albeit O 
to O 
levels O 
lower O 
than O 
that O 
of O 
adults O 
. O 

The O 
cellular O 
mechanism O 
governing O 
the O 
diminished O 
proliferative O 
response O 
of O 
neonatal B-cell_type 
T I-cell_type 
lymphocytes I-cell_type 
to O 
anti B-protein 
- I-protein 
CD2 I-protein 
may O 
therefore O 
be O 
due O 
to O 
decreased O 
NF B-protein 
kappa I-protein 
B I-protein 
induction O 
, O 
reduced O 
IL B-protein B-RNA 
- I-protein I-RNA 
2 I-protein I-RNA 
mRNA I-RNA 
expression O 
and O 
deficient O 
IL B-protein 
- I-protein 
2 I-protein 
production O 
. O 

Although O 
anti B-protein 
- I-protein 
CD28 B-protein I-protein 
MoAb I-protein 
costimulation O 
enhances O 
all O 
of O 
the O 
above O 
signals O 
, O 
NF O 
kappa O 
B O 
and O 
IL O 
- O 
2 O 
levels O 
remain O 
lower O 
than O 
in O 
adults O 
, O 
suggesting O 
the O 
need O 
for O 
further O 
activation O 
requirements O 
in O 
the O 
neonate O 
. O 

TCL1 O 
oncogene O 
activation O 
in O 
preleukemic B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
from O 
a O 
case O 
of O 
ataxia O 
- O 
telangiectasia O 
. O 

The O 
TCL1 B-DNA 
oncogene I-DNA 
on O 
human B-DNA 
chromosome I-DNA 
14q32 B-DNA 
. I-DNA 
1 I-DNA 
is O 
involved O 
in O 
chromosome O 
translocations O 
[ O 
t B-DNA 
( I-DNA 
14 I-DNA 
; I-DNA 
14 I-DNA 
) I-DNA 
( I-DNA 
q11 I-DNA 
; I-DNA 
q32 I-DNA 
. I-DNA 
1 I-DNA 
) I-DNA 
and O 
t B-DNA 
( I-DNA 
7 I-DNA 
; I-DNA 
14 I-DNA 
) I-DNA 
( I-DNA 
q35 I-DNA 
; I-DNA 
q32 I-DNA 
. I-DNA 
1 I-DNA 
) I-DNA 
] O 
and O 
inversions O 
[ O 
inv14 B-DNA 
( I-DNA 
q11 I-DNA 
; I-DNA 
q32 I-DNA 
. I-DNA 
1 I-DNA 
) I-DNA 
] O 
with O 
TCR B-DNA 
alpha I-DNA 
/ I-DNA 
beta I-DNA 
loci I-DNA 
in O 
T O 
- O 
cell O 
leukemias O 
, O 
such O 
as O 
T O 
- O 
prolymphocytic O 
( O 
T O 
- O 
PLL O 
) O 
. O 

It O 
is O 
also O 
involved O 
in O 
T O 
- O 
acute O 
and O 
- O 
chronic O 
leukemias O 
arising O 
in O 
cases O 
of O 
ataxia O 
- O 
telangiectasia O 
( O 
AT O 
) O 
, O 
an O 
immunodeficiency O 
syndrome O 
. O 

Similar O 
chromosomal O 
rearrangements O 
occur O 
also O 
in O 
the O 
clonally O 
expanded O 
T B-cell_type 
cells I-cell_type 
in O 
AT O 
patients O 
before O 
the O 
appearance O 
of O 
the O 
overt O 
leukemia O 
. O 

We O 
have O 
analyzed O 
the O 
expression O 
of O 
TCL1 B-RNA 
mRNA I-RNA 
and O 
protein B-protein 
in O 
peripheral B-cell_type 
blood I-cell_type 
lymphocytes I-cell_type 
( O 
PBLs B-cell_type 
) O 
from O 
four O 
AT O 
cases O 
and O 
from O 
healthy O 
controls O 
. O 

We O 
found O 
that O 
the O 
TCL1 B-DNA 
gene I-DNA 
was O 
overexpressed O 
in O 
the O 
PBLs B-cell_type 
of O 
an O 
AT O 
patient O 
with O 
a O 
large B-cell_line 
clonal I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
population I-cell_line 
exhibiting O 
the O 
t O 
( O 
14 O 
; O 
14 O 
) O 
translocation O 
but O 
not O 
in O 
the O 
lymphocytes B-cell_type 
of O 
the O 
other O 
cases O 
. O 

Fluorescence O 
in O 
situ O 
hybridization O 
of O 
the O 
TCL1 B-DNA 
genomic I-DNA 
locus I-DNA 
to O 
lymphocyte O 
metaphases O 
from O 
the O 
AT O 
patient O 
with O 
the O 
T O 
- O 
cell O 
clonal O 
expansion O 
showed O 
that O 
the O 
breakpoint O 
of O 
the O 
t O 
( O 
14 O 
; O 
14 O 
) O 
translocation O 
lies O 
within O 
the O 
TCL1 B-DNA 
locus I-DNA 
and O 
is O 
accompanied O 
by O 
an O 
inverted B-DNA 
duplication I-DNA 
of O 
the O 
distal B-DNA 
part I-DNA 
of O 
chromosome B-DNA 
14 I-DNA 
. O 

These O 
data O 
indicate O 
that O 
TCL1 B-DNA 
is O 
activated O 
in O 
preleukemic B-cell_line 
clonal I-cell_line 
cells I-cell_line 
as O 
a O 
consequence O 
of O 
chromosome O 
translocation O 
involving O 
sequences O 
from O 
the O 
TCR B-DNA 
locus I-DNA 
at O 
14q11 B-DNA 
. O 

Deregulation O 
of O 
TCL1 B-DNA 
is O 
the O 
first O 
event O 
in O 
the O 
initiation O 
of O 
malignancy O 
in O 
these O 
types O 
of O 
leukemias O 
and O 
represents O 
a O 
potential O 
tool O 
for O 
clinical O 
evaluation O 
. O 

C B-protein 
/ I-protein 
EBP I-protein 
proteins I-protein 
activate O 
transcription O 
from O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
type I-DNA 
1 I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
in O 
macrophages O 
/ O 
monocytes B-cell_type 
. O 

Three O 
binding O 
sites O 
for O 
C B-protein 
/ I-protein 
EBP I-protein 
proteins I-protein 
are O 
found O 
in O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
type I-DNA 
1 I-DNA 
( I-DNA 
HIV I-DNA 
- I-DNA 
1 I-DNA 
) I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
( O 
LTR B-DNA 
) O 
( O 
V O 
. O 
M O 
. O 
Tesmer O 
, O 
A O 
. O 
Rajadhyaksha O 
, O 
J O 
. O 
Babin O 
, O 
and O 
M O 
. O 
Bina O 
, O 
Proc O 
. O 
Natl O 
. O 
Acad O 
. O 
Sci O 
. O 
USA O 
90 O 
: O 
7298 O 
- O 
7302 O 
, O 
1993 O 
) O 
. O 

We O 
have O 
determined O 
the O 
functional O 
role O 
of O 
C B-protein 
/ I-protein 
EBP I-protein 
proteins I-protein 
and O 
C B-DNA 
/ I-DNA 
EBP I-DNA 
sites I-DNA 
in O 
regulating O 
transcription O 
from O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
LTR B-DNA I-DNA 
in O 
monocytes B-cell_type B-cell_type 
/ I-cell_type 
macrophages I-cell_type 
. O 

Inhibition O 
of O 
endogenous B-protein 
C B-protein I-protein 
/ I-protein I-protein 
EBP I-protein I-protein 
proteins I-protein I-protein 
, O 
using O 
either O 
an O 
excess O 
of O 
C B-DNA 
/ I-DNA 
EBP I-DNA 
binding I-DNA 
sites I-DNA 
or O 
a O 
trans B-DNA 
- I-DNA 
dominant I-DNA 
negative I-DNA 
inhibitor I-DNA 
, O 
demonstrated O 
that O 
C B-protein 
/ I-protein 
EBP I-protein 
proteins I-protein 
are O 
required O 
for O 
basal O 
and O 
activated O 
levels O 
of O 
HIV O 
- O 
1 O 
LTR B-DNA 
transcription O 
in O 
the O 
promonocytic B-cell_line 
cell I-cell_line 
line I-cell_line 
U937 I-cell_line 
. O 

Northern O 
( O 
RNA O 
) O 
blots O 
and O 
binding O 
assays O 
showed O 
that O 
NF B-protein 
- I-protein 
IL6 I-protein 
is O 
the O 
only O 
known O 
C B-protein 
/ I-protein 
EBP I-protein 
family I-protein 
member I-protein 
which O 
is O 
increased O 
when O 
U937 B-cell_line 
cells I-cell_line 
are O 
activated O 
. O 

Mutational O 
analyses O 
of O 
the O 
HIV O 
- O 
1 O 
LTR B-DNA 
showed O 
that O 
one O 
C B-DNA 
/ I-DNA 
EBP I-DNA 
site I-DNA 
is O 
required O 
for O 
normal O 
LTR B-DNA 
transcription O 
both O 
before O 
and O 
after O 
cellular O 
activation O 
and O 
that O 
the O 
two O 
3 O 
' O 
C B-DNA 
/ I-DNA 
EBP I-DNA 
sites I-DNA 
are O 
functionally O 
equivalent O 
. O 

However O 
, O 
transcription O 
from O 
crippled B-DNA 
HIV I-DNA 
- I-DNA 
1 I-DNA 
LTRs B-DNA I-DNA 
lacking O 
C B-DNA 
/ I-DNA 
EBP I-DNA 
sites I-DNA 
can O 
still O 
be O 
induced O 
following O 
activation O 
of O 
U937 B-cell_line 
cells I-cell_line 
. O 

Several O 
models O 
are O 
suggested O 
for O 
how O 
elevated O 
NF B-protein 
- I-protein 
IL6 I-protein 
may O 
participate O 
in O 
an O 
autostimulatory O 
loop O 
involving O 
HIV O 
infection O 
, O 
macrophage O 
activation O 
, O 
cytokine B-protein 
expression O 
, O 
and O 
HIV O 
replication O 
. O 

Human O 
immunodeficiency O 
virus O 
type O 
- O 
2 O 
gene O 
expression O 
: O 
two O 
enhancers B-DNA 
and O 
their O 
activation O 
by O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
activators O 
. O 

The O 
human O 
immunodeficiency O 
viruses O 
( O 
HIVs O 
) O 
may O 
include O 
a O 
spectrum O 
of O 
retroviruses O 
with O 
varying O 
potential O 
to O 
infect O 
their O 
host O 
, O 
undergo O 
long O 
periods O 
of O 
latent O 
infection O 
, O 
and O 
induce O 
pathology O 
. O 

Since O 
expression O 
of O 
the O 
viruses O 
is O 
in O 
large O 
part O 
regulated O 
by O 
the O 
sequence B-DNA 
elements I-DNA 
in O 
their O 
long B-DNA 
terminal I-DNA 
repeats I-DNA 
( O 
LTRs B-DNA 
) O 
, O 
this O 
study O 
was O 
directed O 
to O 
an O 
analysis O 
of O 
the O 
regulatory B-DNA 
elements I-DNA 
in O 
the O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
LTR I-DNA 
. O 

The O 
HIV B-DNA 
- I-DNA 
2 I-DNA 
LTR I-DNA 
was O 
found O 
to O 
contain O 
two O 
enhancers B-DNA 
. O 

One O 
of O 
these O 
enhancers B-DNA 
is O 
, O 
in O 
part O 
, O 
identical O 
to O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
enhancer I-DNA 
. O 

This O 
enhancer B-DNA 
in O 
HIV O 
- O 
1 O 
is O 
the O 
T B-DNA 
- I-DNA 
cell I-DNA 
activation I-DNA 
response I-DNA 
element I-DNA 
; O 
in O 
HIV O 
- O 
2 O 
, O 
however O 
, O 
it O 
is O 
the O 
second B-DNA 
enhancer I-DNA 
that O 
is O 
mainly O 
responsible O 
for O 
activation O 
in O 
response O 
to O 
T O 
- O 
cell O 
activators O 
. O 

The O 
second O 
enhancer B-DNA 
interacts O 
with O 
two O 
nuclear B-protein 
binding I-protein 
proteins I-protein 
( O 
85 O 
kD O 
and O 
27 O 
kD O 
mobility O 
) O 
that O 
appear O 
to O 
be O 
required O 
for O 
optimal O 
enhancer O 
function O 
and O 
activation O 
. O 

Observations O 
such O 
as O 
these O 
encourage O 
the O 
speculation O 
that O 
there O 
may O 
be O 
subtle O 
differences O 
in O 
the O 
regulation O 
of O 
HIV O 
- O 
1 O 
and O 
HIV O 
- O 
2 O 
expression O 
that O 
may O 
be O 
relevant O 
to O 
the O 
possible O 
longer O 
latency O 
and O 
reduced O 
pathogenicity O 
of O 
HIV O 
- O 
2 O 
. O 

NF B-protein 
- I-protein 
M I-protein 
( O 
chicken B-protein 
C I-protein 
/ I-protein 
EBP I-protein 
beta I-protein 
) O 
induces O 
eosinophilic O 
differentiation O 
and O 
apoptosis O 
in O 
a O 
hematopoietic B-cell_line 
progenitor I-cell_line 
cell I-cell_line 
line I-cell_line 
. O 

CAAT B-DNA B-protein 
/ I-DNA I-protein 
enhancer I-DNA I-protein 
binding I-protein 
proteins I-protein 
( O 
C B-protein 
/ I-protein 
EBPs I-protein 
) O 
are O 
transcriptional O 
activators O 
implicated O 
in O 
the O 
differentiation O 
processes O 
of O 
various O 
cell O 
lineages O 
. O 

We O 
have O 
shown O 
earlier O 
that O 
NF B-protein 
- I-protein 
M I-protein 
, O 
the O 
chicken B-protein 
homolog I-protein 
of O 
C B-protein 
/ I-protein 
EBP I-protein 
beta I-protein 
, O 
is O 
specifically O 
expressed O 
in O 
myelomonocytic O 
and O 
eosinophilic O 
cells O 
of O 
the O 
hematopoietic O 
system O 
. O 

To O 
investigate O 
the O 
role O 
of O 
NF B-protein 
- I-protein 
M I-protein 
in O 
hematopoietic B-cell_line 
cell I-cell_line 
lineage I-cell_line 
commitment O 
, O 
we O 
constructed O 
a O 
conditional O 
form O 
of O 
the O 
protein O 
by O 
fusing O 
it O 
to O 
the O 
hormone B-protein 
binding I-protein 
domain I-protein 
of O 
the O 
human B-protein 
estrogen I-protein 
receptor I-protein 
. O 

This O 
construct O 
was O 
stably O 
expressed O 
in O 
a O 
multipotent B-cell_line 
progenitor I-cell_line 
cell I-cell_line 
line I-cell_line 
transformed O 
by O 
the O 
Myb B-protein 
- I-protein 
Ets I-protein 
oncoprotein I-protein 
. O 

We O 
report O 
here O 
that O 
both O 
NF B-protein B-DNA 
- I-protein I-DNA 
M I-protein I-DNA 
- I-DNA 
dependent I-DNA 
promoter I-DNA 
constructs I-DNA 
and O 
resident O 
genes O 
could O 
be O 
activated O 
by O 
addition O 
of O 
beta O 
- O 
estradiol O 
to O 
the O 
NF B-protein B-protein B-cell_line 
- I-protein I-protein I-cell_line 
M I-protein I-protein I-cell_line 
- I-protein I-cell_line 
estrogen I-protein I-cell_line 
receptor I-protein I-cell_line 
expressing I-cell_line 
progenitors I-cell_line 
. O 

At O 
the O 
same O 
time O 
, O 
we O 
observed O 
a O 
down O 
- O 
regulation O 
of O 
progenitor B-protein 
- I-protein 
specific I-protein 
surface I-protein 
markers I-protein 
and O 
the O 
up O 
- O 
regulation O 
of O 
differentiation B-protein 
markers I-protein 
restricted O 
to O 
the O 
eosinophil B-cell_type 
and O 
myeloid B-cell_type 
lineages I-cell_type 
. O 

In O 
addition O 
to O 
the O 
onset O 
of O 
differentiation O 
, O 
cell O 
death O 
was O 
induced O 
with O 
typical O 
apoptotic O 
features O 
. O 

Our O 
results O 
suggest O 
that O 
NF B-protein 
- I-protein 
M I-protein 
plays O 
an O 
important O 
role O 
in O 
commitment O 
along O 
the O 
eosinophil B-cell_type 
lineage I-cell_type 
and O 
in O 
the O 
induction O 
of O 
apoptosis O 
. O 

Prolactin B-protein 
and O 
interleukin B-protein B-protein 
- I-protein I-protein 
2 I-protein I-protein 
receptors I-protein 
in O 
T B-cell_type 
lymphocytes I-cell_type 
signal O 
through O 
a O 
MGF B-protein 
- I-protein 
STAT5 I-protein 
- I-protein 
like I-protein 
transcription I-protein 
factor I-protein 
. O 

The O 
cell O 
surface O 
receptors O 
for O 
PRL B-protein 
and O 
interleukin B-protein 
- I-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
are O 
structurally O 
distinct O 
, O 
but O 
share O 
regulatory O 
tasks O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

They O 
can O 
stimulate O 
proliferation O 
and O 
activate O 
transcription O 
of O 
over O 
- O 
lapping O 
sets O 
of O 
genes O 
of O 
T B-cell_type 
cells I-cell_type 
. O 

PRL B-protein 
and O 
IL B-protein 
- I-protein 
2 I-protein 
receptor O 
activation O 
are O 
both O 
linked O 
to O 
the O 
Jak B-protein 
/ I-protein 
Stat I-protein 
( O 
signal B-protein 
transducer I-protein 
and I-protein 
activator I-protein 
of I-protein 
transcription I-protein 
) O 
pathway O 
. O 

We O 
investigated O 
the O 
ability O 
of O 
PRL B-protein 
and O 
IL B-protein 
- I-protein 
2 I-protein 
to O 
activate O 
Stat B-protein 
proteins I-protein 
in O 
different O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

The O 
DNA O 
binding O 
specificities O 
, O 
the O 
reactivities O 
toward O 
Stat O 
- O 
specific O 
antisera O 
, O 
and O 
the O 
mol O 
wt O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
- O 
and O 
PRL B-protein B-protein 
- I-protein 
induced I-protein 
DNA I-protein 
- I-protein 
binding I-protein 
proteins I-protein 
in O 
Nb2 O 
and O 
C196 O 
T O 
cell O 
lines O 
were O 
investigated O 
. O 

A O 
comparison O 
with O 
the O 
Stat B-protein 
proteins I-protein 
induced O 
by O 
interferon B-protein 
- I-protein 
gamma I-protein 
, O 
PRL B-protein 
, O 
and O 
IL B-protein 
- I-protein 
6 I-protein 
in O 
T47D B-cell_line 
mammary I-cell_line 
tumor I-cell_line 
cells I-cell_line 
was O 
made O 
. O 

We O 
found O 
that O 
these O 
parameters O 
were O 
indistinguishable O 
for O 
one O 
of O 
the O 
PRL O 
- O 
and O 
IL O 
- O 
2 O 
- O 
induced O 
factors O 
. O 

A O 
transcription O 
factor O 
closely O 
related O 
to O 
mammary B-protein 
gland I-protein 
factor I-protein 
- I-protein 
Stat5 I-protein 
is O 
rapidly O 
activated O 
upon O 
interaction O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
and O 
PRL B-protein 
with O 
their O 
respective O 
receptors O 
. O 

Activation O 
of O 
a O 
second O 
protein O 
related O 
to O 
Stat1 B-protein 
was O 
also O 
observed O 
. O 

Our O 
results O 
emphasize O 
the O 
role O 
of O 
PRL B-protein 
as O 
a O 
regulator O 
of O 
the O 
immune O 
response O 
and O 
indicate O 
that O 
the O 
Stat B-protein 
factors I-protein 
mammary B-protein 
gland I-protein 
factor I-protein 
- I-protein 
Stat5 I-protein 
and O 
Stat1 B-protein 
play O 
a O 
role O 
in O 
the O 
regulation O 
of O 
gene O 
expression O 
during O 
T O 
cell O 
development O 
. O 

ETS1 B-protein 
transactivates O 
the O 
human B-DNA 
GM I-DNA 
- I-DNA 
CSF I-DNA 
promoter I-DNA 
in O 
Jurkat B-cell_line 
T I-cell_line 
cells I-cell_line 
stimulated O 
with O 
PMA O 
and O 
ionomycin O 
. O 

Activation O 
of O 
T B-cell_type 
helper I-cell_type 
cells I-cell_type 
results O 
in O 
coordinate O 
expression O 
of O 
a O 
number O 
of O 
cytokines B-protein 
involved O 
in O 
differentiation O 
, O 
proliferation O 
and O 
activation O 
of O 
the O 
haematopoietic O 
system O 
. O 

Granulocyte B-protein 
- I-protein 
macrophage I-protein 
colony I-protein 
- I-protein 
stimulating I-protein 
factor I-protein 
( O 
GM B-protein 
- I-protein 
CSF I-protein 
) O 
is O 
one O 
such O 
cytokine B-protein 
whose O 
increased O 
expression O 
results O 
partly O 
from O 
increases O 
in O 
transcription O 
. O 

Cis B-DNA 
- I-DNA 
acting I-DNA 
elements I-DNA 
with O 
NF B-DNA 
kappa I-DNA 
B I-DNA 
, O 
AP B-DNA 
- I-DNA 
1 I-DNA 
and O 
ETS B-DNA 
- I-DNA 
like I-DNA 
motifs I-DNA 
have O 
been O 
identified O 
in O 
the O 
promoter O 
region O 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
gene I-DNA 
, O 
which O 
are O 
important O 
for O 
transcriptional O 
activity O 
following O 
PMA O 
and O 
ionomycin O 
stimulation O 
. O 

A O 
number O 
of O 
the O 
ETS B-protein 
family I-protein 
of O 
transcription B-protein 
factors I-protein 
are O 
expressed O 
in O 
T B-cell_type 
cells I-cell_type 
, O 
including O 
ETS1 B-protein 
and O 
ELF1 B-protein 
. O 

Here O 
we O 
describe O 
the O 
ability O 
of O 
these O 
factors O 
to O 
interact O 
with O 
a O 
site O 
( O 
GM5 B-DNA 
) O 
, O 
located O 
within O 
the O 
CLE0 B-DNA 
element I-DNA 
, O 
- B-DNA 
47 I-DNA 
to I-DNA 
- I-DNA 
40 I-DNA 
upstream I-DNA 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
transcription I-DNA 
initiation I-DNA 
site I-DNA 
. O 

Exogenous O 
ETS1 B-protein 
, O 
but O 
not O 
ELF1 B-protein 
, O 
can O 
transactivate O 
GM B-protein 
- I-protein 
CSF I-protein 
, O 
through O 
the O 
GM5 B-DNA 
site O 
, O 
in O 
a O 
PMA O 
/ O 
ionomycin O 
dependent O 
manner O 
. O 

Other O 
unidentified O 
ETS B-protein 
- I-protein 
like I-protein 
factors I-protein 
present O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
are O 
also O 
capable O 
of O 
binding O 
GM5 B-DNA 
. O 

Mutation O 
of O 
the O 
core O 
ETS B-DNA 
binding I-DNA 
site I-DNA 
from O 
- B-DNA 
GGAA I-DNA 
- I-DNA 
to I-DNA 
- I-DNA 
GGAT I-DNA 
- I-DNA 
prevents O 
the O 
binding O 
of O 
ETS B-protein 
- I-protein 
like I-protein 
factors I-protein 
with O 
the O 
exception O 
of O 
ETS1 B-protein 
. O 

The O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
promoter I-DNA 
, O 
modified O 
in O 
this O 
way O 
to O 
be O 
ETS1 B-protein 
specific O 
, O 
is O 
fully O 
responsive O 
to O 
PMA O 
/ O 
ionomycin O 
induction O 
, O 
in O 
addition O 
to O 
ETS1 B-protein 
transactivation O 
in O 
the O 
presence O 
of O 
PMA O 
and O 
ionomycin O 
. O 

Together O 
these O 
data O 
suggest O 
that O 
ETS1 B-protein 
may O 
be O 
involved O 
in O 
mediating O 
the O 
increased O 
GM B-protein 
- I-protein 
CSF I-protein 
production O 
associated O 
with O 
T B-cell_type 
cell I-cell_type 
activation O 
. O 

Quantitation O 
of O 
beta B-protein B-RNA 
1 I-protein I-RNA 
triiodothyronine I-protein I-RNA 
receptor I-protein I-RNA 
mRNA I-RNA 
in O 
human O 
tissues O 
by O 
competitive O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
. O 

Thyroid O 
hormones O 
act O 
by O 
binding O 
to O 
nuclear B-protein 
receptor I-protein 
proteins I-protein 
, O 
the O 
thyroid B-protein 
hormone I-protein 
receptors I-protein 
( O 
TR B-protein 
) O 
alpha O 
and O 
beta O 
. O 

Data O 
from O 
cell O 
culture O 
and O 
animal O 
studies O 
indicate O 
that O 
TR B-protein 
expression O 
may O 
be O 
regulated O 
to O 
modulate O 
target O 
organ O 
responsiveness O 
to O 
thyroid O 
hormone O 
. O 

To O 
investigate O 
whether O 
such O 
adaptive O 
changes O 
in O 
TR B-protein 
expression O 
occur O 
in O 
humans O 
, O 
we O 
determined O 
the O 
mRNA O 
levels O 
of O 
the O 
hTR B-protein 
beta I-protein 
1 I-protein 
in O 
various O 
thyroid O 
states O 
. O 

Patients O 
with O 
overt O 
hypo O 
- O 
or O 
hyperthyroidism O 
were O 
enrolled O 
in O 
the O 
study O 
. O 

Total B-RNA 
RNA I-RNA 
was O 
isolated O 
from O 
peripheral B-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
and O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
determined O 
by O 
quantitative O 
competitive O 
reverse O 
transcription O 
PCR O 
. O 

For O 
comparison O 
, O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
were O 
determined O 
in O 
lymphocytes B-cell_type 
and O 
normal O 
thyroid O 
tissue O 
of O 
euthyroid O 
patients O 
. O 

Human B-protein B-RNA 
TR I-protein I-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
in O 
lymphocytes B-cell_type 
were O 
1 O 
. O 
8 O 
+ O 
/ O 
- O 
0 O 
. O 
4 O 
, O 
1 O 
. O 
9 O 
+ O 
/ O 
- O 
0 O 
. O 
5 O 
, O 
1 O 
. O 
1 O 
+ O 
/ O 
- O 
0 O 
. O 
4 O 
10 O 
( O 
- O 
18 O 
) O 
mol O 
/ O 
microgram O 
RNA O 
in O 
hypo O 
- O 
, O 
eu O 
- O 
and O 
hyperthyroid O 
patients O 
, O 
respectively O 
, O 
corresponding O 
to O 
an O 
estimated O 
0 O 
. O 
5 O 
- O 
2 O 
molecules O 
per O 
cell O 
. O 

Although O 
the O 
mean O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
were O 
40 O 
% O 
lower O 
in O 
hyperthyroid O 
than O 
in O 
euthyroid O 
subjects O 
, O 
this O 
difference O 
did O 
not O 
reach O 
statistical O 
significance O 
. O 

Similar O 
levels O 
of O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
were O 
detected O 
in O 
thyroid O 
gland O 
from O 
euthyroid O 
patients O 
. O 

In O 
summary O 
, O 
we O 
developed O 
an O 
assay O 
for O 
the O 
quantitative O 
determination O 
of O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
in O 
small O 
human O 
tissue O 
samples O 
, O 
containing O 
as O 
little O 
as O 
50 O 
ng O 
of O 
total O 
RNA O 
. O 

Absolute O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
are O 
very O 
low O 
with O 
an O 
estimated O 
one O 
molecule O 
of O 
mRNA B-RNA 
being O 
present O 
in O 
a O 
mononuclear B-cell_type 
blood I-cell_type 
cell I-cell_type 
or O 
thyrocyte B-cell_type 
. O 

No O 
up O 
- O 
regulation O 
of O 
hTR B-protein 
beta I-protein 
1 I-protein 
was O 
seen O 
in O 
hypothyroid O 
relative O 
to O 
euthyroid O 
patients O 
. O 

However O 
, O 
there O 
is O 
a O 
non O 
- O 
significant O 
trend O 
towards O 
a O 
down O 
- O 
regulation O 
of O 
hTR B-protein B-RNA 
beta I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
levels O 
in O 
hyperthyroid O 
patients O 
. O 

Multiple O 
proteins B-protein 
interact O 
with O 
the O 
nuclear B-DNA 
inhibitory I-DNA 
protein I-DNA 
repressor I-DNA 
element I-DNA 
in O 
the O 
human B-DNA 
interleukin I-DNA 
- I-DNA 
3 I-DNA 
promoter I-DNA 
. O 

T O 
cell O 
expression O 
of O 
interleukin B-protein 
3 I-protein 
( O 
IL B-protein 
- I-protein 
3 I-protein 
) O 
is O 
directed O 
by O 
positive O 
and O 
negative O 
cis O 
- O 
acting O 
DNA O 
elements O 
clustered O 
within O 
300 O 
base O 
pairs O 
of O 
the O 
transcriptional B-DNA 
start I-DNA 
site I-DNA 
. O 

A O 
strong O 
repressor B-protein 
element I-protein 
, O 
termed O 
nuclear B-protein 
inhibitory I-protein 
protein I-protein 
( O 
NIP B-protein 
) O 
, O 
was O 
previously O 
mapped O 
to O 
a O 
segment O 
of O 
the O 
IL B-DNA 
- I-DNA 
3 I-DNA 
promoter I-DNA 
between O 
nucleotides B-DNA 
- I-DNA 
271 I-DNA 
and I-DNA 
- I-DNA 
250 I-DNA 
. O 

Functional O 
characterization O 
of O 
this O 
element O 
demonstrates O 
that O 
it O 
can O 
mediate O 
repression O 
when O 
linked O 
in O 
cis O 
to O 
a O 
heterologous B-DNA 
promoter I-DNA 
. O 

DNA O 
binding O 
experiments O 
were O 
carried O 
out O 
to O 
characterize O 
the O 
repressor O 
activity O 
. O 

Using O 
varying O 
conditions O 
, O 
three O 
distinct O 
complexes O 
were O 
shown O 
to O 
interact O 
specifically O 
with O 
the O 
NIP B-protein B-DNA 
region I-DNA 
, O 
although O 
only O 
one O 
correlates O 
with O 
repressor O 
activity O 
. O 

Complex B-protein 
1 I-protein 
results O 
from O 
binding O 
of O 
a O 
ubiquitous O 
polypeptide O 
that O 
recognizes O 
the O 
3 B-DNA 
' I-DNA 
portion I-DNA 
of O 
this O 
sequence O 
and O 
is O 
not O 
required O 
for O 
repression O 
. O 

Complex B-protein 
2 I-protein 
corresponds O 
to O 
binding O 
of O 
transcription B-protein 
factor I-protein 
( O 
upstream B-protein 
stimulatory I-protein 
factor I-protein 
) O 
to O 
an O 
E B-DNA 
- I-DNA 
box I-DNA 
motif I-DNA 
in O 
the O 
5 B-DNA 
' I-DNA 
portion I-DNA 
of O 
the O 
NIP B-protein B-DNA 
region I-DNA 
. O 

DNA O 
binding O 
specificity O 
of O 
complex O 
3 O 
overlaps O 
with O 
that O 
of O 
upstream B-protein 
stimulatory I-protein 
factor I-protein 
but O 
is O 
clearly O 
distinct O 
. O 

To O 
determine O 
which O 
of O 
the O 
latter O 
two O 
complexes O 
represents O 
NIP B-protein 
activity O 
, O 
we O 
incorporated O 
small O 
alterations O 
into O 
the O 
NIP B-protein B-DNA 
site I-DNA 
of O 
an O 
IL B-DNA B-DNA 
- I-DNA I-DNA 
3 I-DNA I-DNA 
promoter I-DNA I-DNA 
- I-DNA 
linked I-DNA 
reporter I-DNA 
construct I-DNA 
and O 
examined O 
their O 
effects O 
on O 
NIP B-protein 
- O 
mediated O 
repression O 
. O 

Functional O 
specificity O 
for O 
repression O 
matches O 
the O 
DNA O 
binding O 
specificity O 
of O 
complex B-protein 
3 I-protein 
; O 
both O 
repressor O 
activity O 
and O 
complex B-protein 
3 I-protein 
binding O 
require O 
the O 
consensus B-DNA 
sequence I-DNA 
CTCACNTNC O 
. O 

The O 
hematopoietic B-protein 
transcription I-protein 
factor I-protein 
PU B-protein 
. I-protein 
1 I-protein 
is O 
downregulated O 
in O 
human B-cell_line 
multiple I-cell_line 
myeloma I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

PU B-protein 
. I-protein 
1 I-protein 
is O 
a O 
hematopoietic B-protein 
transcription I-protein 
factor I-protein 
belonging O 
to O 
the O 
Ets B-protein 
- I-protein 
family I-protein 
. O 

It O 
is O 
identical O 
to O 
the O 
Spi B-DNA 
- I-DNA 
1 I-DNA 
oncogene I-DNA 
, O 
which O 
is O 
implicated O 
in O 
spleen O 
focus O 
- O 
forming O 
virus O 
- O 
induced O 
murine O 
erythroleukemias O 
. O 

PU B-protein 
. I-protein 
1 I-protein 
seems O 
to O 
be O 
required O 
for O 
early O 
development O 
of O 
multiple B-cell_type 
hematopoietic I-cell_type 
lineages I-cell_type 
, O 
but O 
its O 
expression O 
in O 
mature B-cell_type 
cells I-cell_type 
is O 
preferentially O 
observed O 
in O 
cells O 
of O 
the O 
B B-cell_type 
- I-cell_type 
cell I-cell_type 
- I-cell_type 
and I-cell_type 
monocyte I-cell_type 
/ I-cell_type 
macrophage I-cell_type 
- I-cell_type 
differentiation I-cell_type 
lineage I-cell_type 
. O 

It O 
binds O 
the O 
so O 
- O 
called O 
Pu B-DNA 
box I-DNA 
, O 
an O 
important O 
tissue B-DNA 
- I-DNA 
specific I-DNA 
regulatory I-DNA 
DNA I-DNA 
element I-DNA 
present O 
in O 
a O 
number O 
of O 
genes O 
expressed O 
in O 
these O 
cell B-cell_type 
lineages I-cell_type 
. O 

We O 
have O 
analyzed O 
the O 
expression O 
and O 
activity O 
of O 
PU B-protein 
. I-protein 
1 I-protein 
during O 
human O 
B O 
- O 
cell O 
development O 
using O 
a O 
panel O 
of O 
B B-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
representing O 
different O 
stages O 
of O 
maturation O 
, O 
from O 
early B-cell_line 
precursors I-cell_line 
to O 
differentiated B-cell_line 
plasma I-cell_line 
cells I-cell_line 
. O 

PU B-protein B-RNA 
. I-protein I-RNA 
1 I-protein I-RNA 
mRNA I-RNA 
expression O 
and O 
PU B-protein 
. I-protein 
1 I-protein 
DNA O 
binding O 
activity O 
, O 
as O 
measured O 
by O 
Northern O 
blot O 
analysis O 
and O 
electrophoretic O 
mobility O 
shift O 
assay O 
, O 
respectively O 
, O 
were O 
evident O 
in O 
cell B-cell_line 
lines I-cell_line 
representing O 
pro O 
- O 
B O 
, O 
pre O 
- O 
B O 
, O 
and O 
mature O 
B O 
cells O 
. O 

We O 
could O 
also O 
show O 
Pu B-DNA 
box I-DNA 
- O 
dependent O 
transactivation O 
of O 
a O 
reporter O 
gene O 
in O 
transient O 
transfections O 
in O 
these O 
cell B-cell_line 
lines I-cell_line 
. O 

In O 
contrast O 
, O 
in O 
a O 
number O 
of O 
multiple B-cell_line 
myeloma I-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
representing O 
differentiated B-cell_type 
, I-cell_type 
plasma I-cell_type 
cell I-cell_type 
- I-cell_type 
like I-cell_type 
B I-cell_type 
cells I-cell_type 
, O 
PU B-protein 
. I-protein 
1 I-protein 
DNA O 
binding O 
activity O 
, O 
mRNA O 
expression O 
, O 
and O 
Pu B-DNA 
box I-DNA 
- O 
dependent O 
transactivation O 
were O 
absent O 
or O 
detectable O 
at O 
a O 
very O 
low O 
level O 
. O 

In O 
lymphoblastoid B-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
which O 
exemplify O 
an O 
intermediate O 
stage O 
of O 
B O 
- O 
cell O 
differentiation O 
, O 
a O 
reduced O 
expression O 
and O 
activity O 
were O 
observed O 
. O 

The O 
findings O 
in O 
the O 
human B-cell_line 
multiple B-cell_line I-cell_line 
myeloma I-cell_line I-cell_line 
cell I-cell_line I-cell_line 
lines I-cell_line I-cell_line 
represent O 
the O 
first O 
examples O 
of O 
B B-cell_type 
cells I-cell_type 
with O 
downregulated O 
PU B-protein 
. I-protein 
1 I-protein 
expression O 
and O 
apparently O 
contradict O 
observations O 
in O 
the O 
murine O 
system O 
in O 
which O 
PU B-protein 
. I-protein 
1 I-protein 
is O 
expressed O 
and O 
active O 
in O 
plasmacytoma B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

At O 
present O 
, O 
it O 
is O 
unclear O 
whether O 
the O 
lack O 
of O 
PU B-protein 
. I-protein 
1 I-protein 
expression O 
and O 
activity O 
in O 
human B-cell_line 
multiple B-cell_line I-cell_line 
myeloma I-cell_line I-cell_line 
cell I-cell_line I-cell_line 
lines I-cell_line I-cell_line 
represents O 
a O 
malignancy O 
- O 
associated O 
defect O 
in O 
these O 
cells O 
or O 
exemplifies O 
a O 
normal O 
developmental O 
regulation O 
in O 
terminally B-cell_type 
differentiated I-cell_type 
B B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
. O 

Regulation O 
of O 
granulocyte B-protein 
- I-protein 
macrophage I-protein 
colony I-protein 
- I-protein 
stimulating I-protein 
factor I-protein 
and O 
E B-protein 
- I-protein 
selectin I-protein 
expression O 
in O 
endothelial B-cell_type 
cells I-cell_type 
by O 
cyclosporin O 
A O 
and O 
the O 
T B-protein 
- I-protein 
cell I-protein 
transcription I-protein 
factor I-protein 
NFAT B-protein 
. O 

Nuclear B-protein 
factor I-protein 
of I-protein 
activated I-protein 
T I-protein 
cells I-protein 
( O 
NFAT B-protein 
) O 
was O 
originally O 
described O 
as O 
a O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
athat O 
supported O 
the O 
activation O 
of O 
cytokine B-protein 
gene O 
expression O 
and O 
mediated O 
the O 
immunoregulatory B-protein 
effects O 
of O 
cyclosporin O 
A O 
( O 
CsA O 
) O 
. O 

As O 
we O 
observed O 
that O 
activated B-cell_type 
endothelial I-cell_type 
cells I-cell_type 
also O 
expressed O 
NFAT B-protein 
, O 
we O 
tested O 
the O 
antiinflammatory O 
properties O 
of O 
CsA O 
in O 
endothelial B-cell_type 
cells I-cell_type 
. O 

Significantly O 
, O 
CsA O 
completely O 
suppressed O 
the O 
induction O 
of O 
NFAT B-protein 
in O 
endothelial B-cell_type 
cells I-cell_type 
and O 
inhibited O 
the O 
activity O 
of O 
granulocyte B-protein B-DNA 
- I-protein I-DNA 
macrophage I-protein I-DNA 
colony I-protein I-DNA 
- I-protein I-DNA 
stimulating I-protein I-DNA 
factor I-protein I-DNA 
( I-DNA 
GM B-protein I-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
) I-DNA 
gene I-DNA 
regulatory I-DNA 
elements I-DNA 
that O 
use O 
NFAT B-protein 
by O 
60 O 
% O 
. O 

CsA O 
similarly O 
mediated O 
a O 
reduction O 
of O 
up O 
to O 
65 O 
% O 
in O 
GM B-protein B-RNA 
- I-protein I-RNA 
CSF I-protein I-RNA 
mRNA I-RNA 
and O 
protein O 
expression O 
in O 
activated B-cell_type 
endothelial I-cell_type 
cells I-cell_type 
. O 

CsA O 
also O 
suppressed O 
E B-protein 
- I-protein 
selectin I-protein 
, O 
but O 
not O 
vascular B-protein 
cell I-protein 
adhesion I-protein 
molecule I-protein 
- I-protein 
1 I-protein 
( O 
VCAM B-protein 
- I-protein 
1 I-protein 
) O 
expression O 
in O 
endothelial O 
cells O 
, O 
even O 
though O 
the O 
E B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
promoter I-DNA 
is O 
activated O 
by O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
rather O 
than O 
NFAT B-protein 
. O 

Hence O 
, O 
induction O 
of O 
cell O 
surface O 
expression O 
of O 
this O 
leukocyte B-protein 
adhesion I-protein 
molecule I-protein 
by O 
tumor B-protein 
necrosis I-protein 
factor I-protein 
( I-protein 
TNF I-protein 
) I-protein 
- I-protein 
alpha I-protein 
was O 
reduced O 
by O 
40 O 
% O 
in O 
the O 
presence O 
of O 
CsA O 
, O 
and O 
this O 
was O 
reflected O 
by O 
a O 
29 O 
% O 
decrease O 
in O 
neutrophil B-cell_type 
adhesion O 
. O 

The O 
effects O 
of O 
CsA O 
on O 
endothelial B-cell_type 
cells I-cell_type 
were O 
also O 
detected O 
at O 
the O 
chromatin B-DNA 
structure O 
level O 
, O 
as O 
DNasel B-protein B-DNA 
hypersensitive I-DNA 
sites I-DNA 
within O 
both O 
the O 
GM B-protein 
- I-protein 
CSF I-protein 
enhancer O 
and O 
the O 
E B-protein B-DNA 
- I-protein I-DNA 
selectin I-protein I-DNA 
promoter I-DNA 
were O 
suppressed O 
by O 
CsA O 
. O 

This O 
represents O 
the O 
first O 
report O 
of O 
NFAT B-protein 
in O 
endothelial B-cell_type 
cells I-cell_type 
and O 
suggests O 
mechanisms O 
by O 
which O 
CsA O 
could O 
function O 
as O 
an O 
antiinflammatory O 
agent O 
. O 

Costimulation O 
requirement O 
for O 
AP B-protein 
- I-protein 
1 I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
transcription O 
factor O 
activation O 
in O 
T B-cell_type 
cells I-cell_type 
. O 

The O 
transcriptional O 
activity O 
of O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
requires O 
T B-cell_type 
- I-cell_type 
cell I-cell_type 
costimulation O 
delivered O 
by O 
the O 
TCR B-protein 
and O 
the O 
auxiliary B-protein 
receptor I-protein 
CD28 I-protein 
. O 

Several O 
transcription B-protein 
factors I-protein 
participate O 
in O 
IL B-protein 
- I-protein 
2 I-protein 
promoter O 
activation O 
, O 
among O 
which O 
are O 
AP B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
- I-protein 
like I-protein 
factors I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Protein O 
phosphorylation O 
has O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
these O 
two O 
factors O 
: O 
( O 
1 O 
) O 
it O 
induces O 
the O 
transactivating O 
capacity O 
of O 
the O 
AP B-protein 
- I-protein 
1 I-protein 
protein I-protein 
c B-protein 
- I-protein 
Jun I-protein 
; O 
and O 
( O 
2 O 
) O 
it O 
is O 
involved O 
in O 
the O 
release O 
of O 
the O 
cytoplasmic B-protein 
inhibitor I-protein 
, O 
I B-protein 
kappa I-protein 
B I-protein 
, O 
from O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
allowing O 
translocation O 
of O 
the O 
latter O 
into O 
the O 
nucleus O 
. O 

We O 
have O 
recently O 
shown O 
that O 
both O 
phosphorylation O 
processes O 
require O 
T O 
- O 
cell O 
costimulation O 
. O 

Furthermore O 
, O 
in O 
activated B-cell_type 
T I-cell_type 
cells I-cell_type 
, O 
the O 
kinetics O 
of O 
the O 
two O 
phosphorylation O 
events O 
are O 
essentially O 
similar O 
. O 

According O 
to O 
our O 
results O 
, O 
however O 
, O 
the O 
kinases O 
responsible O 
for O 
the O 
two O 
processes O 
are O 
distinct O 
entities O 
. O 

Whereas O 
TPCK B-protein 
inhibits O 
phosphorylation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
and O 
, O 
consequently O 
, O 
activation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
it O 
markedly O 
enhances O 
the O 
activity O 
of O 
JNK B-protein 
, O 
the O 
MAP B-protein 
kinase I-protein 
- I-protein 
related I-protein 
kinase I-protein 
that O 
phosphorylates O 
the O 
transactivation B-protein 
domain I-protein 
of O 
c B-protein 
- I-protein 
Jun I-protein 
. O 

We O 
, O 
therefore O 
, O 
propose O 
the O 
activation O 
scheme O 
presented O 
in O 
FIGURE O 
3 O 
for O 
T O 
- O 
cell O 
costimulation O 
. O 

Costimulation O 
results O 
in O 
the O 
activation O 
of O 
a O 
signaling O 
pathway O 
that O 
leads O 
to O 
the O 
simultaneous O 
induction O 
of O 
the O 
two O 
transcription B-protein 
factors I-protein 
, O 
AP B-protein 
- I-protein 
1 I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Integration O 
of O 
the O 
signals O 
generated O 
by O 
TCR B-protein 
and O 
CD28 B-protein 
engagement O 
occurs O 
along O 
this O 
pathway O 
, O 
which O 
then O 
bifurcates O 
to O 
induce O 
I B-protein 
kappa I-protein 
B I-protein 
phosphorylation O 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
on O 
the O 
one O 
hand O 
, O 
and O 
JNK B-protein 
activation O 
and O 
c B-protein 
- I-protein 
Jun I-protein 
phosphorylation O 
on O 
the O 
other O 
. O 

We O 
are O 
currently O 
engaged O 
in O 
defining O 
where O 
the O 
two O 
signals O 
integrate O 
along O 
the O 
AP B-protein 
- I-protein 
1 I-protein 
/ O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
pathway O 
. O 

Regulation O 
of O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
and O 
cytokine O 
gene O 
expression O 
in O 
myeloid B-cell_type 
cells I-cell_type 
by O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
/ I-protein 
Rel I-protein 
transcription B-protein 
factors I-protein 
. O 

CD4 B-cell_line 
+ I-cell_line 
macrophages I-cell_line 
in O 
tissues O 
such O 
as O 
lung O 
, O 
skin O 
, O 
and O 
lymph O 
nodes O 
, O 
promyelocytic B-cell_type 
cells I-cell_type 
in O 
bone O 
marrow O 
, O 
and O 
peripheral B-cell_type 
blood I-cell_type 
monocytes I-cell_type 
serve O 
as O 
important O 
targets O 
and O 
reservoirs O 
for O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
( O 
HIV O 
- O 
1 O 
) O 
replication O 
. O 

HIV O 
- O 
1 O 
- O 
infected O 
myeloid B-cell_type 
cells I-cell_type 
are O 
often O 
diminished O 
in O 
their O 
ability O 
to O 
participate O 
in O 
chemotaxis O 
, O 
phagocytosis O 
, O 
and O 
intracellular O 
killing O 
. O 

HIV O 
- O 
1 O 
infection O 
of O 
myeloid B-cell_type 
cells I-cell_type 
can O 
lead O 
to O 
the O 
expression O 
of O 
surface B-protein 
receptors I-protein 
associated O 
with O 
cellular O 
activation O 
and O 
/ O 
or O 
differentiation O 
that O 
increase O 
the O 
responsiveness O 
of O 
these O 
cells O 
to O 
cytokines B-protein 
secreted O 
by O 
neighboring O 
cells O 
as O 
well O 
as O 
to O 
bacteria O 
or O 
other O 
pathogens O 
. O 

Enhancement O 
of O 
HIV O 
- O 
1 O 
replication O 
is O 
related O 
in O 
part O 
to O 
increased O 
DNA O 
- O 
binding O 
activity O 
of O 
cellular B-protein 
transcription B-protein I-protein 
factors I-protein I-protein 
such O 
as O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binds O 
to O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
enhancer I-DNA 
region O 
of O 
the O 
long B-DNA 
terminal I-DNA 
repeat I-DNA 
and O 
contributes O 
to O 
the O 
inducibility O 
of O 
HIV O 
- O 
1 O 
gene O 
expression O 
in O 
response O 
to O 
multiple O 
activating O 
agents O 
. O 

Phosphorylation O 
and O 
degradation O 
of O 
the O 
cytoplasmic B-protein 
inhibitor I-protein 
I B-protein 
kappa I-protein 
B I-protein 
alpha O 
are O 
crucial O 
regulatory O 
events O 
in O 
the O 
activation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
DNA O 
- O 
binding O 
activity O 
. O 

Both O 
N O 
- O 
and O 
C O 
- O 
terminal O 
residues O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha O 
are O 
required O 
for O 
inducer O 
- O 
mediated O 
degradation O 
. O 

Chronic O 
HIV O 
- O 
1 O 
infection O 
of O 
myeloid B-cell_type 
cells I-cell_type 
leads O 
to O 
constitutive O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
DNA O 
- O 
binding O 
activity O 
and O 
provides O 
an O 
intranuclear O 
environment O 
capable O 
of O 
perpetuating O 
HIV O 
- O 
1 O 
replication O 
. O 

Increased O 
intracellular O 
stores O 
of O 
latent B-protein 
NF B-protein I-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
may O 
also O 
result O 
in O 
rapid O 
inducibility O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
- O 
dependent O 
cytokine B-protein 
gene O 
expression O 
. O 

In O 
response O 
to O 
secondary O 
pathogenic O 
infections O 
or O 
antigenic O 
challenge O 
, O 
cytokine B-protein 
gene O 
expression O 
is O 
rapidly O 
induced O 
, O 
enhanced O 
, O 
and O 
sustained O 
over O 
prolonged O 
periods O 
in O 
HIV O 
- O 
1 O 
- O 
infected O 
myeloid B-cell_type 
cells I-cell_type 
compared O 
with O 
uninfected B-cell_type 
cells I-cell_type 
. O 

Elevated O 
levels O 
of O 
several O 
inflammatory B-protein 
cytokines I-protein 
have O 
been O 
detected O 
in O 
the O 
sera O 
of O 
HIV O 
- O 
1 O 
- O 
infected O 
individuals O 
. O 

Secretion O 
of O 
myeloid B-protein 
cell I-protein 
- I-protein 
derived I-protein 
cytokines B-protein I-protein 
may O 
both O 
increase O 
virus O 
production O 
and O 
contribute O 
to O 
AIDS O 
- O 
associated O 
disorders O 
. O 

Steroid O 
mediated O 
lysis O 
of O 
lymphoblasts B-cell_type 
requires O 
the O 
DNA O 
binding O 
region O 
of O 
the O 
steroid O 
hormone O 
receptor O 
. O 

Glucocorticoids O 
kill O 
certain O 
types O 
of O 
lymphoblasts B-cell_type 
, O 
but O 
the O 
mechanisms O 
are O 
unknown O 
. O 

It O 
is O 
clear O 
that O 
sufficient O 
numbers O 
of O 
functional O 
glucocorticoid B-protein 
receptors I-protein 
are O 
required O 
to O 
mediate O 
lysis O 
, O 
but O 
whether O 
they O 
do O 
so O 
through O 
the O 
classical O 
model O 
of O 
steroid O 
hormone O 
activation O 
and O 
modulation O 
of O 
gene O 
expression O 
has O 
not O 
been O 
established O 
. O 

In O 
this O 
report O 
we O 
have O 
asked O 
which O 
region O 
( O 
s O 
) O 
of O 
the O 
steroid B-protein 
receptor I-protein 
are O 
important O 
for O 
mediating O 
lysis O 
in O 
leukemic B-cell_type 
T I-cell_type 
lymphoblasts B-cell_type I-cell_type 
. O 

CEM B-cell_line 
- I-cell_line 
ICR I-cell_line 
27 I-cell_line 
leukemic I-cell_line 
lymphoblasts B-cell_type I-cell_line 
, O 
a O 
clone O 
of O 
CEM B-cell_line 
cells I-cell_line 
which O 
lack O 
functional O 
glucocorticoid B-protein 
receptors I-protein 
and O 
therefore O 
are O 
neither O 
lysed O 
by O 
dexamethasone O 
nor O 
capable O 
of O 
showing O 
glutamine B-protein 
synthetase I-protein 
induction O 
, O 
were O 
provided O 
with O 
steroid B-protein 
receptors I-protein 
by O 
DNA O 
transfections O 
of O 
various O 
receptor O 
gene O 
constructs O 
. O 

We O 
measured O 
steroid O 
mediated O 
lysis O 
, O 
receptor O 
number O 
and O 
induction O 
of O 
glutamine B-protein 
synthetase I-protein 
in O 
the O 
transfected B-cell_line 
cells I-cell_line 
. O 

Our O 
results O 
provide O 
evidence O 
that O 
the O 
lysis O 
mechanism O 
in O 
the O 
ICR27 B-cell_line 
lymphoblasts B-cell_type I-cell_line 
is O 
restored O 
when O 
functional O 
receptor O 
number O 
is O 
restored O 
. O 

The O 
DNA B-protein 
binding I-protein 
region I-protein 
specifying O 
high O 
affinity O 
for O 
GRE B-DNA 
sites I-DNA 
is O 
required O 
. O 

Lysis O 
is O 
mediated O 
by O 
any O 
steroid O 
that O 
allows O 
for O 
activation O 
of O 
the O 
receptor O 
containing O 
such O 
a O 
region O 
. O 

Our O 
data O 
support O 
the O 
view O 
that O 
steroid O 
- O 
mediated O 
cell O 
death O 
occurs O 
by O 
a O 
process O 
requiring O 
direct O 
interaction O 
of O 
steroid B-protein 
- I-protein 
receptor I-protein 
complexes I-protein 
with O 
the O 
genome O 
. O 

Functional O 
characterization O 
of O 
the O 
murine B-protein 
homolog I-protein 
of O 
the O 
B B-protein 
cell I-protein 
- I-protein 
specific I-protein 
coactivator I-protein 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
. O 

B O 
cell O 
- O 
specific O 
transcriptional O 
promoter O 
activity O 
mediated O 
by O 
the O 
octamer B-DNA 
motif I-DNA 
requires O 
the O 
Oct1 B-protein 
or O 
Oct2 B-protein 
protein I-protein 
and O 
additional O 
B B-protein 
cell I-protein 
- I-protein 
restricted I-protein 
cofactors I-protein 
. O 

One O 
such O 
cofactor B-protein 
, O 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
, O 
was O 
recently O 
isolated O 
from O 
human B-cell_type 
B I-cell_type 
cells I-cell_type 
. O 

Here O 
, O 
we O 
describe O 
the O 
isolation O 
and O 
detailed O 
characterization O 
of O 
the O 
murine B-protein 
homolog I-protein 
. O 

Full O 
- O 
length O 
cDNAs B-DNA 
and O 
genomic B-DNA 
clones I-DNA 
were O 
isolated O 
, O 
and O 
the O 
gene O 
structure O 
was O 
determined O 
. O 
Comparison O 
of O 
the O 
deduced O 
amino O 
acids O 
shows O 
88 O 
% O 
sequence O 
identity O 
between O 
mouse O 
and O 
human O 
BOB O 
. O 
1 O 
/ O 
OBF O 
. O 
1 O 
. O 

The O 
NH2 B-protein 
- I-protein 
terminal I-protein 
126 I-protein 
amino I-protein 
acids I-protein 
of O 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
are O 
both O 
essential O 
and O 
sufficient O 
for O 
interaction O 
with O 
the O 
POU B-protein 
domains I-protein 
of O 
either O 
Oct1 B-protein 
or O 
Oct2 B-protein 
. O 

This O 
protein O 
- O 
protein O 
interaction O 
does O 
not O 
require O 
the O 
simultaneous O 
binding O 
of O 
Oct B-protein 
proteins I-protein 
to O 
DNA O 
, O 
and O 
high O 
resolution O 
footprinting O 
of O 
the O 
Oct B-DNA 
- O 
DNA O 
interaction O 
reveals O 
that O 
binding O 
of O 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
to O 
Oct1 B-protein 
or O 
Oct2 B-protein 
does O 
not O 
alter O 
the O 
interaction O 
with O 
DNA O 
. O 

BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
can O 
efficiently O 
activate O 
octamer O 
- O 
dependent O 
promoters O 
in O 
fibroblasts B-cell_type 
; O 
however O 
, O 
it O 
fails O 
to O 
stimulate O 
octamer B-DNA 
- I-DNA 
dependent I-DNA 
enhancer I-DNA 
activity O 
. O 

Fusion O 
of O 
subdomains O 
of O 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
with O 
the O 
GAL4 B-protein 
DNA I-protein 
binding I-protein 
domain I-protein 
reveals O 
that O 
both O 
NH2 O 
- O 
and O 
COOH O 
- O 
terminal O 
domains O 
of O 
BOB B-protein 
. I-protein 
1 I-protein 
/ I-protein 
OBF I-protein 
. I-protein 
1 I-protein 
contribute O 
to O 
full O 
transactivation O 
function O 
, O 
the O 
COOH B-protein 
- I-protein 
terminal I-protein 
domain I-protein 
is O 
more O 
efficient O 
in O 
this O 
transactivation O 
assay O 
. O 

Consistent O 
with O 
the O 
failure O 
of O 
full B-protein 
- I-protein 
length I-protein 
BOB B-protein I-protein 
. I-protein I-protein 
1 I-protein I-protein 
/ I-protein I-protein 
OBF I-protein I-protein 
. I-protein I-protein 
1 I-protein I-protein 
to O 
stimulate O 
octamer B-DNA 
- I-DNA 
dependent I-DNA 
enhancer I-DNA 
elements I-DNA 
in O 
non B-cell_type 
B I-cell_type 
cells I-cell_type 
, O 
the O 
GAL4 B-protein 
fusions I-protein 
likewise O 
only O 
stimulate O 
from O 
a O 
promoter O 
- O 
proximal O 
position O 
. O 

Anti B-protein 
- I-protein 
immunoglobulin I-protein 
M I-protein 
activates O 
nuclear B-protein 
calcium I-protein 
/ I-protein 
calmodulin I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinase I-protein 
II I-protein 
in O 
human B-cell_type 
B I-cell_type 
lymphocytes I-cell_type 
. O 

We O 
and O 
others O 
have O 
previously O 
shown O 
that O 
the O 
nuclear B-protein 
protein I-protein 
, O 
Ets B-protein 
- I-protein 
1 I-protein 
, O 
is O 
phosphorylated O 
in O 
a O 
calcium O 
- O 
dependent O 
manner O 
after O 
ligation O 
of O 
immunoglobulin B-protein 
( I-protein 
Ig I-protein 
) I-protein 
M I-protein 
on O 
B B-cell_type 
lymphocytes I-cell_type 
. O 

As O 
this O 
phosphorylation O 
was O 
independent O 
of O 
protein B-protein 
kinase I-protein 
C I-protein 
activity O 
, O 
we O 
tested O 
whether O 
a O 
calcium B-protein 
/ I-protein 
calmodulin I-protein 
- I-protein 
dependent I-protein 
protein I-protein 
kinase I-protein 
( O 
CaM B-protein 
kinase I-protein 
) O 
might O 
phosphorylate O 
the O 
Ets B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
after O 
elevation O 
of O 
intracellular O 
free O 
calcium O 
concentrations O 
. O 

The O 
dephosphorylated O 
form O 
of O 
Ets B-protein 
- I-protein 
1 I-protein 
has O 
been O 
shown O 
to O 
bind O 
to O 
chromatin B-DNA 
, O 
suggesting O 
that O 
the O 
operative B-protein 
kinase I-protein 
should O 
be O 
detectable O 
in O 
the O 
nucleus O 
. O 

We O 
prepared O 
nuclear O 
extracts O 
from O 
two O 
human B-cell_line 
B I-cell_line 
cell I-cell_line 
lines I-cell_line 
in O 
which O 
increased O 
intracellular O 
free O 
calcium O 
levels O 
correlated O 
with O 
increased O 
phosphorylation O 
of O 
the O 
Ets B-protein 
- I-protein 
1 I-protein 
protein O 
. O 

Activity O 
of O 
the O 
CaM B-protein 
kinases I-protein 
was O 
determined O 
using O 
a O 
synthetic O 
peptide O 
substrate O 
both O 
in O 
the O 
absence O 
and O 
presence O 
of O 
an O 
inhibitor O 
specific O 
for O 
the O 
CaM B-protein B-protein 
kinase I-protein I-protein 
family I-protein 
, O 
KN O 
- O 
62 O 
. O 

Stimulation O 
of O 
cells O 
with O 
anti B-protein 
- I-protein 
IgM I-protein 
led O 
to O 
increased O 
activity O 
of O 
a O 
nuclear B-protein 
kinase I-protein 
that O 
could O 
phosphorylate O 
the O 
peptide O 
, O 
and O 
this O 
activity O 
was O 
reduced O 
by O 
10 O 
microM O 
KN O 
- O 
62 O 
. O 

Kinase O 
activity O 
was O 
reduced O 
in O 
lysates O 
preadsorbed O 
using O 
an O 
antibody B-protein 
specific O 
for O 
CaM B-protein 
kinase I-protein 
II I-protein 
. O 

Two O 
- O 
dimensional O 
phosphopeptide O 
maps O 
of O 
the O 
Ets B-protein 
- I-protein 
1 I-protein 
protein O 
from O 
cells O 
incubated O 
with O 
ionomycin O 
or O 
anti B-protein 
- I-protein 
IgM I-protein 
contained O 
two O 
unique O 
phosphopeptides O 
that O 
were O 
absent O 
in O 
untreated O 
cells O 
. O 

Incubation O 
of O 
isolated B-protein 
Ets I-protein 
- I-protein 
1 I-protein 
protein I-protein 
with O 
purified O 
CaM B-protein 
kinase I-protein 
II I-protein 
produced O 
phosphorylation O 
of O 
peptides O 
that O 
migrated O 
identically O 
to O 
those O 
found O 
in O 
cells O 
incubated O 
with O 
either O 
anti B-protein 
- I-protein 
IgM I-protein 
or O 
ionomycin O 
. O 

These O 
data O 
suggest O 
a O 
model O 
of O 
signal O 
transduction O 
by O 
the O 
antigen B-protein 
receptor I-protein 
on O 
B B-cell_type 
lymphocytes I-cell_type 
in O 
which O 
increased O 
intracellular O 
free O 
calcium O 
can O 
rapidly O 
activate O 
nuclear B-protein 
CaM I-protein 
kinase I-protein 
II I-protein 
, O 
potentially O 
resulting O 
in O 
phosphorylation O 
and O 
regulation O 
of O 
DNA B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
. O 

Transcriptional O 
activation O 
and O 
repression O 
, O 
two O 
properties O 
of O 
the O 
lymphoid B-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
Oct B-protein 
- I-protein 
2a I-protein 
. O 

The O 
lymphoid B-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
Oct B-protein 
- I-protein 
2a I-protein 
contains O 
two O 
transcriptional B-protein 
activation I-protein 
domains I-protein 
which O 
are O 
located O 
within O 
the O 
N B-protein 
- I-protein 
terminal I-protein 
and O 
C B-protein 
- I-protein 
terminal I-protein 
regions I-protein 
. O 

To O 
study O 
their O 
differential B-protein 
activation I-protein 
properties I-protein 
, O 
we O 
linked O 
the O 
isolated O 
effector B-protein 
domains I-protein 
to O 
the O 
GAL4 B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
domain I-protein 
. O 

We O 
have O 
shown O 
that O 
both O 
activating O 
regions O 
of O 
Oct B-protein 
- I-protein 
2a I-protein 
, O 
isolated O 
from O 
their O 
natural O 
context O 
, O 
can O 
activate O 
transcription O 
as O 
promoter B-protein 
factors I-protein 
. O 

In O 
contrast O 
to O 
the O 
C B-protein 
- I-protein 
terminus I-protein 
, O 
activation O 
by O 
the O 
N B-protein 
- I-protein 
terminal I-protein 
domain I-protein 
is O 
dependent O 
on O 
a O 
yet O 
unidentified O 
factor O 
( O 
s O 
) O 
binding O 
to O 
the O 
simian B-DNA 
virus I-DNA 
40 I-DNA 
enhancer I-DNA 
. O 

The O 
results O 
obtained O 
by O 
duplication O 
of O 
activation B-protein 
domains I-protein 
or O 
their O 
mixed O 
combination O 
suggest O 
that O 
the O 
domains O 
are O 
functionally O 
independent O 
. O 

However O 
, O 
activation O 
from O 
a O 
remote O 
position O 
could O 
only O 
be O 
achieved O 
with O 
the O 
C B-protein 
- I-protein 
terminus I-protein 
of O 
Oct B-protein 
- I-protein 
2a I-protein 
in O 
B B-cell_type 
cells I-cell_type 
. O 

In O 
lymphoid B-cell_type 
cells I-cell_type 
, O 
higher O 
activation O 
levels O 
were O 
observed O 
, O 
suggesting O 
that O 
distinct O 
B B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
cofactors I-protein 
in O 
concert O 
with O 
the O 
effector B-protein 
domains I-protein 
of O 
Oct B-protein 
- I-protein 
2a I-protein 
might O 
be O 
involved O 
in O 
mediating O 
transcription O 
from O 
proximal O 
and O 
remote O 
positions O 
. O 

Furthermore O 
, O 
we O 
identified O 
a O 
repression O 
domain O 
at O 
the O 
N O 
- O 
terminus O 
of O 
Oct B-protein 
- I-protein 
2a I-protein 
. O 

When O 
transferred O 
to O 
a O 
potent O 
activator O 
, O 
transcriptional O 
stimulation O 
was O 
inhibited O 
efficiently O 
. O 

These O 
results O 
underscore O 
the O 
modular O 
structure O 
of O 
Oct B-protein 
- I-protein 
2a I-protein 
with O 
separable O 
domains O 
for O 
activation O 
and O 
repression O 
and O 
suggest O 
that O 
Oct B-protein 
- I-protein 
2a I-protein 
might O 
have O 
complex O 
regulatory O 
functions O 
in O 
vivo O 
. O 

Nonopsonic O 
phagocytosis O 
of O 
Pseudomonas O 
aeruginosa O 
by O 
macrophages B-cell_type 
and O 
polymorphonuclear B-cell_type 
leukocytes I-cell_type 
requires O 
the O 
presence O 
of O 
the O 
bacterial O 
flagellum O 
. O 

Whereas O 
the O 
mechanism O 
of O 
nonopsonic O 
phagocytosis O 
of O 
Pseudomonas O 
aeruginosa O 
has O 
been O 
described O 
, O 
the O 
bacterial O 
ligands O 
required O 
are O 
poorly O 
understood O 
. O 

To O 
identify O 
the O 
requisite O 
bacterial O 
ligands O 
, O 
studies O 
with O 
isogenic O 
mutants O 
of O 
P O 
. O 
aeruginosa O 
PAK O 
lacking O 
pili O 
, O 
flagella O 
, O 
and O 
the O 
RpoN B-protein 
sigma I-protein 
factor I-protein 
were O 
undertaken O 
. O 

The O 
RpoN O 
mutant O 
, O 
lacking O 
pili O 
, O 
flagella O 
, O 
and O 
nonpilus B-protein 
adhesins I-protein 
, O 
bound O 
poorly O 
and O 
was O 
resistant O 
to O 
ingestion O 
by O 
both O 
macrophages B-cell_type 
and O 
neutrophils B-cell_type 
. O 

Pili O 
were O 
not O 
absolutely O 
required O 
for O 
binding O 
or O 
phagocytosis O 
of O 
P O 
. O 
aeruginosa O 
. O 

The O 
presence O 
of O 
a O 
flagellum O 
was O 
not O 
required O 
for O 
binding O 
of O 
P O 
. O 
aeruginosa O 
to O 
macrophages B-cell_type 
but O 
was O 
critical O 
for O 
the O 
subsequent O 
internalization O 
of O 
the O 
bacterium O 
, O 
suggesting O 
that O 
this O 
factor O 
or O 
a O 
surface O 
ligand O 
associated O 
with O 
its O 
assembly O 
was O 
responsible O 
for O 
stimulation O 
of O 
nonopsonic O 
phagocytosis O 
. O 

Identification O 
of O 
essential O 
GATA B-DNA 
and O 
Ets B-DNA 
binding I-DNA 
motifs I-DNA 
within O 
the O 
promoter O 
of O 
the O 
platelet B-DNA 
glycoprotein I-DNA 
Ib I-DNA 
alpha I-DNA 
gene I-DNA 
. O 

Platelet B-protein 
glycoprotein I-protein 
( O 
GP B-protein 
) O 
Ib B-protein 
- I-protein 
IX I-protein 
- I-protein 
V I-protein 
is O 
a O 
multisubunit B-protein 
adhesion I-protein 
receptor I-protein 
that O 
supports O 
platelet O 
attachment O 
to O 
thrombogenic O 
surfaces O 
at O 
sites O 
of O 
vascular O 
injury O 
. O 

The O 
congenital O 
absence O 
of O 
the O 
receptor O 
results O 
in O 
a O 
bleeding O 
disorder O 
associated O 
with O 
" B-cell_type 
giant I-cell_type 
" I-cell_type 
platelets I-cell_type 
, O 
a O 
condition O 
linking O 
the O 
expression O 
of O 
the O 
complex O 
to O 
platelet O 
morphogenesis O 
. O 

To O 
understand O 
better O 
the O 
expression O 
of O 
the O 
GP B-protein B-protein 
Ib B-protein I-protein 
- I-protein I-protein 
IX I-protein I-protein 
- I-protein I-protein 
V I-protein I-protein 
complex I-protein 
, O 
studies O 
were O 
undertaken O 
to O 
define O 
the O 
essential O 
genetic B-DNA 
elements I-DNA 
supporting O 
the O 
expression O 
of O 
the O 
alpha B-protein 
- I-protein 
subunit I-protein 
of O 
the O 
complex O 
( O 
GP B-protein B-protein 
Ib I-protein 
alpha I-protein 
) O 
. O 

GP B-protein B-DNA 
Ib I-DNA 
alpha I-DNA 
promoter I-DNA 
activity O 
was O 
evaluated O 
by O 
transfection O 
of O 
human B-cell_type 
erythroleukemia I-cell_type 
cells I-cell_type 
with O 
reporter O 
plasmids O 
coding O 
for O 
the O 
enzyme B-protein 
, O 
luciferase B-protein 
. O 

Studies O 
were O 
initiated O 
with O 
a O 
fragment O 
extending O 
2 O 
, O 
738 O 
nucleotides O 
5 O 
' O 
to O 
the O 
transcription B-DNA 
start I-DNA 
site I-DNA 
and O 
lead O 
to O 
the O 
identification O 
of O 
253 O 
nucleotides O 
retaining O 
full O 
promoter O 
activity O 
in O 
human B-cell_type 
erythroleukemia I-cell_type 
cells I-cell_type 
. O 

In O 
cells O 
of O 
nonhematopoietic B-cell_type 
lineage I-cell_type 
, O 
human B-cell_type 
endothelial I-cell_type 
and O 
HeLa B-cell_type 
cells I-cell_type 
, O 
the O 
GP B-protein B-protein B-DNA 
Ib I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
activity O 
was O 
no O 
greater O 
than O 
background O 
levels O 
obtained O 
with O 
promoterless B-DNA 
constructs I-DNA 
. O 

Gel O 
shift O 
assays O 
and O 
site O 
- O 
directed O 
mutagenesis O 
studies O 
defined O 
essential O 
GATA B-DNA 
and O 
Ets B-DNA 
binding I-DNA 
motifs I-DNA 
93 B-DNA 
and I-DNA 
150 I-DNA 
nucleotides I-DNA 
upstream I-DNA 
of O 
the O 
transcription B-DNA 
start I-DNA 
site I-DNA 
, O 
a O 
finding O 
which O 
further O 
substantiates O 
these O 
elements O 
as O 
important O 
determinants O 
of O 
megakaryocytic O 
gene O 
expression O 
. O 

The O 
results O 
define O 
essential O 
cis B-DNA 
- I-DNA 
acting I-DNA 
elements I-DNA 
responsible O 
for O 
the O 
expression O 
of O 
GP B-protein B-protein 
Ib I-protein 
alpha I-protein 
and O 
provide O 
insights O 
into O 
molecular O 
events O 
coinciding O 
with O 
the O 
release O 
of O 
normal B-cell_type 
platelets I-cell_type 
into O 
the O 
bloodstream O 
. O 

CD30 B-protein 
ligation O 
induces O 
nuclear B-protein 
factor I-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
in O 
human B-cell_line 
T I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

CD30 B-protein 
is O 
a O 
recently O 
described O 
member O 
of O 
the O 
tumor B-protein B-protein 
necrosis I-protein I-protein 
factor I-protein I-protein 
/ B-protein I-protein 
nerve I-protein I-protein 
growth I-protein I-protein 
factor I-protein I-protein 
receptor I-protein 
superfamily I-protein 
. O 

In O 
this O 
report O 
, O 
we O 
show O 
that O 
following O 
incubation O 
of O 
L540 B-cell_line 
cells I-cell_line 
( O 
Hodgkin B-cell_line 
' I-cell_line 
s I-cell_line 
disease I-cell_line 
- I-cell_line 
derived I-cell_line 
, I-cell_line 
T I-cell_line 
cell I-cell_line 
- I-cell_line 
like I-cell_line 
, I-cell_line 
CD30 B-protein I-cell_line 
+ I-cell_line 
cells I-cell_line 
) O 
with O 
the O 
agonistic B-protein 
anti I-protein 
- I-protein 
CD30 B-protein I-protein 
monoclonal I-protein 
antibodies I-protein 
( O 
mAb B-protein 
) O 
M44 B-protein 
and O 
M67 B-protein 
, O 
two O 
nuclear B-protein 
factor I-protein 
( I-protein 
NF I-protein 
) I-protein 
- I-protein 
kappa I-protein 
B I-protein 
DNA O 
binding O 
activities O 
were O 
induced O 
in O 
nuclear O 
extracts O 
, O 
as O 
determined O 
in O 
gel O 
retardation O 
assays O 
. O 

The O 
effect O 
of O 
the O 
mAb B-protein 
towards O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
was O 
rapid O 
, O 
as O 
it O 
occurred O 
within O 
20 O 
min O 
, O 
and O 
was O 
sustained O 
for O 
up O 
to O 
6 O 
h O 
. O 

By O 
comparison O 
, O 
an O 
isotype B-protein 
- I-protein 
matched I-protein 
antibody I-protein 
had O 
no O 
effect O 
on O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
. O 

Moreover O 
, O 
in O 
human B-cell_line 
T I-cell_line 
helper I-cell_line 
( I-cell_line 
Th I-cell_line 
) I-cell_line 
clones I-cell_line 
functionally O 
characterized O 
as O 
being O 
of O 
the O 
type O 
0 O 
, O 
type O 
1 O 
and O 
type O 
2 O 
( O 
28 O 
% O 
, O 
< O 
1 O 
% O 
und O 
93 O 
% O 
CD30 O 
+ O 
, O 
respectively O 
) O 
, O 
the O 
extent O 
of O 
CD30 B-protein 
- O 
mediated O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
correlated O 
with O 
the O 
proportion O 
of O 
CD30 B-cell_line 
+ I-cell_line 
cells I-cell_line 
. O 

In O 
all O 
cell O 
lines O 
investigated O 
, O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
complexes I-protein 
induced O 
following O 
CD30 B-protein 
engagement O 
were O 
shown O 
to O 
contain O 
p50 B-protein 
NF I-protein 
- I-protein 
kappa I-protein 
B1 I-protein 
, O 
p65 B-protein 
RelA I-protein 
, O 
and O 
possibly O 
other O 
transcription B-protein 
factors I-protein 
. O 

Collectively O 
, O 
our O 
results O 
demonstrate O 
that O 
nuclear O 
translocation O 
and O 
activation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
rank O 
among O 
the O 
short O 
- O 
term O 
cellular O 
responses O 
elicited O 
following O 
CD30 B-protein 
ligation O 
. O 

Pathogenesis O 
of O 
atherosclerosis O 
. O 

The O 
earliest O 
lesion O 
in O 
the O 
development O 
of O 
an O 
atherosclerotic O 
plaque O 
is O 
the O 
fatty O 
streak O 
. O 

This O 
chronic O 
inflammatory O 
reaction O 
results O 
from O 
a O 
sequence O 
of O 
events O 
that O 
begins O 
with O 
the O 
trapping O 
of O 
low O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
in O 
the O 
subendothelial O 
space O 
of O 
the O 
artery O 
wall O 
. O 

The O 
trapped O 
LDL O 
is O 
seeded O 
with O 
oxidative O 
species O 
released O 
by O 
the O 
overlying O 
endothelium O 
, O 
and O 
lipid O 
oxidation O 
is O 
initiated O 
within O 
the O 
LDL O 
particle O 
. O 
Some O 
of O 
the O 
lipids O 
that O 
result O 
lead O 
to O 
the O 
activation O 
of O 
NFkB B-protein 
- I-protein 
like I-protein 
transcription B-protein I-protein 
factors I-protein I-protein 
that O 
cause O 
the O 
expression O 
of O 
genes O 
whose O 
protein B-protein 
products I-protein 
mediate O 
monocyte O 
binding O 
, O 
monocyte B-cell_type 
chemotaxis O 
into O 
the O 
subendothelial O 
space O 
, O 
and O 
conversion O 
into O 
macrophages B-cell_type 
. O 

At O 
least O 
1 O 
major B-DNA 
gene I-DNA 
modulates O 
the O 
oxidation O 
of O 
LDL O 
lipids O 
and O 
/ O 
or O 
the O 
biologic O 
response O 
to O 
these O 
lipids O 
. O 

The O 
inverse O 
relation O 
between O 
high O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
and O 
atherosclerotic O 
events O 
may O 
in O 
part O 
be O 
due O 
to O 
enzymes B-protein 
associated O 
with O 
HDL O 
that O 
destroy O 
the O 
biologically O 
active O 
lipids O 
generated O 
in O 
LDL O 
. O 

Estrogen B-protein 
and O 
progesterone B-protein 
receptors I-protein 
in O 
vernal O 
keratoconjunctivitis O 
. O 

PURPOSE O 
: O 
Sex O 
- O 
related O 
influences O 
have O 
been O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
vernal O 
keratoconjunctivitis O 
( O 
VKC O 
) O 
, O 
an O 
allergic O 
eosinophilic O 
disease O 
. O 

METHODS O 
: O 
The O 
authors O 
evaluated O 
tarsal O 
and O 
bulbar O 
conjunctival O 
biopsies O 
from O 
seven O 
patients O 
with O 
severe O 
and O 
symptomatic O 
VKC O 
for O 
the O 
presence O 
of O 
estrogen O 
and O 
progesterone B-protein 
receptors I-protein 
by O 
using O 
monoclonal B-protein 
antibodies I-protein 
with O 
a O 
peroxidase O 
- O 
antiperoxidase O 
technique O 
. O 

RESULTS O 
: O 
Both O 
the O 
epithelium O 
and O 
subepithelium O 
of O 
the O 
tarsal O 
and O 
bulbar O 
conjunctiva O 
of O 
patients O 
with O 
VKC O 
, O 
but O 
not O 
those O 
of O 
four O 
nonatopic O 
control O 
subjects O 
, O 
showed O 
intense O 
positive O 
staining O 
for O 
estrogen O 
and O 
progesterone B-protein 
receptors I-protein 
. O 

Immunofluorescence O 
colocalization O 
of O 
both O 
estrogen B-protein 
and O 
progesterone B-protein 
receptors I-protein 
with O 
eosinophil B-protein 
cationic I-protein 
protein I-protein 
showed O 
that O 
approximately O 
70 O 
% O 
of O 
positive B-cell_type 
cells I-cell_type 
were O 
eosinophils B-cell_type 
. O 

CONCLUSIONS O 
: O 
Sexual O 
hormones O 
, O 
through O 
their O 
receptors B-protein 
, O 
may O 
influence O 
the O 
activity O 
of O 
eosinophils B-cell_type 
in O 
patients O 
with O 
VKC O 
. O 

CIITA B-protein 
activates O 
the O 
expression O 
of O 
MHC B-DNA 
class I-DNA 
II I-DNA 
genes I-DNA 
in O 
mouse O 
T O 
cells O 
. O 

It O 
has O 
long O 
been O 
a O 
puzzle O 
that O 
MHC B-protein 
class I-protein 
II I-protein 
molecules I-protein 
are O 
expressed O 
in O 
human B-cell_type 
T I-cell_type 
cells I-cell_type 
after O 
activation O 
but O 
not O 
in O 
mouse B-cell_type 
T I-cell_type 
cells I-cell_type 
; O 
this O 
expression O 
is O 
believed O 
to O 
play O 
a O 
role O 
in O 
the O 
cell O 
mediated O 
immune O 
response O 
. O 

Recently O 
the O 
MHC B-protein 
class I-protein 
II I-protein 
transactivator I-protein 
( O 
CIITA B-protein 
) O 
has O 
been O 
reported O 
to O 
be O 
a O 
major B-protein 
regulatory I-protein 
factor I-protein 
for O 
both O 
the O 
constitutive O 
and O 
IFN O 
inducible O 
expression O 
of O 
MHC B-DNA 
class I-DNA 
II I-DNA 
genes I-DNA 
. O 

Here O 
we O 
show O 
that O 
human B-cell_type 
T I-cell_type 
cells I-cell_type 
expressing O 
MHC O 
class O 
II O 
have O 
CIITA B-protein 
transcripts O 
while O 
MHC O 
class O 
II O 
- O 
negative O 
human B-cell_type 
T I-cell_type 
cells I-cell_type 
and O 
mouse B-cell_type 
T I-cell_type 
cells I-cell_type 
do O 
not O 
. O 

The O 
expression O 
of O 
MHC B-DNA 
class I-DNA 
II I-DNA 
genes I-DNA 
in O 
mouse B-cell_type 
T I-cell_type 
cells I-cell_type 
can O 
be O 
reconstituted O 
upon O 
transfection O 
with O 
the O 
human B-DNA 
CIITA B-protein I-DNA 
cDNA I-DNA 
. O 

These O 
data O 
indicate O 
that O 
the O 
expression O 
of O 
CIITA B-protein 
explains O 
the O 
expression O 
or O 
lack O 
of O 
expression O 
of O 
MHC B-protein 
class I-protein 
II I-protein 
in O 
human B-cell_type 
and O 
mouse B-cell_type 
T I-cell_type 
cells I-cell_type 
respectively O 
. O 

Anti B-protein 
- I-protein 
Ro I-protein 
( I-protein 
SSA I-protein 
) I-protein 
autoantibodies I-protein 
are O 
associated O 
with O 
T B-DNA 
cell I-DNA 
receptor I-DNA 
beta I-DNA 
genes I-DNA 
in O 
systemic O 
lupus O 
erythematosus O 
patients O 
. O 

Several O 
of O 
the O 
heterogeneous O 
clinical O 
manifestations O 
of O 
systemic O 
lupus O 
erythematosus O 
have O 
been O 
associated O 
with O 
specific O 
autoantibodies B-protein 
. O 

Associations O 
between O 
HLA B-protein 
class I-protein 
II I-protein 
antigens I-protein 
and O 
autoantibodies B-protein 
to O 
the O 
ribonucleoproteins B-protein 
Ro B-protein 
( I-protein 
SSA I-protein 
) I-protein 
and O 
La B-protein 
( I-protein 
SSB I-protein 
) I-protein 
have O 
been O 
reported O 
in O 
these O 
patients O 
. O 

Because O 
HLA B-protein 
class I-protein 
II I-protein 
molecules I-protein 
present O 
antigen O 
to O 
T B-protein 
cell I-protein 
receptors I-protein 
( O 
TCRs B-protein 
) O 
, O 
we O 
have O 
searched O 
for O 
a O 
TCR B-DNA 
gene I-DNA 
associated O 
with O 
the O 
production O 
of O 
anti B-protein 
- I-protein 
Ro B-protein I-protein 
( I-protein I-protein 
SSA I-protein I-protein 
) I-protein I-protein 
antibodies I-protein 
. O 

A O 
pair O 
of O 
restriction B-DNA 
fragment I-DNA 
length I-DNA 
polymorphisms I-DNA 
( O 
RFLPs B-DNA 
) O 
, O 
one O 
of O 
which O 
hybridizes O 
to O 
the O 
TCR B-DNA 
constant I-DNA 
region I-DNA 
C I-DNA 
beta I-DNA 
1 I-DNA 
and O 
the O 
other O 
to O 
the O 
C B-DNA 
beta I-DNA 
2 I-DNA 
gene I-DNA 
, O 
has O 
been O 
identified O 
, O 
suggesting O 
these O 
may O 
be O 
genotypic O 
markers O 
for O 
an O 
extended O 
region O 
of O 
the O 
TCR B-DNA 
beta I-DNA 
locus I-DNA 
. O 

This O 
RFLP B-DNA 
pair I-DNA 
occurs O 
in O 
76 O 
% O 
of O 
patients O 
with O 
Ro B-protein 
( I-protein 
SSA I-protein 
) I-protein 
precipitins O 
, O 
84 O 
% O 
of O 
anti O 
- O 
Ro B-protein 
( I-protein 
SSA I-protein 
) I-protein 
- O 
positive O 
patients O 
lacking O 
La B-protein 
( I-protein 
SSB I-protein 
) I-protein 
precipitins B-protein 
, O 
but O 
only O 
41 O 
% O 
of O 
the O 
patients O 
lacking O 
both O 
precipitins B-protein 
( O 
P O 
= O 
0 O 
. O 
0004 O 
) O 
. O 

This O 
disproportionate O 
occurrence O 
in O 
a O 
subset O 
of O 
lupus O 
patients O 
indicates O 
that O 
these O 
RFLPs B-DNA 
are O 
not O 
disease O 
susceptibility O 
markers O 
, O 
but O 
rather O 
are O 
important O 
markers O 
for O 
TCR B-DNA 
genes I-DNA 
whose O 
products O 
are O 
involved O 
in O 
the O 
production O 
of O 
anti B-protein 
- I-protein 
Ro B-protein I-protein 
( I-protein I-protein 
SSA I-protein I-protein 
) I-protein I-protein 
antibodies I-protein 
. O 

The O 
majority O 
of O 
patients O 
who O 
have O 
these O 
RFLPs B-DNA 
and O 
HLA B-protein 
class I-protein 
II I-protein 
antigens I-protein 
previously O 
associated O 
with O 
the O 
anti O 
- O 
Ro B-protein 
( I-protein 
SSA I-protein 
) I-protein 
response O 
make O 
this O 
antibody O 
, O 
suggesting O 
that O 
interactions O 
between O 
products O 
of O 
these O 
loci B-DNA 
occur I-DNA 
in O 
response O 
to O 
Ro B-protein 
( I-protein 
SSA I-protein 
) I-protein 
. O 

Inhibition O 
of O 
NF B-protein 
- I-protein 
AT I-protein 
- O 
dependent O 
transcription O 
by O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
: O 
implications O 
for O 
differential O 
gene O 
expression O 
in O 
T B-cell_type 
helper I-cell_type 
cell I-cell_type 
subsets I-cell_type 
. O 

Activation O 
of O 
individual O 
CD4 B-cell_line 
+ I-cell_line 
T I-cell_line 
cells I-cell_line 
results O 
in O 
differential O 
lymphokine B-protein 
expression O 
: O 
interleukin B-protein 
2 I-protein 
( O 
IL B-protein 
- I-protein 
2 I-protein 
) O 
is O 
preferentially O 
produced O 
by O 
T B-cell_line 
helper I-cell_line 
type I-cell_line 
1 I-cell_line 
( I-cell_line 
TH1 I-cell_line 
) I-cell_line 
cells I-cell_line 
, O 
which O 
are O 
involved O 
in O 
cell O 
- O 
mediated O 
immune O 
responses O 
, O 
whereas O 
IL B-protein 
- I-protein 
4 I-protein 
is O 
synthesized O 
by O 
TH2 B-cell_line 
cells I-cell_line 
, O 
which O 
are O 
essential O 
for O 
humoral O 
immunity O 
. O 

The O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
dependent I-protein 
factor I-protein 
NF B-protein 
- I-protein 
ATp I-protein 
plays O 
a O 
key O 
role O 
in O 
the O 
inducible O 
transcription O 
of O 
both O 
these O 
lymphokine B-DNA 
genes I-DNA 
. O 

However O 
, O 
while O 
IL2 B-protein 
expression O 
requires O 
the O 
contribution O 
of O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
and O 
protein B-protein 
kinase I-protein 
C I-protein 
- O 
dependent O 
signals O 
, O 
we O 
report O 
that O 
activation O 
of O 
human B-protein 
IL4 I-protein 
transcription O 
through O 
the O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathway O 
is O 
diminished O 
by O 
protein B-protein 
kinase I-protein 
C I-protein 
stimulation O 
in O 
Jurkat B-cell_line 
T I-cell_line 
cells I-cell_line 
. O 

This O 
phenomenon O 
is O 
due O 
to O 
mutually O 
exclusive O 
binding O 
of O 
NF B-protein 
- I-protein 
ATp I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
to O 
the O 
P B-DNA 
sequence I-DNA 
, O 
an O 
element O 
located O 
69 B-DNA 
bp I-DNA 
upstream I-DNA 
of O 
the O 
IL4 B-DNA 
transcription I-DNA 
initiation I-DNA 
site I-DNA 
. O 

Human B-DNA 
IL4 I-DNA 
promoter I-DNA 
- O 
mediated O 
transcription O 
is O 
downregulated O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
stimulated O 
with O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
kappa I-protein I-protein 
B I-protein I-protein 
- I-protein 
activating I-protein 
cytokine I-protein 
tumor B-protein 
necrosis I-protein 
factor I-protein 
alpha I-protein 
and O 
suppressed O 
in O 
RelA B-protein B-cell_line 
- I-cell_line 
overexpressing I-cell_line 
cells I-cell_line 
. O 

In O 
contrast O 
, O 
protein B-protein 
kinase I-protein 
C I-protein 
stimulation O 
or O 
RelA B-protein 
overexpression O 
does O 
not O 
affect O 
the O 
activity O 
of O 
a O 
human B-protein B-DNA 
IL4 I-protein I-DNA 
promoter I-DNA 
containing O 
a O 
mouse B-DNA 
P B-DNA I-DNA 
sequence I-DNA I-DNA 
, O 
which O 
is O 
a O 
higher B-DNA 
- I-DNA 
affinity I-DNA 
site I-DNA 
for O 
NF B-protein 
- I-protein 
ATp I-protein 
and O 
a O 
lower B-DNA 
- I-DNA 
affinity I-DNA 
site I-DNA 
for O 
RelA B-protein 
. O 

Thus O 
, O 
competition O 
between O 
two O 
general O 
transcriptional B-protein 
activators I-protein 
, O 
RelA B-protein 
and O 
NF B-protein 
- I-protein 
ATp I-protein 
, O 
mediates O 
the O 
inhibitory O 
effect O 
of O 
protein B-protein 
kinase I-protein 
C I-protein 
stimulation O 
on O 
IL4 B-protein 
expression O 
and O 
may O 
contribute O 
to O 
differential O 
gene O 
expression O 
in O 
TH B-cell_line 
cells I-cell_line 
. O 

Regulation O 
of O 
the O 
balance O 
of O 
cytokine B-protein 
production O 
and O 
the O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
( O 
STAT B-protein 
) O 
transcription O 
factor O 
activity O 
by O 
cytokines B-protein 
and O 
inflammatory O 
synovial O 
fluids O 
. O 

The O 
balance O 
between O 
type O 
1 O 
and O 
2 O 
T O 
helper O 
cell O 
cytokine O 
production O 
plays O 
an O 
important O 
role O 
in O 
several O 
animal O 
models O 
of O 
autoimmunity O 
, O 
and O 
skewed O 
patterns O 
of O 
cytokine B-protein 
expression O 
have O 
been O 
described O 
in O 
human O 
inflammatory O 
diseases O 
. O 

Many O 
cytokines B-protein 
activate O 
signal B-protein 
transducer I-protein 
and I-protein 
activation I-protein 
of I-protein 
transcription I-protein 
( I-protein 
STAT B-protein I-protein 
) I-protein 
transcription I-protein 
factors I-protein 
, O 
which O 
, O 
in O 
turn O 
, O 
activate O 
transcription O 
of O 
inflammatory O 
effector O 
genes O 
. O 

We O 
used O 
mononuclear B-cell_line 
cell I-cell_line 
priming I-cell_line 
cultures I-cell_line 
and O 
inflammatory B-cell_type 
synovial I-cell_type 
fluids I-cell_type 
( O 
SFs B-cell_type 
) O 
derived O 
from O 
arthritis O 
patients O 
to O 
examine O 
the O 
regulation O 
of O 
cytokine B-protein 
production O 
and O 
STAT B-protein 
activity O 
by O 
an O 
inflammatory O 
synovial O 
microenvironment O 
. O 

Exposure O 
to O 
SFs B-cell_type 
during O 
priming O 
resulted O 
in O 
an O 
81 O 
% O 
inhibition O 
of O 
interferon B-protein 
( I-protein 
IFN I-protein 
) I-protein 
- I-protein 
gamma I-protein 
, O 
but O 
not O 
interleukin B-protein 
( I-protein 
IL I-protein 
) I-protein 
4 I-protein 
, O 
production O 
by O 
effector B-cell_type 
cells I-cell_type 
generated O 
in O 
priming O 
cultures O 
. O 

SF O 
suppression O 
was O 
mediated O 
by O 
IL B-protein 
- I-protein 
4 I-protein 
and O 
IL B-protein 
- I-protein 
10 I-protein 
and O 
inhibition O 
of O 
IL B-protein 
- I-protein 
12 I-protein 
expression O 
, O 
and O 
it O 
was O 
reversed O 
in O 
a O 
dominant O 
fashion O 
by O 
exogenous O 
IL O 
- O 
12 O 
. O 

SFs B-cell_type 
blocked O 
the O 
sustained O 
activity O 
of O 
transcription B-protein 
factor I-protein 
Stat1 I-protein 
, O 
but O 
not O 
Stat3 B-protein 
, O 
during O 
the O 
priming O 
period O 
, O 
and O 
Stat1 B-protein 
activity O 
was O 
differentially O 
regulated O 
by O 
cytokines B-protein 
in O 
parallel O 
with O 
their O 
positive O 
or O 
negative O 
regulation O 
of O 
IFN B-protein 
- I-protein 
gamma I-protein 
production O 
. O 

Active O 
Stat3 B-protein 
, O 
but O 
not O 
Stat1 B-protein 
, O 
was O 
detected O 
in O 
cells O 
from O 
inflamed O 
joints O 
. O 

These O 
results O 
suggest O 
a O 
role O 
for O 
altered O 
balance O 
of O 
Stat1 O 
and O 
Stat3 O 
transcriptional O 
activity O 
in O 
the O 
regulation O 
of O 
T B-cell_type 
cell I-cell_type 
differentiation O 
and O 
in O 
the O 
pathogenesis O 
of O 
inflammatory O 
synovitis O 
. O 

Triggering O 
of O 
complement B-protein 
receptors I-protein 
CR1 B-protein 
( O 
CD35 B-protein 
) O 
and O 
CR3 B-protein 
( O 
CD11b B-protein 
/ I-protein 
CD18 I-protein 
) O 
induces O 
nuclear O 
translocation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
( O 
p50 B-protein 
/ I-protein 
p65 I-protein 
) O 
in O 
human B-cell_type 
monocytes I-cell_type 
and O 
enhances O 
viral O 
replication O 
in O 
HIV B-cell_type 
- I-cell_type 
infected I-cell_type 
monocytic I-cell_type 
cells I-cell_type 
. O 

Monocyte B-cell_type 
/ I-cell_type 
macrophages I-cell_type 
may O 
harbor O 
HIV O 
in O 
a O 
nonproductive O 
fashion O 
for O 
prolonged O 
periods O 
of O 
time O 
. O 

Viral O 
gene O 
expression O 
may O 
be O 
reactivated O 
by O 
stimulation O 
of O 
the O 
cells O 
with O 
LPS O 
or O 
cytokines B-protein 
such O 
as O 
TNF B-protein 
- I-protein 
alpha I-protein 
in O 
vitro O 
. O 

The O 
effect O 
of O 
LPS O 
and O 
TNF B-protein 
- I-protein 
alpha I-protein 
is O 
mediated O 
by O 
their O 
ability O 
to O 
induce O 
nuclear O 
translocation O 
of O 
the O 
DNA B-protein 
- I-protein 
binding I-protein 
heterodimer I-protein 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
( O 
p50 B-protein 
/ I-protein 
p65 I-protein 
) O 
, O 
which O 
binds O 
to O 
a O 
specific O 
sequence O 
in O 
the O 
HIV B-DNA 
- I-DNA 
long I-DNA 
terminal I-DNA 
repeat I-DNA 
. O 

The O 
present O 
study O 
demonstrates O 
that O 
triggering O 
of O 
complement B-protein 
receptors I-protein 
CR1 B-protein 
( O 
CD35 B-protein 
) O 
and O 
CR3 B-protein 
( O 
CD11b B-protein 
/ I-protein 
CD18 I-protein 
) O 
enhances O 
viral O 
replication O 
in O 
HIV B-cell_line 
- I-cell_line 
infected I-cell_line 
human I-cell_line 
monocytic I-cell_line 
cells I-cell_line 
. O 

Monocytic B-cell_line 
cell I-cell_line 
lines I-cell_line 
and O 
normal O 
peripheral O 
blood O 
monocytes O 
were O 
infected O 
with O 
HIV O 
- O 
1 O 
in O 
vitro O 
and O 
cultured O 
in O 
the O 
presence O 
or O 
absence O 
of O 
F B-protein 
( I-protein 
ab I-protein 
' I-protein 
) I-protein 
2 I-protein 
fragments I-protein 
of O 
monoclonal B-protein 
anti I-protein 
- I-protein 
CR1 B-protein I-protein 
or O 
anti B-protein 
- I-protein 
CR3 B-protein I-protein 
Abs I-protein 
or O 
with O 
C3 B-protein 
fragments I-protein 
. O 

Stimulation O 
of O 
CR1 B-protein 
or O 
CR3 B-protein 
induces O 
a O 
two O 
- O 
to O 
fourfold O 
increase O 
in O 
the O 
amount O 
of O 
cell O 
- O 
associated O 
and O 
released O 
p24 B-protein 
Ag I-protein 
in O 
cell B-cell_line 
cultures I-cell_line 
that O 
was O 
equivalent O 
to O 
that O 
observed O 
in O 
control B-cell_line 
cultures I-cell_line 
triggered O 
with O 
LPS O 
. O 

We O 
further O 
observed O 
that O 
stimulation O 
of O 
CR1 B-protein 
or O 
CR3 B-protein 
induces O 
the O 
nuclear O 
translocation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
p50 B-protein 
/ I-protein 
p65 I-protein 
in O 
infected B-cell_type 
cells I-cell_type 
. O 

Translocation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
p50 B-protein 
/ I-protein 
p65 I-protein 
was O 
also O 
observed O 
following O 
stimulation O 
of O 
CR1 B-protein 
or O 
CR3 B-protein 
of O 
uninfected B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
monocytes I-cell_type 
from O 
HIV O 
- O 
seronegative O 
donors O 
. O 

The O 
amount O 
of O 
protein O 
translocated O 
was O 
similar O 
to O 
that O 
observed O 
when O 
cells O 
were O 
stimulated O 
with O 
rhTNF B-protein 
- I-protein 
alpha I-protein 
. O 

TNF B-protein 
- I-protein 
alpha I-protein 
did O 
not O 
mediate O 
the O 
translocation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
p50 B-protein 
/ I-protein 
p65 I-protein 
induced O 
by O 
triggering O 
of O 
complement B-protein 
receptors I-protein 
. O 

Taken O 
together O 
, O 
these O 
observations O 
suggest O 
that O 
HIV O 
gene O 
expression O 
may O 
be O 
activated O 
in O 
infected B-cell_type 
monocytes I-cell_type 
through O 
interaction O 
of O 
the O 
cells O 
with O 
complement B-protein 
- I-protein 
opsonized I-protein 
particles I-protein 
and O 
that O 
enhanced O 
viral O 
replication O 
is O 
associated O 
with O 
C3 B-protein 
receptor I-protein 
- O 
mediated O 
nuclear O 
translocation O 
of O 
the O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
complex I-protein 
. O 

Attenuation O 
of O 
gamma B-protein 
interferon I-protein 
- O 
induced O 
tyrosine O 
phosphorylation O 
in O 
mononuclear B-cell_type 
phagocytes I-cell_type 
infected O 
with O 
Leishmania O 
donovani O 
: O 
selective O 
inhibition O 
of O 
signaling O 
through O 
Janus B-protein 
kinases I-protein 
and O 
Stat1 B-protein 
. O 

The O 
induction O 
of O 
gene O 
transcription O 
in O 
response O 
to O 
gamma B-protein 
interferon I-protein 
is O 
impaired O 
in O 
mononuclear B-cell_type 
phagocytes I-cell_type 
infected O 
with O 
Leishmania O 
donovani O 
, O 
and O 
the O 
mechanisms O 
involved O 
are O 
not O 
fully O 
understood O 
. O 

The O 
changes O 
in O 
gene O 
expression O 
brought O 
about O 
by O 
gamma B-protein 
interferon I-protein 
are O 
thought O 
to O 
involve O 
transient O 
increases O 
in O 
the O 
activities O 
of O 
cellular B-protein 
protein I-protein 
tyrosine I-protein 
kinases I-protein 
, O 
including O 
the O 
Janus B-protein 
kinases I-protein 
Jak1 B-protein 
and O 
Jak2 B-protein 
, O 
leading O 
to O 
tyrosine O 
phosphorylation O 
of O 
the O 
transcription B-protein 
factor I-protein 
Stat1 B-protein I-protein 
. O 

To O 
investigate O 
the O 
mechanisms O 
accounting O 
for O 
the O 
impaired O 
responses O 
to O 
gamma B-protein 
interferon I-protein 
, O 
a O 
model O 
system O 
for O 
examining O 
overall O 
changes O 
in O 
protein O 
tyrosine O 
phosphorylation O 
, O 
activation O 
of O 
Jak1 B-protein 
and O 
Jak2 B-protein 
and O 
phosphorylation O 
of O 
Stat1 B-protein 
was O 
developed O 
in O 
phorbol B-cell_line 
12 I-cell_line 
- I-cell_line 
myristate I-cell_line 
13 I-cell_line 
- I-cell_line 
acetate I-cell_line 
- I-cell_line 
differentiated I-cell_line 
U I-cell_line 
- I-cell_line 
937 I-cell_line 
cells I-cell_line 
. O 

Analysis O 
of O 
whole O 
- O 
cell O 
lysates O 
by O 
antiphosphotyrosine O 
immunoblotting O 
showed O 
that O 
incubation O 
with O 
gamma B-protein 
interferon I-protein 
brought O 
about O 
specific O 
increases O 
in O 
phosphotyrosine O 
labeling O 
of O 
several O 
proteins O 
. O 

Increased O 
labeling O 
of O 
these O 
proteins O 
occurred O 
to O 
similar O 
extents O 
in O 
control B-cell_type 
cells I-cell_type 
and O 
in O 
cells O 
that O 
had O 
been O 
infected O 
with O 
L O 
. O 
donovani O 
for O 
16 O 
h O 
. O 

Jak1 B-protein 
, O 
Jak2 B-protein 
, O 
and O 
Stat1 B-protein 
were O 
immunoprecipitated O 
from O 
control O 
and O 
interferon B-cell_line 
- I-cell_line 
treated I-cell_line 
cells I-cell_line 
, O 
and O 
tyrosine O 
phosphorylation O 
of O 
these O 
proteins O 
, O 
detected O 
by O 
antiphosphotyrosine O 
immunoblotting O 
was O 
used O 
to O 
measured O 
their O 
activation O 
. O 

Tyrosine O 
phosphorylation O 
of O 
Jak1 B-protein 
, O 
Jak2 B-protein 
, O 
and O 
Stat1 B-protein 
increased O 
markedly O 
, O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
in O 
U B-cell_line 
- I-cell_line 
937 I-cell_line 
cells I-cell_line 
incubated O 
with O 
gamma B-protein 
interferon I-protein 
. O 

In O 
contrast O 
, O 
in O 
cells O 
infected O 
with O 
L O 
. O 
donovani O 
, O 
tyrosine O 
phosphorylation O 
of O 
Jak1 B-protein 
, O 
Jak2 B-protein 
, O 
and O 
Stat1 B-protein 
was O 
markedly O 
impaired O 
. O 

This O 
effect O 
was O 
dependent O 
upon O 
the O 
duration O 
of O 
exposure O 
to O 
L O 
. O 
donovani O 
and O 
was O 
maximal O 
and O 
complete O 
at O 
16 O 
h O 
. O 

Results O 
similar O 
to O 
those O 
observed O 
with O 
U B-cell_line 
- I-cell_line 
937 I-cell_line 
cells I-cell_line 
were O 
also O 
obtained O 
with O 
human B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
monocytes I-cell_type 
. O 

These O 
findings O 
indicate O 
that O 
infection O 
of O 
human B-cell_type 
mononuclear I-cell_type 
phagocytes I-cell_type 
with O 
L O 
. O 
donovani O 
leads O 
to O 
impaired O 
gamma B-protein 
interferon I-protein 
- O 
mediated O 
tyrosine O 
phosphorylation O 
and O 
selective O 
effects O 
on O 
the O 
Jak O 
- O 
Stat1 B-protein 
pathway O 
. O 

Unresponsiveness O 
to O 
gamma B-protein 
interferon I-protein 
for O 
activation O 
of O 
this O 
pathway O 
may O 
explain O 
impaired O 
transcriptional O 
responses O 
in O 
leishmania B-cell_type 
- I-cell_type 
infected I-cell_type 
cells I-cell_type 
. O 

Mutually O 
exclusive O 
interaction O 
of O 
a O 
novel O 
matrix B-protein 
attachment I-protein 
region I-protein 
binding I-protein 
protein I-protein 
and O 
the O 
NF B-protein 
- I-protein 
muNR I-protein 
enhancer I-protein 
repressor I-protein 
. O 

Implications O 
for O 
regulation O 
of O 
immunoglobulin B-protein 
heavy I-protein 
chain I-protein 
expression O 
. O 

The O 
immunoglobulin B-protein 
heavy I-protein 
chain I-protein 
( O 
IgH B-protein 
) O 
intronic O 
enhancer O 
stimulates O 
transcription O 
from O 
functional O 
promoters O 
in O 
B O 
lymphocytes O 
but O 
not O 
other O 
cell O 
types O 
. O 

The O 
observation O 
that O 
binding O 
sites O 
for O 
the O 
nuclear B-protein 
factor I-protein 
- I-protein 
mu I-protein 
negative I-protein 
regulator I-protein 
( O 
NF B-protein 
- I-protein 
muNR I-protein 
) O 
enhancer O 
repressor O 
overlap O 
nuclear B-protein 
matrix I-protein 
attachment I-protein 
regions I-protein 
( O 
MARs B-protein 
) O 
in O 
this O 
enhancer B-DNA 
has O 
lead O 
to O 
the O 
hypothesis O 
that O 
the O 
cell O 
type O 
specificity O 
of O 
the O 
enhancer B-DNA 
might O 
be O 
controlled O 
by O 
regulating O 
nuclear O 
matrix O 
attachment O 
( O 
Scheuermann O 
, O 
R O 
. O 
H O 
. O 
, O 
and O 
Chen O 
, O 
U O 
. O 
( O 
1989 O 
) O 
Genes O 
& O 
Dev O 
. O 
3 O 
, O 
1255 O 
- O 
1266 O 
) O 
. O 

To O 
understand O 
the O 
role O 
of O 
MARs B-protein 
in O 
IgH B-protein B-DNA 
enhancer I-DNA 
regulation O 
, O 
we O 
have O 
identified O 
a O 
novel O 
MAR B-protein 
- I-protein 
binding I-protein 
protein I-protein 
, O 
MAR B-protein 
- I-protein 
BP1 I-protein 
, O 
from O 
soluble O 
nuclear O 
matrix O 
preparations O 
based O 
on O 
its O 
ability O 
to O 
bind O 
to O 
the O 
MARs B-protein 
associated O 
with O 
the O 
IgH B-protein B-DNA 
enhancer I-DNA 
. O 

Purified O 
MAR B-protein 
- I-protein 
BP1 I-protein 
migrates O 
as O 
a O 
33 B-protein 
- I-protein 
kDa I-protein 
protein I-protein 
, O 
and O 
it O 
can O 
be O 
found O 
in O 
nuclear O 
matrix O 
preparations O 
from O 
a O 
number O 
of O 
different O 
types O 
of O 
lymphoid B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Although O 
specific O 
binding O 
sites O 
have O 
been O 
difficult O 
to O 
localize O 
by O 
chemical O 
or O 
enzymatic O 
footprinting O 
procedures O 
, O 
NF B-protein 
- I-protein 
muNR I-protein 
binding O 
sites O 
are O 
critical O 
for O 
efficient O 
MAR B-protein 
- I-protein 
BP1 I-protein 
binding O 
. O 

Indeed O 
, O 
binding O 
of O 
the O 
IgH B-protein B-DNA 
enhancer I-DNA 
to O 
either O 
intact O 
nuclear O 
matrix O 
preparations O 
or O 
to O 
MAR B-protein 
- I-protein 
BP1 I-protein 
is O 
mutually O 
exclusive O 
to O 
NF B-protein 
- I-protein 
muNR I-protein 
binding O 
. O 

These O 
results O 
are O 
consistent O 
with O 
a O 
model O 
for O 
cell O 
- O 
type O 
specific O 
regulation O 
in O 
which O 
binding O 
of O 
the O 
NF B-protein B-protein 
- I-protein I-protein 
muNR I-protein I-protein 
repressor I-protein 
to O 
the O 
IgH B-protein B-DNA 
enhancer I-DNA 
prevents O 
nuclear O 
matrix O 
attachment O 
in O 
inappropriate O 
cells O 
by O 
interfering O 
with O 
MAR B-protein 
- I-protein 
BP1 I-protein 
/ B-DNA 
enhancer I-DNA 
interaction O 
. O 

PU B-protein 
. I-protein 
1 I-protein 
( O 
Spi B-protein 
- I-protein 
1 I-protein 
) O 
and O 
C B-protein 
/ I-protein 
EBP I-protein 
alpha I-protein 
regulate O 
expression O 
of O 
the O 
granulocyte B-protein B-DNA 
- I-protein I-DNA 
macrophage I-protein I-DNA 
colony I-protein I-DNA 
- I-protein I-DNA 
stimulating I-protein I-DNA 
factor I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-DNA 
gene I-DNA 
. O 

Growth B-protein 
factor I-protein 
receptors I-protein 
play O 
an O 
important O 
role O 
in O 
hematopoiesis O 
. O 

In O 
order O 
to O 
further O 
understand O 
the O 
mechanisms O 
directing O 
the O 
expression O 
of O 
these O 
key O 
regulators O 
of O 
hematopoiesis O 
, O 
we O 
initiated O 
a O 
study O 
investigating O 
the O 
transcription B-protein 
factors I-protein 
activating O 
the O 
expression O 
of O 
the O 
granulocyte B-protein B-DNA 
- I-protein I-DNA 
macrophage I-protein I-DNA 
colony I-protein I-DNA 
- I-protein I-DNA 
stimulating I-protein I-DNA 
factor I-protein I-DNA 
( I-DNA 
GM B-protein I-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
) I-DNA 
receptor I-DNA 
alpha I-DNA 
gene I-DNA 
. O 

Here O 
, O 
we O 
demonstrate O 
that O 
the O 
human B-DNA 
GM B-protein B-protein I-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
directs O 
reporter B-DNA 
gene I-DNA 
activity O 
in O 
a O 
tissue O 
- O 
specific O 
fashion O 
in O 
myelomonocytic B-cell_type 
cells I-cell_type 
, O 
which O 
correlates O 
with O 
its O 
expression O 
pattern O 
as O 
analyzed O 
by O 
reverse O 
transcription O 
PCR O 
. O 

The O 
GM B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
contains O 
an O 
important O 
functional O 
site O 
between O 
positions O 
- O 
53 O 
and O 
- O 
41 O 
as O 
identified O 
by O 
deletion O 
analysis O 
of O 
reporter B-DNA 
constructs I-DNA 
. O 

We O 
show O 
that O 
the O 
myeloid O 
and O 
B B-protein 
cell I-protein 
transcription I-protein 
factor I-protein 
PU B-protein 
. I-protein 
1 I-protein 
binds O 
specifically O 
to O 
this O 
site O 
. O 

Furthermore O 
, O 
we O 
demonstrate O 
that O 
a O 
CCAAT B-DNA 
site I-DNA 
located O 
upstream O 
of O 
the O 
PU B-protein B-DNA 
. I-protein I-DNA 
1 I-protein I-DNA 
site I-DNA 
between O 
positions O 
- O 
70 O 
and O 
- O 
54 O 
is O 
involved O 
in O 
positive O 
- O 
negative O 
regulation O 
of O 
the O 
GM B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
activity O 
. O 

C B-protein 
/ I-protein 
EBP I-protein 
alpha I-protein 
is O 
the O 
major O 
CCAAT B-DNA B-protein 
/ I-DNA I-protein 
enhancer I-DNA I-protein 
- I-protein 
binding I-protein 
protein I-protein 
( O 
C B-protein 
/ I-protein 
EBP I-protein 
) O 
form O 
binding O 
to O 
this O 
site O 
in O 
nuclear O 
extracts O 
of O 
U937 B-cell_line 
cells I-cell_line 
. O 

Point O 
mutations O 
of O 
either O 
the O 
PU B-protein B-DNA 
. I-protein I-DNA 
1 I-protein I-DNA 
site I-DNA 
or O 
the O 
C B-protein B-DNA 
/ I-protein I-DNA 
EBP I-protein I-DNA 
site I-DNA 
that O 
abolish O 
the O 
binding O 
of O 
the O 
respective O 
factors O 
result O 
in O 
a O 
significant O 
decrease O 
of O 
GM B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
activity O 
in O 
myelomonocytic B-cell_type 
cells I-cell_type 
only O 
. O 

Furthermore O 
, O 
we O 
demonstrate O 
that O 
in O 
myeloid O 
and O 
B O 
cell O 
extracts O 
, O 
PU B-protein 
. I-protein 
1 I-protein 
forms O 
a O 
novel O 
, O 
specific O 
, O 
more O 
slowly O 
migrating O 
complex O 
( O 
PU B-protein 
- I-protein 
SF I-protein 
) O 
when O 
binding O 
the O 
GM B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
PU B-protein B-DNA 
. I-protein I-DNA 
1 I-protein I-DNA 
site I-DNA 
. O 

This O 
is O 
the O 
first O 
demonstration O 
of O 
a O 
specific O 
interaction O 
with O 
PU B-protein 
. I-protein 
1 I-protein 
on O 
a O 
myeloid B-DNA 
PU B-protein I-DNA 
. I-protein I-DNA 
1 I-protein I-DNA 
binding I-DNA 
site I-DNA 
. O 

The O 
novel O 
complex O 
is O 
distinct O 
from O 
that O 
described O 
previously O 
as O 
binding O 
to O 
B B-DNA 
cell I-DNA 
enhancer I-DNA 
sites I-DNA 
and O 
can O 
be O 
formed O 
by O 
addition O 
of O 
PU B-protein 
. I-protein 
1 I-protein 
to O 
extracts O 
from O 
certain O 
nonmyeloid B-cell_type 
cell I-cell_type 
types I-cell_type 
which O 
do O 
not O 
express O 
PU B-protein 
. I-protein 
1 I-protein 
, O 
including O 
T B-cell_type 
cells I-cell_type 
and O 
epithelial B-cell_type 
cells I-cell_type 
, O 
but O 
not O 
from O 
erythroid B-cell_type 
cells I-cell_type 
. O 

Furthermore O 
, O 
we O 
demonstrate O 
that O 
the O 
PU B-protein B-protein 
- I-protein I-protein 
SF I-protein I-protein 
complex I-protein 
binds O 
to O 
PU B-protein 
. I-protein 
1 I-protein 
sites O 
found O 
on O 
a O 
number O 
of O 
myeloid B-DNA 
promoters I-DNA 
, O 
and O 
its O 
formation O 
requires O 
an O 
intact O 
PU B-protein B-DNA 
. I-protein I-DNA 
1 I-protein I-DNA 
site I-DNA 
adjacent O 
to O 
a O 
single O 
- O 
stranded O 
region O 
. O 

Expression O 
of O 
PU B-protein 
. I-protein 
1 I-protein 
in O 
nonmyeloid B-cell_type 
cells I-cell_type 
can O 
activate O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
receptor I-DNA 
alpha I-DNA 
promoter I-DNA 
. O 

Deletion O 
of O 
the O 
amino B-protein 
- I-protein 
terminal I-protein 
region I-protein 
of O 
PU B-protein 
. I-protein 
1 I-protein 
results O 
in O 
a O 
failure O 
to O 
form O 
the O 
PU B-protein 
- I-protein 
SF I-protein 
complex O 
and O 
in O 
a O 
concomitant O 
loss O 
of O 
transactivation O 
, O 
suggesting O 
that O 
formation O 
of O 
the O 
PU B-protein B-protein 
- I-protein I-protein 
SF I-protein I-protein 
complex I-protein 
is O 
of O 
functional O 
importance O 
for O 
the O 
activity O 
of O 
the O 
GM B-protein B-DNA 
- I-protein I-DNA 
CSF I-protein I-DNA 
receptor I-DNA 
alpha I-DNA 
promoter I-DNA 
. O 

Finally O 
, O 
we O 
demonstrate O 
that O 
C B-protein B-protein 
/ I-protein I-protein 
EBP I-protein I-protein 
alpha I-protein 
can O 
also O 
active O 
the O 
GM B-protein B-protein B-DNA 
- I-protein I-protein I-DNA 
CSF I-protein I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
promoter I-DNA 
in O 
nonmyeloid B-cell_type 
cells I-cell_type 
. O 

( O 
ABSTRACT O 
TRUNCATED O 
AT O 
400 O 
WORDS O 
) O 
. O 

HMG B-protein 
- I-protein 
I I-protein 
binds O 
to O 
GATA B-DNA 
motifs I-DNA 
: O 
implications O 
for O 
an O 
HPFH O 
syndrome O 
. O 

We O 
have O 
examined O 
binding O 
of O 
the O 
nuclear B-protein 
protein I-protein 
HMG B-protein 
- I-protein 
I I-protein 
to O 
the O 
human B-DNA 
gamma I-DNA 
- I-DNA 
globin I-DNA 
promoter I-DNA 
. O 

We O 
find O 
that O 
HMG B-protein 
- I-protein 
I I-protein 
binds O 
preferentially O 
to O 
the O 
more O 
3 O 
' O 
of O 
a O 
pair O 
of O 
GATA B-DNA 
motifs I-DNA 
in O 
the O 
gamma B-DNA 
- I-DNA 
globin I-DNA 
promoter I-DNA 
; O 
this O 
paired O 
motif O 
is O 
bound O 
by O 
the O 
erythroid B-protein 
factor I-protein 
GATA B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
. O 

A O 
naturally O 
occurring O 
mutation O 
( O 
- O 
175 O 
T O 
- O 
C O 
) O 
in O 
the O 
area O 
bound O 
by O 
HMG B-protein 
- I-protein 
I I-protein 
results O 
in O 
overexpression O 
of O 
gamma B-protein 
- I-protein 
globin I-protein 
in O 
adult B-cell_type 
red I-cell_type 
blood I-cell_type 
cells I-cell_type 
( O 
HPFH B-cell_type 
) O 
and O 
up O 
- O 
regulation O 
of O 
the O 
gamma B-protein B-DNA 
- I-protein I-DNA 
globin I-protein I-DNA 
promoter I-DNA 
in O 
in O 
vitro O 
expression O 
assays O 
; O 
HMG B-protein 
- I-protein 
I I-protein 
does O 
not O 
bind O 
to O 
this O 
mutant B-DNA 
sequence I-DNA 
. O 

A O 
survey O 
of O 
GATA B-DNA 
motifs I-DNA 
from O 
other O 
globin B-DNA 
cis I-DNA 
- I-DNA 
elements I-DNA 
demonstrates O 
HMG B-protein 
- I-protein 
I I-protein 
binding O 
to O 
most O 
of O 
them O 
. O 

These O 
findings O 
implicate O 
HMG B-protein 
- I-protein 
I I-protein 
in O 
the O 
HPFH B-cell_type 
phenotype O 
; O 
we O 
speculate O 
that O 
it O 
may O 
participate O 
in O 
the O 
formation O 
of O 
multiprotein B-protein 
complexes I-protein 
that O 
regulate O 
globin O 
gene O 
expression O 
. O 

Constitutive O 
activation O 
of O 
different O 
Jak B-protein 
tyrosine I-protein 
kinases I-protein 
in O 
human B-protein 
T I-protein 
cell I-protein 
leukemia I-protein 
virus I-protein 
type I-protein 
1 I-protein 
( I-protein 
HTLV I-protein 
- I-protein 
1 I-protein 
) I-protein 
tax I-protein 
protein I-protein 
or O 
virus B-cell_line 
- I-cell_line 
transformed I-cell_line 
cells I-cell_line 
. O 

HTLV O 
- O 
1 O 
infection O 
causes O 
an O 
adult O 
T O 
cell O 
leukemia O 
in O 
humans O 
. O 

The O 
viral B-protein 
encoded I-protein 
protein I-protein 
tax B-protein 
, O 
is O 
thought O 
to O 
play O 
an O 
important O 
role O 
in O 
oncogenesis O 
. O 

Our O 
previous O 
data O 
obtained O 
from O 
a O 
tax B-protein 
transgenic O 
mouse O 
model O 
revealed O 
that O 
tax B-protein 
transforms O 
mouse B-cell_type 
fibroblasts I-cell_type 
but O 
not O 
thymocytes B-cell_type 
, O 
despite O 
comparable O 
levels O 
of O 
tax B-protein 
expression O 
in O 
both O 
tissues O 
. O 

Constitutive O 
tyrosine O 
phosphorylation O 
of O 
a O 
130 B-protein 
- I-protein 
kD I-protein 
protein I-protein 
( O 
s O 
) O 
was O 
observed O 
in O 
the O 
tax B-protein 
transformed B-cell_line 
fibroblast I-cell_line 
B I-cell_line 
line I-cell_line 
and O 
in O 
HTLV B-cell_line 
- I-cell_line 
1 I-cell_line 
transformed I-cell_line 
human I-cell_line 
lymphoid I-cell_line 
lines I-cell_line 
, O 
but O 
not O 
in O 
thymocytes B-cell_type 
from O 
Thy O 
- O 
tax O 
transgenic O 
mice O 
. O 

Phosphotyrosine O 
immunoprecipitation O 
followed O 
by O 
Western O 
blot O 
analysis O 
with O 
a O 
set O 
of O 
Jak B-protein B-protein 
kinase I-protein I-protein 
specific I-protein 
antibodies I-protein 
, O 
identified O 
p130 O 
as O 
Jak2 B-protein 
in O 
the O 
tax B-protein 
transformed O 
mouse B-cell_line 
fibroblastic I-cell_line 
cell I-cell_line 
line I-cell_line 
and O 
Jak3 B-protein 
in O 
HTLV B-cell_line 
- I-cell_line 
1 I-cell_line 
transformed I-cell_line 
human I-cell_line 
T I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Phosphorylation O 
of O 
Jak2 B-protein 
in O 
tax B-protein B-cell_line 
transformed I-cell_line 
cells I-cell_line 
resulted O 
from O 
high O 
expression O 
of O 
IL B-protein 
- I-protein 
6 I-protein 
. O 

Tyrosine O 
phosphorylation O 
of O 
this O 
protein O 
could O 
also O 
be O 
induced O 
in O 
Balb B-cell_line 
/ I-cell_line 
c3T3 I-cell_line 
cells I-cell_line 
using O 
a O 
supernatant O 
from O 
the O 
B B-cell_line 
line I-cell_line 
, O 
which O 
was O 
associated O 
with O 
induction O 
of O 
cell O 
proliferation O 
. O 

Both O 
phosphorylation O 
and O 
proliferation O 
were O 
inhibited O 
by O 
IL B-protein B-protein 
- I-protein I-protein 
6 I-protein I-protein 
neutralizing I-protein 
antibodies I-protein 
. O 

Constitutive O 
phosphorylation O 
of O 
Jak B-protein 
kinases I-protein 
may O 
facilitate O 
tumor O 
growth O 
in O 
both O 
HTLV O 
- O 
1 O 
infected O 
human O 
T B-cell_type 
cells I-cell_type 
and O 
the O 
transgenic O 
mouse O 
model O 
. O 

Regulation O 
of O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
mRNA I-RNA 
expression O 
by O 
hydroxyurea O 
in O 
human B-cell_line 
K562 I-cell_line 
cells I-cell_line 
during O 
erythroid O 
differentiation O 
[ O 
published O 
erratum O 
appears O 
in O 
Biochim O 
Biophys O 
Acta O 
1995 O 
Dec O 
27 O 
; O 
1264 O 
( O 
3 O 
) O 
: O 
409 O 
] O 
. O 

Hydroxyurea O 
( O 
HU O 
) O 
is O 
an O 
antitumor O 
agent O 
which O 
also O 
induces O 
hemoglobinization O 
during O 
erythroid O 
differentiation O 
. O 

In O 
addition O 
, O 
HU O 
stimulates O 
the O 
synthesis O 
of O 
fetal B-protein 
hemoglobin I-protein 
in O 
sickle O 
cell O 
anemia O 
patients O 
. O 

To O 
further O 
understand O 
its O 
mechanism O 
of O 
action O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
HU O 
on O 
regulation O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
expression O 
prior O 
to O 
the O 
onset O 
of O 
erythroid O 
differentiation O 
of O 
K562 B-cell_line 
cells I-cell_line 
. O 

HU O 
induced O 
a O 
dose O 
- O 
dependent O 
stimulation O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
synthesis O 
. O 

The O 
levels O 
of O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
mRNA I-RNA 
was O 
elevated O 
4 O 
to O 
7 O 
. O 
5 O 
- O 
fold O 
by O 
HU O 
within O 
2 O 
h O 
. O 

This O 
was O 
followed O 
by O 
a O 
gradual O 
decline O 
to O 
the O 
basal O 
level O 
by O 
24 O 
h O 
. O 

Both O 
nuclear O 
run O 
- O 
on O 
and O 
actinomycin O 
D O 
pulse O 
experiments O 
strongly O 
indicate O 
that O 
HU O 
regulates O 
c B-RNA 
- I-RNA 
jun I-RNA 
mRNA I-RNA 
expression O 
by O 
increasing O 
the O 
rate O 
of O 
synthesis O 
as O 
well O 
as O 
stabilizing O 
the O 
c B-DNA B-RNA 
- I-DNA I-RNA 
jun I-DNA I-RNA 
mRNA I-RNA 
. O 

In O 
addition O 
, O 
the O 
level O 
of O 
jun B-protein 
protein I-protein 
was O 
elevated O 
by O 
2 O 
to O 
5 O 
- O 
fold O 
within O 
4 O 
h O 
in O 
HU B-cell_line 
treated I-cell_line 
cells I-cell_line 
. O 

Furthermore O 
, O 
concentrations O 
of O 
HU O 
below O 
250 O 
microM O 
slightly O 
increased O 
the O 
5X O 
AP B-protein 
- I-protein 
1 I-protein 
/ B-protein 
CAT I-protein 
activity O 
. O 

These O 
results O 
strongly O 
suggest O 
that O 
HU O 
induces O 
both O 
transcriptional O 
and O 
post O 
- O 
transcription O 
regulation O 
of O 
c B-DNA 
- I-DNA 
jun I-DNA 
during O 
erythroid O 
differentiation O 
. O 

In O 
vivo O 
and O 
in O 
vitro O 
effects O 
of O 
glucocorticoids O 
on O 
lymphocyte O 
proliferation O 
in O 
man O 
: O 
relationship O 
to O 
glucocorticoid B-protein 
receptors I-protein 
. O 

Interrelations O 
between O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
system O 
( O 
HPA O 
) O 
and O 
the O 
immune O 
system O 
represent O 
a O 
well O 
- O 
documented O 
biological O 
phenomenon O 
. O 

While O 
in O 
vitro O 
administration O 
of O 
glucocorticoids O 
may O 
inhibit O 
concanavalin O 
A O 
( O 
Con O 
A O 
) O 
- O 
and O 
phytohemagglutinin O 
( O 
PHA O 
) O 
- O 
induced O 
T O 
- O 
cell O 
proliferation O 
, O 
pokeweed B-protein 
mitogen I-protein 
( O 
PWM B-protein 
) O 
- O 
driven O 
B O 
- O 
cell O 
mitogenesis O 
is O 
relatively O 
resistant O 
to O 
glucocorticoids O 
. O 

To O 
further O 
explore O 
the O 
link O 
between O 
the O 
HPA O 
and O 
the O 
immune O 
system O 
in O 
relation O 
to O 
glucocorticoid B-protein 
receptor I-protein 
function O 
, O 
dose O 
- O 
response O 
curves O 
were O 
obtained O 
for O 
Con O 
A O 
- O 
and O 
PHA B-protein 
- O 
induced O 
T O 
- O 
cell O 
mitogenesis O 
, O 
PWM B-protein 
- O 
generated O 
B O 
- O 
cell O 
mitogenesis O 
and O 
spontaneous O 
lymphocyte O 
proliferation O 
in O 
13 O 
healthy O 
controls O 
. O 

Glucocorticoid O 
effects O 
were O 
assessed O 
in O 
vivo O 
by O 
depletion O 
of O 
endogenous O 
glucocorticoids O 
after O 
oral O 
administration O 
of O 
1 O 
. O 
5 O 
g O 
metyrapone O 
( O 
MET O 
) O 
and O 
subsequent O 
glucocorticoid O 
replacement O 
, O 
and O 
in O 
vitro O 
by O 
incubation O 
of O 
the O 
cells O 
with O 
different O 
doses O 
of O 
dexamethasone O 
( O 
DEX O 
) O 
. O 

There O 
was O 
a O 
significant O 
decrease O 
in O 
PWM B-protein 
- O 
induced O 
B O 
- O 
cell O 
mitogenesis O 
and O 
a O 
more O 
pronounced O 
effect O 
of O 
DEX O 
administered O 
in O 
vitro O 
on O 
spontaneous O 
lymphocyte O 
proliferation O 
after O 
MET O 
treatment O 
when O 
compared O 
with O 
the O 
DEX O 
plus O 
MET O 
pretreated O 
condition O 
in O 
vivo O 
. O 

These O 
data O 
suggest O 
that O 
the O 
inhibition O 
of O 
spontaneous O 
lymphocyte O 
proliferation O 
by O 
glucocorticoids O 
in O 
vitro O 
is O 
related O 
to O 
glucocorticoid B-protein 
receptor I-protein 
function O 
. O 

The O 
decrease O 
in O 
PWM B-protein 
- O 
generated O 
B O 
- O 
cell O 
proliferation O 
following O 
cortisol O 
depletion O 
by O 
MET O 
may O 
be O 
seen O 
in O 
connection O 
with O 
impaired O 
glucocorticoid O 
- O 
mediated O 
induction O 
of O 
interleukin B-protein 
- I-protein 
1 I-protein 
receptor I-protein 
synthesis O 
. O 

Transcription O 
specific O 
differences O 
visualized O 
by O 
fluorescence O 
in O 
situ O 
hybridization O 
pattern O 
on O 
interphase O 
nuclei O 
of O 
different O 
cell O 
types O 
. O 

Application O 
of O 
a O 
" O 
formamide O 
free O 
" O 
and O 
thus O 
" O 
material O 
preserving O 
" O 
in O 
situ O 
hybridization O 
technique O 
using O 
the O 
cDNA B-DNA 
of O 
the O 
myf3 B-DNA 
gene I-DNA 
revealed O 
the O 
following O 
results O 
: O 
Human B-cell_type 
rhabdomyosarcoma I-cell_type 
cells I-cell_type 
, O 
characterized O 
by O 
a O 
high O 
expression O 
of O 
myf3 B-DNA 
show O 
intensive O 
hybridization O 
signals O 
in O 
their O 
interphase O 
. O 

RNase B-protein 
treatment O 
prior O 
to O 
hybridization O 
considerably O 
reduces O 
the O 
size O 
of O 
this O 
signals O 
. O 

In O 
comparison O 
, O 
isolated O 
nuclei O 
of O 
human B-cell_type 
lymphocytes I-cell_type 
in O 
which O 
no O 
need O 
for O 
the O 
expression O 
of O 
this O 
gene O 
exists O 
, O 
show O 
barely O 
hybridization O 
signals O 
. O 

Correspondingly O 
, O 
RNase B-protein 
treatment O 
had O 
no O 
effect O 
on O 
hybridization O 
pattern O 
at O 
all O 
. O 

In O 
conclusion O 
an O 
increased O 
transcription O 
efficiency O 
of O 
a O 
cell O 
type O 
specific O 
gene O 
is O 
accompanied O 
by O 
a O 
higher O 
hybridization O 
accessibility O 
in O 
the O 
corresponding O 
cell O 
nuclei O 
. O 

Oncogenicity O 
of O 
human O 
papillomavirus O 
- O 
or O 
adenovirus O 
- O 
transformed O 
cells O 
correlates O 
with O 
resistance O 
to O 
lysis O 
by O 
natural B-cell_type 
killer I-cell_type 
cells I-cell_type 
. O 

The O 
reasons O 
for O 
the O 
dissimilar O 
oncogenicities O 
of O 
human O 
adenoviruses O 
and O 
human O 
papillomaviruses O 
( O 
HPV O 
) O 
in O 
humans O 
are O 
unknown O 
but O 
may O 
relate O 
to O 
differences O 
in O 
the O 
capacities O 
of O 
the O 
E1A B-protein 
and O 
E7 B-protein 
proteins I-protein 
to O 
target B-cell_type 
cells I-cell_type 
for O 
rejection O 
by O 
the O 
host B-cell_type 
natural I-cell_type 
killer I-cell_type 
( I-cell_type 
NK I-cell_type 
) I-cell_type 
cell I-cell_type 
response O 
. O 

As O 
one O 
test O 
of O 
this O 
hypothesis O 
, O 
we O 
compared O 
the O 
abilities O 
of O 
E1A B-protein 
- O 
and O 
E7 B-protein 
- O 
expressing O 
human O 
fibroblastic O 
or O 
keratinocyte O 
- O 
derived O 
human O 
cells O 
to O 
be O 
selectively O 
killed O 
by O 
either O 
unstimulated B-cell_type 
or O 
interferon B-cell_line 
( I-cell_line 
IFN I-cell_line 
) I-cell_line 
- I-cell_line 
activated I-cell_line 
NK I-cell_line 
cells I-cell_line 
. O 

Cells O 
expressing O 
the O 
E1A B-protein B-protein 
oncoprotein I-protein 
were O 
selectively O 
killed O 
by O 
unstimulated B-cell_line 
NK I-cell_line 
cells I-cell_line 
, O 
while O 
the O 
same O 
parental B-cell_type 
cells I-cell_type 
but O 
expressing O 
the O 
HPV O 
type O 
16 O 
( O 
HPV O 
- O 
16 O 
) O 
or O 
HPV O 
- O 
18 O 
E7 B-protein B-protein 
oncoprotein I-protein 
were O 
resistant O 
to O 
NK O 
cell O 
lysis O 
. O 

The O 
ability O 
of O 
IFN B-cell_line 
- I-cell_line 
activated I-cell_line 
NK I-cell_line 
cells I-cell_line 
to O 
selectively O 
kill O 
virally O 
transformed O 
cells O 
depends O 
on O 
IFN B-protein 
' O 
s O 
ability O 
to O 
induce O 
resistance O 
to O 
NK O 
cell O 
lysis O 
in O 
normal O 
( O 
i O 
. O 
e O 
. O 
, O 
non B-cell_line 
- I-cell_line 
viral I-cell_line 
oncogene I-cell_line 
- I-cell_line 
expressing I-cell_line 
) O 
but O 
not O 
virally B-cell_line 
transformed I-cell_line 
cells I-cell_line 
. O 

E1A B-protein 
blocked O 
IFN B-protein 
' O 
s O 
induction O 
of O 
cytolytic O 
resistance O 
, O 
resulting O 
in O 
the O 
selective O 
lysis O 
of O 
adenovirus B-cell_line 
- I-cell_line 
transformed I-cell_line 
cells I-cell_line 
by O 
IFN B-protein B-cell_line 
- I-cell_line 
activated I-cell_line 
NK I-cell_line 
cells I-cell_line 
. O 

The O 
extent O 
of O 
IFN B-protein 
- O 
induced O 
NK O 
cell O 
killing O 
of O 
E1A B-protein B-cell_line 
- I-cell_line 
expressing I-cell_line 
cells I-cell_line 
was O 
proportional O 
to O 
the O 
level O 
of O 
E1A B-protein 
expression O 
and O 
correlated O 
with O 
the O 
ability O 
of O 
E1A B-protein 
to O 
block O 
IFN B-protein 
- O 
stimulated O 
gene O 
expression O 
in O 
target B-cell_type 
cells I-cell_type 
. O 

In O 
contrast O 
, O 
E7 B-protein 
blocked O 
neither O 
IFN B-protein 
- O 
stimulated O 
gene O 
expression O 
nor O 
IFN B-protein 
' O 
s O 
induction O 
of O 
cytolytic O 
resistance O 
, O 
thereby O 
precluding O 
the O 
selective O 
lysis O 
of O 
HPV B-cell_line 
- I-cell_line 
transformed I-cell_line 
cells I-cell_line 
by O 
IFN B-protein B-cell_line 
- I-cell_line 
activated I-cell_line 
NK I-cell_line 
cells I-cell_line 
. O 

In O 
conclusion O 
, O 
E1A B-protein 
expression O 
marks O 
cells O 
for O 
destruction O 
by O 
the O 
host O 
NK B-cell_type 
cell I-cell_type 
response O 
, O 
whereas O 
the O 
E7 B-protein B-protein 
oncoprotein I-protein 
lacks O 
this O 
activity O 
. O 

Regulation O 
of O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
by O 
PKC O 
- O 
and O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
signal O 
transduction O 
pathways O 
. O 

The O 
Ca B-protein 
( I-protein 
2 I-protein 
+ I-protein 
) I-protein 
- I-protein 
dependent I-protein 
phosphatase I-protein 
calcineurin B-protein 
, O 
a O 
target O 
of O 
FK506 O 
and O 
CsA O 
, O 
synergizes O 
with O 
PKC B-protein 
- O 
induced O 
activation O 
of O 
nuclear B-protein 
factor I-protein 
( I-protein 
NF I-protein 
) I-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

We O 
have O 
investigated O 
whether O 
this O 
synergy O 
is O 
present O 
in O 
other O 
cell O 
types O 
and O 
the O 
mechanism O 
( O 
s O 
) O 
by O 
which O 
these O 
two O 
pathways O 
lead O 
to O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activation O 
. O 

While O 
this O 
synergy O 
is O 
present O 
in O 
other O 
cell O 
types O 
, O 
in O 
the O 
monocytic B-cell_line 
cell I-cell_line 
line I-cell_line 
U937 I-cell_line 
calcineurin B-protein 
is O 
also O 
sufficient O 
to O 
activate O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
. O 

Having O 
previously O 
shown O 
that O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
and O 
PKC O 
- O 
dependent O 
pathways O 
synergize O 
by O 
accelerating O 
the O 
degradation O 
of O 
IkB B-protein 
alpha I-protein 
, O 
we O 
focused O 
on O 
the O 
regulation O 
of O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
. O 

While O 
PKC B-protein 
- O 
dependent O 
pathways O 
sequentially O 
result O 
in O 
the O 
phosphorylation O 
and O 
in O 
an O 
incomplete O 
degradation O 
of O 
IkB B-protein 
alpha I-protein 
in O 
T B-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
co O 
- O 
activation O 
of O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathways O 
accelerates O 
the O 
rate O 
of O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
and O 
results O 
in O 
its O 
complete O 
degradation O 
. O 

Activation O 
of O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathways O 
alone O 
do O 
not O 
result O 
in O 
the O 
phosphorylation O 
and O 
/ O 
or O 
degradation O 
of O 
IkB B-protein 
alpha I-protein 
in O 
Jurkat B-cell_line 
T I-cell_line 
or O 
in O 
U937 B-cell_line 
cells I-cell_line 
. O 

Treatment O 
of O 
T B-cell_type 
cells I-cell_type 
with O 
the O 
selective O 
PKC B-protein 
inhibitor O 
GF109203X O 
abrogates O 
the O 
PMA O 
- O 
induced O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
/ O 
degradation O 
irrespective O 
of O 
activation O 
of O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathways O 
, O 
but O 
not O 
the O 
phosphorylation O 
and O 
degradation O 
of O 
IkB B-protein 
alpha I-protein 
induced O 
by O 
TNF B-protein 
- I-protein 
alpha I-protein 
, O 
a O 
PKC B-protein 
- O 
independent O 
stimulus O 
. O 

Contrary O 
to O 
the O 
interaction O 
with O 
PKC B-protein 
, O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathways O 
synergize O 
with O 
TNF B-protein 
- I-protein 
alpha I-protein 
not O 
at O 
the O 
level O 
of O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
, O 
but O 
at O 
the O 
level O 
of O 
its O 
degradation O 
. O 

These O 
results O 
indicate O 
that O 
Ca O 
( O 
2 O 
+ O 
) O 
- O 
dependent O 
pathways O 
, O 
including O 
the O 
phosphatase B-protein 
calcineurin B-protein 
, O 
participate O 
in O 
the O 
regulation O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
a O 
cell O 
specific O 
fashion O 
and O 
synergize O 
with O 
PKC B-protein 
- O 
dependent O 
and O 
- O 
independent O 
pathways O 
at O 
the O 
level O 
of O 
IkB B-protein 
alpha I-protein 
phosphorylation O 
and O 
degradation O 
. O 

Vitamin O 
E O 
therapy O 
of O 
acute O 
CCl4 O 
- O 
induced O 
hepatic O 
injury O 
in O 
mice O 
is O 
associated O 
with O 
inhibition O 
of O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
binding O 
. O 

Oxidative O 
stress O 
, O 
with O 
reactive O 
oxygen O 
intermediate O 
formation O 
, O 
may O 
represent O 
a O 
common O 
mechanism O 
by O 
which O 
liver O 
injury O 
is O 
induced O 
by O 
diverse O 
etiologies O 
. O 

Oxidative O 
stress O 
enhances O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
) O 
activity O 
, O 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activity O 
has O 
been O 
shown O 
to O 
enhance O 
the O 
expression O 
of O 
cytotoxic B-protein 
cytokines I-protein 
. O 

Acute O 
hepatic O 
injury O 
caused O 
by O 
reactive O 
oxygen O 
intermediate O 
production O 
was O 
induced O 
by O 
an O 
intraperitoneal O 
injection O 
of O 
CCl4 O 
in O 
mice O 
. O 

This O 
injury O 
was O 
significantly O 
inhibited O 
by O 
intravenous O 
pretreatment O 
of O 
the O 
mice O 
with O 
a O 
water O 
- O 
soluble O 
emulsion O 
of O 
alpha O 
- O 
tocopherol O 
. O 

Alpha O 
- O 
tocopherol O 
treatment O 
of O 
the O 
mice O 
given O 
the O 
CCl4 O 
also O 
reduced O 
the O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binding O 
to O 
levels O 
approaching O 
those O 
found O 
in O 
normal O 
mice O 
. O 

In O 
vitro O 
treatment O 
of O 
a O 
monocyte O 
/ O 
macrophage O 
cell O 
line O 
with O 
CCl4 O 
led O 
to O 
enhanced O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binding O 
and O 
an O 
increase O 
in O 
tumor B-protein B-RNA 
necrosis I-protein I-RNA 
factor I-protein I-RNA 
- I-protein I-RNA 
alpha I-protein I-RNA 
( I-RNA 
TNF B-protein I-RNA 
- I-protein I-RNA 
alpha I-protein I-RNA 
) I-RNA 
messenger I-RNA 
RNA I-RNA 
levels O 
. O 

Liver O 
specimens O 
taken O 
from O 
patients O 
with O 
acute O 
fulminant O 
hepatitis O 
had O 
markedly O 
increased O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binding O 
activity O 
in O 
comparison O 
with O 
the O 
binding O 
of O 
normal O 
livers O 
. O 

These O 
data O 
demonstrate O 
that O 
abolishing O 
acute O 
hepatic O 
injury O 
with O 
alpha O 
- O 
tocopherol O 
, O 
a O 
free O 
radical O 
scavenger O 
, O 
also O 
eliminated O 
increased O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
binding O 
. O 

It O 
is O 
tempting O 
to O 
speculate O 
that O 
enhanced O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
expression O 
caused O 
by O 
free O 
radical O 
production O 
/ O 
oxidative O 
stress O 
may O 
modulate O 
liver O 
injury O 
, O 
perhaps O 
through O 
an O 
effect O 
on O 
cytotoxic B-protein 
cytokine I-protein 
synthesis O 
. O 

Immunosuppression O 
by O 
glucocorticoids O 
: O 
inhibition O 
of O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activity O 
through O 
induction O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
synthesis O 
[ O 
see O 
comments O 
] O 
. O 

Glucocorticoids O 
are O 
among O 
the O 
most O 
potent O 
anti O 
- O 
inflammatory O 
and O 
immunosuppressive O 
agents O 
. O 

They O 
inhibit O 
synthesis O 
of O 
almost O 
all O 
known O 
cytokines B-protein 
and O 
of O 
several O 
cell B-protein 
surface I-protein 
molecules I-protein 
required O 
for O 
immune O 
function O 
, O 
but O 
the O 
mechanism O 
underlying O 
this O 
activity O 
has O 
been O 
unclear O 
. O 
Here O 
it O 
is O 
shown O 
that O 
glucocorticoids O 
are O 
potent O 
inhibitors O 
of O 
nuclear B-protein 
factor I-protein 
kappa I-protein 
B I-protein 
( O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
) O 
activation O 
in O 
mice O 
and O 
cultured B-cell_line 
cells I-cell_line 
. O 

This O 
inhibition O 
is O 
mediated O 
by O 
induction O 
of O 
the O 
I B-protein 
kappa I-protein 
B I-protein 
alpha O 
inhibitory O 
protein O 
, O 
which O 
traps O 
activated O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
in O 
inactive B-protein 
cytoplasmic I-protein 
complexes I-protein 
. O 

Because O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
activates O 
many O 
immunoregulatory B-DNA 
genes I-DNA 
in O 
response O 
to O 
pro O 
- O 
inflammatory O 
stimuli O 
, O 
the O 
inhibition O 
of O 
its O 
activity O 
can O 
be O 
a O 
major O 
component O 
of O 
the O 
anti O 
- O 
inflammatory O 
activity O 
of O 
glucocorticoids O 
. O 

Transcriptional O 
repression O 
of O 
the O 
interleukin B-DNA 
- I-DNA 
2 I-DNA 
gene I-DNA 
by O 
vitamin O 
D3 O 
: O 
direct O 
inhibition O 
of O 
NFATp B-protein 
/ I-protein 
AP I-protein 
- I-protein 
1 I-protein 
complex I-protein 
formation O 
by O 
a O 
nuclear B-protein 
hormone I-protein 
receptor I-protein 
. O 

T O 
- O 
lymphocyte O 
proliferation O 
is O 
suppressed O 
by O 
1 O 
, O 
25 O 
- O 
dihydroxyvitamin O 
D3 O 
[ O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
] O 
, O 
the O 
active O 
metabolite O 
of O 
vitamin O 
D3 O 
, O 
and O 
is O 
associated O 
with O 
a O 
decrease O 
in O 
interleukin O 
2 O 
( O 
IL O 
- O 
2 O 
) O 
, O 
gamma O 
interferon O 
, O 
and O 
granulocyte O 
- O 
macrophage O 
colony O 
- O 
stimulating O 
factor O 
mRNA O 
levels O 
. O 

We O 
report O 
here O 
that O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
- O 
mediated O 
repression O 
in O 
Jurkat B-cell_line 
cells I-cell_line 
is O 
cycloheximide O 
resistant O 
, O 
suggesting O 
that O 
it O 
is O 
a O 
direct O 
transcriptional O 
repressive O 
effect O 
on O 
IL B-protein 
- I-protein 
2 I-protein 
expression O 
by O 
the O 
vitamin B-protein 
D3 I-protein 
receptor I-protein 
( O 
VDR B-protein 
) O 
. O 

We O 
therefore O 
examined O 
vitamin O 
D3 O 
- O 
mediated O 
repression O 
of O 
activated O 
IL B-protein 
- I-protein 
2 I-protein 
expression O 
by O 
cotransfecting O 
Jurkat B-cell_line 
cells I-cell_line 
with O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
/ I-DNA 
reporter I-DNA 
constructs I-DNA 
and O 
a O 
VDR B-protein B-DNA 
overexpression I-DNA 
vector I-DNA 
and O 
by O 
DNA O 
binding O 
. O 

We O 
delineated O 
an O 
element O 
conferring O 
both O 
DNA O 
binding O 
by O 
the O 
receptor O 
in O 
vitro O 
and O 
1 O 
, O 
25 O 
( O 
OH O 
) O 
2D3 O 
- O 
mediated O 
repression O 
in O 
vivo O 
to O 
a O 
short O 
40 B-DNA 
- I-DNA 
bp I-DNA 
region I-DNA 
encompassing O 
an O 
important O 
positive B-DNA 
regulatory I-DNA 
element I-DNA 
, O 
NF B-DNA 
- I-DNA 
AT I-DNA 
- I-DNA 
1 I-DNA 
, O 
which O 
is O 
bound O 
by O 
a O 
T B-protein 
- I-protein 
cell I-protein 
- I-protein 
specific I-protein 
transcription I-protein 
factor I-protein 
, O 
NFATp B-protein 
, O 
as O 
well O 
as O 
by O 
AP B-protein 
- I-protein 
1 I-protein 
. O 

VDR B-protein B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
mutants I-protein 
were O 
unable O 
to O 
either O 
bind O 
to O 
this O 
element O 
in O 
vitro O 
or O 
repress O 
in O 
vivo O 
; O 
the O 
VDR B-protein B-protein 
DNA I-protein 
- I-protein 
binding I-protein 
domain I-protein 
alone O 
, O 
however O 
, O 
bound O 
the O 
element O 
but O 
also O 
could O 
not O 
repress O 
IL B-protein 
- I-protein 
2 I-protein 
expression O 
. O 

These O 
results O 
indicate O 
that O 
DNA O 
binding O 
by O 
VDR B-protein 
is O 
necessary O 
but O 
not O 
sufficient O 
to O 
mediate O 
IL B-protein 
- I-protein 
2 I-protein 
repression O 
. O 

By O 
combining O 
partially B-protein 
purified I-protein 
proteins I-protein 
in O 
vitro O 
, O 
we O 
observed O 
the O 
loss O 
of O 
the O 
bound O 
NFATp B-protein B-protein 
/ I-protein 
AP I-protein 
- I-protein 
1 I-protein 
- I-protein 
DNA I-protein 
complex I-protein 
upon O 
inclusion O 
of O 
VDR B-protein 
or O 
VDR B-protein B-protein 
- I-protein 
retinoid I-protein 
X I-protein 
receptor I-protein 
. O 

Order O 
of O 
addition O 
and O 
off O 
- O 
rate O 
experiments O 
indicate O 
that O 
the O 
VDR B-protein B-protein 
- I-protein 
retinoid I-protein 
X I-protein 
receptor I-protein 
heterodimer I-protein 
blocks O 
NFATp B-protein B-protein 
/ I-protein 
AP B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
complex I-protein 
formation O 
and O 
then O 
stably O 
associates O 
with O 
the O 
NF B-DNA B-DNA 
- I-DNA I-DNA 
AT I-DNA I-DNA 
- I-DNA I-DNA 
1 I-DNA I-DNA 
element I-DNA 
. O 

This O 
direct O 
inhibition O 
by O 
a O 
nuclear O 
hormone O 
receptor O 
of O 
transcriptional B-protein 
activators I-protein 
of O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
gene I-DNA 
may O 
provide O 
a O 
mechanistic O 
explanation O 
of O 
how O 
vitamin O 
derivatives O 
can O 
act O 
as O 
potent O 
immunosuppressive O 
agents O 
. O 

Tissue O 
- O 
specific O 
regulation O 
of O 
the O 
rabbit B-DNA 
15 B-protein I-DNA 
- I-protein I-DNA 
lipoxygenase I-protein I-DNA 
gene I-DNA 
in O 
erythroid B-cell_type 
cells I-cell_type 
by O 
a O 
transcriptional B-DNA 
silencer I-DNA 
. O 

The O 
15 B-DNA 
- I-DNA 
lipoxygenase I-DNA 
( I-DNA 
lox I-DNA 
) I-DNA 
gene I-DNA 
is O 
expressed O 
in O 
a O 
tissue O 
- O 
specific O 
manner O 
, O 
predominantly O 
in O 
erythroid B-cell_type 
cells I-cell_type 
but O 
also O 
in O 
airway B-cell_type 
epithelial I-cell_type 
cells I-cell_type 
and O 
eosinophils B-cell_type 
. O 

We O 
demonstrate O 
in O 
this O 
report O 
that O 
the O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
DNA I-DNA 
of O 
the O 
15 B-DNA 
- I-DNA 
lox I-DNA 
gene I-DNA 
contains O 
sequences O 
which O 
down O 
- O 
regulate O 
its O 
activity O 
in O 
a O 
variety O 
of O 
non B-cell_line 
- I-cell_line 
erythroid I-cell_line 
cell I-cell_line 
lines I-cell_line 
but O 
not O 
in O 
two O 
erythroid B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

The O 
element O 
has O 
characteristics O 
of O 
a O 
transcriptional B-DNA 
' I-DNA 
silencer I-DNA 
' I-DNA 
since O 
it O 
functions O 
in O 
both O 
orientations O 
. O 

The O 
main O 
activity O 
of O 
the O 
silencer B-DNA 
has O 
been O 
mapped O 
to O 
the O 
first O 
900 O 
bp O 
of O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
DNA I-DNA 
, O 
which O 
contains O 
nine O 
binding O 
sites O 
for O 
a O 
nuclear B-protein 
factor I-protein 
present O 
in O 
non O 
- O 
erythroid B-cell_type 
cells I-cell_type 
but O 
not O 
in O 
erythroid B-cell_type 
cells I-cell_type 
. O 

These O 
binding O 
sites O 
have O 
similar O 
sequences O 
and O 
multiple O 
copies O 
of O 
the O 
binding B-DNA 
sites I-DNA 
confer O 
tissue O 
- O 
specific O 
down O 
- O 
regulation O 
when O 
attached O 
to O 
a O 
minimal B-DNA 
lox B-DNA I-DNA 
promoter I-DNA I-DNA 
fragment I-DNA 
. O 

The O 
5 B-DNA 
' I-DNA 
flanking I-DNA 
DNA I-DNA 
also O 
contains O 
a O 
cluster O 
of O 
three O 
binding B-DNA 
sites I-DNA 
for O 
the O 
GATA B-protein 
family I-protein 
of O 
transcription B-protein 
factors I-protein 
. O 

Phosphorylation O 
of O 
the O 
transcription B-protein 
factor I-protein 
NFATp B-protein 
inhibits O 
its O 
DNA O 
binding O 
activity O 
in O 
cyclosporin B-cell_line 
A I-cell_line 
- I-cell_line 
treated I-cell_line 
human I-cell_line 
B I-cell_line 
and O 
T B-cell_type 
cells I-cell_type 
. O 

Cyclosporin O 
A O 
( O 
CsA O 
) O 
exerts O 
its O 
immunosuppressive O 
effect O 
by O 
inhibiting O 
the O 
activity O 
of O 
nuclear B-protein 
factor I-protein 
of O 
activated O 
T B-cell_type 
cells I-cell_type 
( O 
NFAT B-protein 
) O 
, O 
thus O 
preventing O 
transcriptional O 
induction O 
of O 
several O 
cytokine O 
genes O 
. O 

This O 
effect O 
is O 
thought O 
to O 
be O 
largely O 
mediated O 
through O 
inactivation O 
of O 
the O 
phosphatase O 
calcineurin B-protein 
, O 
which O 
in O 
turn O 
inhibits O 
translocation O 
of O 
an O 
NFAT B-protein 
component O 
to O 
the O 
nucleus O 
. O 

Here O 
we O 
report O 
that O 
CsA O 
treatment O 
of O 
Raji B-cell_line 
B I-cell_line 
and O 
Jurkat B-cell_line 
T B-cell_line I-cell_line 
cell I-cell_line I-cell_line 
lines I-cell_line I-cell_line 
yields O 
a O 
phosphorylated O 
form O 
of O 
NFATp B-protein 
that O 
is O 
inhibited O 
in O 
DNA O 
- O 
binding O 
and O 
in O 
its O 
ability O 
to O 
form O 
an O 
NFAT B-protein 
complex I-protein 
with O 
Fos B-protein 
and O 
Jun B-protein 
. O 

Immunoblot O 
analyses O 
and O 
metabolic O 
labeling O 
with O 
[ O 
32P O 
] O 
orthophosphate O 
show O 
that O 
CsA O 
alters O 
NFATp B-protein 
migration O 
on O 
SDS O 
- O 
polyacrylamide O 
gel O 
electrophoresis O 
by O 
increasing O 
its O 
phosphorylation O 
level O 
without O 
affecting O 
subcellular O 
distribution O 
. O 

Dephosphorylation O 
by O 
in O 
vitro O 
treatment O 
with O 
calcineurin B-protein 
or O 
alkaline B-protein 
phosphatase I-protein 
restores O 
NFATp B-protein 
DNA O 
binding O 
activity O 
and O 
its O 
ability O 
to O 
reconstitute O 
an O 
NFAT B-protein 
complex I-protein 
with O 
Fos B-protein 
and O 
Jun B-protein 
proteins O 
. O 

These O 
data O 
point O 
to O 
a O 
new O 
mechanism O 
for O 
CsA O 
- O 
sensitive O 
regulation O 
of O 
NFATp B-protein 
in O 
which O 
dephosphorylation O 
is O 
critical O 
for O 
DNA O 
binding O 
. O 

Transcription B-protein 
factors I-protein 
as O 
targets O 
for O 
oxidative O 
signalling O 
during O 
lymphocyte O 
activation O 
. O 

We O 
previously O 
have O 
demonstrated O 
a O 
requirement O 
for O 
oxidative O 
events O 
during O 
cell O 
cycle O 
entry O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
and O 
have O 
hypothesised O 
that O 
reactive O 
oxygen O 
species O 
may O 
act O 
as O 
intracellular O 
signalling O 
agents O 
during O 
lymphocyte O 
activation O 
. O 

In O 
the O 
current O 
study O 
, O 
cysteamine O 
, O 
an O 
aminothiol O 
compound O 
with O 
antioxidant O 
activity O 
, O 
has O 
been O 
used O 
to O 
further O 
investigate O 
the O 
role O 
of O 
oxidative O 
signalling O 
during O 
lymphocyte O 
activation O 
. O 

Treatment O 
of O 
normal O 
human B-cell_type 
peripheral I-cell_type 
blood I-cell_type 
lymphocytes I-cell_type 
with O 
cysteamine O 
in O 
vitro O 
was O 
found O 
to O 
inhibit O 
proliferation O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
with O 
essentially O 
complete O 
inhibition O 
occurring O 
at O 
a O 
dose O 
of O 
400 O 
microM O 
. O 

This O 
inhibitory O 
effect O 
was O 
limited O 
to O 
the O 
first O 
2 O 
h O 
after O 
mitogenic O 
activation O 
, O 
localizing O 
the O 
time O 
- O 
frame O 
of O 
action O 
of O 
cysteamine O 
to O 
within O 
the O 
commitment O 
period O 
. O 

It O 
therefore O 
was O 
of O 
interest O 
to O 
establish O 
which O 
, O 
if O 
any O 
, O 
commitment O 
events O 
were O 
affected O 
by O 
oxidative O 
signalling O 
during O 
cell O 
cycle O 
entry O 
. O 

Taking O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
gene I-DNA 
as O 
a O 
candidate O 
, O 
we O 
examined O 
the O 
effect O 
of O 
cysteamine O 
treatment O 
on O 
early B-DNA 
gene I-DNA 
expression O 
during O 
lymphocyte O 
activation O 
, O 
and O 
on O 
the O 
activity O 
of O 
transcription B-protein 
factors I-protein 
AP B-protein 
- I-protein 
1 I-protein 
, O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
, O 
NF B-protein 
- I-protein 
AT I-protein 
and O 
Oct1 B-protein 
, O 
whose O 
functions O 
are O 
required O 
for O 
expression O 
of O 
the O 
IL B-protein 
- I-protein 
2 I-protein 
mRNA O 
. O 

Cysteamine O 
treatment O 
inhibited O 
both O 
expression O 
of O 
the O 
IL B-protein B-RNA 
- I-protein I-RNA 
2 I-protein I-RNA 
mRNA I-RNA 
and O 
secretion O 
of O 
IL B-protein 
- I-protein 
2 I-protein 
into O 
the O 
culture O 
medium O 
. O 

The O 
inhibitory O 
effect O 
of O 
cysteamine O 
may O 
be O 
mediated O 
at O 
least O 
in O 
part O 
by O 
an O 
effect O 
on O 
transcription B-protein 
factor I-protein 
function O 
, O 
as O 
the O 
DNA O 
binding O 
activities O 
of O 
AP B-protein 
- I-protein 
1 I-protein 
and O 
NF B-protein 
- I-protein 
kappa I-protein 
B I-protein 
extracted O 
from O 
mitogen B-cell_type 
- I-cell_type 
stimulated I-cell_type 
cells I-cell_type 
were O 
significantly O 
inhibited O 
by O 
cysteamine O 
treatment O 
. O 

Interestingly O 
, O 
Oct1 O 
and O 
NF O 
- O 
AT O 
DNA O 
binding O 
activity O 
were O 
not O 
affected O 
by O 
cysteamine O 
treatment O 
, O 
suggesting O 
that O 
oxidative O 
signalling O 
processes O 
operate O 
in O 
a O 
selective O 
manner O 
. O 

The O 
identification O 
of O 
regulatory B-protein 
proteins I-protein 
, O 
such O 
as O 
transcription B-protein 
factors I-protein 
, O 
as O 
molecular O 
targets O 
for O 
oxidative O 
signalling O 
provides O 
further O 
evidence O 
to O 
implicate O 
oxidative O 
signalling O 
as O 
being O 
intimately O 
involved O 
in O 
the O 
G0 O 
to O 
G1 O 
phase O 
transition O 
in O 
T B-cell_type 
lymphocytes I-cell_type 
. O 

Sex O 
and O 
age O 
distribution O 
of O 
1 B-protein 
, I-protein 
25 I-protein 
( I-protein 
OH I-protein 
) I-protein 
2D3 I-protein 
receptors I-protein 
in O 
peripheral B-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
from O 
normal O 
human O 
subjects O 
. O 

Specific O 
receptors O 
for O 
1 O 
, O 
25 O 
Dihydroxyvitamin O 
D3 O 
have O 
been O 
described O 
in O 
human O 
peripheral B-cell_type 
blood I-cell_type 
mononuclear I-cell_type 
cells I-cell_type 
( O 
PBMC B-cell_type 
) O 
. O 

We O 
have O 
tried O 
to O 
find O 
out O 
whether O 
these O 
receptors O 
could O 
show O 
any O 
difference O 
in O 
sex O 
or O 
age O 
distribution O 
. O 

Twenty O 
two O 
healthy O 
men O 
aged O 
21 O 
- O 
66 O 
yr O 
( O 
mean O 
+ O 
/ O 
- O 
SD O 
41 O 
. O 
0 O 
+ O 
/ O 
- O 
13 O 
. O 
6 O 
) O 
and O 
nineteen O 
healthy O 
women O 
aged O 
22 O 
- O 
60 O 
yr O 
( O 
38 O 
. O 
9 O 
+ O 
/ O 
- O 
13 O 
. O 
9 O 
) O 
have O 
been O 
studied O 
. O 

The O 
mean O 
dissociation O 
constant O 
( O 
Kd O 
) O 
was O 
similar O 
in O 
both O 
sexes O 
( O 
1 O 
. O 
35 O 
+ O 
/ O 
- O 
0 O 
. O 
70 O 
x O 
10 O 
( O 
- O 
10 O 
) O 
M O 
in O 
males O 
, O 
1 O 
. O 
13 O 
+ O 
/ O 
- O 
0 O 
. O 
66 O 
x O 
10 O 
( O 
- O 
10 O 
) O 
M O 
in O 
females O 
) O 
, O 
but O 
the O 
concentration O 
of O 
binding O 
sites O 
( O 
Nmax O 
) O 
was O 
significantly O 
lower O 
in O 
females O 
( O 
2 O 
. O 
32 O 
+ O 
/ O 
- O 
0 O 
. O 
92 O 
fmol O 
/ O 
10 O 
( O 
7 O 
) O 
PBMC B-cell_type 
vs O 
4 O 
. O 
43 O 
+ O 
/ O 
- O 
1 O 
. O 
38 O 
fmol O 
/ O 
10 O 
( O 
7 O 
) O 
PBMC B-cell_type 
in O 
males O 
; O 
p O 
= O 
0 O 
. O 
0001 O 
) O 
. O 

Neither O 
Kd O 
nor O 
Nmax O 
were O 
significantly O 
correlated O 
with O 
age O 
. O 

No O 
difference O 
was O 
found O 
between O 
pre O 
and O 
postmenopausal O 
women O 
. O 

Further O 
studies O 
are O 
needed O 
to O 
elucidate O 
if O 
this O 
sex O 
difference O 
in O 
PBMC B-cell_type B-protein 
receptors I-protein 
for O 
1 O 
. O 
25 O 
Dihydroxyvitamin O 
D3 O 
is O 
of O 
any O 
pathophysiological O 
relevance O 
. O 

Expression O 
of O 
Id2 O 
and O 
Id3 O 
mRNA O 
in O 
human B-cell_type 
lymphocytes I-cell_type 
. O 

Helix B-protein B-protein 
- I-protein I-protein 
loop I-protein I-protein 
- I-protein I-protein 
helix I-protein I-protein 
( I-protein 
HLH B-protein I-protein 
) I-protein 
transcription I-protein 
factors I-protein 
are O 
involved O 
in O 
cellular O 
growth O 
and O 
differentiation O 
. O 

The O 
Id B-protein 
( O 
inhibitor O 
of O 
DNA O 
binding O 
and O 
differentiation O 
) O 
HLH B-protein 
proteins I-protein 
, O 
in O 
a O 
dominantly O 
negative O 
fashion O 
, O 
regulate O 
transcriptional O 
activities O 
of O 
basic B-protein 
HLH I-protein 
proteins I-protein 
. O 

We O 
examined O 
by O 
northern O 
hybridization O 
the O 
expression O 
of O 
Id2 O 
and O 
Id3 O 
mRNA O 
in O 
human B-cell_line 
leukemia I-cell_line 
/ I-cell_line 
lymphoma I-cell_line 
lines I-cell_line 
and O 
patient O 
samples O 
, O 
as O 
well O 
as O 
resting O 
and O 
activated B-cell_line 
normal I-cell_line 
human I-cell_line 
lymphocytes I-cell_line 
from O 
peripheral O 
blood O 
( O 
PBL B-cell_type 
) O 
. O 

The O 
Id2 B-protein B-RNA 
mRNA I-RNA 
was O 
abundantly O 
expressed O 
in O 
5 B-cell_line 
/ I-cell_line 
12 I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
and O 
3 B-cell_line 
/ I-cell_line 
4 I-cell_line 
B I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
, O 
and O 
Id3 B-protein B-RNA 
mRNA I-RNA 
was O 
detected O 
in O 
4 B-cell_line 
/ I-cell_line 
12 I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
and O 
3 B-cell_line 
/ I-cell_line 
4 I-cell_line 
B I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Interestingly O 
, O 
Id2 B-protein 
, O 
but O 
not O 
Id3 B-protein 
, O 
mRNA O 
was O 
strongly O 
expressed O 
in O 
4 B-cell_line 
/ I-cell_line 
5 I-cell_line 
T I-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
infected O 
with O 
human O 
T O 
- O 
cell O 
leukemia O 
virus O 
type O 
I O 
( O 
HTLV O 
- O 
I O 
) O 
( O 
ATL B-cell_line 
- I-cell_line 
1k I-cell_line 
, O 
MT B-cell_line 
- I-cell_line 
2 I-cell_line 
, O 
S B-cell_line 
- I-cell_line 
LB1 I-cell_line 
) O 
and O 
type O 
II O 
( O 
Mo B-cell_line 
) O 
. O 

Another O 
unexpected O 
finding O 
was O 
that O 
T O 
- O 
cell O 
leukemias O 
and O 
T B-cell_line 
- I-cell_line 
cell I-cell_line 
lines I-cell_line 
often O 
expressed O 
either O 
Id2 B-protein 
or O 
Id3 B-protein B-RNA 
mRNA I-RNA 
. O 

In O 
addition O 
, O 
resting B-cell_type 
PBL B-cell_type I-cell_type 
constitutively O 
expressed O 
prominent O 
levels O 
of O 
Id2 B-protein B-RNA 
mRNA I-RNA 
, O 
but O 
not O 
Id3 B-protein B-RNA 
mRNA I-RNA 
. O 

Upon O 
PHA B-protein 
- O 
stimulation O 
, O 
Id2 B-protein 
expression O 
decreased O 
and O 
Id3 B-protein 
levels O 
increased O 
with O 
biphasic O 
kinetics O 
. O 

Taken O 
together O 
, O 
our O 
studies O 
revealed O 
three O 
unexpected O 
findings O 
which O 
require O 
further O 
analysis O 
: O 
( O 
1 O 
) O 
expression O 
of O 
Id2 B-protein B-RNA 
mRNA I-RNA 
is O 
often O 
associated O 
with O 
lymphocytic O 
transformation O 
by O 
HTLV O 
- O 
I O 
or O 
- O 
II O 
; O 
( O 
2 O 
) O 
T O 
- O 
cells O 
usually O 
express O 
either O 
Id2 B-protein 
or O 
Id3 B-protein B-RNA 
mRNA I-RNA 
, O 
but O 
B O 
- O 
cells O 
often O 
express O 
both O 
simultaneously O 
; O 
( O 
3 O 
) O 
non O 
- O 
dividing O 
, O 
normal O 
PBL B-cell_type 
express O 
high O 
levels O 
of O 
Id2 B-protein 
and O 
no O 
Id3 B-protein B-RNA 
mRNA I-RNA 
; O 
and O 
with O 
the O 
onset O 
of O 
cellular O 
proliferation O 
, O 
levels O 
of O 
Id2 B-protein B-RNA 
mRNA I-RNA 
decrease O 
while O 
levels O 
of O 
Id3 B-protein B-RNA 
mRNA I-RNA 
increase O 
, O 
suggesting O 
that O 
regulation O 
of O 
expression O 
of O 
these O 
closely O 
related O 
genes B-DNA 
is O 
disparate O 
. O 

Salicylates O 
inhibit O 
lipopolysaccharide O 
- O 
induced O 
transcriptional O 
activation O 
of O 
the O 
tissue O 
factor O 
gene O 
in O 
human B-cell_type 
monocytic I-cell_type 
cells I-cell_type 
. O 

Binding O 
of O 
plasma B-protein 
Factor I-protein 
VII I-protein 
/ I-protein 
VIIa I-protein 
to O 
the O 
tissue B-protein 
factor I-protein 
( I-protein 
TF I-protein 
) I-protein 
receptor I-protein 
initiates O 
the O 
coagulation B-protein 
protease I-protein 
cascades O 
. O 

TF O 
expression O 
by O 
circulating B-cell_type 
monocytes I-cell_type 
is O 
associated O 
with O 
thrombotic O 
and O 
inflammatory O 
complications O 
in O 
a O 
variety O 
of O 
diseases O 
. O 

Transcriptional O 
activation O 
of O 
the O 
human B-DNA 
TF I-DNA 
gene I-DNA 
in O 
monocytic B-cell_type 
cells I-cell_type 
exposed O 
to O 
bacterial O 
lipopolysaccharide O 
( O 
LPS O 
) O 
is O 
mediated O 
by O 
binding O 
of O 
c B-protein 
- I-protein 
Rel I-protein 
/ I-protein 
p65 I-protein 
heterodimers I-protein 
to O 
a O 
kappa B-DNA 
B I-DNA 
site I-DNA 
in O 
the O 
TF B-DNA 
promoter I-DNA 
. O 

Here O 
, O 
we O 
report O 
that O 
a O 
family O 
of O 
anti O 
- O 
inflammatory O 
agents O 
, O 
known O 
as O 
the O 
salicylates O 
, O 
inhibited O 
LPS O 
induction O 
of O 
TF O 
activity O 
and O 
TF B-DNA 
gene I-DNA 
transcription O 
in O 
human B-cell_type 
monocytes I-cell_type 
and O 
monocytic B-cell_line 
THP I-cell_line 
- I-cell_line 
1 I-cell_line 
cells I-cell_line 
at O 
clinically O 
relevant O 
doses O 
. O 

Furthermore O 
, O 
sodium O 
salicylate O 
blocked O 
the O 
LPS O 
- O 
induced O 
proteolytic O 
degradation O 
of O 
I B-protein 
kappa I-protein 
B I-protein 
alpha I-protein 
, O 
which O 
prevented O 
the O 
nuclear O 
translocation O 
of O 
c B-protein 
- I-protein 
Rel I-protein 
/ I-protein 
p65 I-protein 
heterodimers I-protein 
. O 

In O 
contrast O 
, O 
two O 
other O 
nonsteroidal O 
anti O 
- O 
inflammatory O 
drugs O 
, O 
ibuprofen O 
and O 
indomethacin O 
, O 
did O 
not O 
inhibit O 
LPS O 
induction O 
of O 
the O 
TF B-DNA 
gene I-DNA 
. O 

These O 
results O 
indicated O 
that O 
salicylates O 
inhibited O 
LPS O 
induction O 
of O 
TF B-DNA 
gene I-DNA 
transcription O 
in O 
monocytic B-cell_type 
cells I-cell_type 
by O 
preventing O 
nuclear O 
translocation O 
of O 
c B-protein 
- I-protein 
Rel I-protein 
/ I-protein 
p65 I-protein 
heterodimers I-protein 
. O 

The O 
clinical O 
benefits O 
of O 
salicylates O 
in O 
the O 
treatment O 
of O 
several O 
diseases O 
, O 
including O 
atherosclerosis O 
and O 
rheumatoid O 
arthritis O 
, O 
may O 
be O 
related O 
to O 
their O 
ability O 
to O 
reduce O 
monocyte O 
gene O 
expression O 
. O 

Activation O 
of O 
the O 
signal O 
transducer O 
and O 
transcription O 
( O 
STAT B-protein 
) O 
signaling O 
pathway O 
in O 
a O 
primary O 
T O 
cell O 
response O 
. O 

Critical O 
role O 
for O 
IL B-protein 
- I-protein 
6 I-protein 
. O 

The O 
T O 
cell O 
activation O 
is O 
initiated O 
by O 
interaction O 
of O 
specific O 
Ags B-protein 
with O 
TCR B-protein 
, O 
followed O 
by O 
activation O 
of O 
intracellular O 
biochemical O 
events O 
leading O 
to O 
activation O 
of O 
several O 
genes O 
. O 

The O 
activation O 
of O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription B-protein 
( I-protein 
STAT I-protein 
) I-protein 
proteins I-protein 
in O 
a O 
primary O 
TCR B-protein 
- O 
mediated O 
activation O 
of O 
T B-cell_type 
cells I-cell_type 
have O 
been O 
explored O 
. O 

In O 
purified B-cell_type 
human I-cell_type 
peripheral I-cell_type 
blood I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
, O 
nuclear B-protein 
STAT I-protein 
proteins I-protein 
were O 
activated O 
approximately O 
3 O 
h O 
after O 
activation O 
by O 
cross O 
- O 
linked O 
anti B-protein 
- I-protein 
CD3 I-protein 
Abs I-protein 
. O 

These O 
STAT B-protein 
proteins I-protein 
were O 
detected O 
by O 
using O 
the O 
IFN B-DNA 
- I-DNA 
gamma I-DNA 
- I-DNA 
activated I-DNA 
sequence I-DNA 
( O 
GAS B-DNA 
) O 
and O 
related O 
oligonucleotides O 
as O 
probes O 
in O 
electrophoretic O 
mobility O 
shift O 
assay O 
. O 

Analysis O 
of O 
the O 
nuclear O 
extracts O 
with O 
anti B-protein 
- I-protein 
STAT I-protein 
Abs I-protein 
indicated O 
that O 
they O 
contained O 
STAT B-protein 
- I-protein 
3 I-protein 
and O 
additional O 
proteins O 
crossreactive O 
with O 
the O 
STAT B-protein 
family I-protein 
. O 

The O 
induction O 
of O 
STAT B-protein 
activity O 
was O 
inhibited O 
completely O 
by O 
pretreatment O 
with O 
either O 
cycloheximide O 
or O 
cyclosporin O 
A O 
, O 
thus O 
indicating O 
that O 
the O 
induction O 
was O 
due O 
to O 
a O 
secondary B-protein 
factor I-protein 
produced O 
by O 
the O 
activated O 
T B-cell_type 
cells I-cell_type 
. O 

As O 
neutralizing B-protein 
anti I-protein 
- I-protein 
IL B-protein I-protein 
- I-protein I-protein 
6 I-protein I-protein 
Abs I-protein 
effectively O 
down O 
- O 
regulated O 
the O 
early O 
induction O 
of O 
STAT B-protein 
proteins I-protein 
and O 
as O 
exogenously O 
added O 
IL B-protein 
- I-protein 
6 I-protein 
rapidly O 
activated O 
DNA O 
binding O 
similar O 
to O 
TCR B-protein 
- O 
mediated O 
bindings O 
, O 
it O 
can O 
be O 
concluded O 
that O 
IL B-protein 
- I-protein 
6 I-protein 
is O 
the O 
factor O 
responsible O 
for O 
the O 
activation O 
of O 
STAT B-protein 
proteins I-protein 
in O 
a O 
primary O 
T O 
cell O 
response O 
. O 

The O 
normal O 
cell O 
cycle O 
activation O 
program O 
is O 
exploited O 
during O 
the O 
infection O 
of O 
quiescent B-cell_type 
B I-cell_type 
lymphocytes I-cell_type 
by O 
Epstein O 
- O 
Barr O 
virus O 
. O 

B B-cell_type 
lymphocytes I-cell_type 
in O 
the O 
peripheral O 
circulation O 
are O 
maintained O 
in O 
a O 
non O 
- O 
proliferative O 
state O 
. O 

Antigen O 
recognition O 
stimulates O 
limited O 
proliferation O 
, O 
whereas O 
infection O 
with O 
Epstein O 
- O 
Barr O 
virus O 
( O 
EBV O 
) O 
results O 
in O 
continual O 
proliferation O 
and O 
the O 
outgrowth O 
of O 
immortal B-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

Because O 
it O 
is O 
not O 
clear O 
at O 
which O 
point O 
in O 
cell O 
cycle O 
the O 
peripheral B-cell_type 
B B-cell_type I-cell_type 
lymphocytes I-cell_type I-cell_type 
are O 
arrested O 
, O 
we O 
characterized O 
the O 
expression O 
of O 
several O 
cell B-DNA 
cycle I-DNA 
- I-DNA 
associated I-DNA 
genes I-DNA 
in O 
quiescent O 
and O 
stimulated O 
cells O 
. O 

We O 
show O 
that O 
the O 
expression O 
of O 
four O 
cell B-DNA 
genes I-DNA 
, O 
cdc B-DNA 
- I-DNA 
2 I-DNA 
, O 
cyclin B-DNA 
E I-DNA 
, O 
CD23 B-DNA 
, O 
and O 
cyclin B-DNA 
D2 I-DNA 
, O 
are O 
up O 
- O 
regulated O 
approximately O 
100 O 
- O 
fold O 
as O 
a O 
result O 
of O 
EBV O 
- O 
mediated O 
immortalization O 
. O 

Because O 
these O 
genes O 
play O 
a O 
positive O 
role O 
in O 
cell O 
proliferation O 
, O 
we O 
suggest O 
that O 
this O 
regulatory O 
switch O 
contributes O 
to O 
controlling O 
entry O 
into O 
the O 
cell O 
cycle O 
. O 

Transient O 
stimulation O 
of O 
quiescent B-cell_type 
B B-cell_type I-cell_type 
lymphocytes I-cell_type I-cell_type 
with O 
either O 
a O 
cocktail O 
of O 
anti B-protein 
- I-protein 
CD40 I-protein 
, O 
anti B-protein 
- I-protein 
IgM I-protein 
, O 
and O 
IL4 B-protein 
, O 
or O 
EBV O 
results O 
in O 
the O 
rapid O 
expression O 
of O 
the O 
same O 
four O 
genes O 
, O 
suggesting O 
that O 
, O 
after O 
infection O 
, O 
EBV O 
exploits O 
the O 
normal O 
program O 
of O 
B B-cell_type 
- I-cell_type 
lymphocyte I-cell_type 
cell O 
cycle O 
activation O 
. O 

Expression O 
of O 
the O 
chemokine B-protein 
receptor I-protein 
BLR2 B-protein 
/ I-protein 
EBI1 I-protein 
is O 
specifically O 
transactivated O 
by O 
Epstein B-protein 
- I-protein 
Barr I-protein 
virus I-protein 
nuclear I-protein 
antigen I-protein 
2 I-protein 
. O 

In O 
our O 
attempt O 
to O 
identify O 
chemokine B-protein 
receptors I-protein 
that O 
are O 
related O 
to O 
Burkitt B-protein 
' I-protein 
s I-protein 
lymphoma I-protein 
receptor I-protein 
1 I-protein 
( O 
BLR1 B-protein 
) O 
and O 
are O 
expressed O 
in O 
activated B-cell_type 
lymphocytes I-cell_type 
we O 
used O 
RT O 
- O 
PCR O 
resulting O 
in O 
the O 
isolation O 
of O 
a O 
cDNA O 
encoding O 
a O 
seven B-protein 
transmembrane I-protein 
receptor I-protein 
termed O 
BLR2 B-protein 
. O 

The O 
protein O 
shows O 
significant O 
sequence O 
similarities O 
to O 
the O 
family O 
of O 
G B-protein 
- I-protein 
protein I-protein 
coupled O 
chemokine B-protein 
receptors I-protein 
and O 
turned O 
out O 
to O 
be O 
identical O 
to O 
the O 
recently O 
described O 
receptor B-protein 
EBI1 I-protein 
. O 

Northern O 
blot O 
analysis O 
revealed O 
that O 
BLR2 B-protein B-RNA 
mRNA I-RNA 
could O 
be O 
highly O 
stimulated O 
in O 
mitogen O 
- O 
and O 
anti O 
- O 
CD3 O 
- O 
treated O 
peripheral O 
blood O 
lymphocytes O 
. O 

BLR2 B-protein B-RNA 
- I-RNA 
specific I-RNA 
mRNA I-RNA 
could O 
be O 
detected O 
in O 
all O 
Epstein B-cell_line 
- I-cell_line 
Barr I-cell_line 
virus I-cell_line 
positive I-cell_line 
B I-cell_line 
cell I-cell_line 
lines I-cell_line 
. O 

We O 
show O 
that O 
transcription O 
of O 
the O 
BLR2 B-protein B-DNA 
gene I-DNA 
could O 
be O 
specifically O 
induced O 
in O 
Epstein B-cell_line 
- I-cell_line 
Barr I-cell_line 
virus I-cell_line 
negative I-cell_line 
BL I-cell_line 
41 I-cell_line 
cells I-cell_line 
via O 
estrogen O 
- O 
mediated O 
activation O 
of O 
Epstein B-protein 
- I-protein 
Barr I-protein 
virus I-protein 
nuclear I-protein 
antigen I-protein 
2 I-protein 
, O 
a O 
key O 
regulator O 
of O 
viral B-DNA 
and O 
cellular B-DNA 
genes I-DNA 
in O 
immortalized B-cell_line 
B I-cell_line 
cells I-cell_line 
. O 

Our O 
data O 
suggest O 
an O 
involvement O 
of O 
BLR2 B-protein 
in O 
the O 
regulation O 
of O 
migration O 
in O 
activated B-cell_type 
lymphocytes I-cell_type 
and O 
in O 
viral O 
pathogenesis O 
. O 

A O 
central O 
role O 
for O 
a O 
single B-DNA 
c I-DNA 
- I-DNA 
Myb I-DNA 
binding I-DNA 
site I-DNA 
in O 
a O 
thymic B-DNA 
locus I-DNA 
control I-DNA 
region I-DNA 
. O 

Locus B-DNA 
control I-DNA 
regions I-DNA 
( O 
LCRs B-DNA 
) O 
are O 
powerful O 
assemblies O 
of O 
cis B-DNA 
elements I-DNA 
that O 
organize O 
the O 
actions O 
of O 
cell B-protein 
- I-protein 
type I-protein 
- I-protein 
specific I-protein 
trans I-protein 
- I-protein 
acting I-protein 
factors I-protein 
. O 

A O 
2 B-protein 
. I-protein 
3 I-protein 
- I-protein 
kb I-protein 
LCR I-protein 
in O 
the O 
human B-DNA B-DNA 
adenosine I-DNA I-DNA 
deaminase I-DNA I-DNA 
( I-DNA I-DNA 
ADA I-DNA I-DNA 
) I-DNA I-DNA 
gene I-DNA I-DNA 
first I-DNA 
intron I-DNA 
, O 
which O 
controls O 
expression O 
in O 
thymocytes B-cell_type 
, O 
is O 
composed O 
of O 
a O 
200 B-DNA 
- I-DNA 
bp I-DNA 
enhancer I-DNA 
domain I-DNA 
and O 
extended O 
flanking O 
sequences O 
that O 
facilitate O 
activation O 
from O 
within O 
chromatin B-DNA 
. O 

Prior O 
analyses O 
have O 
demonstrated O 
that O 
the O 
enhancer B-DNA 
contains O 
a O 
28 B-DNA 
- I-DNA 
bp I-DNA 
core I-DNA 
region I-DNA 
and O 
local O 
adjacent O 
augmentative O 
cis B-DNA 
elements I-DNA 
. O 

We O 
now O 
show O 
that O 
the O 
core O 
contains O 
a O 
single O 
critical O 
c B-DNA 
- I-DNA 
Myb I-DNA 
binding I-DNA 
site I-DNA 
. O 

In O 
both O 
transiently B-cell_line 
cotransfected I-cell_line 
human I-cell_line 
cells I-cell_line 
and O 
stable O 
chromatin B-cell_line 
- I-cell_line 
integrated I-cell_line 
yeast I-cell_line 
cells I-cell_line 
, O 
c B-protein 
- I-protein 
Myb I-protein 
strongly O 
transactivated B-DNA 
reporter I-DNA 
constructs I-DNA 
that O 
contained O 
polymerized B-DNA 
core I-DNA 
sequences I-DNA 
. O 

c B-protein B-protein 
- I-protein I-protein 
Myb I-protein I-protein 
protein I-protein 
was O 
strongly O 
evident O 
in O 
T B-cell_type 
lymphoblasts I-cell_type 
in O 
which O 
the O 
enhancer B-DNA 
was O 
active O 
and O 
was O 
localized O 
within O 
discrete O 
nuclear O 
structures O 
. O 

Fetal O 
murine O 
thymus O 
exhibited O 
a O 
striking O 
concordance O 
of O 
endogenous O 
c B-DNA 
- I-DNA 
myb I-DNA 
expression O 
with O 
that O 
of O 
mouse B-DNA 
ADA I-DNA 
and O 
human B-DNA 
ADA I-DNA 
LCR I-DNA 
- O 
directed O 
transgene O 
expression O 
. O 

Point O 
mutation O 
of O 
the O 
c B-protein B-DNA 
- I-protein I-DNA 
Myb I-protein I-DNA 
site I-DNA 
within O 
the O 
intact O 
2 B-protein 
. I-protein 
3 I-protein 
- I-protein 
kb I-protein 
LCR I-protein 
severely O 
attenuated O 
enhancer O 
activity O 
in O 
transfections O 
and O 
LCR B-DNA 
activity O 
in O 
transgenic B-cell_line 
thymocytes B-cell_type I-cell_line 
. O 

Within O 
the O 
context O 
of O 
a O 
complex B-DNA 
enhancer I-DNA 
and O 
LCR B-DNA 
, O 
c B-protein 
- I-protein 
Myb I-protein 
can O 
act O 
as O 
an O 
organizer O 
of O 
thymocyte B-DNA 
- I-DNA 
specific I-DNA 
gene I-DNA 
expression O 
via O 
a O 
single O 
binding O 
site O 
. O 

A O 
regulatory B-DNA 
element I-DNA 
in O 
the O 
human B-DNA 
interleukin I-DNA 
2 I-DNA 
gene I-DNA 
promoter I-DNA 
is O 
a O 
binding B-DNA 
site I-DNA 
for O 
the O 
zinc B-protein 
finger I-protein 
proteins I-protein 
Sp1 B-protein 
and O 
EGR B-protein 
- I-protein 
1 I-protein 
. O 

Activation O 
of O 
the O 
interleukin B-protein B-DNA 
2 I-protein I-DNA 
( I-DNA 
IL B-protein I-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
) I-DNA 
gene I-DNA 
after O 
antigen O 
recognition O 
is O 
a O 
critical O 
event O 
for O 
T O 
cell O 
proliferation O 
and O 
effector O 
function O 
. O 

Prior O 
studies O 
have O 
identified O 
several O 
transcription B-protein 
factors I-protein 
that O 
contribute O 
to O 
the O 
activity O 
of O 
the O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
in O 
stimulated B-cell_type 
T I-cell_type 
lymphocytes I-cell_type 
. O 

Here O 
we O 
describe O 
a O 
novel O 
regulatory B-DNA 
element I-DNA 
within O 
the O 
IL B-DNA 
- I-DNA 
2 I-DNA 
promoter I-DNA 
located O 
immediately O 
upstream O 
of O 
the O 
nuclear B-protein B-DNA 
factor I-protein I-DNA 
of I-protein I-DNA 
activated I-protein I-DNA 
T I-protein I-DNA 
cell I-protein I-DNA 
( I-DNA 
NFAT B-protein I-DNA 
) I-DNA 
domain I-DNA 
. O 

This O 
region O 
( O 
termed O 
the O 
zinc B-DNA 
finger I-DNA 
protein I-DNA 
binding I-DNA 
region I-DNA 
( O 
ZIP B-DNA 
) O 
) O 
serves O 
as O 
binding O 
site O 
for O 
two O 
differently O 
regulated O 
zinc B-protein 
finger I-protein 
proteins I-protein 
: O 
the O 
constitutively B-protein 
expressed I-protein 
transcription I-protein 
factor I-protein 
Sp1 B-protein 
and O 
the O 
inducible B-protein 
early I-protein 
growth I-protein 
response I-protein 
protein I-protein 
EGR B-protein 
- I-protein 
1 I-protein 
. O 

In O 
unstimulated B-cell_type 
cells I-cell_type 
which O 
do O 
not O 
secrete O 
IL B-protein 
- I-protein 
2 I-protein 
, O 
only O 
Sp1 B-protein 
binds O 
to O 
this O 
region O 
, O 
while O 
in O 
stimulated B-cell_line 
IL B-protein I-cell_line 
- I-protein I-cell_line 
2 I-protein I-cell_line 
secreting I-cell_line 
cells I-cell_line 
the O 
inducible B-protein 
EGR B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
protein I-protein 
recognizes O 
this O 
element O 
. O 

In O 
Jurkat B-cell_line 
T I-cell_line 
cells I-cell_line 
, O 
the O 
ZIP B-DNA B-DNA 
site I-DNA 
serves O 
as O 
an O 
activator O 
for O 
IL B-protein 
- I-protein 
2 I-protein 
gene O 
expression O 
, O 
and O 
a O 
combination O 
of O 
ZIP B-DNA 
and O 
NFAT B-protein B-DNA 
binding I-DNA 
sites I-DNA 
is O 
required O 
for O 
maximal O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
activity O 
. O 

These O 
results O 
suggest O 
a O 
critical O 
role O 
of O 
the O 
ZIP B-DNA 
site I-DNA 
for O 
IL B-protein B-DNA 
- I-protein I-DNA 
2 I-protein I-DNA 
promoter I-DNA 
activity O 
. O 

Activation O 
of O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
enhancer I-DNA 
by O 
the O 
LEF B-protein 
- I-protein 
1 I-protein 
HMG I-protein 
protein I-protein 
on O 
nucleosome B-DNA 
- I-DNA 
assembled I-DNA 
DNA I-DNA 
in O 
vitro O 
. O 

Lymphoid B-protein 
enhancer I-protein 
- I-protein 
binding I-protein 
factor I-protein 
1 I-protein 
( O 
LEF B-protein 
- I-protein 
1 I-protein 
) O 
is O 
a O 
regulatory B-protein 
high I-protein 
mobility I-protein 
group I-protein 
( I-protein 
HMG I-protein 
) I-protein 
protein I-protein 
that O 
activates O 
the O 
T B-protein B-DNA 
cell I-protein I-DNA 
receptor I-protein I-DNA 
alpha I-protein I-DNA 
( I-DNA 
TCR B-protein I-DNA 
alpha I-protein I-DNA 
) I-DNA 
enhancer I-DNA 
in O 
a O 
context O 
- O 
restricted O 
manner O 
in O 
T B-cell_type 
cells I-cell_type 
. O 

In O 
this O 
paper O 
we O 
demonstrate O 
that O 
the O 
distal O 
region O 
of O 
the O 
human B-DNA 
immunodeficiency I-DNA 
virus I-DNA 
- I-DNA 
1 I-DNA 
( I-DNA 
HIV I-DNA 
- I-DNA 
1 I-DNA 
) I-DNA 
enhancer I-DNA 
, O 
which O 
contains O 
DNA B-DNA 
- I-DNA 
binding I-DNA 
sites I-DNA 
for O 
LEF B-protein 
- I-protein 
1 I-protein 
and O 
Ets O 
- O 
1 O 
, O 
also O 
provides O 
a O 
functional O 
context O 
for O 
activation O 
by O 
LEF B-protein 
- I-protein 
1 I-protein 
. O 

First O 
, O 
we O 
show O 
that O 
mutations O 
in O 
the O 
LEF B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
- I-DNA 
binding I-DNA 
site I-DNA 
inhibit O 
the O 
activity O 
of O 
multimerized B-DNA 
copies I-DNA 
of O 
the O 
HIV B-DNA 
- I-DNA 
1 I-DNA 
enhancer I-DNA 
in O 
Jurkat B-cell_line 
T I-cell_line 
cells I-cell_line 
, O 
and O 
that O 
LEF B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
/ I-protein 
GAL4 I-protein 
can O 
activate O 
a O 
GAL4 B-DNA 
- I-DNA 
substituted I-DNA 
HIV B-DNA I-DNA 
- I-DNA I-DNA 
1 I-DNA I-DNA 
enhancer I-DNA I-DNA 
80 O 
- O 
to O 
100 O 
- O 
fold O 
in O 
vivo O 
. O 

Second O 
, O 
recombinant B-protein 
LEF B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
is O 
shown O 
to O 
activate O 
HIV O 
- O 
1 O 
transcription O 
on O 
chromatin B-DNA 
- I-DNA 
assembled I-DNA 
DNA I-DNA 
in O 
vitro O 
. O 

By O 
using O 
a O 
nucleosome B-protein 
- O 
assembly O 
system O 
derived O 
from O 
Drosophila O 
embryos O 
, O 
we O 
find O 
that O 
the O 
packaging O 
of O 
DNA O 
into O 
chromatin B-DNA 
in O 
vitro O 
strongly O 
represses O 
HIV O 
- O 
1 O 
transcription O 
and O 
that O 
repression O 
can O 
be O 
counteracted O 
efficiently O 
by O 
preincubation O 
of O 
the O 
DNA O 
with O 
LEF B-protein 
- I-protein 
1 I-protein 
( O 
or O 
LEF B-protein 
- I-protein 
1 I-protein 
and O 
Ets B-protein 
- I-protein 
1 I-protein 
) O 
supplemented O 
with O 
fractions O 
containing O 
the O 
promoter B-protein 
- I-protein 
binding I-protein 
protein I-protein 
, O 
Sp1 B-protein 
. O 

Addition O 
of O 
TFE B-protein 
- I-protein 
3 I-protein 
, O 
which O 
binds O 
to O 
an O 
E B-DNA 
- I-DNA 
box I-DNA 
motif I-DNA 
upstream O 
of O 
the O 
LEF O 
- O 
1 O 
and O 
Ets O 
- O 
1 O 
sites O 
, O 
further O 
augments O 
transcription O 
in O 
this O 
system O 
. O 

Individually O 
or O 
collectively O 
, O 
none O 
of O 
the O 
three O 
enhancer B-protein 
- I-protein 
binding I-protein 
proteins I-protein 
( O 
LEF B-protein 
- I-protein 
1 I-protein 
, O 
Ets B-protein 
- I-protein 
1 I-protein 
, O 
and O 
TFE B-protein 
- I-protein 
3 I-protein 
) O 
could O 
activate O 
transcription O 
in O 
the O 
absence O 
of O 
Sp1 B-protein 
. O 

A O 
truncation B-protein 
mutant I-protein 
of O 
LEF B-protein 
- I-protein 
1 I-protein 
( O 
HMG B-protein 
- I-protein 
88 I-protein 
) O 
, O 
which O 
contains O 
the O 
HMG B-protein 
box I-protein 
but O 
lacks O 
the O 
trans B-protein 
- I-protein 
activation I-protein 
domain I-protein 
, O 
did O 
not O 
activate O 
transcription O 
from O 
nucleosomal B-DNA 
DNA I-DNA 
, O 
indicating O 
that O 
bending O 
of O 
DNA O 
by O 
the O 
HMG B-protein 
domain I-protein 
is O 
not O 
sufficient O 
to O 
activate O 
transcription O 
in O 
vitro O 
. O 

We O 
conclude O 
that O 
transcription O 
activation O 
by O 
LEF B-protein 
- I-protein 
1 I-protein 
in O 
vitro O 
is O 
a O 
chromatin B-DNA 
- O 
dependent O 
process O 
that O 
requires O 
a O 
functional O 
trans B-protein 
- I-protein 
activation I-protein 
domain I-protein 
in O 
addition O 
to O 
the O 
HMG B-protein 
domain I-protein 
. O 

HIV B-protein 
- I-protein 
1 I-protein 
envelope I-protein 
glycoproteins I-protein 
induce O 
activation O 
of O 
activated O 
protein B-protein 
- I-protein 
1 I-protein 
in O 
CD4 B-cell_type 
+ I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
[ O 
published O 
erratum O 
appears O 
in O 
J O 
Biol O 
Chem O 
1995 O 
Dec O 
1 O 
; O 
270 O 
( O 
48 O 
) O 
: O 
29038 O 
] O 
. O 

Activation O 
of O 
CD4 B-cell_type 
positive I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
is O 
a O 
primary O 
requirement O 
for O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
entry O 
, O 
efficient O 
HIV O 
replication O 
, O 
and O 
progression O 
to O 
AIDS O 
, O 
Utilizing O 
CD4 B-cell_line 
positive I-cell_line 
T I-cell_line 
cell I-cell_line 
lines I-cell_line 
and O 
purified B-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
from O 
normal O 
individuals O 
, O 
we O 
have O 
demonstrated O 
that O 
native B-protein 
envelope I-protein 
glycoproteins I-protein 
of O 
HIV O 
, O 
gp B-protein 
160 I-protein 
, O 
can O 
induce O 
activation O 
of O 
transcription B-protein 
factor I-protein 
, I-protein 
activated I-protein 
protein I-protein 
- I-protein 
1 I-protein 
( O 
AP B-protein 
- I-protein 
1 I-protein 
) O 
. O 

The O 
stimulatory O 
effects O 
of O 
gp160 B-protein 
are O 
mediated O 
through O 
the O 
CD4 B-protein 
molecule I-protein 
, O 
since O 
treatment O 
of O 
gp160 B-protein 
with O 
soluble O 
CD4 B-protein 
- I-protein 
IgG I-protein 
abrogates O 
its O 
activity O 
, O 
and O 
CD4 B-cell_line 
negative I-cell_line 
T I-cell_line 
cell I-cell_line 
lines I-cell_line 
fail O 
to O 
be O 
stimulated O 
with O 
gp160 B-protein 
. O 

Immunoprecipitation O 
of O 
the O 
gp B-protein 
160 I-protein 
- O 
induced O 
nuclear O 
extracts O 
with O 
polyclonal B-protein 
antibodies I-protein 
to O 
Fos B-protein 
and O 
Jun B-protein 
proteins I-protein 
indicates O 
that O 
AP B-protein B-protein 
- I-protein I-protein 
1 I-protein I-protein 
complex I-protein 
is O 
comprised O 
of O 
members O 
of O 
these O 
family O 
of O 
proteins O 
. O 

The O 
gp160 B-protein B-protein 
- I-protein 
induced I-protein 
AP B-protein I-protein 
- I-protein I-protein 
1 I-protein I-protein 
complex I-protein 
is O 
dependent O 
upon O 
protein O 
tyrosine O 
phosphorylation O 
and O 
is O 
protein O 
synthesis O 
- O 
independent O 
. O 

This O 
stimulation O 
can O 
also O 
be O 
abolished O 
by O 
inhibitors O 
of O 
protein B-protein 
kinase I-protein 
C I-protein 
, O 
but O 
it O 
is O 
unaffected O 
by O 
calcium O 
channel O 
blocker O 
or O 
cyclosporine O 
A O 
. O 

This O 
gp160 B-protein 
treatment O 
adversely O 
affects O 
the O 
functional O 
capabilities O 
of O 
T B-cell_type 
cells I-cell_type 
: O 
pre O 
- O 
treatment O 
of O 
CD4 B-cell_type 
+ I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
with O 
gp160 B-protein 
for O 
4 O 
h O 
at O 
37 O 
degrees O 
C O 
inhibited O 
anti B-protein 
- I-protein 
CD3 I-protein 
- O 
induced O 
interleukin B-protein 
- I-protein 
2 I-protein 
secretion O 
. O 

Effects O 
similar O 
to O 
gp160 B-protein 
were O 
seen O 
with O 
anti B-protein 
- I-protein 
CD4 I-protein 
mAb I-protein 
. O 

The O 
aberrant O 
activation O 
of O 
AP B-protein 
- I-protein 
1 I-protein 
by O 
gp160 B-protein 
in O 
CD4 B-cell_type 
positive I-cell_type 
T B-cell_type I-cell_type 
cells I-cell_type I-cell_type 
could O 
result O 
in O 
up O 
- O 
regulation O 
of O 
cytokines B-protein 
containing O 
AP B-protein B-DNA 
- I-protein I-DNA 
1 I-protein I-DNA 
sites I-DNA 
, O 
e O 
. O 
g O 
. O 
interleukin B-protein 
- I-protein 
3 I-protein 
and O 
granulocyte B-protein 
macrophage I-protein 
colony I-protein 
- I-protein 
stimulating I-protein 
factor I-protein 
, O 
and O 
concurrently O 
lead O 
to O 
T B-cell_type 
cell I-cell_type 
unresponsiveness O 
by O 
inhibiting O 
interleukin B-protein 
- I-protein 
2 I-protein 
secretion O 
. O 